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Preface to ”A Commemorative Issue in Honor of
Professor Nick Hadjiliadis”
This Special Issue of the International Journal of Molecular Sciences comprises a comprehensive 
study on “Metal Complex Interactions with Nucleic Acids and/or DNA”. This Special Issue has been 
inspired by the important contribution of Prof. Nick Hadjiliadis to the field of palladium or/and 
platinum/nucleic acid interactions. It covers a selection of recent research and review articles in the 
field of metal complex interactions with nucleic acids and/or DNA.
Metal complexes have long been recognized as critically important components of nucleic acid 
chemistry, both in the regulation of gene expression and as promising therapeutic agents. The ability 
to recognize, to understand at the molecular level of how metal complexes interact with DNA has 
become an active research area at the interface between biological inorganic chemistry, molecular 
biology, and medicine.
Arguably, the most prominent drug which contains a metal is cisplatin, the most widely used 
anti-cancer drug. The success of cisplatin in chemotherapy and the clarification of its mechanism of 
action through interaction with DNA has motivated a large number of studies on metal complexes 
interaction with nucleic acids or/and DNA. From the foregoing that the reader of this Special Issue 
will gain an appreciation of the real role of the interactions of metal complexes with nucleic acids 
or/and DNA in modern medicine.
This Special Issue on the ”Metal complexes interactions with Nucleic acids and/or DNA” aims 
to provide an overview of this increasingly diverse field, presenting recent developments, and the 
latest research with particular emphasis on metal-based drugs and metal ion toxicity.
Sotiris K. Hadjikakou, Christina N. Banti
Special Issue Editors
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This Special Issue of the International Journal of Molecular Science comprises a comprehensive
study on “Metal Complex Interactions with Nucleic Acids and/or DNA”. This Special Issue has been
inspired by the important contribution of Prof. Nick Hadjiliadis in the field of palladium or/and
platinum/nucleic acid interactions. It covers a selection of recent research and review articles in the
field of metal complex interactions with nucleic acids and/or DNA.
Metal complexes have long been recognized as critically important components of nucleic acid
chemistry, both in the regulation of gene expression and as promising therapeutic agents. The ability
to recognize and understand how metal complexes interact with DNA at the molecular level has
become an active research area at the interface between biological inorganic chemistry, molecular
biology, and medicine. Arguably the most prominent drug which contains a metal is cisplatin, the
most widely used anti-cancer drug. The success of cisplatin in chemotherapy and the clarification of
its mechanism of action through its interaction with DNA has motivated a large number of studies on
metal complex interactions with nucleic acids or/and DNA. Thus, the reader of this Special Issue will
gain an appreciation of the real role of the interactions of metal complexes with nucleic acids or/and
DNA in modern medicine.
This Special Issue on “Metal complex Interactions with Nucleic Acids and/or DNA” provides
an overview of this increasingly diverse field, presenting recent developments and the latest research
with particular emphasis on metal-based drugs and metal ion toxicity.
Inorganic biochemistry or bioinorganic chemistry is a multidiscipline field which involves
inorganic chemistry, biochemistry, spectroscopy, material science, biology, and medicine.
The introduction of metal ions or metal ion binding components into a biological system for
the treatment of diseases is one of the main subdivisions in the field of inorganic biochemistry.
Nowadays, at the forefront of the field is the development of new metallodrugs for diagnostics
(radiopharmaceuticals drugs), medicines (anticancer, antimicrobial/antiparasitic, therapeutic
radiopharmaceuticals, photochemotherapeutic metallodrugs, antiarthritic, antidiabetes, antiviral,
metallodrugs addressing deficiencies syndromes), and tools for chemical biology, biocatalysis, and
bioelectronics, as well as the characterization of metalloproteins, enzymes, and their model complexes.
Recently, biomaterials have been applied in many cases such as cardiovascular medical devices,
orthopedic and dental applications, ophthalmologic applications, bioelectrodes and biosensors, burn
dressings and skin substitutes, sutures, and drug delivery systems. For the coming years, the
well-defined bioavailability, absorption, distribution, metabolism, and excretion of metal-based drugs
will be the main target of new metallodrugs. The use of nanoparticles, micelle emulsions, and liposomal
formulations can open new opportunities for improved delivery, cell uptake, and targeting.
Emeritus Professor Nick Hadjiliadis is one of the pioneers in the field of bioinorganic chemistry.
He graduated from the University of Athens, and subsequently earned a Masters in Science from
Int. J. Mol. Sci. 2018, 19, 3815; doi: www.mdpi.com/journal/ijms1
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the University of Montreal and a Doctor of Chemistry, PhD from the University of Montreal in 1975.
He served as a Professor of Inorganic and General Chemistry at the Department of Chemistry of
the University of Ioannina, Greece, since 1980. He worked on the interaction of metal ions with
nucleobases and nucleosides, as well as with DNA and RNA. This pioneering work led to the first
conclusions elucidating the mechanism of the antitumoral action of cisplatin. His research interests
also included: (i) the synthesis, characterization, and study of the antitumor properties of new metal
complexes (e.g., Pt, Pd, Sn, Sb, etc.); (ii) the study of metalloenzyme models and the clarification of
their mechanism of action. His research on thiamine enzymes in the presence of divalent metal ions,
for which he proposed a mechanism, was also a pioneering work in the field of enzyme/metal ion
interactions. He also studied (iii) the mechanism of action of superoxide dismutase, Cu(II), and Zn(II);
(iv) peptide interactions with metal ions, as models of enzymes or other biological systems; (v) the
involvement of metal ions such as Ni(II) and Cu(II) in carcinogenesis; (vi) the biocatalysis of new
materials; (vii) the mechanism of action of anti-thyroid drugs; (viii) organometallic chemistry, etc. He
has numerous publications (up to 260), which have been cited more than 7000 times with an h-index
of 44. He has been invited to 70 international conferences (as a Lead Speaker). He has coordinated
many research and teaching programs. Important international conferences dedicated to the field of
inorganic biochemistry—such as 5-ISABC, HALCHEM-III, 12-EURASIA, etc.—have been organized
and chaired by him. Furthermore, he mentored many scientists, initiating their careers as academicians
worldwide. Special attention should be paid to his contribution to the foundation and operation of
the Interdisciplinary Program of Postgraduate Studies in Bioinorganic Chemistry, which he led for a
decade. His contribution to the field of Inorganic-Bioinorganic Chemistry is undoubtedly superior in
quality and unique for a Greek scientist. Overall, he contributed to the progress of inorganic chemistry
not only at the University of Ioannina, Greece, but in the whole nation.
Recognizing this contribution of Emeritus Professor Nick Hadjiliadis to the field of inorganic
biochemistry and especially to the field of palladium or/and platinum/nucleic acid interactions, it
is our honour to dedicate the prologue of this commemorative issue of the International Journal of
Molecular Sciences to him.
This Special Issue is composed of 14 articles, which are briefly reviewed below.
Yu-Wen Chen et al. showed that the i-motif DNA sequence may transition to a base-extruded
duplex structure with a GGCC tetranucleotide tract when it is bound to the (CoII)-mediated dimer of
chromomycin A3 [1]. G. Momekov et al. investigated two paramagnetic palladium(III) complexes of
hematoporphyrin IX for their ability to process DNA adducts as well as for their antineoplastic and
apoptogenic activities [2]. E. Makkonen et al. reported a combined quantum mechanics/molecular
mechanics molecular dynamics and time-dependent density functional study of silver-mediated
deoxyribonucleic acid nanostructures [3]. S. Liu et al. investigated the interactions between
ruthenium(II) complexes and 15-mer single- and double-stranded oligodeoxynucleotides and they
tested the thermodynamic base and sequence selectivity [4]. G.K. Latsis et al. investigated two
polyorganotic acetate complexes against DNA with possible implementation towards breast cancer
cells [5]. S. Savino et al. tested the ability of platinum prodrugs of kiteplatin with a-lipoic acid in the
axial position to target in mitochondria [6]. Q.Y. Yang et al. tested the molecular mechanism of two
transition metal complexes with 2-((2-(pyridin-2-yl)hydrazono)methyl)quinolin-8-ol against tumor
cells [7]. M. Hande et al. described the synthesis and hybridization properties of short oligonucleotides
incorporating cyclopalladated benzylamine “warheads” at their 5′-termini [8]. M.F. AlAjmi et al.
evaluated the benzimidazole-derived biocompatible copper(II) and zinc(II) complexes as anticancer
chemotherapeutics [9]. T. Qin et al. examined the binding of zinc cationic porphyrin towards B-DNA
and Z-DNA [10] A.B. Olejniczak et al. presented an overview of the methods for incorporating metal
centers into nucleic acids based on metal–boron cluster complexes (metallacarboranes) as the metal
carriers [11]. Y.H. Lai et al. reviewed the mechanisms by which the regulation of copper homeostasis
modulates the chemosensitivity of tumors to platinum drugs [12]. V. Murray et al. reviewed the
2
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abilities of bleomycin to interact with DNA [13]. N.C. Sabharwal et al. investigated the interactions
between spermine-derivitized tentacle 2 porphyrins and the human telomeric DNA G quadruplex [14].
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: G-rich DNA sequences have the potential to fold into non-canonical G-Quadruplex
(GQ) structures implicated in aging and human diseases, notably cancers. Because stabilization
of GQs at telomeres and oncogene promoters may prevent cancer, there is an interest in
developing small molecules that selectively target GQs. Herein, we investigate the interactions
of meso-tetrakis-(4-carboxysperminephenyl)porphyrin (TCPPSpm4) and its Zn(II) derivative
(ZnTCPPSpm4) with human telomeric DNA (Tel22) via UV-Vis, circular dichroism (CD), and
fluorescence spectroscopies, resonance light scattering (RLS), and fluorescence resonance energy
transfer (FRET) assays. UV-Vis titrations reveal binding constants of 4.7 × 106 and 1.4 × 107 M−1
and binding stoichiometry of 2–4:1 and 10–12:1 for TCPPSpm4 and ZnTCPPSpm4, respectively.
High stoichiometry is supported by the Job plot data, CD titrations, and RLS data. FRET melting
indicates that TCPPSpm4 stabilizes Tel22 by 36 ± 2 ◦C at 7.5 eq., and that ZnTCPPSpm4
stabilizes Tel22 by 33 ± 2 ◦C at ~20 eq.; at least 8 eq. of ZnTCPPSpm4 are required to achieve
significant stabilization of Tel22, in agreement with its high binding stoichiometry. FRET competition
studies show that both porphyrins are mildly selective for human telomeric GQ vs duplex DNA.
Spectroscopic studies, combined, point to end-stacking and porphyrin self-association as major
binding modes. This work advances our understanding of ligand interactions with GQ DNA.
Keywords: G-quadruplex; tentacle porphyrins; Zn(II) porphyrin; anti-cancer therapy; end-stacking
1. Introduction
DNA can exist in a variety of secondary structures [1] in addition to the right-handed
double-stranded (dsDNA) form first proposed by Watson and Crick in 1953. One example is
G-Quadruplex (GQ) DNA, a non-canonical DNA structure formed by guanine rich sequences [2].
The primary structural unit of GQ DNA is a G-tetrad which consists of four guanines associated
through Hoogsteen hydrogen bonding (Figure 1A). G-tetrads interact with each other via π-π stacking,
and are linked by the phosphate sugar backbone, forming GQs. The stability of the GQ is further
enhanced by coordinating cations [3,4]. In fact, biological GQs with 2–4 G-tetrads would not fold
without a cation due to a strong repulsion of guanine carbonyls in the center of each tetrad (Figure 1A).
Unlike dsDNA, GQs exhibit high structural diversity, adopting parallel, mixed-hybrid, and antiparallel
Int. J. Mol. Sci. 2018, 19, 3686; doi:10.3390/ijms19113686 www.mdpi.com/journal/ijms4
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topologies (Figure 1B). Bioinformatics studies suggest that sequences with GQ-forming potential are
prevalent in highly-conserved functional regions of the human genome including telomeres, oncogene
promoters, immunoglobulin switch regions, and ribosomal DNA [5–8], and may regulate numerous
biological processes. Evidence for GQ formation inside the cell was recently presented [9–12], and
studies are underway to better assess their in vivo roles [2].
Figure 1. (A) Four guanines associate via Hoogsteen hydrogen bonding to form a G-tetrad.
M+ represents a central coordinating cation, such as Na+, K+, or NH4+. (B) Schematics of the
physiologically-relevant structures of human telomeric DNA, dAGGG(TTAGGG)3. Grey and red
rectangles represent guanines in anti and syn conformations. Adenines and thymines are represented
as blue and yellow circles, respectively. Strand orientations are depicted with arrows. Mixed-hybrid
conformation is that of Form 2. (C) Structure of ZnTCPPSpm4; the fifth axial water ligand attached to
Zn(II) is not depicted for clarity of the image.
Telomeres protect the ends of eukaryotic chromosomes from degradation and fusion and contain
tandem repeats of dTTAGGG [13]. The 22-mer human telomeric DNA sequence dAGGG(TTAGGG)3
(Tel22) is well-studied and has been shown to form diverse GQ structures in vitro [14–16], see Figure 1B.
The topology, stability, and homogeneity of the human telomeric DNA depends on the DNA
length and the identity of the nucleotides at 5′ and 3′ ends. In addition, the nature of the central
stabilizing cation, the presence of small molecules, annealing temperature and rate, and molecular
crowding reagents impact the resulting secondary structure. In K+, Tel22 forms a parallel GQ with
three G-tetrads and three TTA propeller loops, but only in the presence of molecular crowding
conditions [17,18], some small molecules (e.g., N-methylmesoporphyrin IX, NMM) [19,20], under
crystallization conditions [21], or at high DNA concentration [22]. In Na+, Tel22 adopts an antiparallel
topology with three G-tetrads connected by two lateral loops and one central diagonal loop [23]. In the
dilute K+ solutions favored in this work, Tel22 adopts at least two (3 + 1) mixed-hybrid structures
called Form 1 and Form 2 [24–28]. The two forms have one propeller loop and two lateral loops,
but differ by loop orders; three G-rich strands run in the same direction and opposite from that
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of the fourth strand, hence the name (3 + 1). Other GQ topologies exist under these conditions
(e.g., an antiparallel GQ with two G-tetrads) [29], but at low abundance. It has been proposed that
formation of GQ structures at telomeres inhibits the activity of telomerase, the enzyme responsible
for maintenance of telomeres integrity, leading to cell immortality. Because telomerase is upregulated
in 85–90% of cancers [30], stabilization of GQs by small molecule ligands has emerged as a novel,
selective, anti-cancer therapeutic strategy [31,32].
Porphyrins are one of the earliest classes of DNA ligands. Their interactions with GQ DNA
were first studied in 1998 [33], and with dsDNA as far back as 1979 [34], and are still of great
interest [35]. Porphyrins are aromatic, planar, and the size of their macrocycle (~10 Å) matches
that of a G-tetrad (~11 Å), leading to an efficient π-π stacking. Cellular uptake and localization
studies demonstrate that porphyrins accumulate rapidly in nuclei of normal and tumor cells [36,37] at
levels sufficient for tumor growth arrest; yet they are non-toxic to somatic cells [38]. Porphyrins can
be readily functionalized to optimize their GQ-stabilizing ability and selectivity, solubility, and cell
permeability. Our laboratory and others have characterized binding of numerous porphyrins, including
NMM [19,20,39], meso-tetrakis-(N-methyl-4-pyridyl) porphyrin (TMPyP4) [38,40], and its various
derivatives [41–44] to human telomeric DNA. Porphyrins can bind to GQ DNA via end-stacking,
which has been characterized spectroscopically [45,46], and observed in structural studies [20,47].
Intercalation has been suggested [46,48–50], but is considered energetically unfavorable for short
GQs with 2-4 G-tetrads. Porphyrins can also interact with the grooves [51] and loops [52] of GQs.
Porphyrin metallation is expected to enhance its GQ binding due to the electron-withdrawing property
of the metal, which reduces the electron density on the porphyrin, improving its π-π stacking ability.
The enhancement of porphyrin’s binding to GQ is especially strong when the metal is positioned
above the ion channel of the GQ.
In this work, we focus on two novel tentacle porphyrins, meso-tetrakis-(4-carboxyspermine-
phenyl)porphyrin, TCPPSpm4 and its Zn(II)-derivative, ZnTCPPSpm4, Figure 1C. Binding of
tentacle porphyrins to dsDNA is well studied [53–56], but their interactions with GQ DNA
remain poorly characterized. We introduced spermine groups to enhance the GQ-binding potential,
solubility, and biocompatibility of the porphyrins. Polyamines have been reported to interact with
DNA by both electrostatic forces and via site-specific interactions with the phosphate backbone
and DNA bases [57–59]. In some cases polyamines induced conformational modifications [60].
Spermine was shown to preferentially bind to the major groove of dsDNA [59]. A variety amines (e.g.,
pyrrolidine, piperidine, morpholine, 1-ethylpiperazine, N,N-diethylethylenediamine, and guanidine)
have been incorporated into GQ ligands, leading to improvements in their GQ binding affinities
and water solubility [61–65]. Of equally strong importance, spermine is essential for cellular growth,
differentiation [66], and protection against double-strand breaks. Polyamines are currently being
exploited as a transport system for cancer drugs due to their well-known ability to accumulate in
neoplastic tissues [67–71]. Therefore, we added spermine to meso-tetrakis-(4-carboxyphenyl)porphyrin
not only to improve its GQ-binding, but also to facilitate its delivery to cancer cells in future
biological studies.
We characterized the interactions between human telomeric DNA and TCPPSpm4 or
ZnTCPPSpm4 in a K+ buffer through UV-Vis, fluorescence, and circular dichroism (CD) spectroscopies,
resonance light scattering (RLS), and fluorescence resonance energy transfer (FRET) assays.
We demonstrate that both porphyrins bind tightly to Tel22 GQ with a high binding stoichiometries
(2–4:1 for TCPPSpm4 and 10–12:1 for ZnTCPPSpm4) and stabilize it strongly with mild selectivity
over dsDNA. Our data are consistent with end-stacking binding mode and DNA-assisted
porphyrin self-stacking.
2. Results and Discussion
In this work, we focus on two tentacle porphyrins, meso-tetrakis(4-carboxysperminephenyl)
porphyrin, TCPPSpm4, and its Zn(II) derivative, ZnTCPPSpm4. Both porphyrins are modified with
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four spermine arms, see Figure 1C. The pKa of the spermine amine groups in TCPPSpm4 was measured
to be ~5.8 for the first protonation and ~8 for the second protonation [72]. Therefore, this porphyrin is
expected to be at least tetracationic at pH 7.2 used in this work. Zn(II) was introduced into TCPPSpm4
to improve its GQ binding due to electron-poor nature of the metal. In addition, Zn(II) is coordinated
to an axial water, which is expected to prevent its intercalation into dsDNA, and thus, to improve its
selectivity. Binding of TCPPSpm4 to the GQ aptamer (dTGGGAG)4 was recently characterized [73],
whereas binding of ZnTCPPSpm4 to any of the GQs has not yet been tested. Here, we explore in detail
how both porphyrins interact with human telomeric GQ DNA, Tel22.
2.1. UV-Vis Spectroscopy Demonstrates that TCPPSpm4 and ZnTCPPSpm4 Bind Tightly to Tel22
Due to the excellent chromophoric properties of both porphyrins, their binding to Tel22 was
monitored using Soret band of 415 nm for TCPPSpm4 and 424 nm for ZnTCPPSpm4. We first performed
a dilution study which indicated that the porphyrins maintain their aggregation state, assumed to
be monomeric, in the concentration range of 1–40 μM (Figure S1). Subsequently, both porphyrins
were titrated with Tel22; representative UV-Vis titrations are shown in Figure 2. The extinction
coefficient for the TCPPSpm4-Tel22 complex was determined to be (1.2 ± 0.2) × 105 M−1cm−1 at
429 nm and (0.54 ± 0.04) × 105 M−1cm−1 for ZnTCPPSpm4-Tel22 at 435 nm. The Soret band of
TCPPSpm4 displayed a pronounced red shift (Δλ) of 13.5 ± 0.5 nm and hypochromicity (%H) of
58 ± 6 % upon addition of Tel22. The corresponding values for ZnTCPPSpm4 are similar with Δλ of
11.3 ± 0.6 and % H of 58 ± 5%. Red shift of ~15 nm and %H of ~50% were obtained for TCPPSpm4
binding to another GQ structure formed by (dTGGGAG)4 aptamer [73]. High values of Δλ and %H
indicate strong interactions between the π-systems of porphyrins and GQ, characteristic of either
end-stacking or intercalation. Pasternack et al. found that intercalation of a porphyrin into dsDNA
can be identified by %H > 40% and Δλ ≥ 15 nm [74]. Although supported by molecular dynamics
stimulation studies [50], this mode of binding has not yet been detected in structural studies. On the
other hand, both end-stacking [20,47] and loop binding [52] have been observed in X-ray structures of
porphyrin-GQ complexes.
To extract binding constants, we employed the Direct Fit method, which is the simplest way of
treating the titration data, as it assumes equivalent and independent binding sites. Such data treatment
is justified by the presence of the isosbestic points, yet it is an oversimplification in view of high
stoichiometric ratios obtained (see below) and the presence of detectable shoulders, especially in
final samples. Data analysis yielded a binding constant, Ka, of (4.7 ± 0.7) × 106 M−1 for TCPPSpm4
assuming a binding stoichiometry of 4:1; and Ka of (1.4 ± 0.7) × 107 M−1 for ZnTCPPSpm4 assuming
a binding stoichiometry of 12:1. The high Ka values indicate strong binding between Tel22 and
the porphyrins and correlate well with the high values of Δλ and %H. ZnTCPPSpm4 binds three
times tighter than its free-base analogue, possibly due to the presence of electron withdrawing metal.
This binding is likely further enhanced by electrostatic attractions due to high charges on the porphryins
and by interactions of four spermine arms with the grooves of Tel22 GQ.
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Figure 2. Interactions between porphyrins and Tel22 GQ probed by UV-Vis spectroscopy. (A) A
representative UV-Vis titration of 2.8 μM TCPPSpm4 with 82.6 μM Tel22. Clear isosbestic point is
observed at 424 nm. (B) Best fit (solid line) to the titration data monitored at 415 nm (squares) and
429 nm (circles). (C) A representative UV-Vis titration of 5.8 μM ZnTCPPSpm4 with 46.3 (followed by
185) μM Tel22. Clear isosbestic point is observed at 442 nm. (D) Best fit (solid line) to the titration data
monitored at 424 nm (squares). Concentration of binding sites is defined as the concentration of Tel22
multiplied by the binding stoichiometry (4:1 for TCPPSpm4 and 12:1 for ZnTCPPSpm4). Blue lines and
points correspond to porphryins alone and pink corresponds to porphyrin-Tel22 complex.
To independently verify the stoichiometry for porphyrin-Tel22 binding, we used Job’s method,
also known as the method of continuous variation [75]. In this method, the mole fraction of DNA
and porphyrin is varied while their total concentration is kept constant. The mole fraction at the
maximum or minimum on the plot of absorbance vs mole fraction corresponds to the binding
stoichiometry between the two binding partners [76]. Representative Job plots are depicted in Figure 3.
Job plot experiments for TCPPSpm4-Tel22 system yielded an average mole fraction of 0.70 ± 0.04,
which corresponds to the binding of 2–3 porphyrins to one Tel22. For the ZnTCPPSpm4-Tel22 system,
Job plot yielded a mole fraction value of ~0.9, which corresponds to the binding of nine porphyrin
molecules to one Tel22 GQ. In both cases, binding stoichiometries are somewhat lower than those
obtained via fitting of the UV-vis titration data. Similar discrepancy was also observed in our previous
work where we investigated binding of four different cationic porphyrins to two parallel GQs [77].
Job plot stoichiometry is lower because it represents only the major binding event, while stoichiometry
obtained via fitting of UV-vis titration data encompasses strong, weak, and non-specific binding. It is
also important to remember that binding stoichiometries of 1:1 and 2:1 can be clearly differentiated
via Job’s method, but higher binding stoichiometries are difficult to determine precisely. For example,
binding ratios of 4:1 and 5:1 correspond to molar fractions of 0.8 and 0.83, respectively, which would
likely be impossible to distinguish, given the expected level of data accuracy. The unusually high
binding stoichiometry supports the involvement of multiple binding modes such as end-stacking,
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electrostatic interactions, and groove binding, the latter two resulting from the presence of spermine
arms. It also suggests the possibility of porphyrin self-association on the DNA backbone. The much
higher binding stoichiometry for ZnTCPPSpm4 is puzzling, especially in light of ZnTCPPSpm4′s axial
water molecule, which is expected to inhibit some binding modes, such as porphyrin self-association.
However, slipped self-stacking is still possible.
 
Figure 3. Representative Job plots for (A) 3.1 μM TCPPSpm4 and (B) 2.9 μM ZnTCPPSpm4 in complex
with Tel22 at 25 ◦C. Porphyrins and Tel22 GQ DNA concentrations were maintained equal within
20%. The Job plots were constructed by plotting the difference in the absorbance values at a specified
wavelength vs mole fraction of the porphyrin, X. Pink squares represent data collected by titrating
porphyrins into DNA; blue squares represent data collected by titrating DNA into porphyrins.
2.2. RLS Indicates the Formation of Discrete Stoichiometric Porprhyrin-Tel22 Complexes
Because UV-vis titrations yielded high stoichiometry for porphryin-Tel22 complexes, we employed
the RLS method [78] to check for possible aggregation. In RLS, porphyrin solution is excited close to
its Soret maximum and the scattering is measured at the same wavelength. If aggregated (alone or on
a substrate), porphyrins display enhanced Rayleigh scattering originating from electronic coupling
between the individual molecules in the assembly. To detect communication between porphyrins,
RLS experiments are performed under porphyrin excess, unlike UV-vis titrations, where DNA excess
is used.
The RLS intensity of TCPPSpm4 alone is low (Figure 4A), indicating an absence of aggregation in
agreement with UV-vis dilution studies (Figure S1). The addition of Tel22 does not change the RLS
signal in the [TCPPSpm4]/[Tel22] range of 40–8. Below this ratio, however, RLS signal starts to increase
and reaches a maximum at [TCPPSpm4]/[Tel22] = 2, suggesting the formation of an assembly with
strong electronic communication between porphyrins. Further addition of Tel22 does not change RLS,
indicating that the TCPPSpm4-Tel22 complex is stable. Adding more Tel22 to this solution eventually
leads to drastic decline in RLS signal, owing to the precipitation of the complex (data not shown).
ZnTCPPSpm4 does not aggregate alone or in the [ZnTCPPSpm4]/[Tel22] range of
40–14 (Figure 4B). When more Tel22 is added, however, stable aggregates are formed at
[ZnTCPPSpm4]/[Tel22] ~13, in line with the stoichiometry determined in UV-vis experiments.
Subsequent addition of Tel22 does not change RLS until [ZnTCPPSpm4]/[Tel22] ~2, at which point the
RLS signal rises up to 1:1 ratio then starts to decrease, although the observed changes are small.
Taken together, the RLS data allow us to (i) exclude porphyrin aggregation in the absence of DNA;
(ii) confirm formation of discrete porphryin-Tel22 complexes with a stoichiometry consistent with that
measured in UV-vis; and (iii) exclude existence of large, non-stoichiometric porphryin-Tel22 aggregates.
Overall, RLS and UV-vis data support our hypothesis of DNA-assisted porphyrin self-aggregation on
Tel22 which leads to strong electronic communication between individual porphyrins in the assembly.
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Figure 4. Representative RLS titration of 2.0 μM (A) TCPPSpm4 and (B) ZnTCPPSpm4 with 500
μM Tel22 at 25 ◦C. The amounts of Tel22 added are specified in the legend. Inset reports RLS
intensity at 450 nm vs [porphyrin]/[Tel22] ratio. Note, the scale in the inset is inverted to follow
the progress of the titration which starts with the solution of porphyrin and proceeds toward lower
[porphyrin]/[Tel22] ratios.
2.3. Fluorescence of TCPPSpm4 and ZnTCPPSpm4 Decreases in the Presence of Tel22 Suggesting
DNA-Assisted Porphyrin Self-Association
The steady-state fluorescence emission spectrum of a porphyrin is produced by the first excited
state, S1, and the charge-transfer state between the porphyrin ring and its peripheral substituents (in
this case carboxysperminephenyl groups). The coupling between these two states leads to quenching of
the fluorescence signal, which occurs in polar solvents or when the rotation of peripheral substituents
is unrestricted. TCPPSpm4 fluoresces in aqueous solution, producing a peak at 643 nm and a shoulder
at 702 nm, as has been previously observed [72]. At the same time, ZnTCPPSpm4 produces a split
peak at 607 and 657 nm, Figure 5, suggesting that the rotation of its side-chains is more restricted.
Position and intensity of the fluorescence peak of a porphyrin is strongly sensitive to its
environment and, thus, can report on porphyrin binding to GQ DNA [79]. Addition of Tel22 GQ to
TCPPSpm4 leads to a dramatic decrease in fluorescence intensity and a red shift of 10 and 15 nm
for the 643 and 702 nm peaks, respectively. The spectra at saturating amount of Tel22 are sharper
and better resolved, Figure 5A, suggesting restriction in rotation of the peripheral groups upon GQ
binding. Similarly, the fluorescence intensity of ZnTCPPSPm4 decreased dramatically upon addition
of Tel22, but the red shift observed was significantly smaller, i.e., 5 and 3 nm for the 607 and 657 nm
bands, respectively. In both cases, the original dramatic decrease in signal intensity is followed by a
small increase in the signal at high [Tel22]/[porphyrin] ratios (see Figure S2) suggesting a change in a
mechanism of ligand interactions with Tel22 or with each other. The strong decrease in fluorescence
could be explained by close interactions between porphyrins and Tel22 as well as by self-association of
porphyrins assisted by the DNA backbone. Such interpretation is consistent with reported high binding
stoichiometry, especially for ZnTCPPSpm4. Similar to our case, the steady-state fluorescence of the
Zn(II) derivative of a widely-studied porphyrin, TMPyP4, decreased upon addition of tetrastranded
parallel GQs [77] and poly(dG-dC) dsDNA [80], although in both cases the decrease was not as
dramatic as in the present case.
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Figure 5. Steady-state fluorescence emission spectra for (A) 0.33 μM TCPPSpm4 alone and in the
presence of 19.5 fold excess of Tel22 and (B) 0.47 μM ZnTCPPSpm4 alone and in the presence of 9.1 fold
excess of Tel22. Note, for the ease of comparison, the data were scaled to 1 μM porphyrin.
2.4. FRET Studies Indicate that Both Porphyrins Have Exceptional Stabilizing Ability and Modest Selectivity
toward Tel22 GQ
FRET is a benchmark technique in the quadruplex field enabling facile and reliable measurement
of ligands’ stabilizing ability and selectivity for GQ DNA [81]. We used F21D, a 21-nt sequence of
the human telomeric DNA labeled with 6-FAM fluorescent dye at the 5′ end and a quencher, Dabcyl,
at the 3′ end (5′-6-FAM-GGG(TTAGGG)3-Dabcyl-3′). We have thoroughly characterized the fold and
stability of this sequence in our earlier work [19]. The addition of up to 7.5 eq. of TCPPSpm4 and up
to 20 eq. of ZnTCPPSpm4 to F21D resulted in a concentration-dependent increase in Tm of F21D by
36 ± 2 ◦C and 33 ± 2 ◦C, respectively (Figure 6A; raw data are shown in Figure S3). Our data shows
that both porphyrins stabilize Tel22 GQ to a great extent, but the stabilization curve for ZnTCPPSpm4
is sigmoidal, and only weak stabilization is observed up to 1.6 μM (8 eq.) of the porphyrin. This data
is in agreement with high stoichiometry of the ZnTCPPSpm4-Tel22 complex determined in UV-vis and
Job plot studies.
 
Figure 6. Stabilizing ability and selectivity of TCPPSpm4 and ZnTCPPSpm4 toward human telomeric
DNA investigated via FRET. (A) Dose dependent stabilization, ΔTm, of 0.2 μM F21D as a function
of porphyrin concentration. (B) Stabilization of 0.2 μM F21D with 0.75 μM TCPPSpm4 or 2.2 μM
ZnTCPPSpm4 in the presence of increasing amount of CT DNA (equivalents relative to F21D
are specified in the legend). Concentration of porphyrins was chosen in order to achieve similar
starting Tm for the first sample before any CT DNA was added in order to facilitate the comparison.
The concentration of F21D is expressed per strand, while the concentration of CT DNA is expressed
per base pair. Note, all raw data are presented in Figure S3.
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Selectivity is an essential characteristic of an ideal anticancer GQ ligand, because a drug that
binds readily to dsDNA will require a greater concentration to achieve its therapeutic effect, or even
cause cytotoxicity. Thus, we conducted FRET competition studies in the presence of large excess of
CT DNA and a fixed ligand concentration (Figure 6B). The selectivity ratio, defined as the fold of
competitor necessary to reduce ΔTm by 50%, was calculated to be 270 for TCPPSpm4 and 200 for
ZnTCPPSpm4. While the porphyrins prefer GQ to dsDNA, the observed selectivity ratios are rather
modest. Such modest selectivity is likely due to strong electrostatic interactions between the positively
charged porphyrins and negatively charged DNA (GQ, dsDNA, etc). This hypothesis is supported
by our earlier work showing that reducing the charge on a porphyrin increases its selectivity for
GQ DNA [44]. Our laboratory previously demonstrated that another Zn(II)-metallated porphyrin,
ZnTMPyP4, displays selectivity ratio of 100 toward F21D vs CT DNA, while its free-base analogue
displays a selectivity ratio of 300 [42]. These values are on the same scale and display the same trend as
the one obtained in this work. Overall, FRET studies suggest that both porphyrins are robust stabilizers
of human telomeric DNA, with TCPPSpm4 displaying both superior selectivity and stabilizing ability.
2.5. Circular Dichroism (CD) Signal Decreases upon Addition of Porphyrins Signifying Interaction between
Porphyrins and Tel22
To determine if porphyrin binding alters the topology of the Tel22 GQ, we performed CD
annealing and titration studies. CD is an excellent method to report on the type of GQ fold and
its alteration upon ligand binding. The CD signature of Tel22 in potassium buffer (5 mM KCl) is well
characterized in our previous works [19] and that of others [22], and contains a peak at 295 nm and a
shoulder at ~250 nm. Titration of TCPPSpm4 under kinetic conditions (with short 12 min equilibration)
did not alter the conformation of Tel22, but lead to dramatic decrease in the intensity of 295 nm
peak (Figure 7A). Under similar conditions, ZnTCPPSpm4 caused only a mild decrease of CD signal
intensity (Figure 7B). To investigate the system under thermodynamic equilibrium, Tel22 samples were
annealed with ~2 eq. of porphyrins and equilibrated overnight. The CD signals displayed stronger
decrease (Figure 7C,D), in part caused by minor precipitation. Decrease in CD signal intensity was
also observed upon interaction of TCPPSpm4 with (dTGGGAG)4 GQ aptamer [73]. Other metallated
porphyrins, such as PtTMPyP4 [43], CuTMPyP4, and NiTMPyP4 [82] caused decrease in the intensity
of Tel22 CD signal in potassium buffer, while CoTMPyP4 and ZnTMPyP4 did not [82].
The porphyrin-induced decrease in CD signal intensity could be explained, in part, by DNA
precipitation, most likely caused by highly charged spermine arms of the porphyrin ligands.
The precipitation was minor and was only observed at high porphyrin and DNA concentrations
(above 10 μM DNA). In addition, the observed behavior in CD titrations could be explained by
preferential binding of porphyrins to single-stranded (ssDNA), which disfavors GQ in the GQ DNA
↔ ssDNA equilibrium. This mode of binding was observed for TMPyP4 [83], triarylpyridines [84],
and anthrathiophenedione [85]. However, such data interpretation seems to contradict the observed
stabilization of human telomeric DNA in our FRET studies (Figure 6A). Alternatively, we can explain
the observed decrease in CD signal intensity by proposing that porphyrins bind to GQ DNA by
disrupting and replacing one or more of the G-tetrads, leading to unchanged or even enhanced
stability. Such explanation reconciles our CD and FRET data and was first proposed by Marchand et al.
on the basis of an extensive CD and mass spectrometry study [86].
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Figure 7. CD titration of 15.0 μM Tel22 with up to 4 eq. of (A) TCPPSpm4 and (B) ZnTCPPSpm4.
Samples were incubated for 12 min after each addition of the porphyrin. CD annealing of (C) 10.0 μM
Tel22 with 2.0 eq. of TCPPSpm4 and of (D) 15 μM Tel22 with 2.2 eq. of Zn TCPPSpm4. Data were
collected at 20 ◦C. We have also completed CD melting on the annealed samples and saw no-to-weak
stabilization (Figure S4).
2.6. The Presence of Induced CD (iCD) Confirms Close Contacts between Porphyrins and Tel22
Aromatic Systems
We further characterized porphyrin-Tel22 interactions by investigating changes in the CD Soret
region. Chromophoric but achiral porphyrins produce no CD signal in this region, and the DNA
CD signal is found exclusively in the UV region. However, when DNA and porphyrin interact,
the complex is both chiral and chromophoric, and will produce an iCD when the π-system of a
porphyrin is in close proximity to that of the DNA. For ligand binding to duplex DNA, the type of iCD
has been found to correlate with the binding mode: a positive iCD corresponds to external binding
and a negative one indicates intercalation [87,88]. However, a similar correlation has not yet been
established for porphyrin-GQ interactions due to the scarcity of empirical data on binding modes other
than end-stacking.
The addition of Tel22 to each porphyrin at stoichiometric amounts yielded a bisignate iCD
with a strong positive component (Figure 8). The trough and the peak occur at 410 and 426 nm for
TCPPSpm4-Tel22 and at 427 and 442 nm for ZnTCPPSpm4-Tel22, which is consistent with their Soret
band positions. Once we established the presence of the iCD, we conducted CD titrations in the Soret
region. Due to low iCD signal intensity, the data display high variability, but nevertheless indicate
that the strongest iCD is observed for complexes with the stoichiometric quantities of porphyrins
(4 eq. for TCPPSpm4 and ~12–15 eq. for ZnTCPPSpm4, Figure S5). In sum, the presence of iCD is
consistent with strong binding of both porphyrins to the Tel22, and suggests close proximity of the
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porphyrin ring and G-tetrad(s), indicative of end-stacking. In addition, the split bisignate shape of
iCD indicates that porphyrins are not disorderly distributed on Tel22 and that there is communication
between the porphyrins in the assembly, in agreement with the RLS data described earlier. The iCD
was likewise observed for TCPPSpm4 binding to (dTGGGAG)4 GQ aptamer [73] and to poly(dG-dC)
and CT DNA [89], and for ZnTCPPSpm4 binding to poly(dG-dC) in both B and Z conformations [90].
However, the shape of the iCD was different from that observed in this work, underlining differences
in the binding modes.
 
Figure 8. iCD signature of TCPPSpm4-Tel22 and ZnTCPPSpm4-Tel22 complexes prepared at
stoichiometric amounts of porphyrins and DNA (4:1 for TCPPSpm4 and 12:1 for ZnTCPPSpm4).
The data were scaled to 1 μM porphyrin. The CD scan of porphyrin alone is shown in grey. The data
were smoothed using Savitzky–Golay smoothing filter with a 13-point quadratic function.
3. Materials and Methods
3.1. Porphyrins and Oligonucleotides
TCPPSpm4 and ZnTCPPSpm4 were synthesized as described previously [72,90] and dissolved
in double-distilled water (ddH2O) at 1–5 mM and stored at 4 ◦C in the dark. The concentration
of TCPPSpm4 was determined via UV-Vis spectroscopy using the extinction coefficient of
3.0 × 105 M−1cm−1 at 415 nm at pH 6.5 [72]. The extinction coefficient for ZnTCPPSpm4 was
measured to be 1.34 × 105 M−1cm−1 at 424 nm at pH 7 using Beer’s law (Figure S1). Tel22 was
purchased from Midland Certified Reagent Company (Midland, TX, USA) and dissolved in 5K buffer
(10 mM lithium cacodylate, pH 7.2, 5 mM KCl and 95 mM LiCl). Calf thymus (CT) DNA was
purchased from Sigma-Aldrich and dissolved in a solution of 10 mM lithium cacodylate 7.2 and 1 mM
Na2EDTA at a concentration of 1 mM. The solution was then equilibrated for one week, filtered, and
stored at 4 ◦C. The fluorescently labeled oligonucleotide 5′-6-FAM-GGG(TTAGGG)3-Dabcyl-3′ (F21D)
was purchased from Integrated DNA Technologies (Coralville, IA, USA), dissolved at 0.1 mM in
ddH2O, and stored at −80 ◦C prior to use. The concentrations of all nucleic acids were determined
through UV-Vis spectroscopy at 90 ◦C using the extinction coefficients ε260 nm = 228.5 mM−1cm−1
for Tel22, 247.6 mM−1cm−1 for F21D, and 12.2 mM−1cm−1 (per base pair) for CT DNA. Extinction
coefficients were calculated with the Integrated DNA Technologies OligoAnalyzer (available at https:
//www.idtdna.com/calc/analyzer, accessed on November 20, 2018) which uses the nearest-neighbor
approximation model [91,92].
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To induce GQ structure formation, DNA samples at the desired concentrations alone or in the
presence of 1–2 eq. of porphyrin were heated at 95 ◦C for ten minutes in 5K buffer, allowed to cool to
room temperature over three hours, and equilibrated overnight at 4◦ C. All experiments were done in
5K buffer.
3.2. UV-Vis Titrations and Job Plot
UV-Vis experiments were performed on a Cary 300 (Varian) spectrophotometer with a
Peltier-thermostated cuvette holder (error of ± 0.3 ◦C) using 1 cm methylmethacrylate or quartz
cuvettes and dual beam detection. The sample cuvette contained 2.3–3.1 μM TCPPSpm4 or 1.0–6.4 μM
ZnTCPPSpm4 and the reference cuvette contained 5K buffer. UV-Vis titrations were conducted by
adding small volumes of concentrated Tel22 in a stepwise manner to a 1 mL of porphyrin solutions,
mixing thoroughly, and equilibrating for at least two minutes. UV-vis scans were collected in the range
of 352–500 nm. DNA was added until at least three final spectra were superimposable. All titrations
were performed at least three times. All spectra were corrected mathematically for dilutions, and
analyzed as described previously using a Direct Fit model [19,42] with GraphPad Prism software at
415 and 429 nm for TCPPSpm4 and 424 nm wavelengths for ZnTCPPSpm4. Job plot UV-Vis titration
experiments were performed to independently determine the stoichiometry of ligand-Tel22 binding
interactions. Job plot experiments were conducted for both porphyrins using the procedure and data
processing described in our earlier work [19]. Both porphyrins and DNA were prepared at 3–4 μM.
Job plot experiments were completed at least three times.
3.3. Fluorescence Spectroscopy
3.3.1. Resonance Light Scattering (RLS)
RLS experiments [78] were conducted using a conventional fluorimeter, Fluorolog FL-11
Jobin-Yvon Horiba. A 2.1 mL solution of 2 μM porphyrin in a 1 cm quartz cuvette was titrated
with 0.5 mM annealed and equilibrated Tel22 solution at 25 ◦C. Final concentration of Tel22 varied
between 0.05-10.0 μM, and the total volume of all additions was 42 μL (2%). After each addition of
Tel22, the cuvette was equilibrated for 10 min and the data was collected with the following parameters:
scan range of 380–630 nm, wavelength offset of 0 nm, increment of 1.0 nm, averaging time of 0.5 sec,
number of scans 3 (averaged), and 1.5 nm slits for both excitation and emission.
3.3.2. Fluorescent Titrations
Fluorescence titrations were performed on a Photon Technology International QuantaMaster
40 spectrofluorimeter. A 2.0 mL solution of porphyrin in a 1 cm black quartz cuvette was titrated with
annealed and equilibrated Tel22 solution at 20 ◦C. The concentration of TCPPSpm4 was 0.3 μM, and
the concentration of ZnTCPPSpm4 was ~0.5 μM. Tel22 was added from three different stocks with
increasing concentration: stock 1 was 3–4 μM, stock 2 was 95–150 μM, and stock 3 was 500–850 μM.
Total volume of addition was ~60 μL (3%). After each addition of Tel22, the cuvette was equilibrated
for at least two minutes and the scan was collected with the following parameters: excitation at 420 nm
(at the isosbestic point for TCPPSpm4), emission range of 575–750 nm, increment of 1.0 nm, averaging
time of 0.5 sec, one scan, and 3 nm slits both for excitation and emission.
3.4. Circular Dichroism (CD) Spectroscopy
CD scans and melting experiments were performed on an Aviv 410 spectropolarimeter equipped
with a Peltier heating unit (error of ± 0.3 ◦C) in 1 cm quartz cuvettes. The solution of 10–15 μM
Tel22 was annealed and equilibrated with 2 eq. of porphyrins and CD scans were collected with the
following parameters: 220 to 330 nm spectral width, 1 nm bandwith, 1 sec averaging time, 25 ◦C, and
3–5 scans (averaged). CD melting was performed on the same samples with the following parameters:
294 nm wavelength, 15–90 ◦C temperature range, 30 sec equilibration time, and 10 sec averaging time.
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CD scans were collected before and after the melt to check if the melting process is reversible. CD data
were analyzed as described in our earlier work [19,42].
Two sets of CD titrations were performed. First, 7–15 μM Tel22 was titrated with up to 4 eq.
of 0.44 mM TCPPSpm4 or 5.75 mM ZnTCPPSpm4 in 1 eq. increments. After each addition of the
porphyrin, the sample was equilibrated for 12 min after which CD scans were collected in 220–330 nm
region. Secondly, to detect induced CD signal (iCD) 2–6 μM porphyrin solution was titrated with small
increments of 100–200 μM Tel22. Samples were equilibrated for 10 min and CD spectra were collected
in the 375–480 nm region using 5–10 scans to obtain good signal-to-noise ratio.
3.5. Fluorescence Resonance Energy Transfer (FRET) Assays
FRET studies were conducted according to the published protocol [81]. A solution of 0.2 μM F21D
was incubated in the presence of 0–8 eq. of TCPPSpm4 or 0–20 eq. of ZnTCPPSpm4 and melting curves
were collected. FRET competition experiments were performed using 0.2 μM F21D in the presence
of fixed amounts of TCPPSpm4 (0.75 μM, 3.7 eq.) or ZnTCPPSpm4 (2.2 μM, 11 eq.) and increasing
amounts of CT DNA (up to 96 μM, 480 eq.), and analyzed as described previously [42].
4. Conclusions
There is a great need to develop ligands capable of binding to and regulating the stability of GQs
strongly and selectively. In this work, we characterized interactions of novel spermine-derivatized
porphyrins, TCPPSpm4 and ZnTCPPSpm4, with human telomeric DNA, Tel22. Both porphyrins bind
tightly to the GQ with Ka of (5–14) × 106 M−1 and provide strong stabilization, with the selectivity
ratio of 200–300 over dsDNA. Interestingly, we observe a high binding stoichiometry, which may
indicate multiple binding modes, the most prominent of which are end-stacking and DNA-assisted
self-association of porphyrins. In addition, the spermine arms of the porphyrins likely act as four
tentacles reaching into groves and stabilizing the GQ. The mild selectivity for GQ over dsDNA is likely
due to strong electrostatic interactions between the polycationic ligand and negatively charged DNA
backbone. Consistent with the prior work, addition of Zn(II) to the porphyrin core did not improve
selectivity, in spite of the presence of fifth axial water ligand, but increased Ka three-fold.
Overall, our findings demonstrate that spermine group derivatization is a valid strategy in the
design of novel GQ binders, especially given the fact that polyamines are taken up extensively by
cancer cells [67,68], and thus, could be used for selective cancer targeting. Future work will focus on
optimizing these porphyrins by decreasing their charge (limiting the number of spermine arms to 1–3)
and adding functional groups known to improve GQ selectivity. Biological studies of the new ligands
should also be a priority.
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Abbreviations
GQ Guanine Quadruplex
FRET Fluorescence Resonance Energy Transfer
CD Circular Dichroism
iCD Induced Circular Dichroism
TCPPSpm4 meso-tetrakis-(4-carboxysperminephenyl)porphyrin
ZnTCPPSpm4 Zn(II) meso-tetrakis-(4-carboxysperminephenyl)porphyrin
CT DNA Calf Thymus DNA
F21D 5′-6-FAM-GGG(TTAGGG)3-Dabcyl-3′
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Abstract: We have reported the propensity of a DNA sequence containing CCG repeats to form
a stable i-motif tetraplex structure in the absence of ligands. Here we show that an i-motif DNA
sequence may transition to a base-extruded duplex structure with a GGCC tetranucleotide tract when
bound to the (CoII)-mediated dimer of chromomycin A3, CoII(Chro)2. Biophysical experiments reveal
that CCG trinucleotide repeats provide favorable binding sites for CoII(Chro)2. In addition, water
hydration and divalent metal ion (CoII) interactions also play a crucial role in the stabilization of CCG
trinucleotide repeats (TNRs). Our data furnish useful structural information for the design of novel
therapeutic strategies to treat neurological diseases caused by repeat expansions.
Keywords: i-motif; CCG repeats; trinucleotide repeat DNA; chromomycin A3; neurological disease;
X-ray crystallography; nucleotide flip-out; DNA deformation
1. Introduction
The formation of expanded repeat sequences has long been known to correlate with the
etiology of many human diseases [1–3]. Tandem repeats can form unusual DNA structures,
resulting in consecutive GpC sites that are flanked by mismatched G:G or C:C base pairs in the
X chromosome [2,4,5]. Fragile X syndrome (FXS) is a genetic disorder caused by an expansion
of CGG/CCG tandem repeats in the Fragile X Mental Retardation 1 gene (FMR1) on the X
chromosome [6,7]. The repeats in FMR1 result in a defective protein that has been associated with
symptoms of FXS. Recently, our studies have suggested that the expansion of (CCG)n trinucleotide
repeats (TNRs) may be attributed to the slippage of DNA strands along the hairpin structures, forming
a four-stranded helical structure that is stabilized by intertwining i-motifs during DNA replication [8].
Small molecules that specifically bind to TNR DNA conformations could have applications as
diagnostic tools as well as therapeutic agents against these genetic diseases. For example, naphthyridine
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derivatives can inhibit DNA polymerases during replication because they can selectively recognize and
stabilize the CNG repeat hairpin structures formed by a single-strand DNA expansion [9]. Moreover,
several well-known DNA-binding drugs including actinomycin D, doxorubicin and mitomycin C
have been demonstrated to prevent the amplification of abnormal CNG trinucleotide repeats [10–12].
Chromomycin A3 (Chro), produced by some strains of Streptomyces griseus, is an anthraquinone
glycoside antibiotic belonging to the aureolic acid family [13]. Chro contains di- and trisaccharide
components linked to a β-ketophenol chromophore (anthracene ring) via O-glycosidic bonds at
position 2 and 6, respectively. Chro can bind to divalent metal ions and form a dimer, (Chro)2, that has
a unique fluorescent emission under different environmental conditions [14]. Previously, NiII(Chro)2
has been shown to bind specifically to CCG TNRs via a “forced” induced-fit mechanism [15]. Upon
binding to TNRs, NiII(Chro)2 exhibits a unique fluorescence signature which can potentially be used
to identify fragile X syndrome in clinical specimens.
However, previous studies utilized different DNA sequences, prompting the question of whether
chromomycin compounds are capable of “transforming” an i-motif sequence to a base-extruded
sequence. The identity of the metal ion might also be significant; e.g., Ni may or may not be important
for binding. In the presence of divalent cobalt ions, Chro can also form a metal-coordinated dimer
CoII(Chro)2, which binds selectively to GpC sequences in the minor groove of DNA. In the current
study, experiments were conducted to gain a better understanding of the effects of CoII(Chro)2 on the
i-motif structure of CCG TNRs. The crystal structure of the dT(CCG)3A sequence has been solved in
the presence and absence of the cobalt-containing Chro dimer. These studies revealed that the CCG
repeats can fold into a hairpin structure with tetraplex i-motif formation. CoII(Chro)2 can alter hairpin
formation of CCG repeat DNA and is responsible for the formation of a double-helical conformation
of CCG repeat DNA with dual cytosine flipping. The results also revealed that water-mediated
interactions and divalent cobalt ions are essential to maintain the conformational integrity and stability
of the Chro-DNA complex.
2. Results
2.1. A Non-Canonical DNA Structure of the dT(CCG)3A Sequence Contains an i-Motif Tetraplex Core
The dT(CCG)3A sequence in the absence of CoII(Chro)2 was crystallized in a slightly acidic
environment (pH 6.0) to yield a high resolution structure of 1.71 Å. The initial phase for the dT(CCG)3A
was solved using the previously reported coordinates of PDB ID: 4PZQ. All atoms present in the DNA
molecule were included in the refined structure and exhibited clear electron density, as shown in
the Supplementary Materials Figure S1A. The crystal structure revealed that each asymmetric unit
contained a single-strand dT(CCG)3A molecule, which could form a CCG loop by folding back within
the central CCG unit to generate a hairpin-like structure (Figure 1A,B). Two symmetrical dT(CCG)3A
hairpins joined together by hydrogen bonds to form a tetraplex structure with an i-motif core, which
includes four intercalated C:C+ base pairs flanked by two G:G homopurine base pairs. Moreover,
several stacking interactions were observed in the two symmetrical dT(CCG)3A hairpins, which
were important for maintenance of the i-motif conformation. These stacking interactions included
a 5′ cytosine residue (C5), which protruded into the centre of the i-motif core to form a stacking
interaction with G4 of the other strand. Two flipped-out nucleotides (C6 and G7) in each of the central
CCG loops stacked together with the 5′-end T1 base, which was tilted out into the wide groove. The 3′
ends of two CGA oligonucleotides were aligned in parallel, resulting in C:C+, G:G+ and A:A+ base
pairs forming a right-handed duplex stem. Along with overwound twist angles at the G4–C3 and
C9–G10 steps, CGA oligonucleotides formed two symmetrical hairpins that were tightly twisted in a
clockwise direction to produce a right-handed tetrahelix.
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2.2. Stabilization of the i-Motif Tetraplex by Water Hydration
In total, fifteen bridging water molecules were identified as mediating the interactions between the
two hairpin structures of dT(CCG)3A (Figure 1C,D). Six water molecules (W102, W106, W109, W127,
W128, and W133) mediated the DNA-DNA inter-strand interactions, while ten water molecules (W101,
W110, W112, W113, W117, W118, W123, W130, W132 and W133) mediated the DNA-DNA intra-strand
interactions. Interestingly, W133 was found to mediate both inter- and intra-strand interactions. W110,
W113, and W117 stabilized the central CCG loop structure. Two flipped-out C5 bases in opposite
dT(CCG)3A strands were linked by W128 located at the top of the structure. W102, W109 and W127
water molecules mediated the interactions between the cytosine residues (C2 and C8) at the i-motif
core. W106 linked the pyrimidine base C3 and the purine base G4 by bridging the N2 of G4 and the O2
of C3 in the opposite chain. Moreover, W133 played a key role in stabilizing the structure by mediating
the inter-strand G10-A11 interaction as well as inter-strand C9-G10 interaction of the dT(CCG)3A
hairpin structure. Analysis of the high-resolution crystal structure of the i-motif tetraplex revealed
that water was positioned so as to hold and stabilize the dimeric hairpins via hydrogen bonds. A list
of intra- and inter-strand water-mediated interactions with their respective distances between the
atoms in the two symmetrical dT(CCG)3A hairpins is provided in Table S2. Interestingly, the structure
reported here did not involve metal ions as reported in the previous structure [8], instead relying
exclusively on water-mediated interactions to stabilize the i-motif.
 
Figure 1. The structural features of dT(CCG)3A i-motifs: (A) Schematic diagram of the crystal structure
of two symmetrical dT(CCG)3A strands that fold into a tetraplex i-motif as shown on the left. Guanine
bases are colored in green, adenine in red, thymine in blue, and cytosine in yellow. (B) Representation
of the dT(CCG)3A final refined structure viewed from the narrow-groove (middle) and wide-groove
(right) directions. (C) Inter-strand water cluster stabilizing the single-stranded hairpin structure.
(D) View of the water cluster formed between two hairpins of dT(CCG)3A from the narrow groove.
Each DNA strand is colored magenta or cyan. 2Fo-Fc electron density map of the coordinated waters
(blue spheres) in the refined structure is contoured at 1.0 σ, while the waters coordinating from the
other asymmetric unit are shown as slate-coloured spheres. The hydrogen bonds are represented by
dashed lines within the distance of 3.5 Å.
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2.3. CoII(Chro)2 Complex Induces Conformational Changes in the d[T(CCG)3A]2 DNA Duplex
Chro bound to cobalt divalent cations to form a [CoII(Chro)2] dimer (Figure 2A). To understand
the structure of the dT(CCG)3A sequence in the presence of dimer, CoII(Chro)2 bound to the DNA
sequence was crystallized in a similar manner to that described for the formation of the dT(CCG)3A
i-motif crystals. The electron density map with a resolution of 1.87 Å revealed that all atoms in the
refinement structure had a clear electron density, except for two cytosines (C2 and C13), which were
extruded from the structure due to poor mapping and had to be modelled with an energy minimization
module using Accelrys Discovery Studio Client (v2.5.0.9164) (Figure S1C) [16]. The extruded cytosines
thus form an e-motif structure which might stabilize the packing of the complex within the crystal
lattice. The presence of such structures has been reported previously [17–19]. Analysis of the crystal
structures revealed that CoII(Chro)2 altered the formation of the i-motif tetraplex, which was composed
of two hairpin-like structures. CoII(Chro)2 bound to the pseudo-palindromic duplex DNA sequence
in the minor groove, resulting in the formation of a CoII(Chro)2-d[T(CCG)3A]2 complex (Figure 2B).
The binding resulted in deformation of the DNA resembling the NiII(Chro)2 dimer compounds.
A central d(GGCC) motif was formed due to the extrusion of four cytosines (C5, C6, C16, and C17)
upon binding to a Chro dimer. Unlike the i-motif adopted by dT(CCG)3A dimeric hairpins, the guanine
base of the second CCG unit of each DNA strand was not flipped out, resulting in the re-formation
of a GGCC tetranucleotide tract that provided the flexibility in the DNA to better accommodate
CoII(Chro)2. The four projected cytosines (C5, C6, C16, and C17) interacted with the disaccharide B
ring of (Chro)2 so as to enhance the stability of the extruded residues via hydrogen bonds and van der
Waals forces (Figure 2C). We suppose that the observed conformation for the DNA within the complex
is effectively induced by CoII(Chro)2 binding. Although we cannot exclude the possibility that both the
i-motif and duplex structure co-exist in solution, and CoII(Chro)2 may “choose” the duplex structure
through conformational selection, we consider the possibility to be low for the following reasons:
(1) the i-motif has been shown to be more stable than its duplex counterpart [20] and should be the
favoured conformation, and (2) circular dichroism studies have also shown that the CCG repeats adopt
spectra indicative of the i-motif conformation in solution [21,22].
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Figure 2. Crystal structure of the CoII(Chro)2-d[T(CCG)3A]2 complex. (A) Chemical structure of the
CoII(Chro)2 dimer. (B) Schematic diagram of the CoII(Chro)2-d[T(CCG)3A]2 complex shown on the
left. The cobalt(II) ions and the CoII(Chro)2 complex are drawn in salmon and pink. The refined
structure of the CoII(Chro)2-d[T(CCG)3A]2 complex viewed from the major groove is shown on the
right. The CoII(Chro)2 complex binds to the central G4-C20, G7-C19, C8-G18 and C9-G15 base pairs of
the d[T(CCG)3A]2 DNA structure accompanied by extrusion of four cytosine bases. (C) The extruded
cytosine residues stabilized by the disaccharide B ring of (Chro)2 via hydrogen bonds are shown at
sides with hydrogen bonds indicated by dashed lines. In the middle of the complex, stabilized by van
der Waals forces, is represented with the disaccharide B ring and d[T(CCG)3A]2 duplex viewed from
the minor-groove direction (sphere and solvent-accessible surface respectively).
2.4. Stabilization of the CoII(Chro)2-d[T(CCG)3A]2 Complex by Interacting with Cobalt(II) Ions and
Water Hydration
There were three cobalt ions (Co1, Co2, and Co3, Figure 2B) present in the
CoII(Chro)2-d[T(CCG)3A]2 complex. The Co1 ion formed an octahedral coordination with
two oxygen atoms, O1 and O9, of each chromophore moiety and two oxygen atoms of water in
the centre of the (Chro)2 complex (Figure 3A). The two water oxygen atoms were also involved in
the formation of a hydrogen bond network between the cytosine base of the GGCC tetranucleotide
tract and the chromophore of the (Chro)2 complex. In the major groove, the Co2 and Co3 ions
interacted with N7 of guanine G7 and G18, also forming an octahedral coordination with guanine
and five water molecules (Figure 3B). Water molecules were further involved in the interactions
between the G7 and G4 bases and the G18 and G15 bases. Water bound to the GpG steps of the
tetranucleotide tract, which was formed by extruding two cytosine bases of each DNA strand
(Figure 3C). Previous studies have shown that water molecules commonly play a profound role in
groove binding [23,24]. In the CoII(Chro)2-d[T(CCG)3A]2 complex structure, a total of four water
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molecules were identified as being directly involved in the interaction between CoII(Chro)2 and the
CCG TNRs (Figure 3C). These four water molecules (W15, W19, W29, and W36) stabilized the extruded
cytosine residues and the last guanine in the complex via specific water-mediated interactions with
(Chro)2. W15 and W19 bridged the interactions between the N4 amine on the extruded cytosines and
the O3 oxygen atoms of the disaccharide B ring. W29 and W36 formed water-mediated hydrogen
bonds with the phosphate oxygen atom of the last guanine (G10 and G21) and the O1 oxygen atoms
of the trisaccharide C ring. These interactions mediated by water molecules could also be found in
the NiII(Chro)2-d[TT(CCG)3AA]2 complex structure, indicating that they were indispensable for
recognition of the (Chro)2 ligand by the CCG DNA repeat as well as the stability of the complex.
Figure 3. Coordination of cobalt ions and water mediate interactions in the CoII(Chro)2-d[T(CCG)3A]2
complex structure. (A) Close-up view from the major groove of the CoII(Chro)2-d[T(CCG)3A]2 complex
representing the specific interactions between CoII(Chro)2 and central GGCC steps. The octahedral
coordination of Co1 is also shown on the left. The cobalt ion and two water molecules that mediate
Chro and DNA interactions are represented as salmon and blue spheres, respectively. Coordination
and hydrogen bonds are shown by dashed lines. (B) Close-up view of the CoII(Chro)2-d[T(CCG)3A]2
structure showing the octahedral coordination of Co2 and Co3 ions interacting with the unpaired N7
[G7] and N7 [G18] bases, respectively, and the coordinated water molecules also involved in mediating
the cobalt(II) ions and G4 (G15) base interactions. (C) The bridging water molecules mediate the
interaction between the CoII(Chro) and DNA viewed from the minor groove. The 2Fo-Fc electron
density map is contoured at a 1.0 σ level.
2.5. The Cobalt–Chro Complex Specifically Recognizes the Hairpin Structure of CCG TNRs
Surface plasmon resonance (SPR) was employed to analyse the binding affinity of CoII(Chro)2 to
d(CCG)n. The results revealed that the interactions of CoII(Chro)2 with d(CCG)3 or d(CCG)4 resulted
in a high resonance unit (RU) (Figure 4A), which is indicative of strong binding. However, CoII(Chro)2
failed to bind to d(CCG)2, resulting in a low RU (Figure S2). The binding rate constant (ka) and the
dissociation rate constant (kd) were calculated according to the kinetic 1:1 Langmuir binding model,
and the binding constant (Ka) was calculated from the values of ka and kd respectively (Table 1).
We found that the binding affinity of CoII(Chro)2 for DNA could be enhanced by increasing the
number of CCG repeat units. To determine the selectivity and stabilization effects of CoII(Chro)2
on various TNR DNA sequences, the melting temperature differences (ΔTm) of a duplex DNA were
measured. Various d(CXG)n repeats, where X could be any base and n was the repeat number, were
synthesized and used for binding assays with CoII(Chro)2 at a ratio of 1:4. The results indicated
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that the binding of CoII(Chro)2 to d(CXG)n increases the overall stability of d(CXG)n compared to
controls. The type of trinucleotide repeat also considerably impacted ΔTm (Figure 4B). The binding
of CoII(Chro)2 to d(CAG)3or4 or d(CTG)3or4 resulted in a low ΔTm, indicative of a poor stabilization
effect. By contrast, binding CoII(Chro)2 to d(CCG)3or4 or d(CGG)3or4 resulted in high ΔTm values.
It appears that CoII(Chro)2 binds preferentially to d(CCG)3or4 duplexes compared to other d(CXG)n
repeats, clearly indicating the selective ligand binding.
Figure 4. Binding affinity and stabilizing effects of the CoII(Chro)2 complex on various d(CXG)n
trinucleotide repeats, where X could be any base and n is the repeat number, as shown in the schematic
diagram. (A) Surface plasmon resonance (SPR) sensorgrams representing the binding of the CoII(Chro)2
complex to the immobilized 5′ biotin-labelled hairpin DNAs (CCG2, CCG3, and CCG4). The reactions
were carried out in 50 mM sodium cacodylate buffer (pH 7.3) containing 50 mM NaCl. The resonance
unit (RU) is defined as 1 RU = 1 pg/mm2. (B) Effects of CoII(Chro)2 on the Tm values of various hairpin
DNA fragments measured in 50 mM sodium cacodylate buffer (pH 7.3) containing 50 mM NaCl, with
DNA and CoII(Chro)2 at a 1:4 molar ratio. ΔTm values were obtained by subtracting the Tm value in
the presence of the ligand.
Table 1. Binding parameters for CoII(Chro)2 complexes and various (CCG)n trinucleotide repeats.
Drugs DNA Forms ka (M−1s−1) kd (s−1) Ka (M−1)
CoII(Chro)2
CCG2 null a null a null a
CCG3 4.19 × 103 4.54 × 10−2 9.12 × 104
CCG4 8.15 × 103 5.68 × 10−2 1.43 × 105
a Undetermined.
3. Discussion
Fragile X syndrome (FXS) is a genetic disorder caused by the expansion of CGG/CCG tandem
repeats in the Fragile X Mental Retardation 1 gene (FMR1) on the X chromosome [6,25]. The CGG/CCG
tandem repeats are scattered along the X chromosome, with a high percentage around FMR1
(Figure 5A). Examination of the coding and noncoding sequences of FMR1 revealed the presence of
two CGG/CCG tandem repeats with 9 or 10 copies in the 5′ untranslated region (UTR) (Figure 5B).
No tandem repeats were found in the coding region. The expansion of repeats in FMR1 results in a
defective protein that is known to be associated with the symptoms of FXS [26]. Previous studies have
shown that under physiological conditions, both the G-rich and C-rich single-stranded d(CGG)·d(CCG)
repeats are able to form secondary structures and cause unusual expansions [8,27,28]. The propensity
to form the secondary structure is more pronounced for d(CCG)n than it is for d(CGG)n repeats [29].
This observation suggests that the d(CCG)n strand is more likely to form a hairpin or slippage structure
and exhibit an asymmetric strand expansion during DNA replication. In addition to hairpin structures,
CCG repeats have been reported to adopt a tetraplex structure based on two parallel-oriented hairpins
that are held together by hemiprotonated intermolecular C:C+ pairs [30].
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Figure 5. CGG/CCG tandem repeats on the FMR1 gene and DNA expansion. (A) The distribution of
the CGG/CCG tandem repeats with more than five on chromosome X and the location of the FMR1
gene (the length of chromosome X scaled to 1). There are several CGG/CCG tandem repeats around
the locations of the FMR1 gene in the normal human genome. (B) The gene structure for human FMR1.
There are 2 CGG/CCG tandem repeats with 9 and 10 copies, respectively, found on the 5′ UTR of
FMR1 in the normal human genome. (C) A proposed model for the biological consequences that occur
following binding of the CoII(Chro)2 complex to the slipped CCG repeats at the nascent lagging strand
during DNA replication. In the first cycle of DNA replication, if slipped CCG repeats fold into an
unstable tetraplex i-motif structure on the nascent strand, it would lead to a subsequent expansion
when using the nascent lagging strand as a template in the next cycle of replication. In contrast, when
the CoII(Chro)2 complex recognizes the slipped CCG repeats, the resulting DNA conformational change
may help to stabilize the slipped DNA and lead to the newly generated DNA duplex, with no length
changes in the next cycle of DNA replication.
Recently, researchers have focused on designing novel compounds that can bind to expanded CNG
repeat DNA in a sequence-specific manner. The propensity of small molecules to bind to the substrate
with expanded CNG repeats can inhibit abnormal DNA replication as well as transcription [31–33].
In the present study, we have found that two d(T(CCG)3A)2 sequences can form hairpin structures that
stack together in parallel to form a tetraplex, with a core i-motif surrounded by two G:G homo-base
pairs. A similar structure has been reported previously in which it was shown that divalent cobalt ions
are crucial for maintaining the i-motif structure [8]. However, the i-motifs reported in this work are
exclusively stabilized by water molecules. Many of the water molecules occupy similar positions to the
cobalt ions observed in the previous work. Furthermore, we observed here that several interactions,
including stacking forces, stabilize the extruded residues in the i-motif tetraplex. On the other hand,
the structure of two d(T(CCG)3A)2 sequences in the presence of the CoII(Chro)2 complex clearly shows
a double-stranded helical conformation, which implies a crucial role of CoII(Chro)2 in binding to CCG.
Evidently, the binding of CoII(Chro)2 to the d(T(CCG)3A)2 causes the extrusion of four cytosines in
the repeat motif. It is conspicuous that the chromomycin A3 restores the double-stranded helical
conformation by preventing the repeat DNA motif from forming i-motif structures (Figure S3).
Previously, the NiII(Chro)2 complex has been shown to bind specifically to CCG TNRs via a
“forced” induced-fit mechanism [15]. The CoII(Chro)2 complex structure with DNA shows significant
similarity in overall structure with that of the NiII(Chro)2 complex. However, the stability of these
structures in terms of melting temperature is quite different, which clearly implies the occurrence of
local differences. Analysis of the central GpGpCpC segment surrounding the Chro dimer binding
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site revealed considerable differences between the helical parameters of the NiII and CoII complexes.
Although the unwinding parameters are similar for both structures, prominent variations in the
DNA roll and rise parameters were observed for the central GpC step (Figure S4) [34]. Based on
detailed analysis of the structures, we propose a model to explain how tandem repeats could lead
to sequence expansion during DNA replication (Figure 5C). The binding of the CoII(Chro)2 complex
to the slipped CCG repeats between the nascent and lagging strands during DNA replication could
result in two different situations. If the CCG repeats fold into a tetraplex i-motif structure in the
absence of the CoII(Chro)2 complex during the first DNA replication cycle, DNA polymerase would
use the nascent lagging strand as a template for DNA synthesis, leading to sequence expansion during
the second replication cycle. On the other hand, recognition and binding of CoII(Chro)2 complex to
the slipped CCG repeats would change the DNA conformation, which might slow down the rate of
DNA expansion in the newly generated DNA duplex. After DNA unwinding during replication or
transcription, the two strands become separated. Each single strand possesses CGG and CCG repeats,
and the C-rich ends may again form i-motif structures consisting of double hairpins. This provides
CoII(Chro)2 with binding sites on both single-strand DNA, thus further reducing the rate of DNA
slippage and consequent DNA expansion. The CCG-CoII(Chro)2 complex, therefore, could prevent the
formation of i-motifs and force the DNA to return to a double helical form.
Metal ions often play an important role in either stabilizing DNA structures or stabilizing
crystals [35,36]. Many studies have provided detailed information about the interactions of divalent
metal ions stabilizing DNA duplexes [37–40]. Previous work has also highlighted the role of Co(II)
metal ions in stabilizing drug-DNA complexes [41]. The divalent cations form a tetrahedral or
octahedral coordination complexes with the drug chromophore. It has also been shown that the N7
atom of the purine or N3 of pyrimidine residues as well as exocyclic oxygen atoms and the phosphate
O atoms are the preferential sites of metal binding to stabilize the DNA structures in the complex.
Furthermore, other divalent metal ions, such as Cu(II) and Hg(II), are also known to alter DNA
conformation [42,43]. In the current study, we found that two Co(II) ions can interact with the DNA
backbone to stabilize the overall structure. The two metal ions formed coordination bonds with the
G7-N7/G18-N7 and five water molecules in a six-coordinate octahedral geometry. The coordinated
water molecules were also involved in mediating the interactions between cobalt(II) ions and the G4
(G15) base. Hydrogen bonding between the water molecules and the oxygen atoms of the phosphate
backbone can also stabilize the DNA. Based on these interactions, it can be concluded that the inclusion
of Co(II) is crucial for maintaining the CoII(Chro)2-d(T(CCG)3A)2 complex structure. Since CoII(Chro)2
has been shown to be less toxic to cells compared to the more potent NiII(Chro)2, it may represent
a viable alternative for chromomycin-based drug appropriation or development. In addition, the
DNA-CoII(Chro)2 complex has been shown to display extreme resistance to polyamine-mediated
extraction of the divalent cation, making it an attractive ligand for exploring its therapeutic potential
against CCG-repeat diseases. The potential of other types of metal complexes, such as ruthenium-based
ligands, opens up the possibility of studying the interaction of the complexes with unusual DNA
structures including i-motifs, triplexes and quadruplexes in future [44].
With this work, we complete our overview of chromomycin-based ligands containing a transition
metal ion and their binding effects on repetitive DNA [15,33,45,46]. Our results provide additional
clues to piece together the complete flow of how CCG DNA repeat amplification may arise, and
provide a structural basis to speed the development and screening of specific drugs to treat diseases
caused by the abnormal expansion of repeat DNA motifs.
4. Materials and Methods
4.1. Chemicals and Oligonucleotides
All chemicals used were of reagent grade, obtained from Sigma Chemical Co. (St. Louis, MO,
USA). Deionised water from a Milli-Q system was used for all experimental procedures. Absorbance
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measurements to determine oligonucleotide concentrations were performed in quartz cuvettes using a
Hitachi U-2000 spectrophotometer. The oligonucleotide concentrations were determined by Beer’s
law (A = ε.b.c; A: optical density at 260 nm; ε: extinction coefficient; b: cell path length, 1 cm; and c:
DNA concentration in M). Synthetic oligodeoxynucleotides were purified by gel electrophoresis.
The oligomer extinction coefficients were calculated on the basis of tabulated values for monomer and
dimer extinction coefficients with reasonable assumptions as specified in ref. [47].
4.2. Melting Temperature Measurements
Tm values for the i-motif tetraplex sequence and the hairpin DNAs complexed with
CoII(Chro)2 were determined as previously described using a JASCO UV-VIS spectrophotometer
to monitor the sample absorbance (O.D.) at 260 nm and 295 nm [14,48]. The hairpin DNA,
d(TT(CXG)3-4AATGTTT(CXG)3-4AA, (X = A, T, C, or G), purified from polyacrylamide gel, was the
substrate for the Tm experiments (the hairpin loop is underlined). The experiments were performed
by increasing the temperature from 5 to 95 ◦C at a rate of 0.5 ◦C/min and recording the temperature
every 30 s. Tm values (temperature corresponding to the dissociation of half of the DNA structures)
were determined from polynomial fitting of the observed curves. The first derivative of the absorbance
with respect to the temperature (dA/dT) of the melting curve was computed and used to determine
the Tm value.
4.3. SPR Analysis
The affinity, association and dissociation between the drug and the DNA duplexes were measured
using a BIAcore 3000 A surface plasmon resonance (SPR) instrument (Pharmacia, Uppsala, Sweden)
equipped with a sensor chip SA5 from Pharmacia that monitored changes in the refractive index
at the surface of the sensor chip. These changes were generally assumed to be proportional
to the mass of the molecules bound to the chip and are recorded in resonance units (RU) [49].
The 5′-biotin-labelled hairpin DNA, biotin-d(TT(CCG)2-4AATGTTT(CCG)2-4AA), purified from
polyacrylamide gel electrophoresis, was used in the SPR experiments (the hairpin loop is underlined).
To control the amount of DNA bound to the chip surface, the biotinylated oligomer was manually
immobilized onto the surface of a streptavidin chip. Solutions of the metal-derived Chro complexes
buffered with 50 mM sodium cacodylate at pH 7.3 in 50 mM NaCl were used. Different concentrations
of the complexes were passed over the surface of the chip for 180 s at a flow rate of 10 μL min−1 to
reach equilibrium; one of the flow cells remained blank as a control. Blank buffer solution was then
passed over the chip to initiate the dissociation reaction, and this procedure was continued for 300 s
to complete the reaction. The surface was then recovered by washing it with 10 μL of a 10 mM HCl
solution. The sensorgrams for the interactions between the hairpin DNA duplex and the drug were
analysed using version 3 of the BIAcore evaluation software.
4.4. Crystallization of d(T(CCG)3A) and CoII(Chro)2-d[T(CCG)3A]2 Complex
Crystals yielding both the structures of the d(T(CCG)3A) i-motif and CoII(Chro)2-d[T(CCG)3A]2
complex were obtained in a similar fashion. Both were crystallized using the sitting drop
vapour diffusion method. The crystals of d(T(CCG)3A) were obtained from a solution of
1.0 mM single-stranded DNA, 50 mM sodium cacodylate (pH 6.0), 1 mM magnesium chloride,
3% 2-methylpentane-2,4-diol, and 0.5 mM cobalt(II) chloride. The solution for crystallization was
equilibrated against 500 μL of 30% MPD at 4 ◦C. Cylinder-shaped crystals of d(T(CCG)3A) appeared
after 4 weeks. Crystals of the CoII(Chro)2-d[T(CCG)3A]2 complex were grown by co-crystallizing
0.75 mM single-stranded DNA, 1.5 mM Chro, and 3 mM CoCl2, in 50 mM sodium cacodylate buffer
(pH 6.0), 1 mM MgCl2, 1 mM spermine and 1% MPD, equilibrated against 500 μL of 30% MPD. Because
Chro is yellow, the yellowish colour and the rod-shaped morphology of the crystals implied formation
of the d[(TT(CCG)3AA)]2-CoII(Chro)2 complex; these were harvested after 4 weeks.
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4.5. Data Collection, Processing, and Refinement of d(T(CCG)3A) and CoII(Chro)2-d[T(CCG)3A]2
Complex Structures
The diffraction data for the d(T(CCG)3A) crystal in space group P43212 with unit-cell parameters
a = b = 38.23, c = 54.23 Å, were collected at 110 K on an ADSC Q315r detector at beamline 13B1
of the National Synchrotron Radiation Research Center (Taiwan). The software package HKL2000
was used to index, integrate, and scale the X-ray diffraction data [50]. The reported resolution of
1.71 Å, at which the structure was refined, is based on the correlation coefficient (CC*) between the
data and the model (PDB ID: 4PZQ) using the PHENIX suite (v1.8.4-1496) [51]. The nucleotides in
d(T(CCG)3A) are numbered from T1 to A11 in each strand. The structure was refined using the Refmac5
program in the CCP4 suite [52]. The DNA force field parameters reported by Parkinson et al. were
used [53]. The diffraction data in space group P3212 with unit-cell parameters a = b = 46.4, c = 73.8 Å,
for the d[(T(CCG)3A)]2-CoII(Chro)2 complex crystal were collected using the same equipment at 100 K.
Fluorescence scanning revealed a strong peak at the CoII wavelength, consistent with the presence
of CoII ions in the structure. Multiple-wavelength anomalous diffraction (MAD) data were collected
from three wavelengths using cobalt as the anomalous scattering atom. The diffraction spots were
indexed, integrated and scaled using the HKL-2000 software package, followed by CoII substructure
localization using SHELX C/D/E. The resulting well-defined MAD electron density maps were used
to build initial models using the program Coot. These structures were refined using the PHENIX
program (v1.8.4-1496) using the high remote wavelength data for subsequent refinements. Most of the
atoms in the structure were well-resolved and readily assigned in the density map, revealing a clear
conformation of the DNA duplex in complex with CoII(Chro)2, except the uninterpretable region of
the bases at the 5′ end of the DNA. B-factor analysis also suggested that the bases at the 5′ end of DNA
were thermally less well ordered. Moreover, a well-defined MAD electron density map at a resolution
of 1.87 Å was used to build the initial models for d(T(CCG)3A) DNA alone. The force field of Chro
was generated using the atomic coordinates of a 0.89 Å resolution crystal structure of CoII(Chro)2.
The DNA nucleotide geometry parameters reported by Parkinson et al. were used. The full data
collection and refinement statistics are given in Table S1. Coordinates and experimental data can be
downloaded from www.wwpdb.org using the PDB IDs in Table S1.
4.6. Bioinformatics Analysis
The human genome sequence and the accompanying information pertaining to the gene structure
of human FMR1 were obtained from Ensembl version 91 (with genome assembly GRCh38.p10).
We developed in-house software to search the sequence pattern including not less than six CGG
tandem repeats against the chromosome X sequence. Statistical analysis was conducted using R
Statistical Software (version 3.5.1) (R Foundation for Statistical Computing, Vienna, Austria) [54].
The FMR1 gene structure was displayed using GSDS 2.0 [55].
5. Conclusions
In this report we have demonstrated the propensity of CCG repeats to undergo base pairing
between the hemiprotonated cytosine residues of one C-rich hairpin duplex and the cytosine residues
of a second hairpin duplex to form a stable i-motif tetraplex structure. The i-motif tetraplex was found
to be stabilized by water molecules. The formation of i-motif tetramers may lead to DNA expansion
during replication due to the presence of both matched and mismatched base pairs in the CCG repeat
region in hairpin or slipped structures. In addition, we found that specific binding of CoII(Chro)2 to
d(CCG)n sequences induced conformational changes of the CCG repeat DNA from i-motif to DNA
duplex with cytosine-cytosine flip out. The specificity of CoII(Chro)2 towards (CCG)n may be partly
due to the intrinsic instability and flexibility of C–C mismatches, sufficient to allow adoption of
the geometrically optimal conformation that causes cytosines to extrude out of the helix and form
the GGCC tetranucleotide patch. Extending the concept further, we hypothesize that TNR-binding
compounds may induce a variety of sequences to form specific cognate structural motif(s) representing
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a substantial step towards the development of new therapeutic or diagnostic agents to treat these
neurological diseases.
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Abstract: Two paramagnetic PdIII complexes of hematoporphyrin IX ((7,12-bis(1-hydroxyethyl)-
3,8,13,17-tetramethyl-21H-23H-porphyn-2,18-dipropionic acid), Hp), namely a dinuclear one
[PdIII2(Hp-3H)Cl3(H2O)5]·2PdCl2, Pd1 and a mononuclear metalloporphyrin type [PdIII(Hp-2H)
Cl(H2O)]·H2O, Pd2 have been synthesized reproducibly and isolated as neutral compounds at
different reaction conditions. Their structure and solution stability have been assayed by UV/Vis
and EPR spectroscopy. The compounds researched have shown in vitro cell growth inhibitory effects
at micromolar concentration against a panel of human tumor cell lines. A DNA fragmentation test
in the HL-60 cell line has indicated that Pd1 causes comparable proapoptotic effects with regard
to cisplatin but at substantially higher concentrations. Pd1 and cisplatin form intra-strand guanine
bis-adducts as the palladium complex is less capable of forming DNA adducts. This demonstrates
its cisplatin-dissimilar pharmacological profile. The test for efficient removal of DNA-adducts by
the NER synthesis after modification of pBS plasmids with either cisplatin or Pd1 has manifested
that the lesions induced by cisplatin are far better recognized and repaired compared those of Pd1.
The study on the recognition and binding of the HMGB-1 protein to cisplatin or Pd1 modified DNA
probes have shown that HMG proteins are less involved in the palladium agent cytotoxicity.
Keywords: palladium(III) complexes; hematoporphyrin IX; antiproliferative activity; DNA binding
and repair; HMGB-1 protein; apoptosis
1. Introduction
Cisplatin and the clinically accepted platinum drugs have a great importance for the
cancer treatment. They have been applied in most anticancer chemotherapeutic regimens [1–4].
Intensive studies in this area date back to the mid-sixties of the 20th century, with Rosenberg’s
remarkable discovery of the medicinal power of the inorganic coordination compound “nicknamed”
cisplatin [1,5–7]. Since then, cisplatin has revolutionized cancer treatment converting the formerly
fatal disease, largely curable [8]. Nowadays, cisplatin is still the most successful anticancer drug in the
world, and is widely used in the treatment of a multitude of different cancers. Still, regardless of the
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achievements of cisplatin and the related platinum-based drugs—carboplatin—a second generation,
and oxaliplatin—third generation, and those of regional use in specific countries, such as nedaplatin,
lobaplatin, and heptaplatin, their application is limited [9]. The restrictions are due to their major
drawbacks: effectiveness against a limited range of cancers and its intrinsic resistance, development of
acquired resistance [10,11], severe side-effects [12,13], and low solubility. Hence, the efforts in the field
of antitumor drugs design target introduction of new formulas possessing both a widened spectrum of
chemotherapy and an improved clinical profile [3,4,9,14]. Intensive research on drug development
processes during the past years shows that the invention of universal compounds active against many
cancer types is a task difficult to accomplish. The right way is to develop drugs effective against a small
group or a subgroup of cancers. Thus, the successful route leading to new efficient drugs inducing
a better tumor response in individual patients is to design a pharmacological agent targeting specific
abnormalities in particular cancer cells [4].
There are several approaches to develop new metal-based antitumor agents. Historically,
the first one follows the correspondence between anticancer activity and the molecular structure of
cisplatin [3,4,15]. Thus, a variety of cisplatin-similar platinum(II) complexes with different ligands have
been synthesized and tested. The numerous results achieved have led to a set of rules for constructing
a molecular structure that appeared to be required in order to manifest antitumor activity [7]. According
to the rules, the neutral platinum complex with square-planar geometry, containing two cis-am(m)ine
carrier ligands (capable of participating in a hydrogen bonding formation) and two cis-coordinated
leaving groups (Cl− ligands) possesses the necessary structural features for intravenous administration
into the blood stream. It is considered that the complex should remain largely unchanged during
circulation and after entering the cells a substitution of one or two more labile ligands occurs thereby
activating the complex. This requirement underlines the necessity to render the complex inactive
during the transport and determines that the ligand exchange rates should be compatible to the rates
of cell division processes [1,16]. The platinum(II) complexes whose structure follows these rules
represent the so-called classical platinum chemotherapeutics. Numerous investigations have been
conducted in order to determine the mechanism by which these drugs carry out their anticancer
action [17] and most results concerns cisplatin. In general, the main steps cover: cellular uptake
by passive diffusion [18] or active transport via the copper transporters CTR1 and CTR2 [19,20];
aquation followed by activation; DNA platination and cellular processing of Pt-DNA lesion leading to
apoptosis or to the cell survival. Nuclear DNA is considered the ultimate target of cisplatin and related
platinum therapeutics and their capability to form bifunctional DNA crosslinks causing the DNA
distortion. Thus, the platinum induced kink in the DNA molecules leads to a chain of events including
protein recognition and eventual apoptosis. Unfortunately, some of the platinum compounds can be
activated in biological milieu before reaching the tumor cell and they can also interact with nontarget
biomolecules. Furthermore, it is clear that DNA is the ultimate pharmacological target of the platinum
drugs, but the important issue here is to discern tumor cells from healthy cells. Now it is accepted
that the classical platinum compounds can enter in each cell, however the healthy cells and some
of the tumor cells can reverse the damage and remove the platinum compounds. Therefore, it is
clear that the compounds belonging to this group cannot offer any advantages over cisplatin. Indeed,
more than ten other cisplatin related derivatives are currently in clinical trials and the experimental
data show [21,22] that they have not overcome considerably many of the disadvantages arising from
this common structure. However, the achievement analysis in this field demonstrates that metal
coordination compounds can play an important part in anticancer treatment regimes.
Another route to create new metal-based anticancer agents is focused on the mechanism of their
antitumor action [23]. In this respect one could distinguish compounds capable of interacting in two
different mechanisms: compounds that cause DNA distortion, here including cisplatin- similar and
cisplatin dissimilar interactions [3,24–26] and compounds interacting with the key protein targets
(including enzymes) that are selective for the specific malignancy and/or that regulate apoptosis,
and/or that are responsible for cell invasion and metastasis [27,28]. The classical approach based
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on cell viability assay and characterization of the compounds that bind to DNA and adducts
formed has been applied for more than forty years and now this is the first stage for evaluation.
Nowadays, the drug design concepts are based on one side on the chemical nature of the compounds
and on the other side—on the cancer cells biochemistry. Thus, the new strategies for design and
synthesis result in the development of new classes of antitumor agents, the so called “classical
nonplatinum metal compounds” and “nonclassical metal compounds” [3] and thus several compounds
(e.g., NKP-1339 [29], NAMI-A [30], Satraplatin [31], etc.) are proposed that are on the “verge” of clinical
application. These strategies are consistent with requirements for: a comparatively soluble prodrug’s
form; existence of an inactivated form in the blood stream; selective cellular uptake; activation of the
drug form in the tumor cells; appropriate tumor cell damage.
Metal coordination compounds with their inherent properties can meet these requirements to
a great extent. Their specific three-dimensional structures combined with suitable electronic and
ligand exchange properties are attractive for the creation of a successful formula [3,4]. The transition
series metal complexes having variable oxidation states and coordination numbers, and the ability
to bind, of different strength, to a wide variety of donor functional groups are some of the most
tested compounds. A special attention is paid to the metals from second and third transition series.
They usually exchange their ligands slowly, on the same time scale as the cell division processes.
Their comparatively inert behavior keeps them as prodrugs, which have to be activated by ligand
substitution reaction in the cells. In general, from a chemical point of view, the successful drug
should be a well soluble compound with lipophilicity and acid-base properties determining a selective
uptake. The drug should be activated inside the tumor cells and attack the target molecules by ligand
substitution reactions. It is necessary to interact predominantly with target molecules and the formed
adducts should be stable enough in order to provoke proper cell death. It means that a key element
in the design processes is the control on the kinetics of ligand substitution reactions in vivo and
the thermodynamic stability of the initial, intermediate, and final complexes produced during the
antitumor action. In addition, the redox properties determined in terms of both metal and ligand are
of special interest. As a part of antitumor mechanism, the change of the metal oxidation state can
trigger ligand release and the participation of the ligands in in vivo redox reactions could produce
reactive oxygen species. Also, the possibility to achieve light-triggered activation of an excited-state of
the metal complexes in tumor cells instead of their ground-state gives additional advantages in the
drugs design. All these considerations give the reason to conclude that a properly selected metal ion
with regard to its nature, oxidation state, and coordination polyhedron with right ligands in the inner
coordination sphere can create a drug able to overcome some of cisplatin’s disadvantages.
Recently, a series of hematoporphyrin IX (7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H-23H-
porphyn-2,18-dipropionic acid, Hp) complexes [32–39] of platinum, palladium, and gold (Scheme 1)
have been tested as tumor growth inhibitors. Hematoporphyrin IX and its derivatives are well known
for their widespread application in the photodynamic therapy and diagnosis [40]. It is considered that,
due to their acid-base and hydrophobic properties, the porphyrins could preferably accumulate in the
neoplastic tissues [41–43]. In fact the selective uptake of porphyrins in malignant tissue cells is due to
complex mechanisms, the most important of them being the LDL-receptor mediated endocytosis of
porphyrin—lipoprotein complexes formed in the systemic circulation [40].
A new strategy for cytotoxic agents design with improved properties has been proposed in our
group, based on the capabilities of this ligand to stabilize unusual oxidation states of the metals. Thus,
three PtIII (d7) [32,33], two PdIII (d7) [34], and one AuII (d9) [35,36] complexes of Hp were obtained
and characterized. The metal ions in the complexes have distorted octahedral coordination. Because
of the metals’ electronic configuration, the complexes manifest paramagnetic behavior. Further they
show comparatively high cytotoxicity in in vitro tests against a panel of human cell lines [32–34,36].
Great efforts have been made in order to understand the effect of the ligand coordination to the
antitumor behavior of the complexes. The ligand Hp has a polydentate nature. Three different modes
of coordination have been established [37] studying its interaction with metal ions representatives of
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first [38,39], second [34], and third transition series [32,33,35,36]. Coordination via the four pyrrole
N-atoms in the porphyrin framework and forming of metalloporphyrin-type complexes is the most
widespread mode of binding, typical of all metal ions under investigation. Coordination via two
N-atoms of adjacent pyrrole rings to the metal ions in cis-position leads to the so called “sitting atop”
type complexes (SAT). Coordination via the side chains deprotonated propionic COO− groups, outside
the porphyrin macrocycle is a less common mode of coordination. The nitrogen donor atoms of the
imino (>N) and aza (=N-) groups of the pyrrole rings, as well as the outside COO− groups determine
the nature and the size of three different coordination modes. The metal ions choose a different mode
of coordination as a function of their nature and properties.
Scheme 1. Structures of the hematoporphyrin IX complexes of platinum(III), gold(II) and palladium(III).
Due to its intrinsic inertness, PtIII forms stable complexes with the three different modes of Hp
coordination (Scheme 1) in the proper reaction conditions [32]. All these complexes with distinct
coordination patterns exert concentration dependent antiproliferative activity against a spectrum of
cell lines representing some important types of neoplastic diseases in humans. They have also proven
to be far less cytotoxic against the human embryonal kidney cell line HEK-293T compared to cisplatin.
It has been discovered that the “sitting atop” complex Pt1, with PtN4 coordination plane formed
by two adjacent porphyrin pyrrole nitrogens and two NH3-molecules in cis-position as well as the
metalloporphyrin-type complex Pt2 possess higher potency compared to Pt3. In the latter, PtIII is
coordinated to the deprotonated propionic carboxylic groups from the side chains of hematoporphyrin
IX. The better solubility of Pt2 compared to Pt1 makes it preferable in research. Thus, its characteristics,
such as superior proapoptotic activity that strongly correlates with its cytotoxicity and significantly
higher degree of accumulation in tumor cells compared to the reference drug cisplatin, make it a reliable
representative of the group of the “metal-based drugs that break the rules” [4].
Another promising representative of this group of compounds is the octahedral gold(II) (d9)
complex of hematoporphyrin IX, Au1 [35] that is structurally similar to Pt2. The comparison of its
cytotoxicity to that of Pt2 manifests that the AuII complex exerts superior activity exactly against the
T-cell leukaemia SKW3. These data correlate well with the estimated specific inhibiting effect of gold
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species upon immune cells and T-cells [36]. Nevertheless, the compound exerts well-pronounced
proapoptotic properties against malignant cells and it is less cytotoxic than cisplatin for the human
kidney. Furthermore, this compound demonstrated significant intracellular accumulation presumably
mediated by formation of FCS-lipoprotein complexes and subsequent endocytosis.
Two relatively new members of this group compounds are the PdIII (d7) coordination compounds
of hematoporphyrin IX [34]. The dinuclear [PdIII2(Hp-3H)Cl3(H2O)5]·2PdCl2, Pd1 and mononuclear
[PdIII(Hp-2H)Cl(H2O)]·H2O, Pd2 have been obtained during the interaction of the ligand with
PdIICl42− in alkaline-aqueous medium. In the dinuclear complex, Pd1, one of the PdIII ions is
coordinated to the deprotanated COO− groups from the side chains of the porphyrin ligand and the
second PdIII ion—to two adjacent pyrrole N-atoms on the top of the porphyrin ring. The compound
is spontaneously obtained at a large metal excess from the reaction in alkaline-aqueous medium.
It is accepted that because of the greater kinetic lability of PdIII compared to PtIII both places for
coordination are occupied simultaneously and thus a dinuclear PdIII-Hp-PdIII system is formed.
The PdIII ion in the mononuclear complex, Pd2 is incorporated in the porphyrin core. The PdIII centers
in both complexes have a distorted octahedral coordination filled with additional donor species such
as Cl− and H2O.
As a member of the platinum group metals, palladium, with its coordination compounds, is also
extensively tested for antitumor activity [44–47]. Because of lanthanoid contraction, both metals
palladium and platinum in oxidation state +2 have close ionic radii. They adopt a square-planar
geometry and behave like soft acids, forming strong bonds with nitrogen and sulfur-containing
ligands [48]. While the equilibrium constants, characterizing the stability of their isostructural
complexes differ slightly (only about ten times higher for PtII complexes), their kinetic behavior
with respect of the ligand substitution is completely dissimilar as a consequence of the lower electron
density of PdII. The complexes of PdII simple analogues of PtII-antitumor drugs undergo aquation
and ligand exchange reaction 104 to 105 times more rapidly. The fast hydrolysis of the leaving groups
leads to the formation of very reactive PdII-aquated-species, unable to reach their pharmacological
targets as active compounds. It is accepted that the toxic side effects are a result of inactivation of
certain enzymes due to binding to the thiol groups of cysteine residues and obviously the much higher
reaction rates typical of PdII compounds are favorable for general toxicity.
In order to tune the kinetic behavior and thermodynamic stability of the new compounds
proposed as antitumor agents different approaches can be applied. Here, beside the construction of
special coordination polyhedra, the intermediate oxidation state +3 of palladium centers has been
applied as a factor of great importance. The less common oxidation state of palladium +3 provides
many advantages of its complexes, such as a controlled delay of the ligand substitution reactions
and reactivity, an octahedral geometry with axial ligands that could alter the redox potential and
lipophilicity. The promising antiproliferative activity in micromolar concentration range that has been
shown by the PdIII-Hp complexes [34] together with the remarkable cytotoxicity against the K-562
cells with more than 4 fold lower IC50 value compared to cisplatin, characteristic for the dinuclear
compound Pd1, is the basis for further detailed biological investigation on the mechanism of action of
these new proposed cisplatin-dissimilar agents.
2. Results
2.1. Synthesis and Characterization in Solution
The PdIII-complexes that undergo extensive biological screening have been obtained from the
interaction of the initial palladium(II) salt ([PdIICl42−]) and hematoporphyrin IX. The coordination
reaction proceeds in alkaline-aqueous medium on air. The ligand used for the syntheses is dissolved
in 5 × 10−2 M KOH solution. The initial acidity of the reaction system has been adjusted within the
range of pH values from 11.2 to 11.5 (by adding KOH). The reactions always start by spontaneous
increase of the reaction acidity (ΔpH = 3–4) within 3 to 4 h. The creation of paramagnetic complex
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species during the interaction has been followed by the EPR method. The EPR spectra were registered
of samples taken from the reaction systems and frozen. A very wide signal (ΔHpp ~250 G) with
g ~2.12 has been observed in the EPR spectrum of the 1:1 molar ratio reaction system during the first
few hours. Further, the interaction continues with appearance of two different signals of variable
intensities (Figure 1a): a narrow signal (ΔHpp = 7.2 G) with g = 2.000, typical for a radical formation
and a wide low-intensive signal (ΔHpp ~45 G) with g ~2.06 without a hyperfine structure. Two days
later, together with a radical’s singlet, an additional third signal was observed with increasing intensity
displaying a hyperfine structure. The final spectrum registered (Figure 1b) consists mainly of two
signals: a singlet with parameters proving the presence of a stable radical overlaying a signal of
two-component axial anisotropy and principal values of the g-tensor determined by the experiment
as g  = 2.037 and gII = 1.979. The parameters measured for the superhyperfine coupling tensor are
a  = 17.8 × 10−4 cm−1 and aII = 14.8 × 10−4 cm−1.
Figure 1. X-band EPR spectra of frozen solutions of the reaction system Pd:Hp = 1 (130 K): (a) a day
from the beginning of the reaction; (b) a week later (operating frequency 9.500 GHz).
The spectral changes in the electronic-absorption spectra during the interaction in alkaline-
aqueous medium refer to the bands of the free ligand spectrum as follows [49]: an intensive
band belonging to a transition S0 ⇒ S2 at 376 nm (B or Soret) and four Q-bands at 505, 540, 567,
and 621 nm from the transitions to nondegenerated orbitals of the first exited state S1, with intensities
IV > III > II > I, typical of etio-type porphyrins. Two separate stages during the interaction can be
distinguished. A slight hypsochromic shift of the Soret band has been observed in the beginning
followed by a decrease of its intensity, widening, and a batochromic shift by ~15 nm. During this
period of the reaction, the four Q-bands have been shifted batochromically. They have changed their
intensities as IV > III ~II > I and have reduced to three (~516, 558, and 620sh nm) several hours later
with intensities: III ~II > I. The UV/Vis spectra measured in the second stage of the interaction have
been characterized by the Soret band at 390 nm and two Q-bands at 520 and 559 nm; the long-wave
one being the more intensive. Regardless of the metal-to-ligand ratios, in the final spectrum of the
interaction, the Q-bands have always reduced to two.
The reaction has been directed to obtaining the particular PdIII-complexes as neutral compounds
at different metal-to-ligand ratios. The electronic absorption spectra of the reaction systems before the
isolation of the complexes are presented on Figure 2.
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Figure 2. Electronic absorption spectra of: (a) Hp; (b) reaction system Pd:Hp = 4 before isolating
complex Pd1; (c) reaction system 1:1 before isolating complex Pd2.
A dinuclear PdIII complex with a composition [PdIII2(Hp-3H)Cl3(H2O)5]·2PdCl2, Pd1 is the
main product of the interaction at a metal excess (Pd:Hp ≥ 4). The compound was separated
spontaneously from the reaction system with coprecipitated 2 molecules of the initial PdCl2 at pH ~8.
A mononuclear complex with a composition [PdIII(Hp-2H)Cl(H2O)]·H2O, Pd2, was the main product
from the interaction at equimolar ratio of the reagents or a slight excess of one of the reagents.
The compound was isolated as a neutral one by addition of hydrochloric acid (5 × 10−2 M HCl).
The solid-state structure of the complexes and the mode of ligand coordination were studied in detail
using magnetic measurements, EPR spectra, thermal and elemental analyses, and IR and UV/Vis
spectroscopy [34].
The EPR and UV/Vis spectra were also used to characterize the solution-structure of the complexes
and to assay their stability. Both complexes are slightly soluble in water and their solubility is pH
dependent. Moderate solubility was achieved by increasing the pH value with KOH or using solvents
such as DMSO (dimethyl sulfoxide) or DMF (N,N-dimethyl formamide). In the UV/Vis spectrum of
hematoporphyrin IX recorded in DMSO, the Soret band (400 nm, lgε = 5.02) with a shoulder (376sh,
lgε = 4.89) and the four Q-bands (502 nm, lgε = 3.77; 536 nm, lgε = 3.61; 572 nm, lgε = 3.84; 623 nm,
lgε = 3.17) can be readily distinguished (Figure 3a). The UV/Vis spectra of DMSO solutions of the
complexes display the characteristic three component (for Pd1: 507 nm (lgε = 3.68), 546 nm (lgε = 3.68),
567 nm (lgε = 3.63)) and two component (for Pd2: 512 nm (lgε = 3.58), 548 (lgε = 3.74)) pattern in the
region of Q-bands (Figure 3b,c).
The EPR spectrum of the DMSO solution of the complex Pd1 (Figure 4a) contains more than
two signals. Two of them possess axial symmetry with principal values of g-tensors, respectively for
the first: g  = 2.057 and gII = 2.496 with readily observed superhyperfine structure in perpendicular
region (a = 15.31 × 10−4 cm−1) and for the second—g  = 2.029 and gII = 2.354. The wide signal
at ~3050 G was assigned to an exchange interaction of two paramagnetic centers in the molecule.
In addition, a low intensive signal with g = 1.990 and Hpp = 8 G was assigned to a stable radical.
The EPR spectrum of the complex Pd2 dissolved in DMSO (Figure 4b) shows only a signal with
two-component axial anisotropy and principal values of the g-tensor measured from the experiment
as g  = 2.038 and gII = 1.979. The superhyperfine structure measured from the experimental spectrum
is well resolved both in perpendicular and parallel regions. The determined principal values of the
axial superhyperfine coupling tensor are a  = 16.65 × 10−4 cm−1 and aII = 13.85 × 10−4 cm−1.
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Figure 3. Electronic absorption spectra of Hp and its complexes dissolved in DMSO: (a) Hp; (b) complex
Pd1; (c) complex Pd2.
 
(a) (b) 
Figure 4. X-band EPR spectra of Hp complexes dissolved in DMSO, frozen solutions at 130 K (a) Pd1,
operating frequency 9.513 GHz; (b) Pd2, operating frequency 9.502 GHz.
2.2. In Vitro Tumor Cell Growth Inhibition
The cell growth inhibitory effects of the complexes subjected to detailed biological screening were
evaluated in a panel of human tumor cell lines with distinct cell type and origin in order to determine
the most sensitive class of cell lines. The cytotoxicity was assessed using standard MTT-dye reduction
assay [50,51]. The pilot studies covered the cell lines: SKW-3 (T-cell leukemia), LAMA-84 and K-562
cells (chronic myeloid leukemia), and 5637 (urinary bladder cancer) and the data were published
in a previous research [34]. In addition, several leukemic and solid cell lines have been explored,
namely: HL-60 (Acute myeloid leukemia), HD-MY-Z (Hodgkin-lymphoma), EJ (Urinary bladder
carcinoma), and MCF-7 (Mammary gland carcinoma). The tested compounds inhibited the growth of
tumor cells in a concentration-dependent manner. The IC50 values were calculated using nonlinear
regression analysis and are summarized in Table 1. Normally, the tested palladium compounds exert
lower activity compared to that of the referent drug cisplatin. The results showed also that as a rule
the dinuclear complex Pd1 demonstrated superior activity in contrast to the metalloporphyrin type
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complex Pd2 (Table 1). Furthermore, it should be underlined, that Pd1 exerts remarkable activity
against K-562 cells, as the compound tested caused 50% cell growth inhibition at more than 4-fold lower
concentration with regard to the reference agent [34]. Noteworthy, its activity against the HD-MY-Z
cell line is comparable to that of cisplatin.
Table 1. Comparative antiproliferative activity of the investigated palladium complexes (Pd1 and Pd2)
and cisplatin in a panel of tumor cell lines after 72 h continuous exposure (MTT-dye reduction assay).




SKW-3 2 T-cell leukemia 34.4 ± 2.2 77.9 ± 5.1 10.1 ± 1.4
K-562 2 Chronic myeloid leukemia 2.1 ± 0.9 31.9 ± 4.3 9.4 ± 2.1
LAMA-84 2 Chronic myeloid leukemia 40.0 ± 3.4 94.0 ± 6.2 18.3 ± 2.6
HL-60 Acute myeloid leukemia 75.2 ± 2.9 >200 8.2 ± 1.9
HD-MY-Z Hodgkin-lymphoma 14.1 ± 4.5 >200 10.2 ± 3.4
5637 2 Urinary bladder carcinoma 96.0 ± 1.1 177.2 ± 10.2 4.4 ± 1.7
EJ Urinary bladder carcinoma 117.2 ± 6.9 >200 9.3 ± 1.8
MCF-7 Mammary gland carcinoma 79.4 ± 4.2 >200 6.5 ± 1.1
1 Arithmetic mean ± standard deviation of at least eight independent experiments. 2 Data have been published
in [34].
2.3. Induction of Apoptosis
The ability of the palladium complexes to induce programmed cell death was evaluated using
the more active complex Pd1 compared to cisplatin in HL-60 cells. The assessment has been made
with a commercially available DNA-fragmentation kit allowing semi-quantitative determination of
the degree of oligonucleosomal genomic DNA fragmentation. The results concerning the HL-60
cell line (Figure 5) proved that both, Pd1 and cisplatin cause significant increase in the apoptotic
histone-associated DNA fragments, but the comparison of their behavior shows that the novel dinuclear
compound causes comparable proapoptotic effects at substantially higher concentrations, which is in
line with the tumor cell line chemosensitivity bioassay (Figure 5).
Figure 5. Apoptotic DNA-fragmentation in HL-60 cells after 24 h exposure to complex Pd1 and cisplatin.
The cytosolic mono- and oligo-nucleosomzal enrichment was determined using a commercially
available ELISA kit. Each bar is representative for three independent experiments. Asterisks indicate
statistical significance vs. the untreated control with p ≤ 0.05 (*) or p ≤ 0.01 (**) taken as significance
levels; NS = non-significant (paired Student’s t-test).
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2.4. DNA-Modification
In order to evaluate in parallel the ability of Pd1 and cisplatin to form intra-strand guanine
bis-adducts, we investigated their binding to a synthetic 40-base DNA fragment bearing a single GG
sequence [52]. Optimal binding to the target DNA molecule was observed at molar ratio 1:50 for
cisplatin and molar ratio 1:100 for Pd1, respectively, after overnight incubation (Figure 6). Cisplatin
treatment led to a total inhibition of the BamH1-mediated fragmentation of the DNA-probe indicating
a high metallation ability. The dinuclear palladium complex Pd1 also inhibited the nuclease activity as
is evident by the low quantity of digested fragment but failed in the totally hamper the fragmentation
of the target DNA-molecule.
Figure 6. Metallation of a 40-base DNA fragment following treatment with cisplatin (molar ratio 1:50)
and Pd1 (molar ratios 1:100 and 1:200). The level of metal binding following interactions between the
tested complexes and the DNA probe was analyzed after BamH1 treatment, electrophoretic analysis
in 5% native polyacrilamide gel, and ethidium bromide staining. On the picture: C, unmodified
DNA; CB, BamH1-digested DNA; cis, cisplatin-modified DNA; cisB, cisplatin-modified DNA (1:50)
BamH1-digested; Pd, Pd1-modified DNA; PdIB, Pd1-modified DNA (1:100) BamH1-digested, PdIIB,
Pd1-modified DNA (1:200) BamH1-digested.
2.5. DNA-Repair Synthesis
The elucidation of the cellular processing of metallodrug-induced DNA-adducts is of crucial
importance for delineation of the pharmacological behavior of the antitumor agents [53,54]. The results
of the DNA-repair experiments run under optimal conditions: plasmid:drug ratios 1:750, overnight
are shown on Figure 7. The adducts induced by cisplatin or Pd1 treatment were recognized and
efficiently repaired by the nucleotide excision repair (NER) enzymes. It was found that the level of
DNA-repair of pBS plasmid after treatment with Pd1 was far less efficient than that encountered by
the cisplatin-modified DNA probe. These findings indicate that the Pd1 would have advantageous
behavior against tumor cells, characterized by an overexpression of the NER-enzymatic machinery,
mediating one of the most important mechanisms of post-target resistance to platinum drugs.
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Figure 7. Relative efficiency of the nucleotide excision repair process in pBS plasmids modified by
treatment with cisplatin or Pd1 (plasmid:drug ratio 1:750, overnight). Repair of cisplatin-modified pBS
is set as 1.
2.6. HMGB-1 Binding to Pd1 or Cisplatin-Modified DNA
The ability of high mobility group box (HMGB)-1 protein to bind metallated 40-base DNA
fragments was investigated in a cell-free system by electrophoretic mobility shift assay (EMSA).
The modification of the DNA probe with the reference cytotoxic drug cisplatin resulted in the
emergence of a more slowly migrating band indicating the specific binding of HMGB-1 to the platinated
40-base DNA fragments [55,56] (Figure 8). As seen on the electrophoregram depicted in Figure 8 of
the DNA probe modification with the reference cytotoxic drug cisplatin resulted in the emergence of
a more slowly migrating band indicating the specific binding of HMGB-1 to the platinated 40-base
DNA fragments. In a dissimilar manner, the Pd1-modified DNA was not recognized as evidenced by
the similar mobility of both Pd1-lesioned and untreated DNA probes. Thus it would be expected that
the Pd1-modified DNA would not be shielded by the HMGB-1, indicating a further discrepancy in the
molecular pharmacology of the presented class of agents vs. the classical cisplatin analogs.
Figure 8. Binding of HMGB-1 protein to DNA-modified by either cisplatin or Pd1 as determined by
electrophoretic mobility shift assay (EMSA). DNA:protein molar ratio 1:9.
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3. Discussion
In the framework of the design of new antitumor agents, two paramagnetic PdIII—complexes
of hematoporphyrin IX were obtained and biologically tested as representatives of the group of
cisplatin-dissimilar metal-based coordination compounds. The reaction conditions for their synthesis
were chosen to provide obtaining of Pd3+ species [57] and their stabilization in solution and solid state
through formation of Hp-complexes [32–35]. The complexes were synthesized during the interaction of
an initial PdII compound as a chloride complex ([PdCl42−]) with the twofold deprotonated at peripheral
propionic acid groups hematoporphyrin IX ligand ([Hp-2H]2−) in alkaline-aqueous medium achieved
by adding KOH. All measurements performed during the interaction manifested that a redoxy process
takes place together with the coordination reaction. The large spontaneous increase of the acidity of
the reaction system together with the appearance of the EPR signals (Figure 1) proved that the studied
process is a very complicated coordination reaction with production of a mixture of paramagnetic
metal complexes and stable radicals. The appearance of two-component anisotropic EPR signals
with different parameters during the interaction indicates also formation of complex species with
different inner coordination sphere of the paramagnetic metal centers. The mode of Hp coordination
can be distinguished by using UV/Vis characterization of the reaction system. Coordination via the
side deprotonated propionic COO− groups could be supposed because of the hypsochromic shift of
the Soret band owing to the porphyrin plane distortion. The spectral changes that follow are most
probably connected to a distortion of the porphyrin ring symmetry owing to the coordination through
two adjacent pyrrole N-atoms and formation of lower symmetry complex species. The reduction of
the Q-bands number to two at the end of the reaction is owing to degeneration of the exited state S1
orbitals [58] and proves the formation of a metalloporphyrin type complex (D4h symmetry).
Two of the complex species formed during the interaction PdCl42−-Hp-2H have been isolated at
proper reaction conditions. A dinuclear compound Pd1 was the main product from the interaction
at a metal excess (Pd:Hp ≥ 4) and was spontaneously precipitated at pH ~8 and a mononuclear
metalloporphyrin type complex Pd2 was the main product of the interaction at an equimolar ratio of
the reagents and was precipitated by adding hydrochloric acid (5 × 10−2 M HCl). The composition of
the complexes was derived from the elemental analyses and the content of H2O and Cl− in the inner
or the outer coordination sphere was proven by studying their thermal behavior [34]. The molecular
structure of the complexes in solid state was deduced based on detailed investigations of their magnetic
properties and spectroscopic characterization, published in [34].
A crucial issue in developing a new drug formulation is to study the structure of the compound in
solution and to establish the relationship with the solid state structure. The data presented here
relate to the behavior of the complexes in DMSO solutions. The low temperature EPR spectra
(Figure 4a,b) of the complexes dissolved in DMSO show characteristic EPR spectral patterns of
paramagnetic Pd-compounds. The EPR spectra recorded several hours (5–8 h) after the dissolving
correspond well to the solid state EPR spectra [34]. The two anisotropic EPR signals observed
in the spectrum of Pd1 possess axial symmetry. The principal values of the g-tensors of the
two anisotropic signals gII > g  > 2.0023 are consistent with formation of an elongated octahedral
coordination with (dz2)1-ground state. A five-component superhyperfine structure is observed only in
the perpendicular region of the low-field signal. The principal value of the superhyperfine coupling
tensor a⊥(N) = 15.31 × 10−4 cm−1 (I(14N) = 1) and the number of superhyperfine lines typical for
interaction of the uncoupled electron with two 14N nuclei proved coordination of one Pd3+ via two
of the pyrrole nitrogen donors of the Hp ligand. The absence of a superhyperfine structure from 14N
nuclei on the upfield EPR signal is due to coordination out of the porphyrin ring through the propionic
acid groups. The wide signal observed at ~3050 G could be assigned to exchange singlet–triplet
interaction between the two unpaired electrons of the differently coordinated Pd3+-centers in the
molecule of Pd1. Hence the EPR spectra proved the formation of a Pd3+-L-Pd3+ system where each of
the Pd-ions possesses different coordination. The presence of a signal for a radical could be explained
with significant delocalization of the unpaired electron density because of electron-acceptor properties
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and significant flexibility of the porphyrin moiety. The complex Pd2 features a completely different
EPR spectrum pattern in solution containing exactly one two-component anisotropic signal. The signal
displays axial anisotropy with principal values of the g-tensor g  > 2.0023 > gII proving formation
of a compressed octahedral structure with (dx2 − y2)1 ground state. Superhyperfine lines were
observed both in perpendicular and parallel regions. The principal values of the axially symmetrical
superhyperfine coupling tensor are typical for the interaction of an uncoupled electron with 14N (I = 1)
nuclei. The nine superhyperfine lines are readily distinguished in the perpendicular region and prove
coordination of Pd3+ into the four pyrrole N-donors in the porphyrin ring. Thus the spectrum confirms
the existence of a stable metalloporphyrin type complex in solution.
It is well-known that changes in the conjugation and the symmetry of the Hp-ligand can affect
the UV/Vis absorption spectra and can be used to obtain data about the mode of Hp coordination at
complex species in solution [32–39]. While the metal binding through inner nitrogen atoms induces
strong changes in the visible region of the spectra, the variations in the peripheral substituents causes
minor changes owing to geometrical deformation of the porphyrin ring. The UV/Vis spectra were
recorded of the studied compounds dissolved in DMSO. It was found that the position of the Soret
band is sensitive to the processes such as acid-base equilibria and aggregation, and also to the modes
of metal coordination. It is accepted that the Soret band appears at 376 nm if the propionic acid
groups are deprotonated and shifts in accordance with the electronic density distribution caused
by protonation and metal-coordination. The major component of the Soret band in the spectrum of
the free ligand dissolved in DMSO (400 nm, lgε = 5.02) is batochromically shifted compared to the
spectrum registered in alkaline-aqueous medium. The shoulder observed at 376 nm is due to the
protolitic equilibrium Hp + 2Solv ⇔ [Hp-2H]2− + 2[HSov]+, which is clearly shifted to the neutral Hp
molecules in the weakly proton-acceptor solvent DMSO. In the spectra of the complexes this band is
observed at 399 nm (Pd1) and 396 nm (Pd2), respectively. Thus it indicates that the propionic acid
groups are engaged in the processes of coordination or protonation.
The spectrum pattern in the area of Q-bands is determined by the symmetry group of the
porphyrin macrocycle. The two diagonally located hydrogen atoms at pyrrolic nitrogens in the
molecule of the free ligand define a D2h symmetry and hence a four number Q-bands spectrum.
The loose of a proton gives a monoprotic ligand form. Many metal ions at proper pH value (6 < pH < 10)
interact with the monoprotic ligand anion and bind with its two cis-disposed pyrrole N-donors on the
top of the macrocycle forming sitting-atop (SAT) complex. The metal in these complexes is located out
of the porphyrin plane and distorts it. The symmetry of the structure is lower (approximately between
C4v → C1) than that of both metalloporphyrins (D4h) where the two ammine hydrogens are substituted
by the metal located coplanar on the porphyrin ring and the free Hp ligand (D2h). This reflects on
the Q-bands number reduction and changes their intensities. Hence the observed spectrum of the
complex Pd1 in the area of Q-bands containing mainly three Q-bands (507, 546, and 567 nm) with
intensity IV ~III > II is consistent with coordination through the two cis-disposed pyrrole N-donors on
the top of the porphyrin macrocycle substituting one of the pyrrolic nitrogen. Further on, the slight
red shift of the Q-bands: IV and III and a blue shift of the Q band II with degeneration of the Qx
and Qy orbitals connected with vibronic structure supports simultaneous coordination on the top
of the porphyrin ring and out-side the porphyrin macrocycle through the peripheral deprotonated
carboxylic groups. The typical two Q-band spectrum of the complex Pd2 indicates unambiguously
a D4h symmetry achieved at coordination through the four N-heteronuclei in the porphyrin macrocycle.
The intensive bands at 270 (lgε = 4.98) and 323 nm (lgε = 4.81) in the spectrum of Pd1 as well as the one
at 280 (lgε = 3.99) in the spectrum of Pd2 were assigned to the ligand-to-metal charge transfer bands of
the Pd-Cl bonds. This proves the presence of Cl− ions in the palladium ions inner coordination sphere.
The spectroscopic characteristics observed were unchangeable within more than five days.
Hence in this period the compounds, dissolved in DMSO solution are paramagnetic palladium-
hematoporphyrin IX complexes as follows: (1) for Pd1—a dinuclear Pd-Hp-Pd system, with two
PdIII ions that occupied two coordination places—at the porphyrin ring binding out-of-plan through
49
Int. J. Mol. Sci. 2018, 19, 2451
two cis-disposed N-donors and at the two peripheral propionic acid groups; (2) for Pd2—normal
metalloporphyrin of PdIII. Furthermote, this is the reason to accept that during the biological
investigation the active species in solution are these palladium complexes of hematoporphyrin IX.
The cytotoxic screening of the two palladium(III) complexes was conducted on a wide spectrum
of cell lines—representatives of the main human cancer types. The results of the MTT-dye reduction
assay [50,51] unambiguously indicate that the two compounds exert concentration-dependent
antiproliferative effects against the chosen spectrum of cell lines. Data analysis shows that the tested
palladium compounds are generally less active than cisplatin, causing half-maximal inhibition of
cell viability at generally higher concentrations (Table 1). It has also been proven that the dinuclear
palladium complex Pd1 demonstrates superior activity as compared to the metalloporphyrin type
complex Pd2. The latter Pd2 compound exerts only marginal activity and fails to cause 50% inhibition
of malignant cell growth against a half of the cell lines under evaluation. Throughout the panel
investigated the anticancer drug cisplatin proved to outclass the novel palladium complexes, with the
only exception of K-562 leukemia whereby Pd1 showed remarkable cytotoxicity [34].
These findings gave us a reason to conduct more detailed pharmacodynamic evaluation of
Pd1 especially regarding its ability to induce apoptosis and to modify DNA. Significant apoptotic
fragmentation of genomic DNA was established after treatment of HL-60 cells with both cisplatin
and Pd1, whereby the proapoptotic effect of Pd1 required the cell exposure to concentrations
significantly higher than its IC50. These data indicate that the cytotoxicity of both compounds is
mediated by induction of apoptosis, although its threshold level was significantly higher for the
palladium compound.
Further experiments were carried out in order to characterize the adduct-forming ability of Pd1
and the cellular processing of the DNA-lesions. The N7 position of guanine is considered as the
ultimate pharmacological target of platinum drugs, leading to formation of intrastrand adducts whose
recognition and processing leads to activation of the cell death signaling pathways [59,60]. On this
ground we studied the metallation of a single strand 40-base DNA fragment in a cell free system.
The palladium compound Pd1 was less capable of forming DNA adducts under the experimental
conditions, thus further demonstrating its cisplatin-dissimilar pharmacological properties. These
findings indicate that although the DNA-modification plays an important role for the mode of
antiproliferative action of Pd1; its capacity to modify DNA is lower as compared to that of cisplatin.
The structural perturbations induced by the DNA-metallation are recognized by diverse proteins
including the DNA-repair enzymatic machinery [59,61,62]. Removal of platinum-DNA adducts by the
nucleotide excision repair (NER) is one of the crucial mechanisms of cellular resistance to cisplatin.
This prompted us to evaluate the efficiency of NER repair synthesis after modification of pBS plasmids
with either cisplatin or Pd1. The lesions induced by cisplatin were far better recognized and repaired
as compared to those of Pd1, implying that, by virtue of the significant structural differences between
the tested complexes, they induce highly dissimilar alterations of DNA conformation. The lower
level of NER-mediated removal and repair of Pd1 modified DNA are an advantageous future of the
novel compound as this would condition retained activity against malignant cells overexpressing the
NER-enzymatic system.
Apart from the DNA-repair enzymes other proteins are also capable of recognizing and binding
cisplatin-modified DNA [59,61,63]. Among these special attention has been paid to the high mobility
group domain (HMG) proteins [55,59,61,64]. They are considered to play crucial role for the cytotoxicity
of platinum drugs, whereby the proposed mechanisms include: (i) shielding of platinated DNA
and steric hindrance against NER-mediated repair of metal-adducts; (ii) “hijacking” i.e., binding of
transcription factors or other regulatory proteins to HMG-associated platinum adducts, thus deviating
them from their normal targets and compromising their role in signal transduction [59,61,63]. On this
ground we evaluated the recognition and binding of HMGB-1 protein to cisplatin or Pd1 modified
DNA probes. As made evident by the results obtained Pd1-induced modification conditions lower
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level of HMGB-1 binding, as compared to cisplatin-lesioned DNA. This implies that the high mobility
group proteins are most probably less involved in the cytotoxicity of the palladium agent.
4. Materials and Methods
4.1. Chemicals and Tested Compounds
All chemicals used were of analytical grade and were obtained by commercial sources and used
without further purification. Agarose, ethanol, DMSO, formic acid, 2-propanol, methanol, EDTA,
ethidium bromide, sodium chloride, Tris hydrochloride, Triton® X-100, L-glutamine were purchased
from AppliChem GmbH, Darmstadt, Germany. The tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and TE buffer were supplied by Merck, Darmstadt, Germany.
Fetal calf serum (FCS), powdered RPMI 1640 medium, the amino acid, sodium pyruvate, human
insulin, and polyacrylamide gel were purchased from Sigma-Aldrich GmbH, Steinheim, Germany.
The referent cytotoxic drug cis-DDP was used as a commercially available sterile dosage form for
clinical application (Platidiam®, Lachema, Czech Republic). The two complexes tested, namely:
cis-[PdIII2(Hp-3H)Cl3(H2O)5]·2PdCl2 (Pd1) and, [PdIII(Hp-2H)Cl(H2O)]·H2O (Pd2) were synthesized,
characterized and purified as previously described [34]. UV-Visible (UV-Vis) (solv. DMSO) λmax/nm,
(logε): complex Pd1: 270 (4.98), 323 (4.81), 399 (5.02), 507 (3.68), 546 (3.68), 567 (3.63); complex Pd2: 280
(3.99), 396 (4.91), 512 (3.58), 548 (3.74).
4.2. Solution Stability Assays
The absorption electronic spectra were recorded on a “Carry” 100 UV-Vis spectrometer. The EPR
spectra were obtained on an X-band “Bruker B-EPR 420” spectrometer at 130 K. The UV-Vis and EPR
spectra were measured after dissolving the Pd-complexes samples in DMSO within the concentration
intervals of (5 × 10−6) ÷ (1 × 10−4) mol/L for UV-Vis spectra and 5 × 10−4–5 × 10−3 mol/L for EPR
spectra, respectively.
4.3. Cell Lines and Culture Conditions
In this study the following cell lines were used: SKW3 (T-cell leukemia), K-562 and LAMA-84
(chronic myeloid leukemia), HL-60 (acute myelocyte leukemia), HD-MY-Z (Hodgkin lymphoma),
5637, EJ (urinary bladder carcinomas), and MCF-7 (mammary gland adenocarcinoma). The cells were
maintained in controlled environment—cell culture flasks at 37 ◦C in an incubator ‘BB 16-Function
Line’ Heraeus (Kendro, Hanau, Germany) with humidified atmosphere and 5% CO2. They were
kept in log phase by supplementing with fresh medium, two or three times a week. SKW3, K-562,
LAMA-84, HL-60, HD-MY-Z, 5637, and EJ cells were grown in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS) and 2 mM L-glutamine. MCF-7 cells were grown as monolayer
adherent cultures in 90% RPMI-1640 supplemented with 10% FBS, non-essential amino acids, 1 mM
sodium pyruvate, and 10 mg/mL human insulin.
4.4. MTT-Dye Reduction Assay
The tumor cell growth inhibitory effects were assessed using the standard 3-[4-dimethylthiazol-
2-yl]-2,5-diphenyl-2H-tetrazolium bromide (MTT)-dye reduction assay as described by Mosmann [50]
with minor modifications [51]. Exponentially growing cells were seeded in 96-well flat-bottomed
microplates (100 μL/well) at a density of 1 × 105 cells per mL and after 24 h incubation at 37 ◦C they
were exposed to various concentrations of the tested compounds for 72 h. At least 8 wells were used
for each concentration. After incubation with the tested compounds 10 μL MTT solution (10 mg/mL
in PBS) aliquots per well were added. The microplates were further incubated for 4 h at 37 ◦C and the
MTT-formazan crystals formed were dissolved by adding 100 μL/well 5% formic acid (in 2-propanol).
The absorption was measured using a microprocessor controlled microplate reader (Labexim LMR1) at
580 nm. The cell survival data were normalized to percentage of the untreated control and were fitted
51
Int. J. Mol. Sci. 2018, 19, 2451
to sigmoidal dose/response curves. The corresponding IC50 values were calculated using non-linear
regression analysis.
4.5. Apoptosis Assay
The typical apoptosis oligonucleosomal DNA fragmentation was examined using a commercially
available “Cell-death detection” ELISA kit (Roche Applied Science, Mannheim, Germany). Cytosolic
fractions of 1 × 104 cells per group (treated or untreated) served as antigen source in a sandwich ELISA,
utilizing primary anti-histone antibody-coated microplate and a secondary peroxidase-conjugated
anti-DNA antibody. The photometric immunoassay for histone-associated DNA fragments
was executed according to the manufacturer’s instructions. The results are expressed as the
oligonucleosome enrichment factor (representing a ratio between the absorption in the treated vs. the
untreated control samples).
4.6. DNA-Binding
The DNA binding of the dinuclear palladium agent and cisplatin was assessed as previously
described [52]. A 40 n.b. fragment (5′ CGCTATCGCTACCTATTGGATCCTTATGCGTTAGTGTA TG
3′), whereby the GG-motif is the recognition sequence of the restriction nuclease BamH1 was used
as a target DNA molecule. The level of DNA modification following interactions between the tested
complex and the 40 n.b. fragment was analyzed after BamH1 treatment, electrophoretic analysis in 5%
native polyacrylamide gel, and ethidium bromide staining, as previously described [52].
4.7. In Vitro DNA Repair
Synthetic pBS plasmids (2.69 kb) served as a DNA probe in this study. They were propagated in
Escherichia coli and extensively purified as closed circular DNA by means of a FlexiPrep Kit (Pharmacia
Biotech, Uppsala, Sweden). Modification of plasmid DNA (200 μg/mL) with the tested palladium
complex or cisplatin was carried out in TE buffer (10 mM Tris, 1 mM EDTA), pH = 7.4, in the dark
at 37 ◦C for 16 h. Following ethanol precipitation, DNA was washed twice in 70% ethanol and
redissolved in TE buffer, and the superhelical form of the plasmid DNA was purified by ethidium
bromide/cesium chloride gradient centrifugation. Cell-free extract (CFE) from exponentially growing
Guerin ascites tumor cells was prepared using a previously described protocol [53], adapted for
in vitro DNA repair studies [54] and stored at −80 ◦C until use. Repair of DNA lesions induced by
the metal complexes was assayed as described elsewhere [52]. Briefly, the standard 50 μL reaction
mixture contained 400 ng of metal complex-treated repair substrate pBS, 400 ng, 45 mM HEPES-KOH,
pH = 7.8, 70 mM KCl, 5 mM MgCl2, 1 mM dithiothreitol, 0.4 mM EDTA, 2 mM ATP, 20 μM each
of dTTP, dGTP, dATP, 2μCi [32P]dCTP (Amersham, 3000Ci/mmol, Amersham Bioscinces, Freiburg,
Germany), 40 mM phosphocreatine, 2.5 μg of creatine phosphokinase, 3% glycerol, 20 μg of bovine
serum albumin, and 80–120 μg of cell-free extract at 30 ◦C for 1 h. Reactions were stopped by adding
EDTA to 20 mM, and mixtures were incubated for 20 min with RNase A (80 μg/mL) followed by
another 20 min with proteinase K (200 μg/mL) in the presence of 0.5% SDS. Plasmid DNA was
purified with phenol/chloroform (1:1) and precipitated by 2 vol of ethanol in the presence of glycogen
(Stratagene, La Jolla, CA, USA, 1 mg/mL) at −70 ◦C. Thereafter the plasmids were linearized by
digestion with EcoRI and resolved by electrophoresis in 0.8% agarose gel containing ethidium bromide
(0.5 μg/mL). After electrophoresis, the gel was photographed under UV illumination, dried under
vacuum, and exposed to Kodak XAR-5 film for 12 h at −70 ◦C. The autoradiograph was scanned with
Gel-Pro Analyser (Media Cybernetics, Bethesda, MD, USA).
4.8. Electrophoretic Mobility Shift Assay (EMSA)
DNA binding assay of HMGB-1 and its truncated form with 32P-labeled cisplatinated DNA
was performed as described previously [55]. In brief, nonlabeled sonicated salmon sperm DNA
was added as a competitor in all experiments except those designed to determine the dissociation
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constants. On completion of electrophoresis the gel was dried and exposed to Amersham hyperfilm.
Quantification of band densities was performed by scanning the autoradiographs with Gel-Pro
Analyzer. In some assays, the reaction mixture prepared for EMSA was supplemented with CFE
preincubated with nonplatinated DNA (500-fold molar excess over the platinated probe) and loaded on
the gel. Isolation and purification of recombinant HMGB-1 were carried out as described elsewhere [56].
5. Conclusions
Two newer members of the group of paramagnetic transition metal complexes of
hematoporhyrin IX [32–39] have been proposed for extended biological screening: a dinuclear
[PdIII2(Hp-3H)Cl3(H2O)5]·2PdCl2 and a mononuclear [PdIII(Hp-2H)Cl(H2O)]·H2O. The complexes
were obtained reproducibly in alkaline-aqueous medium and were isolated as neutral compounds
changing the acidity of the reaction system and the M:L molar ratios. Their structure and stability were
studied in DMSO solutions in details. It was found that the active species in solution are a dinuclear
complex (Pd1) and a mononuclear (Pd2) complex. In the dinuclear complex Pd1, one PdIII ion is
coordinated to the deprotonated COO− groups from the side chains of the porphyrin ligand and
the second PdIII ion—to two adjacent pyrrole N-atoms on the top of the porphyrin ring and thus
a dinuclear PdIII-Hp-PdIII system is created. PdIII in the mononuclear complex, Pd2, is located in the
plane of the porphyrin ring and thus a metalloporphyrin type complex is formed. PdIII centers in both
complexes have a distorted octahedral coordination filled with additional donor species such as Cl−
and solvent molecules.
The compounds tested manifested cell growth inhibitory effects at micromolar concentration
against tumor cell lines with distinct cell type and origin. The calculated IC50 values proved that in
general, palladium complexes exhibit lower activity compared to that of the referent drug cisplatin
and as a rule the metalloporphyrin type complex Pd2 is less active than the dinuclear compound
Pd1. Contrarily to the general trend the Pd1 complex exerts remarkable activity against K-562 cells,
with 50% cell growth inhibition at more than 4-fold lower concentration compared to cisplatin. It also
displays relatively close activity against the HD-MY-Z cell line with regard to the referent drug.
The palladium complexes’ ability to induce programmed cell death was evaluated in a comparative
experiment of Pd1 and cisplatin in HL-60 cells. The two compounds cause significant increase in
the apoptotic histone-associated DNA fragments. However, the novel dinuclear compound causes
comparable proapoptotic effects at substantially higher concentrations and that corresponds to the
tumor cell line chemosensitivity bioassay. The parallel evaluation of Pd1 and cisplatin’s ability to
form intra-strand guanine bis-adducts shows that Pd1 also inhibits the nuclease activity, but failed to
totally hamper the fragmentation of the target DNA-molecule. Hence, although the DNA-modification
plays an important role for the mode of antiproliferative action of Pd1, its capacity to modify DNA is
lower compared to that of cisplatin. The elucidation of DNA-adducts cellular processing by the NER
enzymes demonstrated that the lesions induced by cisplatin were far better recognized and repaired as
compared to those of Pd1. The lower level of NER-mediated removal and repair of Pd1 modified DNA
are an advantageous characteristic of the novel compound and that means that Pd1 would retain the
activity against malignant cells, overexpressing the NER-enzymatic system. The ability of HMGB-1
protein to bind metallated 40-base DNA fragment with the reference cytotoxic drug cisplatin resulted
in a specific binding. In a dissimilar manner, the Pd1-modified DNA was not recognized and it could
be expected that the Pd1-modified DNA would not be shielded by the HMGB-1.
The data analysis of the in-depth biological study unambiguously highlights the differences
in molecular pharmacology of the presented “applicants” for antitumor agents in respect to
cisplatin. Moreover, the advantages of the new compounds provide grounds for joining them to the
“nonclassical metal compounds” group. Their unique structure, based on the octahedral coordination
of palladium(III) stabilized with a ligand with favorable properties, is a prerequisite for constructing
a new formula with a potential of controlling its kinetic behavior as well as the strength of the M-L
bonds of the adducts formed in the biological milieu.
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EMSA Electrophoretic mobility shift assay
NER Nucleotide excision repair
HMGB1 High mobility group protein B1
FCS Fetal calf serum
MTT Tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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Abstract: We report a combined quantum mechanics/molecular mechanics (QM/MM) molecular
dynamics and time-dependent density functional (TDDFT) study of metal-mediated deoxyribonucleic
acid (M-DNA) nanostructures. For the Ag+-mediated guanine tetramer, we found the maug-cc-pvdz
basis set to be sufficient for calculating electronic circular dichroism (ECD) spectra. Our calculations
further show that the B3LYP, CAM-B3LYP, B3LYP*, and PBE exchange-correlation functionals
are all able to predict negative peaks in the measured ECD spectra within a 20 nm range.
However, a spurious positive peak is present in the CAM-B3LYP ECD spectra. We trace the origins
of this spurious peak and find that is likely due to the sensitivity of silver atoms to the amount of
Hartree–Fock exchange in the exchange-correlation functional. Our presented approach provides
guidance for future computational investigations of other Ag+-mediated DNA species.
Keywords: DNA; silver; ECD; QM/MM; TDDFT
1. Introduction
The nucleobases inside highly polymorphic deoxyribonucleic acid (DNA) molecules contain
the essential genetic information for the creation and the functional properties of living organisms.
In addition to hydrogen bonding, DNA is also capable of forming metallo base pairs in the presence of
strongly bound metal ions. Interest in such metal-mediated DNA (M-DNA) nanostructures has rapidly
grown due to their high potential for developing new materials for a wide range of biomedical and
technological applications, such as bioimaging [1–4], metal ion detection [5–7], DNA sequencing [8],
logic gates, and molecular devices [9]. Among the studied metal ions, Ag+ is particularly interesting,
because it has low toxicity to humans and binds exclusively to the base pairs rather than the
sugar–phosphate backbone. C-Ag+-C, G-Ag+-G, T-Ag+-T, A-Ag+-T (where A = adenine, C = cytosine,
G = guanine, and T = thymine) and Ag+- mediated artificial DNA pairs have been reported [10–12].
In recent years, DNA-stabilized color-tunable fluorescent Ag clusters have also been synthesized,
which contain both neutral Ag atoms and Ag+ ions, and are stabilized by Ag+-DNA interactions.
They hold great potential for chemical and biochemical sensor applications and have attracted even
more attention to the study of metal–DNA interactions [3,13].
Although the structures of some specific M-DNAs have been recently resolved via X-ray
diffraction analysis [14–16], the atomic structures of M-DNAs are generally very difficult to obtain
with X-ray crystallography, because M-DNA rarely crystallizes. Therefore, computational chemistry
methods are important tools for deciphering the atomic structure of M-DNA and for interpreting the
experimental spectroscopic data. In this context, electronic circular dichroism (ECD) spectroscopy is a
Int. J. Mol. Sci. 2018, 19, 2346; doi:10.3390/ijms19082346 www.mdpi.com/journal/ijms58
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versatile method to obtain structure information due to its high sensitivity to small structural changes
in chiral optical active molecules, and a broad operational window in various solvent conditions.
By comparing computed with measured ECD spectra, the structure of M-DNA can be inferred.
This approach has been used for mapping the conformal properties of various DNA-based systems
including M-DNAs [17–19]. Additionally, ECD provides a reliable benchmark method for validating
computational approaches, due to its structural sensitivity.
However, modeling the ECD spectra of M-DNAs remains a difficult task. Since the prepared
materials exist mostly in aqueous solution, the effect of the environment on the structures and
properties have to be taken into account. This leads to an increased system size, which is prohibitive
for a full quantum level calculation, and thus requires multi-scale strategies, i.e., hybrid quantum
mechanics/molecular mechanics (QM/MM) methods. In order to compare with experiments, the
structures for simulating ECD need to be chosen carefully from QM/MM simulations, bearing in mind
that they exhibit the key structural properties of the system but are still computationally affordable.
Last, as always with density functional theory (DFT), the used exchange-correlation functional has to
be suitable for the system under study. It is well known that hybrid or long-range corrected hybrid
functionals are usually more accurate for studying organic molecule, whereas the GGA functionals are
commonly used for bulk metal and solid state systems. Currently, it is not fully conclusive how to
choose the optimal exchange-correlation functional for M-DNA systems.
In this work, we chose to study Ag+-mediated guanine tetramer, whose ECD has been reported
recently [20] to systematically study how the basis sets, the exchange-correlation functionals, and the
implicit water affect simulations of the ECD. This work will provide some useful knowledge to choose
suitable computational methods for studying silver-DNA systems and other M-DNAs.
2. Results and Discussion
2.1. QM/MM Molecular Dynamics and the Atomic Structures of the Ag+-Mediated Guanine Tetramer
To unveil the atomic structure of the Ag+-mediated guanine duplex in water, we have previously
performed QM/MM molecular dynamics calculations for the smallest Ag+-mediated guanine duplex
G2-Ag+2 -G2, namely the Ag
+-mediated guanine tetramer [21]. Silver and DNA atoms were treated at
the DFT level. Solvation was modeled with a 4 nm box of classical water molecules and the Amber force
field [22]. The calculations were carried out with the CP2K code [23], and the Perdew–Burke–Ernzerhof
(PBE) exchange and correlation potential [24]. Grimme’s D3 dispersive corrections were used to
account for long-range van der Waals interactions [25]. Before the QM/MM simulations, the system
was first equilibrated at 300 K with a classical NVT run of 2 ns, using the Amber force field. Then
the QM/MM simulations were performed for 21 ps with a time-step of 0.5 ps. In the QM/MM
simulations, van de Waals interactions between the QM and MM regions were approximated by
classical force fields. Electrostatic interactions between the two subsystems were accounted for using
an embedding approach, where point charges located at the water molecules (MM region) can polarize
the Ag+-mediated DNA (QM region). By comparing the root mean square distance of the heavy
atoms to the initial structure positions, we can conclude that the system reached an equilibrium regime
after 16ps. Therefore, we used only the last 5 ps of the trajectory for analysis. Further details of these
simulations can be found in Reference [21].
In this work we adopted the structures for the ECD analysis from our previous QM/MM study.
We briefly recap the structural findings from Reference [21]. In brief, Ag+ ions bind to the N atoms
in the Hoogsteen region (Figure 1a) and the DNA forms a left-handed helix. The Ag–Ag distance
oscillates around an average value of 3.45 Å with a standard deviation of 0.27 Å. A typical structure of
an Ag+-mediated tetramer is shown in Figure 1b.
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Figure 1. (a) Ag+ binds to N7 and N7’ in the Hoogsteen region; (b) One typical structure of G2-Ag+2 -G2
from the final 0.5 ps of the hybrid quantum mechanics/molecular mechanics (QM/MM) simulation.
The structure was taken from our previous work [21] and replotted here. The interplanar H-bond is
highlighted with a green line. Atomic color code: Ag: silver, N: blue, C: black, O: red, P: Olive and
H: white.
2.2. Time-Dependent Density Functional Theory Study for the Optical Properties of the Ag+-Mediated
Guanine Tetramer
Previously we have simulated the ECD of G2-Ag+2 -G2 by linear-response time-dependent density
functional theory (TDDFT) implemented in GPAW [26,27]. GPAW is a DFT code based on the
projector-augmented wave (PAW) method and the wave functions are expanded on uniform real-space
grids. We used the LB94 [28] exchange-correlation functional in that simulation. Although the
simulated average ECD and the measured ECD of G2-Ag+2 -G2 were in satisfactory agreement [21],
it is worthwhile to check how the basis sets and the exchange-correlation functional affect the ECD
simulations when we switch to the Gaussian16 code [29]. One particular question we are interested in
is, can hybrid functionals improve the agreement between the calculated and the measured ECD?
In this work, we employed the Gaussian16 code [29] to simulate the ECD spectra. The details can
be found in the Materials and Methods section.
2.2.1. Experimental ECD Spectra of Ag+-Mediated Guanine Species
The experimental ECD spectra for three Ag+-mediated guanine species obtained from Reference [20]
are shown in Figure 2. The spectra of G6-Ag+6 -G6 and G20-Ag
+
20-G20 exhibit similar features, but the
G2-Ag+2 -G2 spectrum differs. This is possibly due to aggregation induced by the Ag
+ ions, which
prevents a comparison of the intensity between the predicted and the experimental ECD [20,30,31].
However, G2-Ag+2 -G2 presents a good model system to study the ECD of Ag
+-mediated guanine
duplexes, especially in terms of the negative peak locations and the absence of any positive peaks.
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Figure 2. The experimental electronic circular dichroism (ECD) spectra of Ag+ stabilized G2, G6, and
G20. Δε is differential molar extinction coefficients Δε=εL-εR, λ is the wavelength. Data reproduced
with permission from Swasey, S. and Gwinn, E. New J. Phys. 2016, 18, 045008-045025. [20].
2.2.2. Tests for Basis Set Convergence
We first tested the basis set convergence on a single sampled structure. Two popular
hybrid exchange-correlation functionals, B3LYP [32,33] and the Coulomb-attenuated B3LYP
(CAM-B3LYP) [34], were used for the tests. A single compute node with 20 Haswell cores and 40 GB
of shared memory was used. To assure convergence in the range of 180–360 nm, 300 and 150 excited
singlet states were used in the B3LYP and CAM-B3LYP calculations, respectively.
Figure 3 shows the effects of employed basis sets for C, H, N, and O atoms and the related
cost for calculating the ECD spectrum of a single sampled structure. For Ag, the LANL2DZ/ECP
basis set was used in all calculations. Figure 3 shows that B3LYP is more sensitive to the basis sets
when diffusion functions are added. For both functionals, basis set convergence is reached by the
minimally augmented Dunning basis set, maug-cc-pvdz. It gives practically the same ECD spectra
as the aug-cc-pvdz and 6-311++G**, which have been previously used for M-DNAs and pure base
pair systems [19,35,36] with good performance. The capability of maug-cc-pvdz to match aug-cc-pvdz
has been shown previously for other systems and similar to this study, doing so with much lower
computational cost [37]. Based on the results presented in Figure 3, maug-cc-pvdz was chosen for the
remainder of this work.
The two functionals give significantly different ECD spectra. CAM-B3LYP exhibits two peculiar
positive peaks at 204 and 234 nm that are absent in the B3LYP spectrum. In the following, we will
trace the origin of this difference and try to find the best functionals for studying the optical properties
of Ag+-DNA.
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Figure 3. (main figures) The effects of basis sets and exchange correlation-functional on the ECD
spectrum of a single snapshot structure and (inset figures) the related cpu time costs. (a) B3LYP;
(b) CAM-B3LYP.
2.2.3. Calculated Average ECD and Comparison to the Experimental ECD
Previous work [21] has highlighted the importance of sampling molecular dynamics trajectories
and comparing averaged ECD spectra to experiment. Typically ten sampled structures were found to
be adequate for G2-Ag+2 -G2 in water. Therefore, in this section, we will discuss the calculated average
ECD spectra and compare them to the experimental ECD in Figure 2.
Figure 4 shows the calculated average and individual ECD with the B3LYP and CAM-B3LYP
functionals, respectively. In order to show that ten samples are enough to capture the main features of
the ECD, we have also added the 95% confidence interval of the average ECD in the figure. The negative
peaks predicted by B3YLP lie around 200 and 270 nm, while the CAM-B3YLP peaks are around 190 and
260 nm. They are both shifted towards the short wavelength region compared to experiment (peaks
around 220 and 280 nm). The B3LYP ECD is in good agreement with the experimental ECD spectrum.
The main difference is a small shoulder (<20 M−1cm−1) between 220 and 240 nm. This shoulder
becomes much more pronounced in CAM-B3YLP (about 50 M−1cm−1). Such a shoulder, or in fact
any positive peak, is not present in the experimental ECD spectra. This poses the question of whether
CAM-B3YLP predicts artifacts for our system. To make sure the peculiar positive feature in the
CAM-B3LYP spectra is not due to the solution, we have calculated the ECD in an implicit solution
environment. The positive peak remains. More details can be found in the Appendix A.
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Figure 4. The average and individual ECD spectra of ten sampled structures with B3LYP (a) and
CAM-B3LYP (b). Spectra are not shifted, but presented as calculated.
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In the following, we will investigate different reasons for the difference between B3LYP and
CAM-B3LYP and for CAM-B3LYP’s erroneous behavior.
2.2.4. Amount of Hartree–Fock Exchange
The amount of Hartree–Fock (HF) exchange in hybrid functionals is known to be crucial in
studying transition metal complexes [38,39], and lowering the amount of HF exchange in B3LYP from
20 % to 15 % has proven to be a valid modification to correctly obtain energetics for proton and electron
transfer reactions in comparison with experimental values [38–41]. We have also tested this modified
B3LYP, called B3LYP*, for the Ag+-mediated guanine tetramer, along with a pure GGA functional PBE,
which has no HF exchange.
The averaged ECD spectra from ten sampled B3LYP* and PBE structures are shown in Figure 5.
The ECD of the individual samples and the 95% confidence interval of the average ECD are given
in the same figure. The amount of HF exchange has a clear effect, since the positive shoulder has
now vanished. Both B3LYP* and PBE successfully predict the two negative peaks in the experimental
ECD. B3LYP* gives a better agreement with the intensity of the peaks in the experimental ECD of
G2-Ag+2 -G2, but PBE predicts the positions of the peaks more accurately. There are spurious peaks in
the individual ECD spectra predicted by PBE in the long wavelength region. However they cancel
each other out in the averaged ECD spectrum. Comparing the ECD spectra from B3YLP, CAM-B3YLP,
B3YLP*, and PBE, we conclude that it is important to adjust the amount of Hartree–Fock exchange in
exchange-correlation functional, in order to predict the ECD of G2-Ag+-G2 accurately. The sensitivity
to the amount of exact exchange might be a common issue for other M-DNA systems, especially for
the Ag+-mediated guanine-rich DNA systems.
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Figure 5. The average and individual ECD spectra of ten sampled structures with (a) the
B3LYP* (15% Hartree–Fock (HF) exchange) and (b) the Perdew–Burke–Ernzerhof (PBE) functionals.
No shiftings of the calculated spectra are done.
2.2.5. Effect of the Long-Range Correction in CAM-B3LYP
B3LYP adequately predicts ECD spectra for many organic molecules [42,43]. However, CAM-B3LYP
is a functional built to overcome the deficiencies of B3LYP and to correctly describe charge transfer,
local excitations, and Rydberg excitations [34]. It has been assessed for a broad set of small main group
and organic molecules [44], and has been demonstrated to outperform B3LYP for chiral alkenes [45],
chiral aromatic nitro compounds [46], and metal-porphyrin complexes [47]. It is very interesting to
understand why for our Ag+-guanine system, CAM-B3YLP gives less accurate ECD spectra than
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B3LYP. For this purpose, we first tested the two functionals on two DNA systems without metal ions:
one is a C2-G2 tetramer taken from a reported B-DNA structure (9BNA in the protein data bank), and
another is a G2-G2 tetramer taken from the same sample used in Figure 3, in which the Ag atoms
were deleted.
Figure 6 shows the experimental ECD of a B-DNA [48,49] (d(m5C-G-C-G-m5C-G)) and the
calculated ECD spectra of the C2-G2 system using B3LYP and CAM-B3LYP. As for the Ag+-mediated
guanine tetramer we removed the sugar–phosphate backbone and optimized the replacement
hydrogen atoms at the B3LYP/6-31G** level. B3LYP predicts the correct positions and intensity
of the peaks in the experimental ECD. On the other hand, CAM-B3LYP also gives overall correct
features, but with a shift of roughly 20 nm towards the lower wavelength region. A shift of the same
order (roughly 20 nm) was also obtained between CAM-B3LYP and B3LYP for G2-G2 as shown in
Figure 7. Although CAM-B3LYP predicts more intensive peaks with shifts to lower wavelengths,
these two functionals give qualitatively the same ECD features for the two DNA structures without
metal ions.

















Figure 6. (a) The structure of a plain B-DNA tetramer. The color of atoms : O: red, C: black, N: blue and
H: white. (b) The corresponding calculated and experimental [48,49] ECD spectra. No shifting of the
calculated spectra are done.


















Figure 7. (a) The structure of a plain guanine tetramer. The color of atoms : O: red, C: black, N: blue
and H: white. (b) The corresponding calculated ECD spectra. No shifting of the calculated spectra
are done.
To further investigate the difference between B3LYP and CAM-B3LYP in our system, we calculated
the ECD spectra of a sampled structure by gradually changing CAM-B3LYP to B3LYP. This was
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done by changing the short-range parameter α and the long-range parameter β in the definition of




1 − [α + β · erf(μr12)]
r12
+
α + β · erf(μr12)
r12
. (1)
The HF exchange has a weight of α at r12 = 0 and α+ β at r12 = ∞. Correspondingly, DFT exchange
is 1 − α at r12 = 0 and 1 − (α + β) at r12 = ∞. The default parameter values for CAM-B3LYP are
α = 0.19, β = 0.46, and μ = 0.33. The parameter μ sets the midpoint behavior, and was kept at the default
value of 0.33. With parameters α = 0.2 and β = 0, B3LYP is obtained.
The results are shown in Figures 8 and 9. Figure 8 shows that we achieve a smooth transformation
from CAM-B3LYP to B3LYP. The absolute intensity of the negative peak in the short wavelength region
reduces and the ECD spectrum shifts towards the long wavelength direction. The positive features
observed in CAM-B3LYP smoothly vanish. Figure 9 also shows the transformation, together with the
involved rotatory strengths of the singlet excitations. The positive peak emerges from a collection of high
intensity excitations, which are gradually shifting towards the higher wavelength region. From these tests,
we can conclude that applying the long-range corrected hybrid function CAM-B3LYP to Ag atoms cause
the unnatural features in the calculated ECD.
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Figure 9. Transformation from CAM-B3LYP to B3LYP by changing the short- and long-range
parameters. (a) CAM-B3LYP (α = 0.19, β = 0.46); (b) α = 0.1925, β = 0.3450; (c) α = 0.1950, β = 0.23;
(d) α = 0.1975, β = 0.1150; and (e) B3LYP (α = 0.2, β = 0).
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Finally, to show the capability of our methodology to predict ECD spectra, our best predictions
without any fitting are shown alongside experimental spectra in Figure 10. The two negative peaks are
predicted within 20 nm.






























Figure 10. The experimental ECD [20] spectra shown along with our best prediction by B3LYP*.
No shiftings of spectra are done.
3. Materials and Methods
In this work, we employed the Gaussian16 code [29] which uses Gaussian type local basis sets
to simulate the ECD spectra. The sugar–phosphate backbones were replaced by hydrogen atoms to
make the computational cost feasible. We argue that this is reasonable, because the sugar–phosphate
backbone is not the main interest of our study and does not affect the optical properties in the
region of interest (long distances from the center Ag+-ions and transitions at high energies [50]).
The replacement hydrogen atoms were then relaxed at the B3LYP/6-31G** level, while keeping the
rest of the atoms frozen.
Singlet transitions were included in excited state calculation so that the high-energy wavelength
region up to 170 nm was covered (to assure convergence up to 180 nm) for the Ag+-mediated tetramer
and guanine tetramer. The first 300, 500, 700, and 150 transitions were included for B3LYP, B3LYP*,
PBE, and CAM-B3LYP calculations, respectively. For B-DNA, the high-energy wavelength region,
up to 210 nm, was covered by the first 60 and 80 transitions for CAM-B3LYP and B3LYP, respectively.
The following relations were used in the ECD spectra simulations [51–53]:



















where Δε is molar circular dichroism (in M−1cm−1), NA is Avogagro’s constant (in mol−1), h is Planck’s
constant (in Js), c is the speed of light (in cm s−1), Rn is length-gauge rotatory strength (in 10−40 cgs),
E is the energy of the incident light (in eV), En is the excitation energy to state n (in eV), and σ is the
exponential half-width in Gaussian convolution (here 0.3 eV was used for the Ag+-mediated tetramer
and 0.2 eV for the B-DNA and plain guanine tetramers).
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4. Conclusions
In summary, we have used TDDFT and QM/MM to study the ECD spectra of the Ag+-mediated
guanine tetramer. We have discussed how the basis sets and the exchange-correlation functional affect
the computed ECD spectra. For the basis sets, convergence is achieved at the maug-cc-pvdz level.
The tested functionals CAM-B3LYP, B3LYP, B3LYP* (15% HF), and PBE all successfully predict two
negative peaks within a 20 nm error. B3LYP* and PBE give the best agreement of the measured ECD.
Conversely, CAM-B3LYP produces a spurious positive feature, which is not observed in experiment.
Our study highlights the importance of the exchange-correlation functional. In future ECD studies of metal
enhanced DNA in water, we recommend to start with the PBE or B3LYP* functionals. Due to the much
lower computational cost and satisfactory accuracy of PBE, it is a better choice for large M-DNA systems.
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Appendix A. Solvent Effect on the CAM-B3LYP Calculated ECD
To investigate if the peculiar positive feature in the CAM-B3LYP spectra is due to the solution,
we calculate the ECD in a solvent environment. We modeled water implicitly by a polarizable
continuum model (PCM) [54]. Here we used a linear-response procedure, where the solvent effect
on the self-consistent field (SCF), density of solute, is computed by adding the required terms to the
TDDFT equations [55]. Figure A1 shows the effects of the implicit solvent model on the average ECD
of ten sampled structures. The positive peak remains.

















Figure A1. The average ECD spectra of ten sampled structures with CAM-B3LYP in the gas phase and
in a polarizable continuum model (PCM) water environment. No calculated spectra were shifted.
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Abstract: Organometallic ruthenium(II) complexes [(η6-arene)Ru(en)Cl][PF6] (arene = benzene (1),
p-cymene (2), indane (3), and biphenyl (4); en = ethylenediamine) are promising anticancer drug
candidates both in vitro and in vivo. In this paper, the interactions between ruthenium(II) complexes
and 15-mer single- and double-stranded oligodeoxynucleotides (ODNs) were thermodynamically
investigated using high performance liquid chromatography (HPLC) and electrospray ionization
mass spectroscopy (ESI-MS). All of the complexes bind preferentially to G8 on the single strand
5′-CTCTCTT7G8T9CTTCTC-3′ (I), with complex 4 containing the most hydrophobic ligand as the
most reactive one. To the analogs of I (changing T7 and/or T9 to A and/or C), complex 4 shows
a decreasing affinity to the G8 site in the following order: -AG8T- (K: 5.74 × 104 M−1) > -CG8C- >
-TG8A- > -AG8A- > -AG8C- > -TG8T- (I) ≈ -CG8A- (K: 2.81 × 104 M−1). In the complementary strand
of I, the G bases in the middle region are favored for ruthenation over guanine (G) bases in the end of
oligodeoxynucleotides (ODNs). These results indicate that both the flanking bases (or base sequences)
and the arene ligands play important roles in determining the binding preference, and the base- and
sequence-selectivity, of ruthenium complex in binding to the ODNs.
Keywords: organometallic ruthenium complexes; anticancer; oligodeoxynucleotide; base/sequence
selectivity; thermodynamics; LC-MS
1. Introduction
Organometallic ruthenium(II) arene complexes [(η6-arene)Ru(YZ)(X)]n+ have interesting
anticancer properties both in vitro and in vivo, including cytotoxic activity towards cisplatin-resistant
cell lines [1–9]. The arene ligand occupies three coordination sites in this type of pseudo-octahedral
complexes and stabilizes Ru in its +2 oxidation state [10]. These mono-functional complexes appear
to have a novel mechanism of action, differing from those of bi-functional cisplatin [11] and of the
Ru(III) anticancer complexes, for example, (ImH)[trans-RuCl4Im(Me2SO)] (NAMI-A, Im = imidazole)
and (IndH)[trans-RuCl4(Ind)2] (KP1019, Ind = indazole), which have entered into clinical trials [12–15].
The cytotoxicity of the chloro ethylenediamine complexes [(η6-arene)Ru(en)Cl][PF6] (arene = benzene,
p-cymene, biphenyl, tetrahydroanthracene, etc.; en = ethylenediamine) increases with the size of
coordinated arene. DNA has been shown to be a potential target for these Ru(II) arene complexes,
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most of which bind selectively to N7 of guanine [16–19]. The biphenyl Ru complex shows a decreasing
activity towards mononucleotides in the following order: 5′-GMP(N7) > 5′-TMP(N3) >> 5′-CMP(N3)
> 5′-AMP (N7/N1), being more discriminatory between guanine (G) and adenine (A) bases than
cisplatin, which exhibits affinity to adenine second to guanine [11]. The formation of H-bonds between
en-NH2 groups of ruthenium complexes and C6O of guanine was found to associate with this selective
coordination [16,17]. The guanine bases in oligonucleotides of different sequences and in calf thymus
DNA have been demonstrated to be the only sites ruthenated by the Ru(II) arene complexes [18,20–23].
Importantly, complexes containing π-rich arene ligands, like biphenyl or tetrahydroanthracene, showed
combined coordination to guanine N7 and non-covalent interactions between the arene ligands and
DNA bases, including arene intercalation and minor groove binding [16,17,20,21].
We have previously demonstrated that the thymine (T) bases in 15-mer single-stranded
oligodeoxynucleotides (ODNs) can kinetically compete with G for binding to ruthenium arene
complexes, but such T-bound mono-ruthenated ODN complexes were not thermodynamically stable
and finally transformed to stable G-bound adducts, including mono-G-bound ODNs and minor
G,T-bound di-ruthenated adducts [24]. Interestingly, the T-bases in G-quadruplex DNA are both
kinetically and thermodynamically competitive with G-bases for ruthenation by ruthenium arene
complexes because G-N7 is involved in H-bonding in G-quadruplex DNA [25].
The chloride ligand in the mono-functional compounds [(η6-arene)Ru(en)(Cl)]+ is readily
hydrolyzed to give the more reactive aqua species [(η6-arene)Ru(en)(H2O)]2+. However, reaction
of the aqua ruthenium complexes with DNA is retarded at high pH, suggesting that Ru–OH2 bonds
are more reactive towards DNA than Ru–OH bonds [24,26,27]. Such behavior appears parallel to
that of Pt(II) diam(m)ine anticancer complexes [28]. The bi-functional complex cisplatin undergoes
a two-step aquation to form 1,2-intrastrand cross-linked DNA adducts, which is thought to be
the main lesions on DNA that triggers apoptosis signaling initiated by high mobility group box
1 (HMGB1) protein recognition [11]. These two steps of hydrolysis, especially the second step, can
be rate-limiting for interactions of cisplatin with DNA bases [28]. For instance, the formation of
5′-GpA intrastrand crosslinks by cisplatin is more preferred than that of 5′-ApG in d(ApGpA) and
d(TpApGpApT) [29]. The rate of hydrolysis of the chloride ligand in the mono-aquated cisplatin
was shown to be the key step that controlled the final bi-functional intrastrand adduct profiles when
cisplatin bound to DNA with various X-purine-purine-Y motif [30]. However, aquation cannot be the
only factor that controls the rate and selectivity of DNA binding of cisplatin. The diaquated form of
cisplatin, [Pt(NH3)2(OH2)2]2+, displays no preference for the 3′- or 5′-guanine in a TpGpGpT sequence
of a hairpin duplex oligonucleotide [31] or a single-stranded oligonucleotide [32]. Surprisingly,
the 5′-guanine in TpGpGpC motif of a single-stranded oligonucleotide is preferred by a factor of two,
and even by a factor of twelve over the 3′-guanine in a duplex oligonucleotide [33]. These indicate
that DNA structure (or/and sequence) is a primary factor for determining the binding preference
of bifunctional cisplatin to DNA. For the mono-functional Ru(II) arene complexes, binding to DNA
may not be as complicated as that of cisplatin, but the varied flanking sequences next to the binding
sites (e.g., guanine bases) may significantly affect the selective ruthenium binding, finally causing
distinct response to the damaged DNA. However, the DNA binding properties, in particular sequence
selectivity, of Ru(II) arene complexes are poorly understood.
In this present work, the interactions of [(η6-arene)Ru(en)Cl][PF6] (arene = benzene (1),
p-cymene (2), indane (3), and biphenyl (4)) with 15-mer single- or double-stranded ODNs have
been thermodynamically investigated using high performance liquid chromatography (HPLC) and
LC-mass spectroscopy (MS). Based on the thermodynamic binding constants, we found the arene
ligands of ruthenium complexes and adjacent bases of guanine have great influence on the binding
affinity of ruthenium to guanine. We elucidated the base-selectivity and sequence-selectivity on the
DNA binding of the ruthenium arene complexes, and hope to provide novel insights into the molecular
mechanism of action of organometallic ruthenium anticancer complexes.
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2. Results
2.1. Reactions of Organometallic Ruthenium(II) Complexes with One-G-centered Single-Stranded ODNs
Chart 1 shows the structures of the Ru(II) arene complexes and sequences of ODNs used in
this work. Firstly, each ruthenium complex was incubated with 1 mol equiv strand I in 50 mM
triethylammonium acetate buffer (TEAA) buffer solution (pH 7) at 310 K for 24 h. The reaction
mixtures were then separated and analyzed by HPLC with ultraviolet (UV) detection at 260 nm
(Figure 1), and each fraction was identified by electrospray ionization mass spectroscopy (ESI-MS).
The observed negatively-charged ions corresponding to ruthenated I are listed in Table 1, and the
mass spectra are shown in Figure S1 in the supplementary materials. The reaction of complex 1
with strand I gave rise to only one mono-ruthenated product, as indicated by the triply-charged ion
[I-{(η6-benzene)Ru(en)}]3− at m/z 1556.56 (Figure S1, supplementary materials). However, minor
amount of di-ruthenated adducts were detected for the reaction mixtures of complexes 2–4 with 1 mol
equiv strand I apart from the respective mono-ruthenated adducts at larger amount compared with
the mono-ruthenated I by complex 1 (Figure 1, Figure S1 in supplementary materials). Moreover, even
in the presence of 2-fold complex 1, only ca. 67% of strand I was ruthenated (Figure 2) to produce
mono-ruthenated ODN complex, while at the same molar ratio (Ru/I = 2.0), over 90% of strand I was
ruthenated by complex 2, 3, or 4, affording the mono-ruthenated ODN as the main product with a
significant amount of di-ruthenated ODN complex (Figure 2).
Short name                    Sequence
I                 5′-C1TCTCTTG8TCTTCTC15-3′
II             3′-G30AGAGAAC23AGAAGAG16-5′


















Chart 1. Structures of ruthenium arene anticancer complexes and sequences of oligodeoxynucleotides
(ODNs) used in this work. ODNs IV–IX are the analogues of strand I with only variations at the
neighboring bases of the central guanine (underlined).
In order to make sure that the reactions of complexes 1–4 with strand I reached equilibrium within
24 h, we analyzed the reaction mixtures of complex 4 with strand I for various times. As shown in
73
Int. J. Mol. Sci. 2018, 19, 2137
Figure 1B, no pronounced changes in the product ratios were observed after 24 h of incubation even in
the presence of 5 mM NaCl, which mimics the concentration of Cl− in nuclear as Cl− was thought to
retard the hydrolysis of ruthenium arene complexes [26], subsequently slowing down their reaction
with ODNs. These results indicate that the reactions of the ruthenium complexes with single-strand
ODNs reached equilibrium within 24 h.
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Figure 1. High performance liquid chromatography (HPLC) chromatograms with ultraviolet (UV)
detection at 260 nm for reactions of ruthenium complexes with single strand I. (A) Complex 1 (i),
2 (ii), 3 (iii), or 4 (iv) with single strand I (0.1 mM, Ru/I = 1.0) in 50 mM triethylammonium acetate
buffer (TEAA) (pH 7) at 310 K for 24 h; (B) complex 1 with I (0.1 mM, Ru/I = 1.0) in 50 mM TEAA
(pH 7) and 5 mM NaCl at 310 K for different times. Peak assignments: a, unruthenated strand I;








































































Figure 2. (A–D) HPLC chromatograms for reaction mixtures of complex 1 (A), 2 (B), 3 (C), or 4 (D) with
single strand I (0.1 mM) at various molar ratios in 50 mM TEAA at 310 K for 24 h. Peak assignments:
a, unruthenated strand I; b, mono-ruthenated I; c, di-ruthenated I. (E) A direct plot (dots) of moles
of ODN-bound 1, 2, 3, or 4 ([Ru]B) as a function of the concentration of free ruthenium complexes
([Ru]F). Computer-fitting (lines) of the experimental data to the ligand–receptor binding Equation (8)
(see details in Supplementary Materials) gave rise to the equilibrium constants for the two-site binding
reactions listed in Table 2.
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Table 1. Negatively-charged ions observed by electrospray ionization mass spectroscopy (ESI-MS) for
the high performance liquid chromatography (HPLC) fractions (Figure 1) from the reaction mixtures of
complexes 1–4 with 1 mol equiv of single-strand I. For mass spectra, see Figure S1.
Ru Complex
m/z: Observed (Calculated)
[I]3− [I + {Ru} 1]3− [I + {Ru}2]3−
1 a: 1477.22 (1477.24) b: 1556.56 (1556.58) — 2
2 a: 1477.22 (1477.24) c: 1575.25 (1575.27) f: 1672.96 (1672.95)
3 a: 1477.22 (1477.24) d: 1569.91 (1569.92) g: 1662.65 (1662.60)
4 a: 1477.22 (1477.24) e: 1581.89 (1581.92) h: 1686.66 (1686.60)
1 {Ru} = {(η6-arene)Ru(en)}2+, arene = benzene (1), p-cymene (2), indane (3), or biphenyl (4); 2 not detectable.
Table 2. Equilibrium binding constants (K) for the reactions of complexes 1–4 with strand I.
Ru Complex K1 (104 M−1) K2 (104 M−1) K1/K2
1 0.79 ± 0.04 0.18 ± 0.03 4.39
2 3.94 ± 0.24 0.51 ± 0.05 7.72
3 2.52 ± 0.13 0.43 ± 0.04 5.86
4 2.92 ± 0.46 2.75 ± 0.47 1.06
We have previously shown that the G8 base in strand I is the main binding site for the
ruthenium biphenyl complex 4, and that T7 and T11 in the same strand are the kinetically favored, yet
thermodynamically unfavored, ruthenation sites by complex 4 [24]. Taking the structural similarity
of the four ruthenium arene complexes into account, we assume that the mono-ruthenated adducts
formed by the reactions of strand I with complexes 1–4 are G8-bound ODN complexes, and the minor
di-ruthenated adducts are G8,Tx-bound (x = 7 or 11) ruthenated I [24].
Next, the reaction mixtures of the four ruthenium complexes with strand I at various molar
ratios of Ru to I were analyzed by HPLC so as to determine the equilibrium binding constants of the
two-site receptor/ligand reaction. The results are shown in Figure 2A,D. On the basis of the HPLC
peak areas with UV detection at 260 nm (the coordination of Ru(II) arene complexes to ODNs had little
effect on their extinction coefficients at 260 nm), the extent of saturation (B in Equation (8) shown in
Materials and Method) of the ODN binding sites was plotted as a function of the amount of unbound
Ru complex (L) [25]. The resulting curves were computer-fitted to Equation (8) (Figure 2E), giving rise
to the equilibrium constants listed in Table 2.
It can be seen that among the four ruthenium complexes, the benzene complex 1 had the lowest
equilibrium constants for both binding steps to strand I, whereas the p-cymene complex 2 exhibits the
highest binding affinity to strand I for the first step, and the biphenyl complex 4 is the most highly
active to bind to strand I for the second step. It is notable that for complexes 2 and 3, the K values
for the first step binding are much higher than those for the second step, but complex 4 has a similar
affinity for both of the binding steps. In other words, complexes 2 and 3 are more discriminative
between the G and T in the single-stranded ODN than complex 4.
To investigate the sequence selectivity of Ru(II) arene complexes binding to DNA, six analogues of
single-stranded ODN I with sequence variants only at the adjacent bases to G8 (Chart 1) were selected
to react with complex 4 at molar ratios of Ru/ODN ranging from 0.2 to 2 under the same conditions
as described above. Analysis of the reaction mixtures by HPLC (Figure 2D, Figures S2A–S7A in
supplementary materials) shows a similar binding profile for complex 4 to all the seven ODNs, that
is, at Ru/ODN = 1.0, about 70% of the ODN was ruthenated, and at Ru/ODN = 2.0, less than 5%
ODN remained intact. However, based on the thermodynamic G8,Ti-diruthenated model (Scheme 1),
the equilibrium constants (Table S1) resulting from the computer-fits of the titration data to Equation (8)
showed a pronounced difference (Figure 3). The equilibrium constants for the first (mono-ruthenation)
step of binding decreased in the following order: -AG8T- (VIII) > -CG8C- (VII) > -TG8A- (IV) > -AG8A-
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(IX) > -AG8C- > (VI) -TG8T- (I) ≈ -CG8A- (V), whereas the equilibrium constants for the second step
of binding, which formed the di-ruthenated ODNs, decreased in the following order: -TG8T- (I) ≈
-CG8A- (IV) > -AG8T- (VIII) > -CG8C- (VII) > -AG8C- (VI) ≈ -TG8A- (IV) > -AG8A- (IX). Except for the
-TG8T- and -CG8A- sequences, the equilibrium constants for the first step of binding of complex 4 to
the other five ODNs are almost two-fold higher than those of the second step of binding, implying











Scheme 1. Schematic representative model for the binding reactions of organometallic ruthenium
anticancer complexes to oligodeoxynucleotides (ODNs) I and IV–IX at the guanine (G) and thymine
(T) sites based on the divalent receptor system. Bare circle with G/T means unoccupied site and black
























Figure 3. Sequence selectivity of organometallic ruthenium complex 4 binding to single-strand ODNs I
and IV–IX. K1 and K2, of which the values are listed in Table S2 in supplementary materials, are the
binding constants of complex 4 to each ODN at the first and the second step of binding, respectively.
2.2. Reactions of Organometallic Ruthenium(II) Complexes with Single-Strand II
The ruthenium complex 1, 2, 3, or 4 was individually incubated with single-strand II,
the complementary strand of I, at a molar ratio of Ru/II = 1.0 or 3.0 in 50 mM TEAA buffer solution at
310 K for 24 h. The reaction mixtures were then analyzed by HPLC and ESI-MS, and the observed
negatively-charged ions for ruthenated II are listed in Table 3. The HPLC chromatograms with TIC
(total ion count) detection and mass spectra of each HPLC fraction are shown in Figure 4 and Figure S8
in supplementary materials, respectively. At a molar ratio of Ru/II = 1.0, a significant amount of mono-
and di-ruthenated II resulted from the reactions of II with complex 2, 3, or 4, but the reaction of the
benzene complex 1 with II afforded only mono-ruthenated II. Even in the presence of three-fold excess
of complex 1, nearly half of strand II remained intact after 24 h of reaction. In contrast, the reaction
of strand II with three-fold excess of complex 2, 3, or 4 resulted in ruthenation of ca. 85% II, giving
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a pronounced amount of triply-ruthenated II. For 3 and 4, a small amount of tetra-ruthenated II,
as indicated by the triply-charged ions at m/z 1938.42 and 1986.32, respectively, were also observed
(Table 3, Figure S8).
Table 3. Negative ions observed by ESI-MS for the HPLC fractions shown in Figure 4 (for mass spectra,
see Figure S8 in supplementary materials).
Ru Complex
m/z: Observed (Calculated)
[II + {Ru} 1]3− [II + {Ru}2]3− [II + {Ru}3]3− [II + {Ru}4]3−
1 b: 1647.31 (1647.28) c: 1726.69 (1726.62) c: 1805.81 (1805.62) — 2
2 d: 1666.32 (1666.30) e: 1764.34 (1764.33) m: 1862.10 (1862.02) — 2
3 f: 1660.96 (1660.96) g: 1753.37 (1753.30) n: 1846.01 (1845.99) n: 1938.42 (1938.34)
4 h: 1672.96 (1672.96) k: 1777.33 (1777.30) p: 1882.04 (1881.99) p: 1986.32 (1986.33)
1 {Ru} = {(η6-arene)Ru(en)}2+ (arene = benzene (1), p-cymene (2), indane (3) or biphenyl (4); 2 Not detected.










































































Figure 4. Total ion count (TIC) chromatograms for reactions of complex 1 (i), 2 (ii), 3 (iii), or 4 (iv) with
single strand II (0.1 mM) at the molar ratio of (A) Ru/II = 1.0 or (B) Ru/II = 3.0 in 50 mM TEAA (pH 7)
at 310 K for 24 h. Peak assignments: a, unruthenated strand II; b, d, f, and h, mono-ruthenated II; c, e,
g, and k, di-ruthenated II; m, n, and p, tri-ruthenated II. Notably the fraction c in (B) contains a little
tri-ruthenated II by 1 and fractions n and p contains a small amount of tetra-ruthenated II by 3 or 4 as
shown in Figure S8 in supplementary materials.
To identify the preferential binding sites of the tested ruthenium complexes in strand II,
a three-fold excess of complex 1 or 2 was incubated with strand II at 310 K for 24 h. The adducts
were digested by snake venom phosphodiesterase (SVP) after removing unbound ruthenium
through centrifugation, and then analyzed by HPLC-ESI-MS in negative mode. The observed ions
corresponding to ruthenated ODN fragments are listed in Table S2 in supplementary materials, and the
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mass spectra are shown in Figure S9 in the supplementary materials. Firstly, the results showed
that the SVP digestion stopped at G21, as evidenced by the detection of doubly-charged ions at
m/z 1050.53 and 1078.24, which are assignable to the mono-ruthenated ODN fragments [F21-1′]2−
and [F21-2′}]2− (F21 = 3′-G21A20A19G18A17G16-5′, 1′ = {(η6-ben)Ru(en)}, 2′ = {(η6-p-cym)Ru(en)),
respectively. These are parallel to the reactions of ODN II with complexes 3–4 [19]. Secondly,
doubly-charged ions at m/z 1225.29 assignable to the di-ruthenated ODN fragment [F21-2′2]2−
were observed, indicating that the fragment 3′-G21A20A19G18A17G16-5′ contains two binding sites
for complex 2, most likely G21 and G18 as for complex 3 reported previously [19]. Thirdly,
the triply-charged ions at m/z 1335.63, which correspond to the ruthenated fragments [F26-2′2]3− (F26 =
3′-G26A25A24C23A22G21A20A19G18A17G16-5′), were detected, providing evidence for the formation of
di- ruthenated II at G21 and G26 by complex 2 as observed for the reaction of the same strand with
complex 4 [19]. These results suggest that G21 in the middle region of single strand II is the common
preferential binding site for complexes 1–4. Additionally, G18 and G26 are the secondary binding
sites for complexes 3 and 4, respectively, and both G21 and G26 are the secondary binding sites for
complex 2.
2.3. Reactions of Organometallic Ruthenium(II) Complexes with Duplex III
Next, mixtures of complex 1 or 4 with duplex III (= I + II) at Ru/III = 1.0 or 6.0 in 50 mM TEAA
buffer (pH 7) containing 100 mM NaClO4 were incubated at 310 K for 48 h, and then analyzed by
HPLC followed by ESI-MS analysis under negative-ion mode. The chromatograms for the reaction
mixture of duplex III with complex 1 or 4 are shown in Figure 5A, and Figures S10A and S11A,
and the corresponding mass spectra for HPLC fractions are shown in Figure 5B, and Figures S10B
and S11B, respectively. The observed ions for the reaction mixtures at the molar ratio of Ru/III = 6.0
are listed in Table 4. It can be seen that at a low reaction molar ratio (Ru/III = 1.0) (Figure 5B), no
ruthenated I by complex 1 or 4 was detected, but a little amount of mono-ruthenated II by complex
1 ([II-1′]4−) and both mono- and di-ruthenated II adducts [II-4′]4− and [II-4′2]4− by complex 4 were
obviously identified (Figure 5B). Even in the presence of six-fold excess of complex 1, only a small
amount of strand I was ruthenated, accompanied with the observation of a pronounced amount of
mono-ruthenated II and a minor amount of di-ruthenated II adducts (Figure S10B). In contrast, for the
binding of complex 4 to duplex III at 4/III = 6.0, a series of multi-ruthenated I and II adducts were
detected by MS following HPLC separation. The last HPLC fraction (peak e in Figure S11A) was
identified as a mixture of tri-ruthenated I, and tetra-, penta-, and hexa-ruthenated II by 4 (Figure S11B).
Meanwhile, little free II (peak a, Figure S11A) remained, while a large amount of unreacted strand I
(peak b, Figure S11A) was detected in the reaction mixture of complex 4 to duplex III at 4/III = 6.0.
It is noticed that under the given chromatographic conditions, the HPLC separation denatured the
duplex, as well as its ruthenated adducts, into single-stranded ODNs, but a small amount of ruthenated
duplex III was still detected in the fraction c and d in the forms of di-, tri-, tetra-, and penta-ruthenated
duplex III (Figure S11B in supplementary materials).
Circular dichroism (CD) spectroscopy was introduced to elucidate the effect of the Ru arene
complexes on the conformation of duplex ODN III. A CD spectrum provides unique signals in
diagnosing changes in DNA conformation during drug-DNA interactions, for example, the maximum
positive adsorption at ~275 nm attributed to DNA base stacking, and the maximum negative adsorption
at ~245 nm assigned to the right-handed helicity of duplex DNA, may change in both intensity and
wavelength subject to reactions of DNA with drug molecules [34]. CD spectra for 15-mer duplex III (in
50 mM TEAA buffer containing 100 mM NaClO4) in the absence and presence of increasing amounts
of Ru arene complexes 1, 2, or 4 are compared as shown in Figure 5C and Figure S12 in supplementary
materials, with the applied molar ratios of Ru/III = 1.0, 3.0, and 6.0, respectively. Cisplatin was
also introduced to interact with the duplex DNA III as a reference. The 15-mer duplex used in our
experiments has a typical B-DNA conformation in the 100 mM NaClO4 solution with the maximum
positive absorption (base stacking) at ~277 nm and the maximum negative absorption (right-handed
78
Int. J. Mol. Sci. 2018, 19, 2137
helicity) at ~242 nm. The increasing concentration of the ruthenium complexes made more Ru bind
to the duplex DNA, leading to an obvious decrease in the intensity of both positive and negative CD
signals. Complex 4 resulted in the largest decrease in the signal intensity and caused the two absorption
bands to both approach the baseline gradually (Figure S12C). Another interesting variation was that
the maximal positive absorption wavelength had a little red-shift from 277 nm to 282 nm because of
the increasing level of ruthenation by complex 4, while the other two Ru complexes caused no obvious
band shift in the CD spectrum of the duplex ODN. At the same molar ratio (Ru/III = Pt/III = 6.0),
the intensity decrease of positive signal caused by the ruthenium complexes and cisplatin was in the
following order: 1 < 2 < cisplatin < 4, while for negative signal, the order was as follows: 1 < cisplatin















































Figure 5. (A) HPLC chromatograms with ultraviolet (UV) detection at 260 nm for the reaction mixture
of duplex III with complex 1 (i) or complex 4 (ii) (Ru/III = 1.0) in 50 mM TEAA buffer (pH 7) and
100 mM NaClO4 incubated at 310 K for 48 h; (B) mass spectra for HPLC fractions shown in (A);
(C) circular dichroism (CD) spectra of free duplex III (black) and the reaction mixtures of duplex III
with complex 1 (red), 2 (green), 4 (blue) and cisplatin (magenta) incubated at 310 K for 24 h at a molar
ratio of Ru/III or Pt/III = 6.0.
Table 4. Negatively-charged ions observed by ESI-MS coupled to denatured HPLC for reaction mixture
of Ru complex 1 or 4 with duplex III (Ru/III = 6.0, III = I + II). For chromatograms and mass spectra,
see Figures S10 and S11 in supplementary materials.
Ru Complex Observed (Calculated) m/z Observed Ions
1
1107.89 (1107.91) [I]4−
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Table 4. Cont.





















1 1′ = {(η6-benzene)Ru(en)}2+; 4′ = {(η6-biphenyl)Ru(en)}2+.
3. Discussion
Through recognizing different sequences of nucleic acids, the repressor and activator proteins can
regulate the gene expressions. The selective manipulation of gene expression can be achieved by using
small molecules that can target DNA to selectively activate or repress gene expression have a high
potential for being anticancer therapeutics [35–39]. Therefore, it is of great importance to study the
base and sequence selectivity of anticancer metallodrugs and candidates as DNA binders.
The most studied organometallic ruthenium(II) complexes are [(η6-arene)Ru(en)(Cl)]+, where
arene = biphenyl (bip), tetrahydroanthracene (tha), dihydroanthracene (dha), p-cymene (cym),
or benzene (ben) have been previously reported to bind preferentially to N7 of guanosine and
to N3 of thymidine, but weakly to N3 of cytidine, and little to adenosine . Such base-selectivity
appears to be enhanced by strong intra-molecular H-bonding between the en NH2 groups and
exocyclic oxygens. However, reacting with the single-stranded ODNs d(ATACATG7G8TACATA)
(X), d(TATG25TACCATG18TAT) (XI) or the duplex XII (= X + XI), the biphenyl Ru(II) complex was
demonstrated to bind only to N7 of guanine bases (G7, G8, G18, and G25), but not to thymine residues
in either of the single- or double-stranded ODNs [20]. We have recently shown that thymine bases
in single-strand I and its analogs are kinetically competitive with guanine bases for binding to
organometallic ruthenium(II) complexes [24]. The T-bound mono-ruthenated adducts are not stable
and could dissociate or transfer to G-bound adducts or G8,Tx-diruthenated adducts [25]. In the present
work, our thermodynamic studies further prove that the di-ruthenated adducts formed by the reactions
of complexes 2–4 with single strand I and IV–IX bearing a single G base were still detectable even
after 24 h of reaction at 310 K. The binding constants of Ru complexes 1–4 to both G8 and Tx in the
single-stranded ODNs increase with the size of the arene ligands, consistent with previous reports [16].
The similar binding preference of Ru to G over T was also observed for the reactions of the ruthenium
complexes with the duplex ODN III. In these cases, the thymine ruthenation occurred only when
the most of guanine bases in the duplex III were ruthenated. This is just the opposite with the base
selectivity of Zn(II)–acridinylcyclen complexes, which bound to G only after most of T was occupied
in GpT, d(GTGTCGCC), or in duplex d(CGCTAGCG)2 in neutral or basic solution [40]. However,
in acidic solution or nonpolar solvent, the attack of Zn to T was restricted because of the protonation
of T-N3 [41]. We have also found that the competition resulting from the protonation of T-N3 reduces
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the binding affinity of the ruthenium arene complexes to T-N3 in single-stranded ODNs [24]. At pH
4.8, no T-bound adducts were detected in the reaction mixtures of the biphenyl complex 4 with strand
I at Ru/I = 1.0.
The intercalation between the aromatic ligands of Ru arene complexes and the purine ring of
DNA was one of driving forces for the (arene)Ru-G-N7/T-N3 coordination, especially for these with
arene ligands with more than one ring, like biphenyl and tetrahydroanthracene [16,20,23,42–45].
The intercalating ligands in coordinately saturated octahedral RuII, OsII, and RhIII complexes showed
similar function in increasing their DNA-binding affinity, and conferred them with capacity recognizing
DNA bases via shape selection [46]. The strong π–π stacking of acridine–thymine rings was also found
to enhance the affinity of Zn(II)–acridinylcyclen complexes to N3 of dT [47]. However, for some metal
complexes, e.g., trans-[Pt(quinoline)(NH3)-(9EtG)Cl]+, the rigid quinoline ring retards the binding
of Pt to N7 of 5′-GMP [48]. On the other hand, when the extended arene ligand rings in transition
metal complexes intercalate into DNA bases, it may extend the phosphate spacing along the helix
axis; as a consequence, lengthening and unwinding DNA helices [49,50]. Such intercalation distorts
the structure of DNA helices, and makes the hidden sites, for example, T-N3, which participated in
H-bonding with adenine base in duplex DNA, exposed for metal attacking. The reaction of complex 4
with duplex III produced pronounced amounts of G, T-bound di-/tri- ruthenated strand I, but only
G-bound mono-ruthenated strand I formed by reaction of complex 1 with the same duplex ODN,
strongly supporting this deduction [16,51].
Although both cisplatin and the Ru arene complexes can bind to DNA, and unwind and loosen
the DNA helices, the changes in the helical structure of the bound DNA are different. For example,
cisplatin unwinds DNA duplex to about 25◦ [52], while ruthenium complexes only unwind at most
14◦ [23]. The main reason is that cisplatin mainly forms intrastrand crosslinks, which bend the helices
toward the platinated sites, while ruthenium complexes form mono-functional adducts accompanied
by the intercalation of arene ligands between nucelobases, bending DNA duplexes toward the direction
opposite to the ruthenated site. Therefore, the changes in the helicity of DNA due to Ru binding
are dependent on the size of arene ligands of the Ru complexes as evidenced by CD spectra shown
in Figure 5C.
Furthermore, our thermodynamic data demonstrate that the arene ligands of the ruthenium
complexes regulate not only base selectivity, but also sequence selectivity of these complexes to DNA.
For instance, there are six G residues in the single strand II. Our studies show that G21 in the middle
region is the common binding site for all the four ruthenium complexes, and that G18 in the 5’-region
and G26 in the 3′-region are the secondary binding site for complexes 3 and 4, respectively, while both
G18 and G26 are the secondary binding site for complex 2. These results imply that the ruthenium
arene complexes preferentially bind to guanine bases in the middle region of the ODN strand.
For the reactions of polyanionic DNA and the cationic [(η6-arene)Ru(en)(H2O)]2+, which is the
reactive species of the Ru arene complexes produced by hydrolysis in aqueous solution, electrostatic
interactions and H-bonding are the initial recognition forces between Ru complexes and DNA prior to
Ru–DNA coordination [16]. Such binding is noncovalent and reversible. It may significantly influence
the site preference of DNA-metal bindings, which are kinetically controlled [53]. It is proposed that
the preferential binding of cisplatin to guanines is predominantly a result of electrostatic attraction
of the platinum toward the most nucleophilic sites [54,55], for example, the nitrogen N7 atoms of
purines as they are the most electron-dense and accessible sites in DNA for electrophilic attack by
platinum, or by ruthenium in this work. Moreover, the G-N7 sites are exposed in the major groove
of the double helix, and are not involved in base-pair hydrogen-bonding [56,57], which makes G-N7
sites more favored for metalation. However, variations at the neighboring bases of G may cause a
change in the microenvironment that in turn modulates metal coordination and alters the affinity of
Ru atom to guanine. Indeed, our thermodynamic studies show that the binding constants of complex
4 to the centered G base in seven 15-mer single-stranded ODNs containing a variation in the flanking
bases of the G site are significantly different. The binding constant of complex 4 to G in -A7G8T9-
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sequence is nearly two-fold higher than that to G in -C7G8A9- sequence. An interesting result was
that for the single-G sequences with adenine being the flanking base in one side, the affinity of Ru to
G decreased with the variation of the other side base in an order as follows: T > A > C, whether A
was at the 3′- or 5′-side of the central G site. This is in line with the reactivity order of the biphenyl
organometallic ruthenium complex to mononucleotides where Ru binding to A and C is much weaker
than binding to G and T, implying that the binding of the ruthenium complex to an adjacent T base may
be synergetic to the thermodynamically favored G-binding [24,25]. It has been previously reported that
the flanking bases play an important role in the sequence selectivity of the bindings of cis-platinum
anticancer drugs to DNA [58]. One of the early studies on this topic demonstrated that the reaction of
cisplatin (cis-[PtCl2(NH3)2]) with salmon sperm DNA gave rise to chelating adducts with Pt–GG (65%)
and Pt–AG (25%), but no Pt–GA adducts (0%) additional to Pt–G mono-functional adduct (10%) [59].
However, the mechanism of crosslinking did not necessarily follow the sequence selectivity of the
initial coordination. The fact that the 5′-monoplatinated adducts are formed more rapidly than the
3′-monoplatinated adducts may reflect the inherently greater reactivity of the 5′-G compared with the
3′-G [60]. To explain the differences, Kozelka and Chottard et al. proposed a model according to which
the neighboring bases have an influence on the sequence selectively of Pt–G coordination by changing
the electronegativity of the N7 site, and presenting different steric hindrances when platinum complex
approaches the G-N7 site [61]. Other non-metallic DNA-binding drugs, like aflatoxin [62] and nitrogen
mustards [63], also showed discriminated reactivity to G-N7 upon the local sequence context.
4. Materials and Methods
4.1. Materials
[(η6-arene)Ru(en)Cl][PF6] (arene = benzene (ben) (1), p-cymene (cym) (2), indane (ind) (3),
and biphenyl (bip) (4); en = ethylenediamine; Chart 1) were synthesized as described in the
literature [2,17,64,65]. Triethylammonium acetate buffer (TEAA, 1 M) was purchased from AppliChem
(Darmstadt, Germany), and acetonitrile (HPLC grade) from Tedia (Fairfield, OH, USA). HPLC-purified
15-mer oligodeoxynucleotides (ODNs, Chart 1) were obtained from TaKaRa (Dalian, China), and the
concentration was determined by UV at 260 nm absorption according to the instruction of manufacturer.
Snake venom phosphodiesterase (SVP) was purchased from Orientoxin (Shandong, China). Microcon
YM-3 ultrafilters were purchased from Millipore (Billerica, MA, USA). Aqueous solutions were
prepared using MilliQ water (MilliQ Reagent Water System, Molsheim, France).
4.2. Sample Preparation
Stock solutions of Ru(II) arene complexes (5 mM) were prepared by dissolving individual complex
in deionized water and diluted as required before use. The ODNs were dissolved in water to give
2 mM stock solutions. The reaction mixtures containing 0.1 mM single-stranded ODNs in 50 mM TEAA
(pH 7) or 0.4 mM duplex III in 50 mM TEAA buffer containing 100 mM NaClO4 (pH 7) and various
concentrations of Ru complexes were incubated at 310 K in the dark for 24 h, unless otherwise stated,
and then separated or analyzed by HPLC or/and HPLC-ESI-MS. The general procedure to identify the
binding sites of Ru complexes on ODNs was similar to that reported in our previous works by using
exonuclease digestions combined with HPLC-ESI-MS [19] and the top-down MS method [24,66].
4.3. High Performance Liquid Chromatography (HPLC)
An Agilent 1200 series HPLC system was applied coupled with a quaternary pump, a 20-μL
Rheodyne sample injector, and a UV-Vis diode-array-detector (DAD) detector. All the HPLC data was
processed by the Chemstation data processing system. Water containing 20 mM TEAA and acetonitrile
containing 20 mM TEAA were used as mobile phases A and B, respectively. HPLC assays for reaction
mixtures of Ru(II) arene complexes with different single-stranded ODNs were carried out on a Varian
Pursuit XRs C18 reversed-phase column (100 × 2.0 mm, 3 μm, 0.2 mL·min−1, Varian, Inc., Palo Alto,
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CA, USA). The gradient for separating reaction mixtures of complexes 2 and 4 with strand I (Chart 1)
was as follows: 8% solvent B from 0 to 3 min, increasing to 60% at 10 min, 80% from 11 min to 15 min,
and resetting to 8% at 16 min. The same gradient was also applied to separate the reaction mixtures
of complex 4 with other six single-stranded ODNs. For reaction mixtures of complexes 1 and 3 with
strand I, the applied gradient was as follows: from 8% to 18% during first 10 min, 80% from 11 min
to 15 min, and resetting to 8% at 16 min. The gradient was also applied to separate the reaction
mixtures of complexes 1 and 4 with strand II (Chart 1). The same column was used to separate the
products from enzymatic digestions of ruthenated ODNs by exonucleases prior to MS analysis with
a gradient as follows: 1% to 5% solvent B from 0 to 5 min, 5% from 5 to 8 min, then increasing to
80% and keeping it from 15 to 21 min, and finally resetting to 1% at 22 min. An Agela C8 column
(50 × 2.1 mm, 0.2 mL min−1, Agela Technology, Tianjin, China) was used to separate the reaction
mixtures of ruthenium complexes with duplex III (Chart 1) prior to MS analysis with a gradient as
follows: 1% solvent B for 3 min, 5% to 10% from 4 to 9 min and kept at 10% for 5 min, then increased
to 80% at 15 min and retained for 4 min, and finally reset to 1% at 20 min.
4.4. Electrospray Ionization Mass Spectroscopy (ESI-MS)
A Micromass Q-TOF (Waters Corp., Manchester, UK) coupled with an Agilent 1200 system was
applied under negative-ion mode for the online HPLC-ESI-MS assays. The HPLC conditions were
the same as described above, with a flow rate of 0.2 mL·min−1 and a splitting ratio of 1/3 into mass
spectrometer. All the MS data was analyzed and post-processed by a Masslynx (ver. 4.0, Wasters Corp.,
Manchester, UK) data processing system. The MS conditions were similar as in our previously reported
paper [19] and the typical conditions are as follows: spray voltage 2.8~3.8 kV; cone voltage 55~70 V;
desolvation temperature 393 K; source temperature 373 K; cone gas flow rate 50 L·h−1; desolvation gas
flow rate 500 L·h−1; and collision energy 10 V. Mass spectra were acquired in the range of 200–3000 m/z
with mass accuracy of all measurements within 0.01 m/z unit, which were calibrated versus a NaI
calibration file. All the m/z values are the mass-to-charge ratios of the most abundant isotopomer for
observed ions.
4.5. Circular Dichroism (CD) Spectroscopy
For CD spectroscopy analysis, the reaction mixtures, containing 15 μL 0.1 mM duplex III in
100 mM NaClO4 and 50 mM TEAA (pH 7), and 15 μL various concentrations of Ru complexes in
50 mM TEAA, were incubated at 310 K for 24 h in dark, and then diluted to 5 μM using 50 mM TEAA
buffer prior to CD analysis. CD spectra were recorded by using a Jasco J-810 spectropolarimeter in
the range 220–340 nm in 0.5 nm increments with an average time of 1 s, the cell path-length was 1 cm.
Each spectrum was the average of ten scans and corrected by the blank buffer solution.
4.6. Determination of Equilibrium Binding Constants of Organometallic Ruthenium Complexes to ODNs
The peak areas of ruthenated ODNs separated by HPLC with UV detection at 260 nm were
used to determine the equilibrium binding constants of Ru(II) arene complexes to single-stranded
ODNs. Klotz’s methods (affinities from a stoichiometric perspective) were applied to construct the
reaction model and determine the stoichiometric equilibrium constants (Scheme 1) [67]. The G- and
T-bound two-site divalent model was applied as there are only G- and T-binding sites of ruthenium
complexes on each single strand ODN identified as described previously [24]. Although there are
more than one T binding sites on single strands I and IV–VI, it is difficult to fully separate the
different G8, Ti-bound ODN adducts by HPLC [24]. Therefore, for clarity, the HPLC peak areas
corresponding to di-ruthenated ODN adducts with different T-sites were summed to calculate the
content of di-ruthenated species.
For the divalent receptor system, the uptake of ligand L (Ru complexes) by receptor R (ODNs)
can be described by two steps:
R + L = RL1 (1)
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RL1 + L = RL2 (2)
with the following equilibrium constants:
K1 = [RL1]/[R] [L] (3)
K2 = [RL2]/[RL1] [L] (4)
Thus,
[RL1] = K1 [R] [L] (5)
[RL2] = K2 [RL1] [L] = K1 K2 [R] [L]2 (6)
Therefore, the extent of site occupation (B) can be defined as follows:
B = mole of bound ligand/mole of total receptor = ([RL1] + 2[RL2])/([R] + [RL1] + [RL2]) (7)
Replacing [RL1] and [RL2] by Equations (5) and (6) into Equation (7), we obtain the stoichiometric
binding equation:
B = (K1 [L] + 2 K1 K2 [L] 2)/(1 + K1 [L] + K1 K2 [L] 2) (8)
where K1 and K2 are the binding constants for the first and the second step of reaction, respectively.
The B −−− [L] data obtained by HPLC analysis were fitted computationally using Equation (8) to
give rise to the stoichiometric equilibrium constants K1 and K2.
5. Conclusions
In summary, we have thermodynamically studied the reactions of the organometallic
ruthenium(II) anticancer complexes [(η6-arene)Ru(en)Cl][PF6] (arene = benzene (1), p-cymene (2),
indane (3), biphenyl (4); en = ethylenediamine) with the 15-mer one-G-containing single-stranded
ODN I; its complementary strand II and the duplex III (= I + II); and a series of analogue strands
of I by HPLC, ESI-MS, and CD spectroscopy. Different arene ligands regulate the reactivity of the
ruthenium complexes towards G and T of strand I, with complex 2 being the most discriminatory one
between G and T bases, and complex 4 the most reactive one. In the complementary single-strand II,
G21 is the common preferential binding site for complexes 1–4; G18 and G26 are the secondary binding
sites for complexes 3 and 4, respectively; and both G21 and G26 are the secondary binding sites for
complex 2. This implies that the G bases in the middle region are more favored for ruthenation than G
bases in the end of ODNs. When reacted with different single-G-containing ODNs, complex 4 shows
a decreasing affinity to the G8 site in the following order: -AG8T- (K: 5.74 × 104 M−1) > -CG8C- >
-TG8A- > -AG8A- > -AG8C- > -TG8T- (I) ≈ -CG8A- (K: 2.81 × 104 M−1), indicating that adjacent bases
play an important role in the sequence selectivity of the bindings of the organometallic ruthenium(II)
complexes to DNA, perhaps related to the arene intercalation and the steric hindrance of adjacent
bases. Among the tested ruthenium complexes, complex 4 caused the most severe distortion to DNA
duplex conformation as a result of the intercalation of biphenyl ligand into bases. These findings
provide a molecular basis for better understanding in the base and sequence selectivity of the binding
of ruthenium arene anticancer complexes to DNA, and is helpful to design and development of novel
ruthenium-based anticancer complexes.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/
2137/s1.
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Abstract: Two known tin-based polymers of formula {[R3Sn(CH3COO)]n} where R = n-Bu– (1)
and R = Ph– (2),were evaluated for their in vitro biological properties. The compounds were
characterized via their physical properties and FT-IR, 119Sn Mössbauer, and 1H NMR spectroscopic
data. The molecular structures were confirmed by single-crystal X-Ray diffraction crystallography.
The geometry around the tin(IV) ion is trigonal bi-pyramidal. Variations in O–Sn–O···Sn′ torsion
angles lead to zig-zag and helical supramolecular assemblies for 1 and 2, respectively. The in vitro cell
viability against human breast adenocarcinoma cancer cell lines: MCF-7 positive to estrogens receptors
(ERs) and MDA-MB-231 negative to ERs upon their incubation with 1 and 2 was investigated. Their
toxicity has been studied against normal human fetal lung fibroblast cells (MRC-5). Compounds 1
and 2 exhibit 134 and 223-fold respectively stronger antiproliferative activity against MDA-MB-231
than cisplatin. The type of the cell death caused by 1 or 2 was also determined using flow
cytometry assay. The binding affinity of 1 and 2 towards the CT-DNA was suspected from the
differentiation of the viscosity which occurred in the solution containing increasing amounts of 1
and 2. Changes in fluorescent emission light of Ethidium bromide (EB) in the presence of DNA
confirmed the intercalation mode of interactions into DNA of both complexes 1 and 2 which have
been ascertained from viscosity measurements. The corresponding apparent binding constants
(Kapp) of 1 and 2 towards CT-DNA calculated through fluorescence spectra are 4.9 × 104 (1) and
7.3 × 104 (2) M−1 respectively. Finally, the type of DNA binding interactions with 1 and 2 was
confirmed by docking studies.
Keywords: biological inorganic chemistry; acetic acid; organotins; bio-polymer; anti-cancer activity;
cell cycle
1. Introduction
Platinum-based compounds are at the focal point of research on potent anticancer drugs since the
discovery of the anticancer potential of cisplatin, back during 70’s [1–4]. However, platinum-based
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cancer treatments are being dominated by serious side effects [5]. Moreover, cancer cells resistance
against platinum based drugs is developed in a short while [6]. Nowadays, organometallic compounds,
with a different pharmacological profile than that of platinum one, are developed and tested against
various types of cancer cells [7].
During the last decades the anticancer activity of organotin compounds (OTCs) has been well
studied [8–29]. Therefore, the investigation of new OTCs of low toxicity and improved anticancer
activity are known to induce apoptosis in several cancer cell lines [17–19]. Their activity can be coupled
to the lipophilicity of alkyl or aryl groups attached to the tin atoms [21]. In addition, due to their
lipophilicity, OTCs are able to permeate membranes and reach the cell nucleus, where the dissociable
ligands yield intermediate molecules capable of binding DNA [16,26].
The advantages of the use of polymeric drugs as anticancer agents have been described earlier [30].
This is because: (i) the polymers overcome cellular resistance mechanisms; (ii) the polymers could
be used as carriers in high-dose chemotherapy; (iii) polymers are filtered out by the kidneys more
slowly than small compounds increasing the body retention time; (iv) the size and structure of the
polymer provide more binding sites to cellular targets; (v) the polymers can be act as hybrid drugs
incorporating multiple anticancer agents against cells through different mechanisms; and (vi) the
polymers accumulate in solid tumors more than in normal tissues [30].
In the course of our studies on the design and synthesis of new metallodrugs [13–29], the known
{[R3Sn(CH3COO)]n} where R = n-Bu– (1) and R = Ph– (2) compounds were isolated from the reaction
between acetic acid with tributyltin or triphenyltin oxides. The compounds were characterized via
their physical properties and their FT-IR, 119Sn Mössbauer, and 1H NMR spectroscopic data, while their
structures were verified by single-crystal X-Ray diffraction crystallography. The enhancement on the
biological activity against tumor cells of the polymeric 1 and 2 is studied in relation to their polymeric
intermolecular architecture (helical and zig-zag). The presence of acetic acid is also, expected to adjust
the lipophilicity of the metallodrugs. The in vitro cell viability against MCF-7 (estrogen receptor (ER)
positive) and MDA-MB-231 (estrogen receptor (ER) negative) was evaluated. Their genotoxicity has
been studied against normal human fetal lung fibroblast cells (MRC-5). The type of the cell death
caused by 1 and 2 was studied by flow cytometry assay. Finally, conclusions on Structure Activity
Relationship are derived, in the light of the results obtained for OCT’s from our group up to now.
2. Results and Discussion
2.1. General Aspects
Complexes 1 and 2 were synthesized as pale white powders by refluxing a benzene solution of
tri-aryl-tin oxide and acetic acid (glacial) in a 1:1 molar ratio (Scheme 1), using a Dean–Stark water trap.
 
Scheme 1. Preparation route of 1 and 2.
The formulae of 1 and 2 were first deduced by melting point and spectroscopic data. Crystals of
the complexes 1 and 2 are stable in air. Complexes 1 and 2 are soluble in DMSO, DMF, toluene, ethanol,
acetone, and diethyl-ether.
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2.2. Solid State
2.2.1. Vibrational Spectroscopy
The νas(COO−) vibrations are observed at 1584 (1) and 1574 (2) cm−1 respectively, while the bands
at 1418 (1) and 1416 (2) cm−1 are assigned to νs(COO−) (Figure S1). The Δν [νas(COO−) − νs(COO−)]
value is 166 (1) and 158 (2) cm−1, respectively. Monodentate coordination of the carboxylic group
results in significantly higher difference values Δv than those observed for the ionic compounds of the
ligand [20], while when the ligand chelates, the Δv is considerably smaller than that observed for its
ionic compounds. For asymmetric bidentate coordination, the values are in the range of monodentate
one [20]. When the –COO− group bridges metal ions, the Δv values are higher than that of the
chelating mode and nearly the same as that observed for ionic compounds [20]. In the case of sodium
acetate, the Δv[vas(COO−)−vs(COO−)] value is 170 cm−1 [31]. Since the Δν values in 1 and 2 (166 (1)
and 158 (2) cm−1) is in the range of the corresponding one of sodium acetate (170 cm−1) the bridging
coordination mode is concluded for the carboxylic group in 1 and 2 (Figure S1). Bands at 493 (1) and
457 (2) cm−1 in the spectra of 1 and 2 are assigned to the ν(Sn–O) bond vibrations [20], while the
corresponding bands at 672, 614 (1) and 730, 698 (2) cm−1 are assigned to the antisymmetric and
symmetric vibrations of Sn–C bonds [29].
2.2.2. 119Sn Mössbauer Spectroscopy





Figure 1. 119Sn Mössbauer spectra of 1 (A) and 2 (B) at 80 K.
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The spectrum of 1 consists of one asymmetric Lorentzian doublet. The absorption line intensity
asymmetry could be attributed to the recoilless fraction (f) asymmetry, which could be a consequence
of vibrational-bond anisotropic involving the Sn ions [32]. Preferred orientation of the crystallites in
the powdered sample cannot also be excluded in order to justify this asymmetry. The occurrence of
one Lorentzian double, indicates either the existence of one type of Sn atom in 1 or one structural
isomer [25,29]. The corresponding spectrum of 2 consists by two symmetric Lorentzian doublets.
The occurrence of two symmetric Lorentzians, however, indicates two kinds of tin centers under
different environment in 2 with 85–15% molar ratio [25,29]. The values of the Isomer Shifts
(I.S.) of +1.44 (1), 1.28 (2A) and 1.15 (2B) mm·s−1 corresponds to the (4+) oxidation state [25,29].
The quadrupole splitting parameter (ΔEq) values are 3.57 (1), 3.35 (2A) and 1.33 (2B) mm·s−1. Therefore,
trigonal-bibyramidal (tbp) geometry should be concluded for tin(IV) ions in 1 and 2A as in the case of
tbp R3Sn(IV) (eg-R3 = alkyl) geometry where the ΔEq values lie between 2.50–4.00 mm·s−1 [25,29]. On
the contrary, tetrahedral (tet) geometry R3Sn(IV) results in to ΔEq values of 1.30–3.00 mm·s−1 [25,29],
tet conformation should be attributed to the tin(IV) atoms in 2B.
2.2.3. Crystal and Molecular Structures of [Bu3SnCH3COO]n (1) and [Ph3SnCH3COO]n (2)
Crystals suitable for X-ray analysis were obtained by slow evaporation of diethyl-ether solutions
of 1 and 2. Their formula was confirmed here by single crystal X-ray diffraction analysis at ambient
conditions. The structure of 1 is identical to that already reported by M. Adeel Saeed et. al. [33]. Thus
1 crystallizes in P21/c space group, a = 10.1845(3), b = 20.2542(7), c = 16.2466(6) Å, β = 94.739(3)◦,
V = 3339.87 Å3; while the reported one crystallizes in P21/c space group, a = 10.386(4), b = 20.924(3),
c = 16.584(6) Å, β = 92.87(2)◦, V = 3599(2) Å3 [33]. Although, 2 crystallizes in Pn space group with
a = 16.7427(6), b = 10.0426(2), c = 25.5119(8) Å, α = 89.999(2), β = 100.936(3), γ = 89.998(2)◦,
V = 4211.68 Å3, the already reported crystallizes in P21/c, space group, a = 8.969(4), b = 10.146(5),
c = 19.540(7) Å, β = 93.70(4)◦, V = 1774.5 Å3 [34] suggesting a polymorphism between 2 and the
published one. However, the extended disorder on the density observed in 2 prevent its accurate
refinement allowing only qualitative conclusions to be drawn. Although the obtained X-ray data do
not allow discussion about bond lengths and angles, they are of sufficient quality to determine the




Figure 2. Molecular diagrams of 1 (A) and 2 (B).
Three C atoms from the alkyl groups and two O atoms from two de-protonated CH3COOH
molecules form the trigonal bipyramidal arrangement around the Sn ions in 1. The average C–O bond
lengths found in 1 and 2 (1.260 ± 0.020 Å), indicates a bond order of 1.5 e. This delocalization of the
electron density in the –COO− group suggests a charge distribution shown in Scheme 2.
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Scheme 2. Charge distribution.
2.3. Solution Studies
1H-NMR Spectroscopy
The 1H-NMR spectrum of free acetic acid in DMSO-d6 is dominated by a single resonance signal
at 1.91 (s, H) ppm for the methyl protons, which is shifted upon its coordination to the tin(IV) ion at
1.776 (s, H) ppm in 1 and at 1.758 (s, H) ppm in 2 (Figure S2). In the case of 1 four additional signals
are observed at 1.52 ppm (t, Ha(–aCH2–Sn)), 1.27 ppm (m, Hb(–bCH2–CH2–Sn)), at 1.00 ppm (m,
Hc((–cCH2–CH2–CH2–Sn)), and 0.84 ppm (t, Hd ((dCH3–CH2–CH2–CH2–Sn)) of the butyl substituent
bind on tin(IV) ions (Figure S2). These four signals (1.52–0.84 ppm) have been replaced by the signals
at 7.79–7.45 ppm in the spectrum of 2 (Figure S2), which were attributed into the aromatic protons
of phenyl substituent of organotin moieties. Since the cells were incubated for 48 h the stability of 1
and 2 is checked for this period with 1H-NMR spectroscopy. No changes were observed between the
initial spectra of freshly prepared solutions and the corresponding spectra when measured after 48 h
confirming the retention of the structures in solution (Figure S2).
2.4. Biological Tests
2.4.1. Anti-Proliferative Activity
Organotin compounds 1 and 2 were tested for their in vitro cytotoxic activity against human
breast adenocarcinoma cell lines, MCF-7 and MDA-MB-231, by the mean of sulforhodamine B (SRB)
assay [16,17]. The cells were incubated for 48 h with 1 and 2. Since ERs are expressed in 65% of human
breast cancer, (a hormone dependent malignancy) the MCF-7 and MDA-MB-231 cells were used in
order to ascertain the influence of the ER’s in the mechanism of action of 1 and 2 [16,17]. MCF-7
cells serve as a valuable model system to elucidate pathways of hormone response and resistance.
Especially, the MCF-7 cells were used for studying estrogen response both in vitro and in vivo [35].
MDA-MB-231 human breast cancer cells, on the other hand, are used as a model of ER-negative breast
cancers [36].
The IC50 values of 1 and 2 against MCF-7 cells lie in the range of nM and they are 0.25 ± 0.02
and 0.21 ± 0.01 μM respectively, while their corresponding IC50 values against MDA-MB-231 cells
are 0.20 ± 0.01 and 0.12 ± 0.01 μM. The activity of 1 follows reverse order to the corresponding one
of 2 against these cell lines suggesting no interference of the estrogen receptors to their mechanism.
By taking into account the IC50 value of cisplatin against MCF-7 and MDA-MB-231 cells (5.5 ± 0.4
and 26.7 ± 1.1 μM respectively), both 1 and 2 exhibit extremely cytotoxic activity against these cell
lines. These values indicate 22 and 26-fold higher activity of 1 and 2 against MCF-7 cells than cisplatin
and 134 and 223-fold against MDA-MB-231 cells. Despite their strong activity against tumor cells,
1 and 2 also exhibit high toxic activity against MRC-5 cells with IC50 values of 0.22 ± 0.01 (1) and
0.11 ± 0.01 (2) μM, respectively. The IC50 values against MCF-7, MDA-MB-231, and MRC-5 cells of
organotin compounds studied from our group, are summarized in Table 1. The following conclusions
are made: (i) tri-organotin derivatives are more active than the corresponding di-organtin ones;
(ii) organotin derivatives of carboxylic acids are generally more active than those of other types of
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ligands; (iii) organotin compounds are also highly toxic, even more toxic than cispaltin; (iv) however
the selectivity index, which is defined as the IC50 value against MRC-5 towards the corresponding
value against MCF-7, and is an indicator of the therapeutic potency of a compound (the higher the
value is, the better potency), shows that 1 and 2 are more potent therapeutics (TPI values of 0.88
(1) and 0.52 (2)) than cisplatin (TPI = 0.20). (v) The tri-n-butyl tin compound of thiobarbituric acid
(n-Bu)3Sn(o-HTBA)(H2O) exhibits the higher TPI value of 1.6 (Table 1).




MCF-7 MDA-MB-231 MRC-5 TPI * Ref.
1 0.25 ± 0.02 0.20 ± 0.01 0.22 ± 0.01 0.88 [present]
2 0.21 ± 0.01 0.12 ± 0.01 0.11 ± 0.01 0.52 [present]
{[Ph3Sn]2(mna)·[(CH3)2CO]} 0.030 >0.200 [18]
[Me2Sn(Sal)2] 0.142 ± 0.043 0.0975 ± 0.00015 0.69 [19]
[(n-Bu)2Sn(Sal)2] 0.108 ± 0.0026 0.1041 ± 0.0002 0.96 [19]
[(n-Bu)3Sn(Sal)] 0.724 ± 0.0054 0.0981 ± 0.0001 0.14 [19]
[Ph3Sn(Sal)] 0.121 ± 0.0037 0.0945 ± 0.000.2 0.78 [19]
[(n-Bu)3Sn(pHbza)] 0.325 ± 0.0023 0.0784 ± 0.0002 0.24 [19]
{[Ph3Sn(o-HTBA)]}n 0.103 0.203 0.130 1.26 [17]
(n-Bu)3Sn(o-HTBA)(H2O) 0.068 0.106 0.108 1.59 [17]
[(tert-Bu–)2(HO–Ph)]2SnCl2 3.12 ± 0.38 [14]
[(tert-Bu–)2(HO–Ph)]2Sn(PMT)2 7.86 ± 0.87 [14]
[(tert-Bu–)2(HO–Ph)]2Sn(MPMT)2 0.58 ± 0.1 [14]
{[(tert-Bu–)2(HO–Ph)]2SnCl(PYT)} >30 [14]
[(tert-Bu–)2(HO–Ph)]2SnCl(MBZT)} >30 [14]
Ph3SnCl 0.130 0.166 0.141 1.08 [16]
[Ph3SnOH]n 0.070 0.165 0.090 1.29 [16]
[(Ph2Sn)4Cl2O2(OH)2] >10 >10 >10 [16]
Me2Sn((tert-Bu–)2(HO–Ph–S))2 19.20 ± 1.70 19.50 ± 1.40 1.02 [15]
Et2Sn(((tert-Bu–)2(HO–Ph–S))2 6.20 ± 0.80 7.30 ± 0.60 1.18 [15]
(n-Bu)2Sn–(((tert-Bu–)2(HO–Ph–S))2 0.40 ± 0.06 0.61 ± 0.07 1.53 [15]
Ph2Sn(((tert-Bu–)2(HO–Ph–S))2 6.20 ± 0.80 12.40 ± 1.40 2.00 [15]
[(tert-Bu–)2(HO–Ph)]2Sn(((tert-Bu–)2(HO–Ph–S))2 >30 >30 >30 [15]
Me3Sn((tert-Bu–)2(HO–Ph–S)) 4.90 ± 0.50 3.36 ± 0.13 0.69 [15]
Ph3Sn(((tert-Bu–)2(HO–Ph–S)) 0.25 ± 0.03 0.22 ± 0.01 0.88 [15]
Cisplatin 5.5 ± 0.4 26.7 ± 1.1 1.1 ± 0.2 0.20 [37]
* TPI = IC50(MRC-5)/IC50(MCF-7), mna = 2-mercapto-nicotinic acid, salH = salicylic acid, pHbzaH =
p-Hydroxyl-benzoic acid, H2TBA = 2-thiobarbituric acid, PMTH = 2-mercapto-pyrimidine, MPMTH =
2-mercapto-4-methyl-pyrimidine, PYTH = 2-mercapto-pyridine, MBZTH = 2-mercapto-benzothiazole.
2.4.2. Evaluation of Genotoxicity by Micronucleus Assay In Vitro
Micronucleus assay is a reliable and an accessible technique to evaluate the appearance of
genetic damage on a cell. The detection of micronucleus (MN) indicates mutagenic, genotoxic, or
teratogenic effects [37]. In the presence of exogenous genotoxic factors, the MN is formed due to
the metaphase–anaphase transition of the mitotic cycle. The possible induction of micronucleus
frequencies was evaluated when MRC-5 cells were treated by 1 and 2 at the concentrations of their
IC50 values. The micronucleus frequency in the MRC-5 cell culture without treatment is 0.91 ± 0.02%,
while it is 1.0 ± 0.1% upon treatment with DMSO. However, the micronucleus frequencies are slightly
increased when the cells are incubated with 1 and 2 to 2.10 ± 0.04% (1) and 2.19 ± 0.03% (2) (Figure S3).
The compounds 1 and 2 show a slightly increase in micronucleus frequency in contrast to the control or
to cisplatin (1.6%) at its IC50 value of 26 μM [37]. Cisplatin is used as a reference control. Doxorubicin
has also been used as reference control from other groups. MRC-5 cells show slight increasing MN’s
when they are treated with 1 and 2 than the case of cisplatin indicating higher genotoxocity indeed.
However, the treatment of MRC-5 cells with 0.18 μM or 0.014 μM of doxorubicin increases the percent
of micronucleus at (94.7 ± 20.0)% and (17.00 ± 1.73)%, respectively, in contrast to the control ones
(15.0 ± 2.64)% [38]. Thus, despite its higher genotoxicity of 1 and 2 towards MRC-5 cells than cisplatin
both exhibit significant lower MN percentage than doxorubicin a medication against tumors in humans
in used. It is therefore considered that 1 and 2 are nongenotoxic substances.
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2.4.3. Cell Cycle Studies
Internucleosomal DNA fragmentation has been described as one of the main characteristics of the
apoptotic process and can be identified by a sub-G1 peak on DNA frequency histograms [37]. Therefore,
the apoptotic type of the cell deaths caused by the regulation of cell cycle progression because of 1 and
2 can be evaluated by flow cytometric analysis since these cells give a sub-G1 peak [37]. The percentage
of cells in the phases of the cell cycle was analyzed after 48 h exposure of MCF-7 cells with 1 and 2 at
their IC50 values.
The effect on the cell cycle which is illustrated in Figure 3, as the number of cells towards DNA
content in sub-G1, G0/G1, S, and G2/M phases is caused by 1 and 2. The untreated cells are spread
in 6.1% sub-G1 phase, 46.5% in G0/G1, 18.3% in S, and 28.9% in G2/M phases. After incubation of
MCF-7 cells with 1 and 2, a significant increase in the number of apoptotic cells in sub-G1 phase (14.4%
(1), 24.1% (2), respectively) was observed towards the control group (6.1%). In the case of 1, the cells
in G0/G1 phase are reduced to 37.9%, on the contrary, with 46.5% for the untreated cells while in the
case of 2, the corresponding value decrease to 35.8%. However, the percentage of MCF-7 cells in S
phase, was increased to 25.1% (1), 22.9% (2). Finally, the percentage of MCF-7 cells in G2/M phase was
reduced to 22.1% (1) and 17.1% (2), respectively. In the DMSO-treated cells, the distribution in phases
sub-G1 (6.5%), G0/G1 (42.7%), S (20.6%), and G2/M (29.5%) were similar to the corresponding ones of
control cells’. All the data obtained in cell cycle studies of 1 and 2 are summarized in Table 2.
Table 2. Cell cycle studies data of 1 and 2.
Description
Phases of cell cycle
Sub-G1 G0/G1 S G2/M
Untreated cells 6.1% 46.5% 18.3% 28.9%
Treated cells with
DMSO 6.5 42.7 20.6 29.5
1 14.4 37.9% 25.1 22.1
2 24.1 35.8%. 22.9 17.1
In conclusion, 1 and 2 stimulate S-phase cell cycle arrest, thus suppressing cell proliferation by
inhibiting DNA synthesis, in accordance to other anticancer agents (resveratrol, mitomycin C, and
hydroxyurea) [37]. Likewise, cisplatin causes cell cycle arrest at S and G2/M phases and the percentage
of MCF-7 cells in sub-G1 phase is increased, exhibiting an increasing number of apoptotic cells [37].
To summarize, metal drugs of this type induce cell cycle arrest either in G0/G1 or in S phase (like
cisplatin), resulting in MCF-7 cell growth inhibition. Therefore, the reduced cell growth caused by 1
and 2 is attributed to the apoptotic type of cell death, in accordance to the way of action of cisplatin [37].
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Figure 3. Number of MCF-7 cells in sub-G1, G0/G1, S, and G2/M phases, upon their treatment with 1
and 2. The meaning of color labeling is white= Sub-G1, blue= G0/G1, green= S, pink= G2/M.
2.4.4. Detection of the Loss of the Mitochondrial Membrane Permeabilization (MMP Assay)
The releasing of cytochrome c in the cytosol through the loss of mitochondrial membrane
permeability activates the mitochondrion cell apoptosis pathway [37]. The induction of loss in
mitochondrial membrane permeability in tumor cells is one of the main accomplishments of targeted
chemotherapy. The MMP assay is based on the cationic hydrophobic mitochondrial potential dye which
accumulates in normal mitochondria. When cells are treated with a metallo-agent, the mitochondrial
membrane permeability collapses, and the fluorescence emission of the dye decreases simultaneously.
The MCF-7 cells were treated with 1 and 2 at their IC50 values, for 48 h, and the fluorescence of
the MMP assay dye decreased by 6.71% (1) and 6.52% (2), respectively. When the MCF-7 cells are
treated with cisplatin at its IC50 values (5.5 μM) the fluorescence of the MMP assay dye decreased by
54.9% [37]. Therefore, the MMP assay should not support mitochondrial membrane permeability loss.
Thus, 1 and 2 cause cell death by a different mechanism. Since apoptosis has been observed from cell
cycle studies, it should be activated by a different mechanism than mitochondrion pathways.
2.4.5. DNA Binding Studies
DNA is the main target of the successful chemotherapeutics, the interaction of 1 and 2 towards
CT-DNA was investigated by viscosity measurements and fluorescence spectroscopic studies.
96
Int. J. Mol. Sci. 2018, 19, 2055
(a) Viscosity measurements: DNA length changes upon its incubation with anticancer agents
affect strongly affecting the viscosity of its solution. Thus (i) if the agent intercalates in the DNA strands,
this results in its lengthening and a viscosity increase; (ii) if the agent interacts electrostatically with the
DNA, no effect on DNA length is caused and therefore no significant change in viscosity is observed;
(iii) however, in case the DNA strands are cleaved by an agent, the length of the DNA decreases, and
also, the viscosity decreases significantly (iv) bending of the DNA helix caused by the agent reduces
the viscosity. Therefore, viscosity exhibits high sensitivity to changes in the DNA and it is used for
the study of the binding modes of an agent towards DNA [39]. The solution of CT-DNA (10 mM) is
incubated with increasing amounts of 1 and 2 so that the [compound]/[DNA] molar ratio reaches
r = 0.27. The relative viscosity of the solution which contains the agent/DNA/buffer, towards the
corresponding one which contains DNA/buffer, increased for both compounds (Figure 4), suggesting
an intercalation mode of interaction between 1 and 2 and CT-DNA.
 
Figure 4. Effect of increasing concentrations of 1 and 2 on the relative viscosity of CT-DNA at 25 ◦C.
([DNA] = 10 mM, r = [compound]/[DNA], n is the viscosity of DNA in the presence of 1 or 2 and no is
the viscosity of DNA alone).
(b) Fluorescence Spectroscopic Studies: In order to verify the intercalation mode of 1 and 2 towards
CT-DNA, fluorescence spectroscopic studies were carried out. In the fluorescence spectroscopic studies
the dye ethidium bromide (EB) is used. In the presence of DNA, EB emits, due to its strong intercalation
between the adjacent DNA base pairs [37]. The displacement of EB during titration with the agent
suggests an intercalative binding mode. The emission data of the solutions of EB with CT-DNA at
610 nm, with increasing concentrations of 1 and 2 (0–250 μM) upon their excitation at 532 nm, were
recorded (Figure 5). The decreasing percent in fluorescence upon increasing of concentration of 1
and 2 at 610 nm was 31.5% (1) and 30.1% (2), respectively, confirming that both compounds can
interact with DNA by the intercalation mode. The corresponding apparent binding constants (Kapp)
of 1 and 2 towards CT-DNA calculated through fluorescence spectra are (4.9 ± 0.5) × 104 (1) and
(7.3 ± 1.3) × 104 (2) M−1, respectively, indicating stronger binding affinity of the triphenyltin than the
tri-n-butyltin acetates.
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Figure 5. Emission spectrum of EB bound to DNA (peak around 610 nm) decreases in order of the
concentration of the complex (1 (A) and 2 (B)). The arrows show the intensity changing upon increasing
complex concentration. Inset shows the plots of emission intensity Io/I vs. [complex].
(c) Computational studies—molecular docking: In order to verify the type of interaction between
DNA with 1 or 2 molecular docking calculations were performed. Small aromatic molecules can
typically bind to DNA by intercalation. Generally, either a planar molecule or a fragment is inserted
between two adjacent DNA base pairs to form a hydrophobic pocket in the DNA structure. This
non-covalent interaction is usually stabilized by π-interactions; at the same time, additional interactions
with the groves are possible. Statistically, the CG intercalation site is preferable for intercalation [40].
Upon ligand binding, the DNA structure is slightly elongated and accommodates a small gap between
two consecutive base pairs for the intercalators. Consequently, the latter can act as potent antitumor
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drugs and mutagens, inhibiting DNA replication and transcription. Targeting DNA sequences is a
challenging task for docking software, especially when intercalation sites are unavailable, because gap
openings cannot be simulated with rigid receptors. Moreover, it has been shown that popular docking
software fails to predict the intercalation into canonical B-DNA when analogous solved structures are
lacking [41]. For these reasons, the DNA target chosen for our study was 1DSC (PDB: www.rcsb.org)
which is an octamer d(GAAGCTTC)2 complexed with actinomycin D [42]. Actinomycin D is a
potent antibiotic with high antibacterial and antitumor activity. It intercalates to DNA by localizing
a phenoxazone ring at a GpC sequence while the two cyclic polypeptides of the drug bind to the
DNA minor groove. 1DSC has been already used successfully for docking of metal complexes [43]
and organic compounds [44] acting as DNA intercalators. The geometry of compounds 1 and 2
is trigonal bipyramidal (TBP) in the solid state. However, upon solvation in aqueous media their
structure are converted to tetrahedral by cleavage of the Sn-O(acetate) dative bond. Tetrahedral metal
complexes, unlike those with TBP geometry, can effectively bind to DNA by intercalation, although
they normally cannot penetrate as deep as square planar complexes [45]. The optimized structures of
the two organotin compounds [R3Sn(CH3COO)], (R = n-Bu (1), Ph– (2)) were used as ligands for DNA
docking using AutodockVina. Molecular docking evaluates affinity potentials through a precalculated
grid finding favorable binding positions for a flexible ligand towards a rigid macromolecular target.
Complexes 1 and 2 were successfully docked into the B-DNA duplex and the lowest energy poses are
depicted in Figure 6. The tri-phenyl derivative can adopt two different conformations intercalating in
the GC region through either one pnenyl-ring (Figure 6(2a)) or the carboxylic moiety (Figure 6(2b))
with computed binding free energies −5.5 and −5.1 kcal/mol, respectively. The planarity of the
phenyl ring favors π-π stacking interactions with the DNA base pairs, while additional hydrogen
bonding interactions with the carboxylate O (G4:N2-Lig O, 2.97 Å and Lig O-C5O4, 3.1 Å) and with the
pi-orbitals of the phenyl ring (G12:N2-Lig pi, 2.96 Å and G4:N2-Lig pi, 3.6 Å). On the other hand, the
minimum energy conformation of the tri-n-butyl-derivative shows a semi-intercalation into the same
GC region (Figure 6(1)) with lower binding affinity (−3.7 kcal/mol). The structure is also stabilized by
hydrogen bonding through the carboxylic moiety (G4:N2-Lig O, 3.13 Å). Possibly, the bulk and agile
butyl groups significantly increase the steric hindrance and prevent the intercalation. These results
support the experimental results showing that the phenyl derivative exhibits higher antitumor activity
possibly through its intercalative mode of action (Table 1).
 
Figure 6. DNA docking and H-bonding interactions between B-DNA and compounds 1 and (2a, 2b).
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3. Experimental
3.1. Materials and Instruments
All solvents used were of reagent grade, (Aldrich, Merck, Darmstadt, Germany) and they were
used with no further purification. Infrared spectra in the region of 4000–370 cm−1 were obtained in
KBr pellets with a Jasco FT-IR-6200 spectrometer. The 1H-NMR spectra were recorded on a Bruker
AC 250, 400 MHFT-NMR instrument in DMSO-d6. Chemical shifts are given in ppm using 1H-TMS as
internal reference. Elemental analysis for C, H, N, and S were carried out with a Carlo Erba EA MODEL
1108 (Waltham, MA, USA). The 119Sn Mőssbauer spectra were collected at sample temperature of
80 K using a constant acceleration spectrometer equipped with a Ca119mSnO3 source kept at room
temperature. The isomer shift values of the components used to fit the spectra are given relative to
SnO2 at room temperature. The 119Sn Mőssbauer spectra were recorded with Constant acceleration
WissEl-Wissenschaftliche Elektronik GmbH spectrometer (Starnberg, Germany).
3.2. Synthesis and Crystallization of {[(n-Bu)3Sn(CH3COO)]n} (1) and {[Ph3Sn(CH3COO)]n} (2)
Although the synthesis of these compounds is already known [33,34] we briefly described the
procedure follows here. 0.5 mmol of tri-n-butyltin oxide (C24H54OSn2, 0.298 g) for 1, or triphenyltin(IV)
hydrooxide (C24H16OSn, 0.183 g) for 2, were diluted with 0.5 mmol acetic acid, in 20 mL benzene
in a 100-mL spherical flask. The flask was fitted with a Dean–Stark moisture trap and the reaction
mixture was refluxed for 3 h. The solution was filtered and the clear filtrate was concentrated to
dryness. Crystals of 1 and 2, suitable for X-ray analysis, were formed by slow evaporation of a diethyl
ether solution.
1: Yield: 40%; m.p: 75–76 ◦C; (C14H30O2Sn)n·(MW = 349.04); elemental analysis: found C = 48.23,
H = 6.65%; calcd: C = 48.18, H = 8.66%. MID-IR (cm−1) (KBr): 3045 w, 2330 w, 2295 s, 1959 w, 1821
w, 1659 s, 1643 w, 1573 w, 1555 s, 1428 s, 1334 vs, 1261 vs, 1077 vs, 1025 w, 997 w, 729 w, 696 w, 665 w,
609 w, 499 w, 455 w. 1H NMR (ppm) in DMSO-d6: 1.776 (s), 1.578–1.501 (q), 1.327–1.236 (q), 1.043–1.001
(t), 0.880–0.843 (t).
2: Yield: 40%; m.p: 110–115 ◦C; (C20H18O2Sn)n (MW = 409.02); elemental analysis: found
C = 58.91, H = 4.40%; calcd: C = 58.73, H = 4.43%. MID-IR (cm−1) (KBr): 2400 w, 1574 w, 1556 s, 1415 w,
1384 s, 1015 s, 867 w, 671 w, 612 s. 1H NMR (ppm) in DMSO-d6: 7.850–7.707 (q), 7.452–7.390 (q), 1.758
(single), 1.114–1.079 (t).
3.3. X-Ray Structure Determination
Single crystal X-ray diffraction data for 1 and 2 were collected on an Oxford-Diffraction Supernova
diffractometer, equipped with a CCD area detector utilizing Cu Kα (λ = (1.5418 Å)) radiation. A suitable
crystal was mounted on a Hampton cryoloop with Paratone-N oil and transferred to a goniostat
where it was cooled for data collection. Empirical absorption corrections (multiscan based on
symmetry-related measurements) were applied using CrysAlis RED software [46]. The structures were
solved by direct methods using SIR2004 [47] and refined on F2 using full-matrix least-squares with
SHELXL-2014/7 [48]. Software packages used were as follows: CrysAlis CCD for data collection [46],
CrysAlis RED for cell refinement and data reduction [46], WINGX for geometric calculations [49]. The
non-H atoms were treated anisotropically, whereas the aromatic H atoms were placed in calculated,
ideal positions and refined as riding on their respective carbon atoms. The single crystals of compound
2 exhibited a fairly poor diffraction pattern. As a result moderate quality X-ray data were collected
which did not lead to a publishable crystal structure. For this reason the X-ray data of 2 are not quoted
here and have not been deposited in Cambridge Structural Database.
Supplementary data (1_bu3sn2o_asp_checkcif_new.pdf and 1_bu3sn2o_asp_FINAL.cif) are
available from CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (e-mail:deposit@ccdc.cam.ac.uk), on
request, quoting the deposition numbers CCDC-1846946 (1).
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1: (C14H30O2Sn)n: MW = 349.04, Monoclinic, space group P21/c, a = 10.1845(3), b = 20.2542(7),
c = 16.2466(6) Å, β = 94.739(3)◦, V = 3339.9(2) Å3, Z = 4, T = 100 K, ρ(calc) = 1.388 g·cm−3,
μ = 1.522 mm−1, F(000) = 1440. 22782 reflections measured, 5864 unique (Rint = 0.041), 5131 with
I > 2σ(I). The final R1 = 0.0265 (for 5131 reflections with I > 2σ(I)) and wR2(F2) = 0.0678 (all data),
S = 1.09.
3.4. Biological Tests
Biological experiments were carried in dimethyl sulfoxide Dulbecco’s Modified Eagle’s Medium
solutions (DMEM) DMSO/DMEM (0.02–0.2% v/v) for the complexes 1–2. Stock solutions of the
complexes 1–2, (0.01 M) in DMSO were freshly prepared and diluted in with cell culture medium to
the desired concentrations (0.05–0.4 μM). Results are expressed in terms of IC50 values, which is the
concentration of drug required to inhibit cell growth by 50% compared to control, after 48 h incubation
of the complexes towards cell lines. Since there is no “universal” correct time point to find the IC50
value of a given compound. Generally the inhibitory concentration of the 50% of the cells is determined
at once at the time of the cells (of interest) doubling time, and twice the time of the doubling time. In
cell culture, the vast majority of adherent cell lines display a doubling time between 18 and 24 h. In our
research unit, we prefer to use 48 h since 24 h is too short to determine a reliable IC50 concentration.
The cell viability was determined by SRB assay as previously described [37] and it is briefly described
here: Cells were plated (100 μL per well) in 96-well flat-bottom microplates at various cell inoculation
densities (MCF-7, MDA-MB-231 and MRC-5: 6000, 6000 and 2000 cells/well respectively). Cells were
incubated for 24 h at 37 ◦C and they were exposed to tested agents for 48 h afterwards, followed by
the addition of an equal volume (100 μL) of complete culture medium only in the well containing the
controls, or twice the final drug concentrations diluted in complete culture medium in the wells where
the compounds are tested. Drug activity was measured by means of a SRB colorimetric assay giving
the percent of the survival cells towards the control (untreated cells) absorbance. The culture medium
was aspirated before fixation and 50 μL of 10% cold trichloroacetic acid (TCA) were gently added
to the wells. Microplates were left for 30 min at 4 ◦C, washed five times with deionized water and
left to dry at room temperature for at least 24 h. Subsequently, 70 μL of 0.4% (w/v) sulforhodamine
B (Sigma, Darmstadt, Germany) in 1% acetic acid solution was added to each well and left at room
temperature for 20 min. SRB was removed and the plates were washed five times with 1% acetic acid
before air-drying. Bound SRB was solubilized with 200 μL of 10 mM un-buffered Tris-base solution.
Absorbance was read in a 96-well plate reader at 540 nm.
Evaluation of genotoxicity by micronucleus assay, cell cycle studies, detection of the loss of the
Mitochondrial Membrane Permeabilization (MMP assay), and fluorescence spectral studies were
performed as previously reported [37]. However, they are all quoted here in brief: (a) Micronucleus:
MRC-5 cells were seeded (at a density of 2 × 104 cells/well) in glass cover slips which were afterwards
placed in six-well plates, with 3 mL of cell culture medium and incubate for 24 h. MRC-5 cells
exposed with 1 and 2 in IC50 values for a period of 48 h. After the exposure of 1 and 2, the cover slips
were washed three times with PBS and with a hypotonic solution (75 Mm KCl) for 10 min at room
temperature. The hypotonized cells were fixed by at least three changes of 1/3 acetic acid/methanol.
The cover slips were also washed with cold methanol containing 1% acetic acid. The cover slips were
stained with acridine orange (5 μgr/mL) for 15 min at 37 ◦C. After, the cover slips were rinsed three
times with PBS to remove any excess acridine orange stain. The number of micronucleated cells per
1000 cells was determined. (b) Cell cycle: MCF-7 cells were seeded at a density of 105 cells/well in
six-well plates at 37 ◦C for 24 h. Cells were treated with 1 and 2 at the indicated IC50 values for 48 h.
The cells were then trypsinized and washed twice with phosphate-buffered saline (PBS) and separated
by centrifugation. With the addition of 1 mL of cold 70% ethanol, the cells were incubated overnight
at −20 ◦C. For analysis, the cells were centrifuged and transferred into PBS, incubated with RNase
(0.2 mg/mL) and propidium iodide (0.05 mg/mL) for 40 min at 310 K and then analyzed by flow
cytometry using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). For each
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sample, 10,000 events were recorded. The resulting DNA histograms were drawn and quantified
using the FlowJo software (version FlowJo X 10.0.7r2, Tree Star, Ashland OR, USA). (c) Detection of
the loss of the Mitochondrial Membrane Permeabilization: MCF-7 cells were treated with 1 and 2 at
IC50 values. After 48 h of incubation period of 1 and 2, the cell medium was removed and added the
Dye Loading Solution. The cells were incubated in 5% CO2 at 37 ◦C for 30 min. Afterwards, 50 μL
of Assay Buffer B was added of each well and are incubated for 30 min. The fluorescence intensity is
measured at λex = 540 and λem = 590 nm. The MMP assay kit used was purchased from sigma Aldrich
“Mitochondria Membrane Potential Kit for Microplate Readers, MAK147”. (d) Fluorescent studies:
The fluorescence spectroscopy method using ethidium bromide (EB) was employed to determine the
relative DNA binding properties of complexes 1 and 2 into CT-DNA. The emission data at 610 nm
of the spectra of EB (2.3 μM) solutions which contain CT-DNA (26 μM) in the absence or presence of
various concentrations of complexes 1 and 2 (0–250 μM) were recorded upon their excitation at 532 nm
(Figure 5). The apparent binding constant (Kapp) was calculated using the equation:
KEB[EB] = Kapp[drug] ()
where [drug] is the concentration of the complex at a 50% reduction of the fluorescence, KEB = 107 M−1,
and [EB] = 2.3 μM. The concentration of the drug at a 50% reduction of the fluorescence is calculated
from the diagram Io/I vs. the concentration of the complex [Q] (Figure 5), where, Io and I are the
fluorescence intensities of the CT-DNA in the absence and presence of complexes 1 and 2, respectively.
The fitting of the experimental Io/Ix ratio as a function of concentration (C) was performed utilizing
the linear least-squares fitting algorithm. However, the fitting procedure depends strongly on the
weighting of the data points, i.e., on the knowledge of the standard deviation (SD) of every point in
the experimental spectrum (<1%) since all spectra represent the average of 5000 individually recorded
spectra. As a measure for the goodness of the fit, we used the R2 statistics.
The slope of the Io/Ix ratio as a function of C was estimated equal to a1 = 2100.9 ± 204.8 and
a2 = 3142.4 ± 561.4 for 1 and 2 case, respectively.




















2 + · · ·
In general, sf represents the standard deviation of the function f, sx represents the standard
deviation of x, sy represents the standard deviation of y, and so forth. This formula is based on
the linear characteristics of the gradient of f and therefore it is a good estimation for the standard
deviation of f. Using the above methodology, the parameter Kapp is calculated as 48,950.97 ± 4771.84
and 73,217.92 ± 13,080.62 M−1 for 1 and 2, respectively. More details concerning the calculation of R2,
the error propagation issue and other statistical parameters, see e.g., reference [50]
3.5. Viscosity Measurements
The kinematic viscosity of 1 and 2 was measured with the use of an Ubbelohde-type glass
capillary viscosity-meter. The value of kinematic viscosity was measured as an average from triplicate
measurements of viscosity with an accuracy of 2% at constant temperature. Temperature was set at
298 K by means of an ultra-thermostat.
3.6. Computational Studies—Molecular Docking
Molecular docking studies were carried out with AutodockVina [51] along with the graphical
interface AutodockTools (ADT 1.5.6) [52] using the Lamarckian genetic algorithm (LGA). The DNA
structure (PDB file 1DSC) was considered as a rigid target while no torsional restraints were applied
to the complexes. Docking was performed to the optimized organotin derivatives [R3Sn(CH3COO)],
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(R = n-Bu (1), Ph– (2)) at the B3LYP/3-21G*/LANL2DZ(Sn) level using the Gaussian03Wsoftware
package [53]. Prior to docking, water molecules and the co-crystallized ligand were removed. The
search space was set as a grid box of 40 × 30 × 40 Å and spacing of 1 Å centered at the CG rich area.
Default parameters were used as described in the Vina manual except from “exhaustiveness” which
was set to 24.
4. Conclusions
The discovery of the antitumor activity of organotin compounds goes back to the 1980s when
Gielen first reports on the subject [8,9,11,12]. Later on, the antitumor properties of orgnaotin
compounds were reviewed by Saxena and Hubert [10] and Hadjiliadis et al. [13]. Continuing
our studies on the antitumor activity of organotin compounds, two known compounds of formula
{[R3Sn(CH3COO)]n} where R = n-Bu– (1) and R = Ph (2) with trigonal bipyramidal geometry around
each metal center, were used to investigate their antitumor activity against MCF-7 (positive to ERs)
and MDA-MB-231 (negative to ERs). The mechanism of their action against human breast tumor cells
was also investigated. Compounds 1 and 2 inhibit strongly both cell lines, while their IC50 values are
lei in nanomolar range (Table 1). The estrogen receptors play no significant role in their action. It is
also concluded that (i) the tri-organotin derivatives exhibit stronger activity than the corresponding
di-organotin ones (Table 1); (ii) the organotin derivatives of carboxylic acids are generally more active
than those of other type of ligands (Table 1); (iii) organotin compounds are also highly toxic against
normal MRC-5 cells (Table 1); (iv) the selectivity index, however, shows that 1 and 2 are more potent
therapeutics (TPI values of 0.88(1) and 0.52(2)) than cisplatin (TPI = 0.20) (Table 1) and (v) among all
organotins tested from our group the strongest activity against MCF-7 cells has been obtained from
the triphenyltin derivative of 2-mercapto-nicotinic acid {[Ph3Sn]2(mna)·[(CH3)2CO]} (IC50 = 30 nM)
and the tri-n-butyl tin compound of thiobarbituric acid (n-Bu)3Sn(o-HTBA)(H2O) (IC50 = 68 nM and
TPI = 1.6) (Table 1). The mitochondrial membrane permeability loss is not supported by MMP assay.
Since 1 and 2 are acting through apoptosis on tumor cells (cell cycle studies) this should therefore be
activated through a different pathway than that of the mitochondrion, such as the extrinsic apoptotic
pathway or direct interaction with DNA. The relative viscosity measurements and fluorescence
spectroscopic studies of DNA solutions suggest an intercalation mode of interaction between 1 and 2
and CT-DNA. Docking studies verify the intercalative mode, while the bulk and agile n-butyl groups
significantly increase the steric hindrance prohibiting the intercalation, resulting in higher antitumor
activity of the phenyl derivative instead of the corresponding n-Bu– (Table 1).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/
2055/s1.
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Abstract: Platinum(II) drugs are activated intracellularly by aquation of the leaving groups and
then bind to DNA, forming DNA adducts capable to activate various signal-transduction pathways.
Mostly explored in recent years are Pt(IV) complexes which allow the presence of two additional
ligands in the axial positions suitable for the attachment of other cancer-targeting ligands. Here we
have extended this strategy by coordinating in the axial positions of kiteplatin ([PtCl2(cis-1,4-DACH)],
DACH = Diaminocyclohexane) and its CBDCA (1,1-cyclobutanedicarboxylate) analogue the
antioxidant α-Lipoic acid (ALA), an inhibitor of the mitochondrial pyruvate dehydrogenase
kinase (PDK). The new compounds (cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)], 2, and
cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)], 3), after intracellular reduction, release the precursor Pt(II)
species and two molecules of ALA. The Pt residue is able to target DNA, while ALA could act
on mitochondria as activator of the pyruvate dehydrogenase complex, thus suppressing anaerobic
glycolysis. Compounds 2 and 3 were tested in vitro on a panel of five human cancer cell lines and
compared to cisplatin, oxaliplatin, and kiteplatin. They proved to be much more effective than
the reference compounds, with complex 3 most effective in 3D spheroid tumor cultures. Notably,
treatment of human A431 carcinoma cells with 2 and 3 did not determine increase of cellular ROS
(usually correlated to inhibition of mitochondrial PDK) and did not induce a significant depolarization
of the mitochondrial membrane or alteration of other morphological mitochondrial parameters.
Keywords: platinum(IV) complexes; cisplatin; kiteplatin; α-lipoic acid; DNA; mitochondria;
tumor spheroids
1. Introduction
It is well known that numerous cancer cells preferentially convert glucose to lactate, even in the
presence of oxygen (aerobic glycolysis), for the generation of ATP. This phenomenon was discovered by
Warburg already in the 1920s and is hence reported as the Warburg effect [1,2]. Yet, aerobic glycolysis is
not very efficient from an energetical point of view since it leads to the production of only two molecules
of ATP per molecule of glucose while the complete oxidation of glucose to carbon dioxide and water
produces 32 molecules of ATP. For this reason, cancer cells need huge amounts of glucose to satisfy
their high demand of energy, but, at the same time, they are able to adapt to hypoxic conditions. Cancer
Int. J. Mol. Sci. 2018, 19, 2050; doi:10.3390/ijms19072050 www.mdpi.com/journal/ijms107
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therapy can take advantage of the key feature of glucose metabolism of cancer cells. The pyruvate
dehydrogenase complex is located in the mitochondrial matrix of eukaryotes; the complex acts to
convert pyruvate (a product of glycolysis in the cytosol) to acetyl-coA, which is then oxidized in the
mitochondria to produce energy in the citric acid cycle. Pyruvate dehydrogenase kinase (PDK) is
a kinase enzyme which acts to inactivate the pyruvate dehydrogenase enzyme by phosphorylating
it using ATP; by downregulating the pyruvate dehydrogenase, PDK will decrease the oxidation of
pyruvate in mitochondria and increase the conversion of pyruvate to lactate in the cytosol. An inhibitor
of PDK will activate those enzymes that are able to shift the metabolism toward the complete oxidation
of glucose. A compound that has been used for such purpose (inhibition of PDK) is dichloroacetate
(DCA; Scheme 1), an orphan drug. DCA works to counteract the increased production of lactate
exhibited by tumor cells (anaerobic respiration) by activating the pathway to pull the intermediates
into the citric acid cycle and finish off with oxidative phosphorylation (aerobic respiration) [3].
Scheme 1. Molecular structures of dichloroacetate (DCA), α-lipoic acid (ALA), and α-dihydrolipoic
acid (DHALA).
Also the dithiol compound (R)-(+)-α-lipoic acid (6,8-dithio-octanoic acid; ALA, Scheme 1) is a
potential activator of the pyruvate dehydrogenase complex and can be potentially used to suppress
anaerobic glycolysis [4,5]. ALA is synthesized from octanoic acid in the mitochondria and it is also
taken from food. Apart from being capable to chelate metal ions, ALA has a unique reductive power
and its disulfide group can be easily reduced to form α-dihydrolipoic acid (DHALA; Scheme 1) and
both constitute a low redox potential pair (E’0 = −0.29 V) [6] capable to scavenge a variety of reactive
oxygen species (ROS) [7–10].
ROS and, in general, oxidative stress also play a crucial role in cancer cells being correlated with
cell growth and apoptosis [11]. In particular, ALA was shown to activate apoptosis in human cancer
cell lines by inducing a reversible cell-cycle arrest but failed to trigger apoptosis in non-transformed
cell lines [12]. Apoptosis was potentiated by ALA also in human leukemia cells and, because of its
antioxidant properties, it was suggested that this compound can promote a reducing intracellular
environment that is necessary for the activation of caspases [13]. On the other hand, in neurons and
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in hepatocytes [14,15], ALA was demonstrated to exert a protective activity against apoptosis, thus
showing an opposite activity in tumor and healthy cells.
In another study, exposure of HT-29 human colon cancer cells to ALA caused a dose-dependent
increase of caspase-3-like activity associated with DNA fragmentation. Moreover, in this tumor cell
line ALA was not able to scavenge cytosolic O2·− whereas it was capable to increase the generation of
the superoxide anion radical in the mitochondria [16] preceded by an increased influx of lactate or
pyruvate into the organelles. Oppositely to HT-29 colon cancer cells, no apoptosis was observed in
nontransformed human colonocytes, thus providing evidences for a selective induction of apoptosis
in the cancer cell line by a prooxidant mechanism initiated by an increased uptake of oxidizable
metabolites in the mitochondria.
In vitro cell proliferation inhibition by ALA was also reported for neuroblastoma cell lines
Kelly, SK-N-SH, and Neuro-2a, for breast cancer cell lines SkBr3 [16] and MDA-MB-231, as well
as for leukemia cells Jurkat and CCRF-CEM [17,18]. Moreover, in a xenograft mouse model with
subcutaneous SkBr3 cells, daily treatment with ALA significantly retarded tumor growth, further
supporting the potential anticancer activity of this compound.
Platinum(II) complexes are well-known antiproliferative agents [19] and, among them, cisplatin,
carboplatin, and oxaliplatin (Scheme 2) have received Food and Drug Administration approval and are
used in the clinic worldwide [19–21]. However, the appearance of resistance and induction of severe
side effects limit the use of these drugs [20]. In order to overcome at least some of these drawbacks,
new platinum drugs based on the platinum(IV) core have been developed. In this context, we have
recently focused on Pt(IV) complexes [22,23] derived from kiteplatin, [PtCl2(cis-1,4-DACH)] (DACH =
diaminocyclohexane; Scheme 2) including a derivative having two DCA ligands in axial positions [24];
the aim was to obtain a dual acting complex endowed with the ability to target both nuclear DNA
and mitochondria. Kiteplatin contains an isomeric form of the diamine ligand 1R,2R-DACH present
in oxaliplatin and is effective against both cisplatin-resistant (ovarian C13*) and oxaliplatin-resistant
(colon LoVo-OXP) cancer cell lines, suggesting that the spectrum of activity of this compound could be
different from that of cisplatin and oxaliplatin [25–28]. The newly synthesized Pt(IV) complexes with
DCA, cis,trans,cis-[PtCl2(DCA)2(cis-1,4-DACH)] and cis,trans,cis-[Pt(CBDCA)(DCA)2(cis-1,4-DACH)]
(CBDCA = 1,1-cyclobutanedicarboxylate), were tested in vitro against a series of different tumor cell
lines, some of which were selected for their resistance to cisplatin and oxaliplatin, and the antitumor
activity of the lead compound, cis,trans,cis-[PtCl2(DCA)2(cis-1,4-DACH)], was also assessed in vivo in
a syngeneic murine model of solid tumor (the Lewis Lung Carcinoma).
Scheme 2. Sketches of clinically used platinum(II) drugs (Cisplatin, Carboplatin, and Oxaliplatin) and
of Kiteplatin.
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Tested compounds induced a substantial increase of ROS production, blockage of oxidative
phosphorylation, hypopolarization of the mitochondrial membrane, and caspase-3/7-mediated
apoptotic cell death. These effects could be a consequence of the DCA released after intracellular
reduction of the Pt(IV) complexes.
On this basis we decided to explore the conjugation of ALA (another activator of the
pyruvate dehydrogenase complex like DCA) in the axial positions of a Pt(IV) derivative of
kiteplatin and in this paper we report the synthesis, characterization, and biological activity
of two kiteplatin derivatives, cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2; Scheme 3) and
cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)] (3; Scheme 3).
Scheme 3. Sketches of the two novel kiteplatin Pt(IV) derivatives investigated in this work:
cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2) and cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)] (3).
It could be expected that the new compounds could mitigate some side effects of platinum-drug
therapy such as ototoxicity and nephrotoxicity. In fact, it has been shown that pretreatment with
ALA significantly reduces apoptotic cell death of the inner and outer hair cells in cisplatin-treated
organ of Corti explants and attenuates ototoxicity via marked lowering of the expression levels of
proinflammatory cytokines and other cisplatin-induced biomarkers of ototoxicity in cisplatin-treated
HEI-OC1 cells [29]. Moreover, it has been shown that lipoic acid also prevents cisplatin-induced
nephrotoxicity in rats [30].
2. Results and Discussion
2.1. Synthesis and Characterization
It was demonstrated that compounds that support pyruvate dehydrogenase reaction (such as
DCA and ALA) are promising agents in cancer therapy since they are able to target the glucose
metabolism of cancer cells [31]. In particular, the antioxidant ALA is able to induce apoptosis in HT-29
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human colon cancer cells via an increased ROS production in mitochondria by enhancing the uptake
of pyruvate and lactate from glycolysis into the mitochondria [16]. Oxidation of the monocarboxylates
pyruvate and lactate in the citric acid cycle increases the delivery of reductive equivalents to the
respiratory chain with the final result of drastically increasing the mitochondrial production of O2·−
which, in turn, triggers apoptosis in the cancer cells.
We have already reported on kiteplatin-Pt(IV) complexes having DCA in the axial positions
with the lead compound, cis,trans,cis-[PtCl2(DCA)2(cis-1,4-DACH)] showing encouraging antitumor
activity also in vivo in the solid syngeneic murine model Lewis Lung Carcinoma [24]. In this
work we have extended the investigation to Pt(IV) kiteplatin derivatives containing, in the axial
positions, the antioxidant ALA: namely cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2) and
cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)] (3).
Lipoic acid has been already used as a ligand in platinum complexes. In particular, an amide
formed by lipoic acid and aniline was used as a linker between a platinum complex and gold
nanoparticles [32], while polynuclear platinum complexes with lipoic acid were patented for the
prophylaxis or treatment of cancer [33]. To the best of our knowledge, this is the first time that
mononuclear platinum complexes with lipoic acid have been prepared and tested in vitro for their
potential application as antitumor drugs.
Naturally occurring α-Lipoic acid is in the (R)-(+) configuration, however, in this work
we have used the commercially available racemic (±)-α-Lipoic acid that was activated into its
anhydride by DCC conjugation and then reacted with the Pt(IV)-dihydroxido derivative of kiteplatin
cis,trans,cis-[Pt(CBDCA)(OH)2(cis-1,4-DACH)] (1). The NMR characterization of compound 1 is
reported in the Experimental Section and in the Supplementary Information (Figures S1–S3).
Cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2) has been characterized by elemental analysis,
ESI-MS, and NMR. The ESI-MS (+) spectrum showed the presence of a peak at m/z = 885.15
corresponding to [2 + Na]+ and the experimental isotopic pattern was in good agreement with the
theoretical one (data not shown). The NMR characterization of compound 2 was obtained with the
help of a 2D COSY experiment (Figure 1). Assignment of protons started from the methylenic protons
of coordinated ALA. The triplet integrating for 4 protons falling at 2.22 ppm and the multiplet at
1.48 ppm, correlated by a COSY cross peak, were assigned to CH2 in α and β positions, respectively,
of the lipoato ligand (see Scheme 3 for numbering of protons). The multiplet located at 1.32 ppm
was assigned to the CH2γ protons since it shows COSY cross peaks with the CH2 in β position and
the multiplets at 1.62 and 1.51 ppm; these latter were assigned to the protons in δ’ and δ positions,
respectively. The 1,2-dithiolane ring showed 5 different signals. The multiplet resonating at 3.58 ppm
was assigned to the ε CH based on a COSY a cross peak with the proton δ and two additional cross
peaks with the multiplets resonating at 2.39 and 1.85 ppm assigned, respectively, to the methylenic
protons ζ’ and ζ. The characterization of the lipoato ligand ends with the attributions of the multiplets
at 3.17 and 3.11 ppm to the methylenic protons η’ and η, these latter signals showing cross peaks with
the protons ζ and ζ’.
With reference to the cis-1,4-DACH ligand, the singlet with platinum satellites (2JH-Pt = 66 Hz;
see Figure 2) located at 7.76 ppm was assigned to the aminic protons, at lower field with respect to
the corresponding signal in compound 1 (6.47 ppm). The deshielding is probably due to the presence
of the carboxylic groups of coordinated ALA in axial positions (hydrogen bonds between axial C=O
and coordinated NH2 were found in similar systems) [34]. The methynic (Ha) and methylenic (Hb,c)
protons of coordinated DACH give, respectively, a singlet at 2.84 and a broad signal (integrating for
eight protons) at 1.63 ppm. Finally, the multiplet at 2.40 ppm (partially overlapping with ζ’) and the
quintet at 1.78 ppm were assigned to the cyclobutane protons of CBDCA.
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Figure 1. Selected region of the 2D COSY (700 MHz) spectrum obtained for cis,trans,cis-
[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2) in DMSO-d6. Numbering of protons is reported in Scheme 3.
The asterisks indicate residual solvent peaks.
Figure 2. [1H, 195Pt]-HSQC 2D spectrum (1H 300 MHz) obtained for cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-
1,4-DACH)] (2) in DMSO-d6.
The [1H-195Pt]-HSQC 2D NMR spectrum of compound 2 in DMSO-d6 (Figure 2) exhibits two cross
peaks, located at 7.76/1932.7 and 2.84/1932.7 ppm (1H/195Pt), correlating the aminic and methynic
protons of cis-1,4-DACH with the platinum atom. The 195Pt chemical shift is found at lower field
with respect to that of the precursor compound 1 (1617.6 ppm in DMSO-d6) but is in good agreement
with that reported for similar Pt(IV) dicarboxylato derivatives with the platinum atom in a N2O4
coordination environment [35].
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The assignment of 13C signals has been accomplished by a [1H, 13C]-HSQC 2D NMR spectrum
(Figure 3) and data are reported in the Experimental Section.
Figure 3. [1H, 13C]-HSQC (1H 700 MHz) of cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2) in
DMSO-d6. Numbering of protons is reported in Scheme 3. The asterisk indicates the residual
solvent peak.
Compound 3, cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)], was prepared with a procedure similar to
that used for compound 2, the only differences being the starting platinum(IV) derivative of kiteplatin,
cis,trans,cis-[PtCl2(OH)2(cis-1,4-DACH)], and the purification step that required the use of a less polar
solvent such as n-pentane. Compound 3 has been characterized by elemental analysis, ESI-MS, and
NMR. The ESI-MS (+) spectrum showed the presence of a peak at m/z = 813.07 corresponding to
[3 + Na]+ and the experimental isotopic pattern of the peak resulted to be in agreement with the
theoretical one (data not shown). The NMR characterization (in DMSO-d6) of compound 3 was
obtained with the help of a 2D COSY experiment (Figure S4) and is similar to that reported for complex
2 with the exclusion of the signals belonging to the CBDCA ligand. The assignment of 13C signals has
been accomplished by a [1H, 13C]-HSQC 2D NMR spectrum (Figure S5). The [1H-195Pt]-HSQC 2D
NMR spectrum of compound 3 in DMSO-d6 (Figure S6) exhibits two cross peaks, located at 8.19/1217.6
and 2.98/1217.6 ppm (1H/195Pt), correlating the aminic and methynic protons of cis-1,4-DACH with
the platinum atom. The 195Pt chemical shift is found at lower field with respect to that of the precursor
compound cis,trans,cis-[PtCl2(OH)2(cis-1,4-DACH)] (964.6 ppm in DMSO-d6) [36] and is in good
agreement with that reported for similar Pt(IV) derivatives with the platinum atom in a Cl2N2O2
coordination environment [37,38]. All the NMR data are reported in the Experimental Section while
the NMR spectra are reported in the Supplementary Information (Figures S4–S6).
2.2. Biological Assays
The in vitro antitumor potency of the ALA Pt(IV) kiteplatin-derivatives 2 and 3 was evaluated
on a panel of human cancer cells and compared to that of cisplatin (CDDP), oxaliplatin (OXP),
and kiteplatin as well as to that of [Pt(CBDCA)(cis-1,4-DACH)]. Cell lines representative of lung
(H157), colon (HCT-15), breast (MCF-7), cervical (A431), and ovarian (2008) carcinoma have been
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included. The cytotoxicity was evaluated by means of the MTT test for 72 h incubation with different
concentrations of the tested compounds. IC50 values, calculated from dose-survival curves, are
reported in Table 1.
Table 1. In vitro antitumor activity.
Compound
IC50 (μM) ± S.D.
2008 MCF-7 A431 HCT-15 H157 Average
[Pt(CBDCA)(cis-1,4-DACH)] 25.47 ± 4.11 20.58 ± 3.15 13.56 ± 2.18 30.58 ± 5.25 19.21 ± 4.15 21.9
2 3.15 ± 0.85 3.05 ± 0.89 2.25 ± 0.52 2.31 ± 0.56 3.44 ± 0.97 2.8
3 0.34 ± 0.09 1.12 ± 0.57 0.10 ± 0.04 0.61 ± 0.15 0.99 ± 0.31 0.6
CDDP 2.22 ± 1.02 10.58 ± 0.82 2.10 ± 0.87 15.28 ± 2.63 2.12 ± 0.89 6.5
OXP 1.65 ± 0.46 4.52 ± 0.95 3.71 ± 0.76 1.15 ± 0.43 5.99 ± 1.85 3.4
Kiteplatin 1.89 ± 1.04 3.10 ± 1.42 3.95 ± 1.11 2.66 ± 0.95 2.08 ± 0.66 2.7
CDDP: cisplatin, OXP: oxaliplatin. S.D. = standard deviation. Cells (3–5 × 104 mL−1) were treated for 72 h with
different concentrations of tested compounds. Cytotoxicity was assessed by the MTT test. IC50 values were
calculated by a four parameter logistic model (p < 0.05).
The two ALA derivatives 2 and 3 proved to be much more effective than the reference compounds
kiteplatin and [Pt(CBDCA)(cis-1,4-DACH)]. The higher potency of complex 3, compared to that
of complex 2, reflects the one order magnitude higher potency of kiteplatin compared to that of
[Pt(CBDCA)(cis-1,4-DACH)]. However, an effect due to the release of ALA after reduction of the Pt(IV)
complexes is also evident. Notably, over the five tested cell lines the IC50 values of 2 and 3 were, in
the order, about 7 and 4 times lower than those of the reference Pt(II) complexes. In addition, both
Pt(IV) complexes showed, on average, an in vitro antitumor potency superior to those of the reference
metallodrugs CDDP and OXP. Among Pt(IV) ALA derivatives, complex 3 was the most effective with
an in vitro antitumor potential roughly an order of magnitude higher than that of CDDP and about
5.5 times greater than that of OXP.
The marked cell-killing effect observed against human A431 squamous cervical carcinoma cells
prompted us to evaluate the in vitro antitumor activity of the Pt(IV) ALA derivatives on 3D cell
cultures. As opposed to 2D monolayer cultures, cells growing in 3D culture systems form spheroids
that are comprised of cells in various stages. The outer layers of the spheroid, being highly exposed
to the medium, are mainly comprised of viable, proliferating cells whereas the core cells receiving
less oxygen, growth factors, and nutrients, tend to be in a quiescent or hypoxic state [39]. Such
cellular heterogeneity resembles that of in vivo tumors, making 3D cell cultures more predictive than
conventional 2D monolayer cultures in screening antitumor drugs. Table 2 summarizes the IC50 values
obtained after treatment of 3D cell spheroids of human A431 cervical cancer cells with the Pt(IV) ALA
complexes as well as kiteplatin, [Pt(CBDCA)(cis-1,4-DACH)], CDDP, and OXP used as references.
Table 2. Cytotoxicity towards human A431 cancer cell spheroids.
IC50 (μM) ± S.D.
[Pt(CBDCA)(cis-1,4-DACH)] 2 3 Kiteplatin CDDP OXP
A431 98.9 ± 6.8 58.4 ± 3.8 30.2 ± 5.1 65.2 ± 5.8 71.1 ± 3.9 65.3 ± 5.2
Spheroids (3 × 103 cells/well) were treated for 72 h with increasing concentrations of tested compounds. The growth
inhibitory effect was evaluated by means of MTT test. IC50 values were calculated from the dose-survival curves by
the four parameter logistic model (p < 0.05). S.D. = standard deviation.
Consistently with 2D studies, complex 3 proved to be the most effective compound, showing
an efficacy (in decreasing cancer spheroid viability) about 2 times higher than those of CDDP, OXP,
and kiteplatin. Conversely, complex 2 was slightly more effective than CDDP, OXP, and kiteplatin but
markedly less cytotoxic than 3.
Based on previous findings highlighting the ability of ALA derivatives to affect PDK (thus
leading to ROS production and mitochondria hampering) [16–18], we investigated the effects of Pt(IV)
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ALA kiteplatin derivatives on mitochondria. In particular, we investigated the ROS production and
the alteration of the mitochondrial membrane potential and of the mitochondrial morphological
parameters. A preliminary NMR investigation revealed that the ALA ligands conjugated in the axial
positions of the Pt(IV) complexes maintained their oxidized state also in the presence of glutathione.
This finding was in line with literature data reporting the potentials of redox systems such as
NAD+/NADH, GSSG/GSH, dehydroascorbate/ascorbate, etc. [6]. Hence, we are confident that
the ALA ligand is released after the complexes have entered the tumor cells and can be reduced only
after reduction of the Pt(IV) complexes to their Pt(II) counterparts.
Treatment of A431 cells with derivatives 2 and 3 did not determine any substantial increase in cellular
ROS basal production (Figure 4A), whereas 2 h treatment with antimycin, a classical inhibitor of the
mitochondrial respiratory chain at the level of complex III, caused a remarkable increase of the hydrogen
peroxide content (about 6 times greater than that of control cells). Consistently, treatment with 2 and 3 did
not induce a significant increase of A431 human cancer cells with depolarized mitochondria (Figure 4B)
or any morphological alteration of mitochondria parameters (Figure 4C). Indeed, mitochondria of A431
cancer cells treated with 3 were conserved in shape and ultrastructure (cristae).
Figure 4. Effects induced by Pt(IV) ALA kiteplatin derivatives at mitochondrial level. (A) ROS
production in A431 cells. Cells were pre-incubated in PBS/10 mM glucose medium for 20 min at 37 ◦C
in the presence of 10 mM CM-H2DCFDA and then treated with 2, 3, or antimycin (1 μM). Fluorescence
of DCF was measured at 485 nm (excitation) and 527 nm (emission). (B) Effects on mitochondrial
membrane potential. A431 cells were treated for 24 h with 2, 3, or antimycin (1 μM) and stained with
TMRM (10 nM). Fluorescence was estimated at 490 nm (excitation) and 590 nm (emission). Data are
the means of five independent experiments. Error bars indicate S.D. ** p < 0.01. (C) TEM analysis of
A431 cells treated for 24 h with 1 μM of 2 and 3. Cells were processed through standard procedures as
reported in the Experimental section. (a) Control; (b) 2; (c) 3.
Overall, these results suggest that 2 and 3 do not activate a macroscopic antimitochondrial mechanism.
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3. Materials and Methods
3.1. Chemicals, Instrumentation, and Platinum Complexes Precursors
Commercial reagent grade chemicals ((±)-α-Lipoic acid, dicyclohexylcarbodiimmide (DCC),
4-(dimethylamino)pyridine; Sigma-Aldrich, Milan, Italy) and solvents were used as received without
further purification. 1H-NMR, COSY, and [1H, 13C]-HSQC 2D NMR spectra were recorded on Bruker
Avance DPX 300 MHz and Bruker Avance III 700 MHz instruments. 1H and 13C chemical shifts were
referenced using the internal residual peak of the solvent (DMSO-d6: 2.50 ppm for 1H and 39.51 ppm
for 13C). [1H, 195Pt]-HSQC spectra were recorded on Bruker Avance DPX 300 MHz instrument (Bruker
Italia S.r.L., Milano, Italy). 195Pt NMR spectra were referenced to K2PtCl4 (external standard placed at
−1620 ppm with respect to Na2[PtCl6]) [37]. Electrospray Mass Spectrometry: ESI-MS was performed
with a dual electrospray interface and a quadrupole time-of-flight mass spectrometer (Agilent 6530
Series Accurate-Mass Quadrupole Time-of- Flight (Q-TOF) LC/MS; Agilent Technologies Italia S.p.A.,
Cernusco sul Naviglio, Italy). Elemental analyses were carried out with an Eurovector EA 3000 CHN
Instrument (Eurovector S.p.A., Milano, Italy).
Kiteplatin, [Pt(CBDCA)(cis-1,4-DACH)] (DACH = diaminocyclohexane; CBDCA = 1,1-
cyclobutanedicarboxylate) [40] and cis,trans,cis-[PtCl2(OH)2(cis-1,4-DACH)] [36] were prepared
according to already reported procedures and all analytical data were in good agreement with the
given formulation.
3.2. Synthesis of cis,trans,cis-[Pt(CBDCA)(OH)2(cis-1,4-DACH)] (1)
This compound was prepared according to a procedure reported in the literature with slight
modifications [41]. Briefly, a solution of [Pt(CBDCA)(cis-1,4-DACH)] (100 mg; 0.22 mmol) in 40 mL of
H2O was treated with a solution of H2O2 in H2O (30% w/w, 450 μL). The mixture was stirred at room
temperature for 24 h in the dark. The resulting suspension was filtered and the filtrate was concentrated
under reduced pressure to a minimum volume. Addition of acetone induced the formation of a white
precipitate that was isolated by filtration of the mother liquor, washed with acetone, and dried under
vacuum. Yield 77% (82 mg, 0.17 mmol). Anal.: calculated for C12H22N2O6Pt (1): C, 29.69; H, 4.57; N,
5.77%. Found: C, 29.53; H, 4.71; N, 5.63%. ESI-MS: calculated for C12H22N2O6PtNa [1 + Na]+: 508.10.
Found: 508.10 m/z. 1H-NMR (DMSO-d6): 6.47 (4H, NH2), 2.80 (2H, CHa), 2.52 (4H, CHd,f ), 2.02
(4H, CHb), 1.77 (2H, CHe), 1.48 (4H, CHc), 0.35 (2H, OH) ppm. 195Pt NMR (DMSO-d6): 1617.60 ppm.
13C-NMR (DMSO-d6): 47.57 (Ca), 31.67 (Cd,f ), 19.23 (Cb,c), 15.69 (Ce) ppm.
3.3. Synthesis of cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (ALA = (±)-α-Lipoic Acid) (2)
α-Lipoic anhydride was prepared according to a procedure reported in the literature with slight
modifications [42]. A mixture of (±)-α-lipoic acid (727 mg, 3.52 mmol) and DCC (494 mg, 2.39 mmol)
was stirred in 26 mL of methylene chloride for about 15 h at room temperature. The solution was
filtered, to remove the byproduct dicyclohexylurea (DCU), treated with 4-(dimethylamino)pyridine
(1.4 mg, 0.0117 mmol) and 1 (57 mg, 0.117 mmol) and left under stirring at room temperature for 24 h.
The resulting suspension was filtered and the solution treated with 120 mL of diethyl ether which
induced the formation of a white precipitate that was isolated by filtration of the mother liquor, washed
several times with diethyl ether, and dried under vacuum. Yield 35% (35 mg, 0.041 mmol). Anal.:
calculated for C28H46N2O8PtS4·1/3diethyl ether (2·1/3 C4H10O): C, 39.73; H, 5.61; N, 3.25%. Found:
C, 39.73; H, 5.45; N, 3.43%. ESI-MS: calculated for C28H46N2O8PtS4Na [2 + Na]+: 885.16. Found: m/z
885.15. 1H-NMR (DMSO-d6): 7.76 (4H, NH2), 3.58 (2H, CHε; see Scheme 3 for numbering of protons),
3.17 (2H, CHη’), 3.11 (2H, CHη), 2.84 (2H, CHa), 2.40 (4H, CHd,f ), 2.39 (2H, CHζ’), 2.22 (4H, CHα), 1.85
(2H, CHζ), 1.78 (2H, CHe), 1.63 (8H, CHb,c), 1.62 (2H, CHδ’), 1.51 (2H, CHδ), 1.48 (4H, CHβ), 1.32 (4H,
CHγ) ppm. 195Pt NMR (DMSO-d6): 1932.70 ppm. 13C-NMR (DMSO-d6): 55.93 (Cε), 48.02 (Ca), 39.69
(Cζ), 37.98 (Cη), 35.69 (Cα), 33.92 (Cδ), 30.47 (Cd,f ), 28.09 (Cγ), 24.73 (Cβ), 19.35 (Cb,c), 15.21 (Ce) ppm.
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3.4. Synthesis of cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)] (3)
This compound was prepared as described for complex 2 with some differences in the purification
step. Briefly, a solution of ALA (448 mg, 2.17 mmol) and DCC (299 mg, 1.45 mmol) was stirred
in 16 mL of methylene chloride for about 15 h at room temperature. The byproduct DCU was
removed by filtration and the solution treated with 4-(dimethylamino)pyridine (0.88 mg, 0.0072 mmol)
and cis,trans,cis-[PtCl2(OH)2(cis-1,4-DACH)] (30 mg, 0.072 mmol) and left under stirring at room
temperature for 24 h. The suspension was filtered and the resulting yellow solution was concentrated
to 10 mL under reduced pressure. Addition of 40 mL of diethyl ether and 10 mL of n-pentane induced
the formation of a yellow precipitate that was isolated by filtration of the mother liquor, washed
several times with diethyl ether, and dried under vacuum. Yield 53% (30 mg, 0.038 mmol). Anal.:
calculated for C22H40Cl2N2O4PtS4·1/3diethyl ether (3·1/3 C4H10O): C, 34.36; H, 5.36; N, 3.44%. Found:
C, 34.56; H, 5.19; N, 3.90%. ESI-MS: calculated for C22H40Cl2N2O4PtS4Na [3 + Na]+: 813.07. Found:
m/z 813.07. 1H-NMR (DMSO-d6): 8.19 (4H, NH2), 3.59 (2H, CHε; see Scheme 3 for numbering of
protons), 3.23–3.08 (4H, CHη’,η), 2.98 (2H, CHa), 2.43 (2H, CHζ’), 2.26 (4H, CHα), 1.88 (2H, CHζ),
1.67 (2H, CHδ’), 1.61 (8H, CHb,c), 1.54 (2H, CHδ), 1.52 (4H, CHβ), 1.38 (4H, CHγ) ppm. 195Pt NMR
(DMSO-d6): 1217.60 ppm. 13C-NMR (DMSO-d6): 55.79 (Cε), 49.47 (Ca), 39.62 (Cζ), 37.72 (Cη), 35.93
(Cα), 33.92 (Cδ), 27.93 (Cγ), 24.84 (Cβ), 19.76 (Cb,c) ppm.
3.5. Experiments with Cultured Human Cells
Pt(IV) compounds 2 and 3 were dissolved in DMSO just before running the experiment and
a calculated amount of drug solution was added to the cell growth medium to a final DMSO
concentration of 0.5%, which had no detectable effect on cell viability. Cisplatin, kiteplatin, and
[Pt(CBDCA)(cis-1,4-DACH)] were dissolved in 0.9% NaCl solution.
3.6. Cell Culture Studies
Human lung (H157), colon (HCT-15), and breast (MCF-7) carcinoma cell lines were obtained
by American Type Culture Collection (ATCC, Rockville, MD, USA). The human ovarian 2008
adenocarcinoma cells were kindly provided by Prof. G. Marverti (Dept. of Biomedical Science
of Modena University, Modena, Italy). Human cervical (A431) carcinoma cells were kindly provided
by Prof. F. Zunino (Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy). Cell lines were
maintained using the following culture media containing 10% fetal calf serum (Euroclone, Milan, Italy),
antibiotics (50 units/mL penicillin and 50 μg/mL streptomycin), and L-glutamine (2 mM): (i) RPMI for
HCT-15, A431, MCF-7 and 2008 cells; (ii) DMEM medium for A375 cells.
3.7. Cytotoxicity Assays
The growth inhibitory effect toward tumor cell lines was evaluated by means of the MTT as
previously described [24]. Cancer cells were seeded in 96-well microplates in growth medium (100 μL,
3–8 × 103 cells/well, depending upon the growth characteristics of the cell line) and then incubated in
a 5% carbon dioxide atmosphere at 37 ◦C. Following 24 h, the medium was replaced with a fresh one
containing the compound to be tested. Triplicate cultures were established for each treatment. After
72 h, 10 μL of a 5 mg/mL MTT saline solution were added to each well and microplates were incubated
for five additional hours. Subsequently 100 μL of a sodium dodecyl sulfate (SDS) solution in 0.01 M
HCl were added to each well. After an overnight incubation, the inhibition of cell growth induced
by the tested compound was evaluated by measuring the absorbance at 570 nm using a BioRad 680
microplate reader (BioRad Laboratories S.r.L.; Segrate, Italy). The average absorbance for each drug
dose was expressed as a percentage of the control and plotted versus drug concentration. IC50 values
were obtained from the dose-response curves by means of the 4-PL model (p < 0.05). IC50 values are
the drug concentrations that reduce the mean absorbance at 570 nm to 50% of those of the untreated
control wells.
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3.8. Spheroid Cultures
Spheroids were initiated in liquid overlay by seeding 3 × 103 A431 cells/well in phenol red free
RPMI-1640 medium (Sigma Chemical Co.; Sigma-Aldrich, Milan, Italy), containing 10% FCS and
supplemented with 20% methyl cellulose stock solution. A total of 150 μL of this cell suspension
was transferred to each well of a round bottom, non-tissue culture 96 well-plate (Greiner Bio-one,
Kremsmünster, Austria) to allow spheroid formation within 72 h.
3.9. ROS Production
The production of ROS was measured in A431 cells (104 cells per well) grown for 24 h in 96-well
plates in RPMI medium without phenol red (Sigma Chemical Co.). Cells were then washed with PBS
and loaded with 10 μM 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester
(CM–H2DCFDA; Molecular Probes-Invitrogen) for 25 min, in the dark. Afterwards, cells were washed
with PBS and incubated with increasing concentrations of tested complexes. Fluorescence increase
was estimated with a plate reader (Fluoroskan Ascent FL, Labsystem, Finland) at 485 (excitation) and
527 nm (emission). Antimycin (1 μM, Sigma Chemical Co.), a potent inhibitor of Complex III in the
electron transport chain, was used as positive control.
3.10. Mitochondrial Membrane Potential (ΔΨ)
The ΔΨ was assayed using the Mito-ID® Membrane Potential Kit according to the manufacturer’s
instructions (Enzo Life Sciences, Farmingdale, NY, USA). Briefly, A431 cells (5 × 103 cells per well)
were seeded in 96-well plates; after 24 h, cells were washed with PBS and loaded with Mito-ID
Detection Reagent for 30 min at 37 ◦C in the dark. Afterwards, cells were washed with PBS and
incubated with increasing concentrations of tested complexes. Fluorescence was estimated using a
plate reader (Fluoroskan Ascent FL, ThermoScientific, Vantaa, Finland) at 490 nm (excitation) and
590 nm (emission).
3.11. Transmission Electron Microscopy (TEM) Analyses
About 106 A431 cells were seeded in 24-well plates and, after 24 h incubation, treated with the
tested compounds and incubated for additional 24 h. Cells were then washed with cold PBS, harvested,
and directly fixed with 1.5% glutaraldehyde buffer with 0.2 M sodium cacodylate, pH 7.4. After washing
with buffer and post-fixation with 1% OsO4 in 0.2 M cacodylate buffer, specimens were dehydrated
and embedded in epoxy resin (Epon Araldite; Fisher Scientific Italia, Rodano (MI), Italy). Sagittal serial
sections (1 μm) were counterstained with toluidine blue; thin sections (90 nm) were given contrast by
staining with uranyl acetate and lead citrate. Micrographs were taken with a Hitachi H-600 electron
microscope (Hitachi, Tokyo, Japan) operating at 75 kV. All photos were typeset in Corel Draw 11.
3.12. Statistical Analysis
All values are the means ± S.D. of no less than three measurements starting from three different
cell cultures. Multiple comparisons were made by ANOVA followed by the Tukey–Kramer multiple
comparison test (** p < 0.01) using GraphPad Prism 5.03 for Windows software (GraphPad Software,
La Jolla, CA, USA).
4. Conclusions
A considerable amount of evidence has demonstrated that platinum drugs are activated
intracellularly by aquation of the leaving groups and subsequent covalent binding to DNA, forming
DNA adducts capable to activate various signal-transduction pathways such as those involved in
DNA-damage recognition and repair, cell-cycle arrest, and programmed cell death or apoptosis.
The Pt-DNA adducts cause unwinding and bending of double helix DNA that are recognized by
many cellular proteins. Additional intracellular targets have been used in recent years to obtain
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more potent Pt complexes, mostly explored have been Pt(IV) complexes which allow the presence
of two additional ligands in the axial positions suitable for the attachment of other cancer-targeting
ligands [43,44]. In a previous work, this result was obtained by coordinating in the axial positions
the ligand DCA, an orphan drug capable to inhibit the mitochondrial PDK [24]. Here we have
extended this strategy by coordinating in the axial positions the antioxidant ALA. The new compounds
(cis,trans,cis-[Pt(CBDCA)(ALA)2(cis-1,4-DACH)] (2) and cis,trans,cis-[PtCl2(ALA)2(cis-1,4-DACH)]
(3)), after intracellular reduction, are capable to release kiteplatin (or its CBDCA analogue) and
two molecules of α-Lipoic acid. The Pt(II) residue reaches its target DNA, while ALA could
act on mitochondria as activator of the pyruvate dehydrogenase complex and could suppress
anaerobic glycolysis.
Compounds 2 and 3 were prepared and thoroughly characterized by means of spectroscopic and
spectrometric techniques and their in vitro cytotoxicity was tested on a panel of five human cancer
cell lines and compared to that of cisplatin, oxaliplatin, and kiteplatin. Compounds 2 and 3 were
much more effective than the reference compounds, with complex 3 proving to be the most effective
also in 3D spheroid tumor cells. However, treatment of A431 cells with 2 and 3 did not determine an
increase in cellular ROS basal production, usually correlated with the inhibition of mitochondrial PDK.
In addition, treatment of A431 cells with 2 and 3 did not induce a significant depolarization of the
mitochondrial membrane or any morphological alteration of mitochondria.
The overall results hence suggest that the potentiated activity of the Pt(IV) conjugates 2 and
3, with respect to their Pt(II) precursors, can be due to other types of interactions promoted by the
release of the ALA ligands (at micromolar concentration reached into the treated tumor cells), which,
however, do not appear to significantly affect the macroscopic mitochondrial membrane potential and
the mitochondrial morphological parameters. This aspect deserves further investigation. Moreover,
since it has been shown that pretreatment with ALA significantly attenuates the effect of cisplatin on
HEI-OC1 cells and prevents cisplatin-induced nephrotoxicity in rats, we are planning to evaluate the
toxicity profiles by in vivo investigations.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/xxx/s1.
Author Contributions: Data curation: S.S., C.M., V.G., J.D.H., G.N. and N.M. Investigation: S.S., V.G. and N.M.
Methodology: V.G. Supervision: N.M. Writing—original draft: S.S., V.G., G.N. and N.M.
Funding: This research received no external funding.
Acknowledgments: The Universities of Bari and Padova, the Italian Ministero dell’Università e della Ricerca
(MIUR), and the Inter-University Consortium for Research on the Chemistry of Metal Ions in Biological Systems
(C.I.R.C.M.S.B.) are gratefully acknowledged.




CCCP Carbonylcyanide m-chlorophenyl hydrazone
CDDP cisplatin





DHALA dihydro α-lipoic acid
DCU dicyclohexylurea
DMEM Dulbecco’s Modified Eagle Medium
DMSO dimethylsulfoxide
ESI-MS Electrospray Ionisation Mass Spectrometry
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FCS Fetal calf serum
HSQC Heteronuclear single quantum coherence spectroscopy
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
OXP oxaliplatin
PBS phosphate buffer saline
ROS reactive oxygen species
RPMI Roswell Park Memorial Institute
SDS sodium dodecyl sulfate
TEM Transmission electron microscopy
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Abstract: Two transition metal complexes with 2-((2-(pyridin-2-yl)hydrazono)methyl)quinolin-8-ol
(L), [Cu(L)Cl2]2 (1) and [Ni(L)Cl2]·CH2Cl2 (2), were synthesized and fully characterized. Complex 1
exhibited high in vitro antitumor activity against SK-OV-3, MGC80-3 and HeLa cells with IC50 values
of 3.69 ± 0.16, 2.60 ± 0.17, and 3.62 ± 0.12 μM, respectively. In addition, complex 1 caused cell
arrest in the S phase, which led to the down-regulation of Cdc25 A, Cyclin B, Cyclin A, and CDK2,
and the up-regulation of p27, p21, and p53 proteins in MGC80-3 cells. Complex 1 induced MGC80-3
cell apoptosis via a mitochondrial dysfunction pathway, as shown by the significantly decreased
level of bcl-2 protein and the loss of Δψ, as well as increased levels of reactive oxygen species (ROS),
intracellular Ca2+, cytochrome C, apaf-1, caspase-3, and caspase-9 proteins in MGC80-3 cells.
Keywords: quinolinyl hydrazine; copper(II) complex; cytotoxicity; apoptosis
1. Introduction
Numerous platinum(II) complexes have been successfully used for the treatment of different
types of cancers [1]. Platinum complexes stand out among chemotherapeutic agents for its high
efficacy in combination therapy. However, they also show drawbacks like toxicity and drug
resistance [2]. Especially, the clinical use of cisplatin is severely limited by its unwanted side effects,
including ototoxicity and nephrotoxicity, which reduce patient tolerance during treatment and interfere
with the long-term quality of life [3]. Therefore, it is necessary to explore other nonplatinum complexes
that could offer high efficacy with fewer side effects.
Many studies show that the copper and nickel complexes play an important role in the endogenous
oxidative DNA damage associated with aging and cancer [4–8]. For example, complexes with Cu(II) ion
show high DNA binding and DNA cleavage activities [9], and copper complexes induced reversible
condensation of DNA and apoptosis in osteosarcoma MG-63 cell lines [10]. Many nickel complexes
bearing biological activity have been reported including Ni(II) complexes with antitumor activity [11,12].
Nickel complexation with lidocaine enhances the DNA binding affinity, DNA cleavage activity,
and cytotoxic properties of lidocaine [13]; Nickel complexes also show considerable cytotoxic activity
against the human hepatocarcinoma cells (Hep-G2), human leukemic cells (HL-60), and human prostatic
carcinoma cells (PC-3) [14]. Therefore, the synthesis and biological testing of copper and nickel complexes
have become an important area of current bioinorganic chemistry research [15–17].
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The compound 8-Hydroxyquinoline (HQ) has attracted considerable interest as a privileged
structure (Scheme 1), and 8-hydroxyquinoline derivatives (HQs) have been explored for a broad range
of biological applications [18], such as metal-chelators for neuroprotection, chelators of metalloproteins,
inhibitors of 2OG-dependent enzymes, Mycobacterium tuberculosis inhibitors, botulinum neurotoxin
inhibitors and anticancer, anti-HIV, antifungal, antileishmanial, and antischistosomal agents [19–21].
The HQs with anticancer or anti-Alzheimer activities include mainly halogenated derivatives [22,23],
diperazino and alkyno derivatives [24,25], nitro derivatives [26–28], carboxylic and carboxamido
derivatives [29–31], amino and imino derivatives [32,33], sulfoxine and sulfonamide derivatives [34–36],
Bis- and poly-HQs [37,38], HQ bioconjugates [39–41], and other HQ derivatives [42]. In addition, it is
well known that quinolinylhydrazones show various important biological activities and the quinoline
ring plays an important role in the development of new anticancer agents [43–47]. For example,
the quinolinylhydrazones exhibit significant cytotoxicity in comparison with similar reported systems
and the apoptosis induction in MCF-7 cancer cells increased when it was coordinated with the gold
nanoparticle surface [48]. Recently, the synthesis of 2-((2-(pyridin-2-yl)hydrazono)methyl)quinolin-8-ol
(L) was reported [49]. The metal complexes of HQs show enhanced tumor cytotoxicity [50–56],
including ruthenium [50,51], gold [52], platinum [53], copper [43,48,49], and vanadium [44] complexes.
However, there are few reports on the synthesis and antitumor activity of Cu(II) and Ni(II) complexes.
Chan et al. found that 8-hydroxy-2-quinolinecarbaldehyde (Scheme 1) showed the highest in vitro
cytotoxicity against the human cancer cell lines, including MDA231, T-47D, Hs578t, SaoS2, K562, SKHep1,
and Hep3B [42].
Therefore, as part of our continuing work on the synthesis, characterization and medicinal
application of metal complexes with HQ [45–47], we report the synthesis and characterization of Cu(II)
and Ni(II) complexes with 2-((2-(pyridin-2-yl)hydrazono)methyl)quinolin-8-ol (L) and the in vitro
cytotoxicities against seven tumor cells and their antitumor mechanism.
Scheme 1. The structures of 8-hydroxyquinoline (HQ), quinolinyl hydrazine (QH) and L.
2. Results
2.1. Synthesis
As outlined in Scheme 2, complexes 1, 2 were synthesized by the reaction of L with CuCl2·2H2O
and NiCl2·6H2O in hot methanol, respectively. They were satisfactorily characterized by mass
spectrometry (MS), elemental analysis (EA), infrared spectroscopy (IR), and single-crystal X-ray
diffraction analysis. The absorptions around 1550–1650 cm−1 of the IR (Figures S3–S5) were assigned
to the imine bond stretching vibrations of L. The imine bonds of complexes 1 and 2 underwent
a left-shift of 10–60 cm−1 upon coordination, indicating the participation of this group in coordination.
The single-crystal structure analysis suggested that the Cu(II) complex was [Cu(L)Cl2]2 (1) and the
Ni(II) complex was [Ni(L)Cl2]·CH2Cl2 (2).
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Scheme 2. The synthetic routes for ligand (L) and its metal complexes 1 and 2. Reagents are as follows:
(a) EtOH, r.t, 16 h; (b) CuCl2 or NiCl2, MeOH/CH2Cl2.
2.2. Crystal Structures of Complexes 1 and 2
The crystal data and refinement details of complexes 1 and 2 are summarized in Table S1
(Supporting Information), and the selected bond lengths and angles are listed in Tables S2 and S3.
The crystal structures of complexes 1 and 2 are shown in Figures 1 and 2. Complexes 1 and 2
have different coordination pattern. Complex 1 was a dinuclear L-Cu-Cl-(μ-Cl)2-Cu-Cl-L complex,
and the Cu(II) ions were coordinated by three Cl and two N atoms from L in a distorted square
pyramidal geometry.
In complex 2, the central NiII adopted an approximately five-coordinated tetragonal
pyramidal geometry.
Figure 1. The crystal structure of Cu(II) complex 1.
Figure 2. The crystal structure of complex 2.
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2.3. Stability in Solution
Ligand L, complexes 1 and 2 were tested for their stabilities in both dimethyl sulfoxide (DMSO)
and Tris-HCl buffer solution (TBS) (TBS solution with pH at 7.35, containing 1% DMSO) by means of
UV-Vis spectroscopy. The time-dependent (in the time course of 0, 12, 24, 36 and 48 h) UV-Vis spectra
of each complex dissolved in TBS solution are shown in Figure S1. There were no obvious changes
in the spectral characteristics and the peak absorptions for ligand L, complexes 1 and 2 over the time
course. In addition, the stabilities of L, complexes 1 and 2 were monitored by high performance liquid
chromatography (HPLC) detected at 245 nm, and no significant change was observed for these three
compounds in TBS at 0, 24, and 48 h (Figure S2). Combining the ESI-MS data, the results suggested
that complex 2 was stable in TBS solution, and complexes 1 was stable in TBS solution as mononuclear
species because it was dissociated in water solution and Tris-HCl buffer (see the results of Figure S9).
2.4. In Vitro Cytotoxicity
The in vitro cytotoxicities of L, complexes 1 and 2 were evaluated by MTT assay in seven human
tumor cell lines Hep-G2, SK-OV-3, MGC80-3, HeLa, T-24, BEL-7402, and NCI-H460 and one normal
liver cell line HL-7702. Each compound was prepared as 2.0 mM DMSO stock solution before it was
diluted in PBS buffer to 20 μM aqueous solutions (containing 2.5% DMSO). These 20 μM aqueous
solutions were stable and no precipitate was formed.
The in vitro antitumor activities of complex 1 were further evaluated by determining the
corresponding IC50 values. As shown in Table 1, the IC50 values of complex 1 against SK-OV-3,
MGC80-3 and HeLa were 3.69 ± 0.16, 2.60 ± 0.17, and 3.62 ± 0.12 μM, respectively, which were
approximately 11.6, 15.6, and 16.2 fold increases compared with that of the free L. In addition, complex 1
exhibited stronger cytotoxicities than cisplatin towards the SK-OV-3, MGC80-3, and HeLa tumor cells.
In summary, complex 1 exhibited a lower IC50 value for MGC80-3 cells than other cells and higher
cytotoxicity than complex 2. Thus, complex 1 was chosen to study the underlying cellular and
molecular mechanisms of its cytotoxicity. (As a support material, Inhibitory rates (%) of compounds
were shown in Table S4)
Table 1. The IC50 a (μM) values of L, complexes 1 and 2 to the selected tumor cells for 48 h.
Compounds Hep-G2 SK-OV-3 MGC80-3 HeLa T-24 BEL-7402 NCI-H460 HL-7702
L 58.40 ± 0.69 42.94 ± 2.64 40.93 ± 0.94 58.73 ± 1.29 85.93 ± 15.11 47.85 ± 0.37 36.93 ± 3.93 48.63 ± 0.34
1 4.51 ± 0.38 3.69 ± 0.16 2.60 ± 0.17 3.62 ± 0.12 4.41 ± 0.06 5.92 ± 0.01 5.01 ± 0.16 12.78 ± 0.55
2 >100 39.77 ± 2.15 38.99 ± 2.42 27.13 ± 6.51 18.97 ± 3.47 51.68 ± 0.66 36.31 ± 3.75 31.73 ± 2.11
Cisplatin b 9.55 ± 0.46 16.32 ± 1.37 12.37 ± 1.53 9.45 ± 2.05 28.15 ± 1.67 19.4 ± 0.58 9.59 ± 0.48 15.87 ± 0.36
a IC50 values are presented as the mean ± SD (standard error of the mean) from five separate experiments. b Cisplatin
was dissolved at a concentration of 1 mM in 0.154 M NaCl.
2.5. Cell Cycle Analysis and Expressions of the Related Proteins
The IC50 value of complex 1 towards the MGC80-3 cells was in the low micromolar range.
To determine the cell cycle phase of growth arrest by complex 1, the DNA content of cells was
estimated by flow cytometry after the cells were stained with propidiumiodide (PI). As shown in
Figure 3, complex 1 caused a dose-dependent accumulation of MGC80-3 cells in the S phase, whereas
most of the control cells were in the G1 and G2/M phase of the cell cycle. Additionally, the cell
population of S phase increased from 20.77% in the control to 60.18% in the MGC80-3 cells treated
with 8 μM of complex 1 for 24 h. After incubating the cells with complex 1 (8 μM) for 24 h, the cell
population of the G2/M phase was decreased to 0.00%. These results indicated that the MGC80-3 cells
were mainly blocked in the S phase.
The protein expression levels of ATR, ATM, Cdc25 A, Cyclin B, Cyclin A, CDK2, p27, p21,
and p53 protein in MGC80-3 cells after treated with complex 1 (2.0, 2.6, 5.2, and 8.0 μM) for 24 h were
determined by Western blot and the results are shown in Figure 4, which demonstrated that complex 1
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caused a dose-dependent inhibition on the protein expression levels of Cdc25 A, Cyclin B, Cyclin A,
and CDK2, and decreased levels of p27, p21, and p53 proteins.
Figure 3. The cell cycle analysis by flow cytometry of MGC80-3 cells treated with complex 1 (2.0, 2.6,
5.2, and 8.0 μM) for 24 h.
Figure 4. The expressions of ATR, ATM, Cdc25 A, Cyclin B, Cyclin A, CDK2, p27, p21, and p53 protein
in MGC80-3 cells after treated with complex 1 (2.0, 2.6, 5.2, and 8.0 μM) for 24 h were analyzed by
Western blot. (A) The same blots were stripped and re-probed with a β-actin antibody to show equal
protein loading; (B) The whole-cell extracts were prepared and analyzed by Western blot analysis
using antibodies against cell cycle protein regulator proteins. The same blots were stripped and
re-probed with the β-actin antibody to show equal protein loading. Western blotting bands from three
independent measurements were quantified with Image J in (A).
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2.6. Apoptosis Assay
Apoptosis assay can provide important information for the preliminary investigation of the
mode of action [55–57]. To determine whether the death of MGC80-3 cells induced by complex 1
resulted from apoptosis or necrosis, common biochemical markers of apoptosis were monitored,
including mitochondrial membrane depolarization, chromatin condensation, and phosphatidylserine
exposure. The cells subjected to annexin V-FITC and PI staining were classified as necrotic
cells (Q1; annexin V−/PI+), early apoptotic cells (Q2; annexin V+/PI−), late apoptotic cells
(Q3; annexin V+/PI+), and intact cells (Q4; annexin V−/PI−). The assay showed (Figure 5) that
complex 1 (1.5, 2.0, 2.6, and 3.6 μM) induced the apoptotic death of MGC80-3 cells as measured by
annexin V staining and flow cytometry. After treatment with complex 1 for 24 h, the populations of
apoptotic cells (Q2+Q3) changed from 7.08% to 27.39% with the increase of complex 1 concentration,
but the population of apoptotic cells (Q2+Q3) of control was only 1.70%. The significantly increased
percentages of apoptotic cells confirmed that complex 1 effectively induced MGC80-3 cell apoptosis in
a dose-dependent manner, which was consistent with the results of the MTT assay.
Figure 5. The Annexin V/propidium iodide assay and flow cytometry assay of MGC80-3 cells treated
with Cu(II) complex 1 (1.5, 2.0, 2.6 and 3.6 μM).
2.7. Loss of Mitochondrial Membrane Potential in MGC80-3 Cells
Growing evidence has shown that mitochondria play a key role in the progression of apoptosis,
and the loss of mitochondrial membrane potential (Δψ) is involved in apoptotic cell death due to the
cytotoxicity of the antitumor compounds [58–60]. The changes in Δψ induced by complex 1 are shown
in Figures 6 and 7. JC-1 staining was used as a fluorescent probe [58]. After the MGC80-3 cells were
treated with complex 1 for 24 h, the Δψ decreased significantly with the increase of dose (from 2.0 to
8.0 μM) of complex 1, suggesting that the induction of apoptosis by complex 1 was associated with the
intrinsic (mitochondrial) pathway.
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Figure 6. The collapse of mitochondrial membrane potential in MGC80-3 cells treated with Cu(II)
complex 1 for 24 h, as determined by JC-1 staining.
Figure 7. The loss of Δψ in MGC80-3 cells treated with complex 1 (2.0, 2.6 and 3.6 μM) for 24 h, and
the cells were examined under a fluorescence microscope (Nikon Te2000, 200×) after being stained
with JC-1.
2.8. Intracellular Ca2+
The mitochondrial membrane potential Δψ can alter the intracellular Ca2+ level, which has been
recognized as a factor in cell death, apoptosis, and injury mediated by various pathways [61,62].
We examined the effects of complex 1 on the mobilization of intracellular Ca2+ in MGC80-3 cells.
As shown in Figure 8, the level of intracellular free Ca2+ in MGC80-3 cells was lower than that of the
control group, but it increased steadily in a dose-dependent manner (2.0, 2.3, and 3.6 μM of complex 1).
Therefore, the changes of the intracellular Ca2+ level could be involved in the induction of apoptosis
by complex 1 in MGC80-3 cells.
129
Int. J. Mol. Sci. 2018, 19, 1874
Figure 8. The effect of complex 1 (2.0, 2.6, and 3.6 μM) on the intracellular free Ca2+ level in MGC80-3
cells for 24 h.
2.9. Reactive Oxygen Species (ROS) Level
The dysregulation of ROS generation could dramatically affect cancer cell structure and result in
cell damage, and consequently cell death and apoptosis [63,64]. To determine whether ROS generation
is involved in the apoptosis or death of MGC80-3 cells induced by complex 1, the ROS level was
measured by a fluorescent marker after the MGC80-3 cells were treated with complex 1 (2.0, 2.6,
and 3.6 μM) for 24 h. As shown in Figures 9 and 10, the levels of ROS in MGC80-3 cells were higher
than that in the control after treatment, and the levels of ROS increased in a dose-dependent manner
(from 2.0 to 3.6 μM of complex 1). The results confirmed that complex 1 stimulated ROS-induced
apoptosis in MGC80-3 cells.
Figure 9. The ROS generation assay by flow cytometry analysis of MGC80-3 cells treated with complex
1 (2.0, 2.6, and 3.6μM). Results are expressed as relative fluorescent intensities (from left to right).
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Figure 10. The ROS generation assay of MGC80-3 cells treated with complex 1 (2.0, 2.6, and 3.6 μM),
and the cells were examined under a fluorescence microscope (Nikon Te2000, 200×).
2.10. Western Blot Assay
To further investigate the mechanism of action of complex 1, the cytochrome C (Cyt C), bcl-2,
bax, and apaf-1 proteins in the mitochondria-related apoptotic pathway were assayed by Western
blot [65]. Figure 11 shows that the levels of bax, Cyt C, and apaf-1 proteins increased significantly and
the level of bcl-2 protein decreased significantly in the MGC80-3 cells after treatment with complex 1
(1.5, 2.0, 2.6, and 3.6 μM) for 24 h. Additionally, the levels of bax, Cyt C, and apaf-1 proteins increased
in a dose-dependent manner. These results further demonstrated that complex 1 may be involved in
mitochondria-related apoptosis [65].
Figure 11. The western blot assay of apoptosis-related protein levels in Hep-G2 cells treated with
complex 1 (1.5, 2.0, 2.6, and 3.6 μM) for 24 h. (A) Western blot was used to determine the expression
levels of bax, cytochrome c, apaf-1, and bcl-2 in MGC80-3 cells treated with complex 1 (1.5, 2.0, 2.6,
and 3.6 μM) for 24 h; (B) Densitometric analysis of apoptotic-related proteins normalized to β-actin.
The relative expression of each protein is represented by the density of the protein band/density of
β-actin band.
2.11. Assessment of Caspase-3/9/8 Activation
To determine whether caspase-3/9 were involved in the induced apoptotic cell death, MGC80-3 cells
were analyzed by flow cytometry after treatment with complex 1 (1.5, 2.0, and 2.6 μM) for 24 h. The results
showing peaks of activated caspase-3 (FITC-DEVD-FMK probes), activated caspase-8 (FITC-IETD-FMK
probes), and activated caspase-9 (FITC-LEHD-FMK probes) for the treated cells are shown in Figure 12.
It is notable that the proportion of cells with activated caspase-3, caspase-9, and caspase-8 increased from
5.04% to 18.70%, 2.59% to 23.9%, and 6.45% to 21.60%, respectively. Therefore, complex 1 could induce
cell apoptosis by triggering the caspase-3/9/8 activity in MGC80-3 cells [66–69].
131
Int. J. Mol. Sci. 2018, 19, 1874
Figure 12. The activation of caspase-3, caspase-8, and caspase-9 in MGC80-3 cells treated with complex
1 (1.5, 2.0, and 2.6 μM) for 24 h.
Taken together, complex 1 induced apoptosis in MGC80-3 cells likely by disrupting mitochondrial
function, which led to a significantly decreased level of bcl-2 protein and loss of Δψ, as well as
a significant increase in the levels of ROS, intracellular Ca2+, Cyt C protein, apaf-1 protein, activated
caspase-3, and activated caspase-9 in MGC80-3 cells.
3. Materials and Methods
3.1. Materials
All chemical reagents, including chloride salts and solvents, were of analytical grade. All materials
were used as received without further purification unless specifically noted. All the synthetic complexes
were dissolved in dimethyl sulfoxide (DMSO) for the preparation of stock solution at a concentration
of 2.0 mM.
3.2. Instrumentation
Elemental analyses (C, H, N) were carried out on a Perkin Elmer Series II CHNS/O 2400 elemental
analyzer. NMR spectra were recorded on a Bruker AV-500 NMR spectrometer. Fluorescence measurements
were performed on a Shimadzu RF-5301/PC spectrofluorophotometer. The region between 200 and 400 nm
was scanned for each sample. UV-Vis spectra were recorded on a TU-1901 ultraviolet spectrophotometer.
3.3. Synthesis
3.3.1. Synthesis of L
The 2-((2-(pyridin-2-yl)hydrazono)methyl)quinolin-8-ol (L) was obtained from the condensation
reaction of 8-hydroxyquinoline-2-carbaldehyde with 2-hydrazinylpyridine in good yield (89.0%) [44],
as shown in Scheme 2. m.p. 238 ◦C; 1H-NMR (500 MHz, DMSO-d6) δ 11.46 (s, 1H, OH), 9.72 (s, 1H,
NH), 8.27 (d, J = 9.0 Hz, 2H), 8.18 (d, J = 4.0 Hz, 1H), 8.14 (d, J = 8.6 Hz, 1H), 7.74–7.68 (m, 1H),
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7.42–7.36 (m, 3H), 7.09 (dd, J = 7.2, 1.5 Hz, 1H), 6.85 (dd, J = 6.9, 5.1 Hz, 1H); 13C-NMR (125 MHz,
DMSO-d6) δ 157.10, 153.61, 153.16, 148.32, 139.65, 138.60, 138.52, 136.57, 128.71, 127.87, 118.22, 117.91,
116.27, 112.41, 107.19; HRMS(EI): Calcd for C15H13N4O [L + H]+, m/z 265.1089, found m/z 265.1086.
IR (cm−1): νNH = 3049 cm−1; νC=N = 1580 cm−1. (The 1H-NMR, 13C-NMR and MS were shown in
Figures S6–S8)
3.3.2. Synthesis of Complex 1
The mixture of ligand L (0.26 g, 1.0 mmol) and CuCl2·2H2O (0.17 g, 1.0 mmol) in 20 mL methanol
was maintained at reflux (70 ◦C) for 6 h to afford complex 1 as black crystals in 70% yield. The black
crystals of complex 1 suitable for X-ray diffraction analysis were subsequently harvested. ESI-MS m/z:
427.0361[Cu(L)Cl + H + 2MeOH]+. Anal. Calcd for C30H24Cl4Cu2N8O2: C, 45.18; H, 3.03; N, 14.05; O,
4.01; Found: C, 45.16; H, 3.02; N, 15.07. IR (cm−1): νNH = 3101 cm−1; νC=N = 1636 cm−1. (The MS was
shown in Figure S9)
3.3.3. Synthesis of Complex 2
By means of the similar procedure, complex 2 was obtained from NiCl2·6H2O as black crystals in
75% yield. The black crystals of complex 2 suitable for X-ray diffraction analysis were subsequently
harvested. ESI-MS m/z: 321.0281 [Ni(L) + H]+. Anal. calcd for C16H14Cl4N4NiO: C, 40.13; H, 2.95; N,
11.70; Found: C, 40.14; H, 2.94; N, 11.69. IR (cm−1): νNH = 3060 cm−1; νC=N = 1615 cm−1. (The MS was
shown in Figure S10)
3.4. X-ray Crystallography
Complexes 1 (0.31 × 0.22 × 0.10 mm) and 2 (0.34 × 0.18 × 0.17 mm) were measured on
an Agilent SuperNova CCD area detector (Rigaku Corporation, Tokyo, Japan) equipped with
a graphite-monochromatic Mo-Kα radiation source (λ = 0.71073 Ǻ) at room temperature 293(2) K.
All non-hydrogen atoms’ positions and anisotropic thermal parameters were refined on F2 by full-matrix
least-squares techniques with the SHELX-97 program package [70]. The hydrogen atoms were added
theoretically, riding on the concerned atoms. The semi-empirical methods from equivalents were used to
correct absorption. The crystallographic data and refinement details of the structures are summarized in
Tables S1–S3 (Supporting Information).
3.5. In Vitro Cytotoxicity
Seven tumor cells Hep-G2, SK-OV-3, MGC80-3, HeLa, T-24, BEL7402, and NCI-H460 and one
normal liver cell HL-7702 were obtained from the Shanghai Cell Bank in the Chinese Academy of
Sciences. Cells were grown in triplicate in 96-well plates (Gibco, Carlsbad, CA, USA) and incubated
at 37 ◦C for 48 h in a humidified atmosphere containing 5% CO2 and 95% air. To investigate the
potential activity of L and complexes 1 and 2, cisplatin was employed as a reference metallodrug.
Cytotoxicity assays were carried out in 96-well flat-bottomed microtite plates that were supplemented
with culture medium and cells. Ligand L, complexes 1 and 2, and cisplatin were dissolved in the culture
medium at various concentrations (1.25, 2.5, 5.0, 10.0, and 20.0 μM) with 1% DMSO and the resulting
solutions were subsequently added to a set of wells. The control wells contained supplemented
medium with 1% DMSO. The microtitre plates were then incubated at 37 ◦C under a humidified
atmosphere containing 5% CO2 and 95% air for 2 days. Cytotoxicity screening was conducted through
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After each incubation
period, the MTT solution (10 mL, 5 mg·mL−1) was added into each well and the cultures were
incubated at 37 ◦C in a humidified atmosphere containing 5% CO2 and 95% air for a further 48 h.
After the removal of the supernatant, DMSO (150 mL) was added to dissolve the formazan crystals.
The absorbance at 490 and 630 nm was read on a plate reader. Relative to the negative control,
cytotoxicity was estimated based on the percentage cell survival in a dose-dependent manner. The final
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IC50 values were calculated by the Bliss method (n = 5). All tests were repeated in at least three
independent experiments.
3.6. Cell Cycle Arrest
The MGC80-3 cells were maintained in Dulbecco’s modified Eagle’s medium with 10.0% fetal calf
serum under 5% CO2 at 37 ◦C. The cells were harvested by trypsinization, rinsed with PBS, and centrifuged
at 3000× g for 10 min. The pellet (105–106 cells) was suspended in PBS (1.0 mL) and kept on ice for 5 min.
The cell suspension was then fixed by the dropwise addition of 9 mL precooled (4 ◦C) 100% ethanol with
vigorous shaking, and the fixed samples were kept at 4 ◦C until use. For staining, the cells were centrifuged,
resuspended in PBS, digested with 150 mL RNase A (250 μg·mL−1), treated with 150 mL PI (0.15 mM),
and then incubated for 30 min at 4 ◦C. PI-positive cells were counted with a fluorescence-activated cell
sorter (FACS). The population of cells in each cell cycle was determined by the Cell Modi FIT software
(Becton Dickinson, version 1.0, San Jose, CA, USA).
3.7. Other Experimental Methods
The supporting information provides the detailed procedures of other experimental methods,
including the measurement of mitochondrial membrane potential (by JC-1 staining), ROS generation,
intracellular free Ca2+, Western blot, and caspase-3/9 activity. The procedures were similar to those
given in the previous work of Chen et al. [71].
3.8. Statistics
Data processing included the Student’s t-test with p ≤ 0.05 taken as significance level, using SPSS
13.0 (IBM, Armonk, NY, USA).
4. Conclusions
Two transition metal complexes with 2-((2-(pyridin-2-yl) hydrazono) methyl)quinolin-8-ol (L),
[Cu(L)Cl2]2 (1) and [Ni(L)Cl2]·CH2Cl2 (2), were synthesized and fully characterized. In vitro antitumor
screening revealed that complex 1 exhibited higher inhibitory activities than cisplatin against SK-OV-3,
MGC80-3, and HeLa cells. In addition, complex 1 caused MGC80-3 cell arrest in the S phase, which led
to the significant down-regulation of the related proteins. Complex 1 can down-regulate the expression
of the bcl-2 protein and upregulate the levels of the bax, Cyt C, and apaf-1 proteins in MGC80-3 cells.
We found that complex 1 induced MGC80-3 cell apoptosis via a mitochondrial dysfunction pathway,
which was mediated by Δψ, ROS, and intracellular Ca2+. Moreover, complex 1 could induce cell
apoptosis by triggering the caspase-3/9/8 activity in MGC80-3 cells. Therefore, complex 1 is a potent
anticancer drug candidate.
Supplementary Materials: Can be found at http://www.mdpi.com/1422-0067/19/7/1874/s1, Full cif
depositions (excluding structure factors) lodged with the Cambridge Crystallographic Data Centre (CCDC
1848527 (for complexes 1), 1848516 (for complexes 2)) contain the supplementary crystallographic data for
this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via
www.ccdc.cam.ac.uk/data_request/cif.
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Abstract: Short oligonucleotides with cyclopalladated benzylamine moieties at their 5′-termini have
been prepared to test the possibility of conferring palladacyclic anticancer agents sequence-selectivity
by conjugation with a guiding oligonucleotide. Hybridization of these oligonucleotides with natural
counterparts was studied by UV and CD (circular dichroism) melting experiments in the absence
and presence of a competing ligand (2-mercaptoethanol). Cyclopalladated benzylamine proved to
be strongly stabilizing relative to unmetalated benzylamine and modestly stabilizing relative to an
extra A•T base pair. The stabilization was largely abolished in the presence of 2-mercaptoethanol,
suggesting direct coordination of Pd(II) to a nucleobase of the complementary strand. In all cases,
fidelity of Watson-Crick base pairing between the two strands was retained. Hybridization of the
cyclopalladated oligonucleotides was characterized by relatively large negative enthalpy and entropy,
consistent with stabilizing Pd(II) coordination partially offset by the entropic penalty of imposing
conformational constraints on the flexible diethylene glycol linker between the oligonucleotide and
the palladacyclic moiety.
Keywords: DNA; oligonucleotide; hybridization; organometallic; palladacycle; palladium
1. Introduction
The groundbreaking discovery of the antitumor activity of cisplatin [1,2] has been followed
by efforts to develop more potent anticancer agents based on transition metal complexes [3–11].
In particular, problems associated with the presently available platinum anticancer compounds,
notably acquired or intrinsic resistance, limited spectrum of activity and relatively high degree of
toxicity [12–14], have prompted interest in transition metals other than platinum for chemotherapeutic
use [4,6–8,15]. Palladium is an attractive candidate because its coordination chemistry is similar to that
of platinum [16,17]. Pd(II) complexes are, however, kinetically approximately five orders of magnitude
more labile than the respective Pt(II) complexes [18]. While the relatively rapid ligand-exchange
of Pd(II) should allow formation of thermodynamic (rather than kinetic) products and thus higher
selectivity than attainable with Pt(II)-based drugs, it is also likely to result in a different mode of
action, at least with simple analogues [19]. No clinically approved palladium-containing drugs are
presently available.
The possibility of using palladacyclic complexes as anticancer agents to circumvent the problems
caused by the kinetic lability of Pd(II) has received attention over the past decade. The high stability of
palladacyclic compounds in physiological media and the resultant low toxicity to normal cells make
them promising candidates for future therapeutic agents [9,20]. The selectivity of these agents could
be further improved by conjugation to a guiding oligonucleotide. The feasibility of this approach has
already been demonstrated with a number of Pt(II)-carrying DNA and PNA oligonucleotides [21–26]
but with palladacyclic modifications we are only aware of a single recent example, a short DNA
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oligonucleotide incorporating a single cyclopalladated phenylpyridine residue in the middle of the
sequence [27]. In that case, coordination of Pd(II) to the opposite base on a complementary strand
was inferred from the abnormally high UV and CD (circular dichroism) signals but the expected
stabilization of the double helix by such coordination could not be demonstrated unambiguously.
Possibly a stable Pd(II)-mediated base pair was formed but could not be readily accommodated within
the base stack, leading to disruption of the double helix.
Herein we describe the synthesis and hybridization properties of short oligonucleotides
incorporating cyclopalladated benzylamine “warheads” at their 5′-termini. At monomer level,
palladacyclic benzylamine derivatives have already been found to exhibit antitumor activity [28,29].
The 5′-terminal position was chosen to avoid disruption of the double helix by suboptimal coordination
geometry. For the same reason, a relatively long and flexible diethylene glycol spacer was used between
the cyclopalladated benzylamine and the oligonucleotide.
2. Results
2.1. Synthesis of the Benzylamine Phosphoramidite Building Block
Synthesis of the protected phosphoramidite building block of benzylamine (1) is outlined in
Scheme 1. First, benzyl bromide was allowed to react with an excess of 2-(2-aminoethoxy)ethanol
to give 2-[2-(benzylamino)ethoxy]ethanol (2). The secondary amino function was then protected as
a trifluoroacetamide by treatment with ethyl trifluoroacetate. Finally, the protected intermediate 3 was
phosphitylated by conventional methods to afford the phosphoramidite building block 1.
Scheme 1. Synthesis of the benzylamine phosphoramidite 1. Reagents and conditions:
(a) 2-(2-aminoethoxy)ethanol, MeCN, 25 ◦C, 16 h; (b) ethyl trifluoroacetate, Et3N, MeOH, 25 ◦C,
16 h; (c) 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite, Et3N, CH2Cl2, N2 atmosphere, 25 ◦C, 3 h.
2.2. Cyclopalladation of 2-[2-(benzylamino)ethoxy]ethanol
Cyclopalladation was first tested at monomer level with 2-[2-(benzylamino)ethoxy]ethanol (2)
by treatment with an equimolar amount of lithium tetrachloropalladate in a mixture of water and
acetonitrile. Near-quantitative conversion of the starting material was achieved overnight. 1H NMR
(nuclear magnetic resonance) spectrum of the product revealed loss of one ortho proton of the phenyl
ring and 13C NMR spectrum a downfield shift of the respective carbon signal. Both results are consistent
with replacement of the ortho proton with Pd(II). The most likely structure of the product is the
chlorido-bridged dimer 4 (Scheme 2), as reported previously on related compounds [30–32]. While only
mononuclear Pd(II) species could be unambiguously identified in the mass spectrum, the splitting of
several peaks in both 1H and 13C NMR is consistent with formation of a dimer, present in both cisoid
and transoid forms.
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Scheme 2. Cyclopalladation of 2-[2-(benzylamino)ethoxy]ethanol (2) and the corresponding modified
oligonucleotides ON1b, ON2b, ON3b and ON4b. Reagents and conditions: a) Li2PdCl4, MeCN, H2O,
25 ◦C, 16 h.
2.3. Oligonucleotide Synthesis
The sequences of the oligonucleotides used in the present study are summarised in Table 1.
Synthesis of the modified oligonucleotides ON1b, ON2b, ON3b and ON4b, having a 5′-terminal
benzylamine moiety, was carried out on an automated DNA synthesizer using conventional
phosphoramidite strategy. Treatment with concentrated aq. ammonia was employed for removal
of the base and phosphate protections and release of the oligonucleotides from the solid support.
Cyclopalladation of oligonucleotides ON1b, ON2b, ON3b and ON4b was carried out as described
above for the monomer 2 (Scheme 2), except that 2.0 equivalents of lithium tetrachloropalladate
was used. All modified oligonucleotides were purified by reversed-phase high performance liquid
chromatography (RP-HPLC), characterized by electrospray ionization mass spectrometry (ESI-MS)
and quantified by UV spectrophotometry.


















1 B refers to unmetalated and BPd to cyclopalladated benzylamine residue. The residues varied in the hybridization
studies have been underlined.
2.4. Hybridization Studies
The impact of the 5′-terminal palladacyclic “warheads” on the hybridization properties of
short oligonucleotides was assessed by recording melting temperatures of duplexes formed by
oligonucleotides ON1b-Pd, ON2b-Pd, ON3b-Pd and ON4b-Pd with the natural counterparts ON2a,
ON2c, ON2g and ON2t. For reference, similar experiments were also carried out on respective
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duplexes formed by oligonucleotides ON1b, ON2b, ON3b, ON4b, ON1a, ON2a, ON3a and ON4a,
having either an unmetalated benzylamine or an adenine residue at their 5′-termini. In all assemblies,
the 5′-terminal residue was placed opposite to a thymine residue of a trinucleotide overhang of
the complementary oligonucleotide (Figure 1). A single base pair within the double helical region,
on the other hand, was varied to test the sensitivity of hybridization to a single-nucleotide mismatch.
All experiments were performed at pH 7.4 (20 mM cacodylate buffer) and ionic strength of 0.10 M
(adjusted with sodium perchlorate) and each sample was first annealed by heating to 90 ◦C and then
slowly cooling down to room temperature.
Figure 1. Outline of the hybridization assays used. X is either adenine or unmetalated or cyclopalladated
benzylamine and Y is any canonical nucleobase. The bullets indicate Watson-Crick base pairing.
The longest matched duplexes ON1x•ON5a all exhibited sigmoidal melting profiles,
with Tm (melting temperature) values ranging from 36 to 41 ◦C (Figure 2A–C). The shorter duplexes
did not fully hybridize even at the lowest temperature applicable (10 ◦C) but their Tm values could
still be determined with reasonable accuracy as inflection points of the melting curves. The melting
temperatures of the mismatched duplexes, on the other hand, were high enough to be determined
reliably only in the case of the longest duplexes ON1x•ON5y. The A•C mismatch was particularly
destabilizing and precluded determination of the Tm in all cases, regardless of the length of the duplex.
Melting temperatures are summarized in Figure 2D for the longest duplexes and in the Supplementary
Materials for all duplexes.
Melting temperatures of the longest matched duplexes ON1a•ON5a, ON1b•ON5a and
ON1b-Pd•ON5a, were 40.4 ± 0.7 ◦C, 35.8 ± 0.6 ◦C and 41.0 ± 0.6 ◦C, respectively. In other words,
the cyclopalladated benzylamine residue was modestly stabilizing relative to an adenine residue
and strongly stabilizing relative to the unmetalated benzylamine residue. To explore the origin of
this stabilization, the UV melting experiments were repeated in the presence of 2-mercaptoethanol
(100 μM). 2-Mercaptoethanol is a strong ligand for soft transition metal ions and would, hence, be
expected to disrupt coordination of Pd(II) to nucleobases. If such coordination is important for duplex
stability, a decrease in Tm on addition of 2-mercaptoethanol should be observed.
Melting temperatures of the longest matching duplexes ON1x•ON5a in the absence and
presence of 2-mercaptoethanol are presented in Figure 3 (all melting temperatures are presented
in the Supporting Information). As expected, melting temperatures of duplexes ON1a•ON5a and
ON1b•ON5a did not change appreciably on addition of 2-mercaptoethanol. With ON1b-Pd•ON5a,
on the other hand, a clear drop in Tm was observed, consistent with stabilizing coordination of Pd(II)
in the absence of competing ligands.
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Figure 2. UV melting profiles for duplexes formed by ON5a with (A) ON1a (cyan circles),
ON2a (magenta triangles), ON3a (yellow squares) and ON4a (black diamonds); (B) ON1b (cyan
circles), ON2b (magenta triangles), ON3b (yellow squares) and ON4b (black diamonds) and (C)
ON1b-Pd (cyan circles), ON2b-Pd (magenta triangles), ON3b-Pd (yellow squares) and ON4b-Pd
(black diamonds); (D) melting temperatures of duplexes formed by ON1a, ON1b and ON1b-Pd
with ON5a (cyan), ON5g (magenta) and ON5t (yellow); pH = 7.4 (20 mM cacodylate buffer);
[oligonucleotides] = 3.0 μM; I(NaClO4) = 0.10 M. The error bars represent standard deviations of
three independent measurements.
T
Figure 3. Melting temperatures of duplexes ON1a•ON5a, ON1b•ON5a and ON1b-Pd•ON5a in the
absence (cyan) and presence (magenta) of 2-mercaptoethanol; pH = 7.4 (20 mM cacodylate buffer);
[oligonucleotides] = 3.0 μM; [2-mercaptoethanol] = 0/100 μM; I(NaClO4) = 0.10 M. The error bars
represent standard deviations of three independent measurements.
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To further elucidate the role of the palladacyclic “warhead”, a detailed thermodynamic analysis of
the hybridization of ON1a•ON5a, ON1b•ON5a and ON1b-Pd•ON5a was carried out as described
in the literature [33]. The resultant enthalpies and entropies of hybridization are presented in Table 2.
With ON1b-Pd•ON5a, both values were significantly more negative than with ON1a•ON5a or
ON1b•ON5a.
Table 2. Thermodynamic parameters of hybridization for ON1a•ON5a, ON1b•ON5a and
ON1b-Pd•ON5a; pH = 7.4 (20 mM cacodylate buffer); [oligonucleotides] = 3.0 μM; I(NaClO4) = 0.10 M.
Duplex ΔH◦/kJ·mol−1 ΔS◦/J·mol−1·K−1
ON1a•ON5a −200 ± 20 −530 ± 50
ON1b•ON5a −200 ± 10 −550 ± 40
ON1b-Pd•ON5a −250 ± 20 −670 ± 50
Secondary structure of duplexes formed by the cyclopalladated oligonucleotides was studied
CD spectropolarimetrically over a temperature range of 10–90 ◦C at 10 ◦C intervals. All the other
conditions were identical to those of the UV melting experiments. With the longest matched duplexes,
the spectra obtained at 10 ◦C were clearly characteristic of a B-type double helix, with prominent
negative and positive signals at 260 and 280 nm, respectively (Figure 4 for ON1b-Pd•ON5a, all spectra
are presented in the Supplementary Materials). Similar, but weaker, signals were observed with
the shorter and/or mismatched duplexes, reflecting their lower melting temperatures. In all cases,
the signals diminished on increasing temperature, consistent with unwinding of the double helix.
θ
λ
Figure 4. CD (circular dichroism) spectra of ON1b-Pd•ON5a, recorded at 10 ◦C intervals between
10 and 90 ◦C; pH = 7.4 (20 mM cacodylate buffer); [oligonucleotides] = 3.0 μM; I(NaClO4) = 0.10 M.
Spectra acquired at extreme temperatures are indicated by thicker lines and thermal shifts of the
minima and maxima by arrows.
3. Discussion
3.1. Duplex Stabilization by the Palladacyclic “Warhead”
The sensitivity of the duplex stabilization by the cyclopalladated benzylamine moiety to
the presence of 2-mercaptoethanol suggests direct coordination of Pd(II) to a base moiety of the
complementary strand. The thymine base directly opposite to the palladacyclic residue appears as the
most likely candidate but, given the length and flexibility of the diethylene glycol linker, coordination
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to other bases of the 3′-overhang cannot be ruled out. The most likely donor atoms within these bases
are the N3 of cytosine and thymine and the N1 of guanine [34–36].
Duplex stabilization by the cyclopalladated benzylamine moiety is rather modest when compared
to stabilizations achieved previously with metal mediated base pairing [37–46]. One should,
however, bear in mind that within a double helix the most stable metal mediated base pairs are
formed between two nucleosides or nucleoside analogues, preorganized to place the donor atoms
at appropriate positions. In the present case the flexible diethylene glycol linker first has to adopt
a conformation conducive to Pd(II) coordination, consistent with the observed highly negative entropy
of hybridization. As a result, the stabilizing enthalpic contribution by Pd(II) coordination is almost
entirely offset by the entropic penalty.
3.2. Impact of the Palladacyclic “Warhead” on Sequence Selectivity
Highly stabilizing modifications are known to be able to override sequence information and
allow hybridization of even highly mismatched oligonucleotides [47]. Even in the present case,
the mismatched duplexes were actually stabilized more than the matched ones by the cyclopalladated
benzylamine moiety. However, the difference in Tm between the matched and the most stable
mismatched duplex (ON1b-Pd•ON5a and ON1b-Pd•ON5g, respectively) was still nearly 18 ◦C,
translating into a 104-fold preference of ON5a over ON5g in hybridization with ON1b-Pd.
4. Materials and Methods
4.1. General Methods
NMR spectra were recorded on Bruker 500 NMR spectrometers (Bruker, Billerica, MA, USA)
and chemical shifts (δ, ppm) are quoted relative to the residual solvent peak as an internal standard.
Mass spectra were recorded on a Bruker Daltonics microTOF-Q mass spectrometer (Bruker, Billerica,
MA, USA). The solvents for organic synthesis were of reagent grade and dried over 4 Å molecular
sieves. For preparation of HPLC elution buffers, freshly distilled triethylamine was used. The other
chemicals, including unmodified oligonucleotides, were commercial products that were used
as received.
4.2. N-benzyl-2,2,2-trifluoro-N-[2-(2-hydroxyethoxy)ethyl]acetamide (3)
2-[2-(benzylamino)ethoxy]ethanol (2, 2.00 g, 10.2 mmol) was dissolved in MeOH (10 mL).
Et3N (2.90 mL, 20.4 mmol) was added and the resulting mixture stirred for 30 min at 25 ◦C.
Ethyl trifluoroacetate (1.46 g, 10.2 mmol) was then added and the reaction mixture stirred for 16 h
at 25 ◦C, after which it was evaporated to dryness to afford the desired product 3 as a mixture of
two slowly interconverting rotamers (2.98 g, near quantitative yield). 1H NMR (CDCl3, 500 MHz,
major rotamer): δ 7.19-7.48 (m, 5H), 4.80 (s, 2H), 3.40-3.70 (m, 8H), 2.82 (br, 1H). 1H NMR (CDCl3,
500 MHz, minor rotamer): δ 7.19-7.48 (m, 5H), 4.82 (s, 2H), 3.40-3.70 (m, 8H), 2.82 (br, 1H).
13C NMR (CDCl3, 125 MHz, major rotamer): δ 157.1 (q, J = 35.8 Hz), 136.3, 128.7, 127.7, 127.6,
116.8 (q, J = 285.9 Hz), 72.5, 67.6, 60.9, 50.3, 46.8 (q, J = 2.9 Hz). (CDCl3, 125 MHz, minor rotamer):
δ 156.9 (q, J = 35.8 Hz), 135.8, 128.8, 127.9, 127.2, 116.8 (q, J = 285.9 Hz), 72.4, 68.9, 61.0, 51.4 (q, J = 3.0 Hz),
46.0. HRMS (ESI+) m/z calcd 314.0974 obsd 314.0972 [M + Na]+.
4.3. 2-[2-(N-benzyl-2,2,2-trifluoroacetamido)ethoxy]ethyl 2-cyanoethyl N,N-diisopropylphosphoramidite (1)
N-benzyl-2,2,2-trifluoro-N-(2-(2-hydroxyethoxy)ethyl)acetamide (3, 670 mg, 2.30 mmol) and
Et3N (1.93 mL, 13.8 mmol) were dissolved in anhydrous CH2Cl2 (7 mL) under N2 atmosphere.
2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (0.616 mL, 2.76 mmol) was added and the
resulting mixture stirred for 3 h at 25 ◦C, after which the reaction was quenched by addition of
saturated aq. NaHCO3 (100 mL). The phases were separated and the aqueous phase was extracted
with CH2Cl2 (100 mL). The combined organic phases were washed with saturated aq. NaHCO3
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(100 mL), dried over anhydrous Na2SO4 and evaporated to dryness. The crude product thus obtained
was passed through a silica gel column eluting with a mixture of EtOAc and hexane (1:1, v/v) to afford
the desired product 1 containing a major impurity of 2-Cyanoethyl N,N-diisopropylphosphonamidate
(859 mg, 72% yield based on 31P NMR). This material was used in oligonucleotide synthesis without
further purification. 1H NMR (CDCl3, 500 MHz, major rotamer): δ 7.22-7.48 (m, 5H), 4.80 (s, 2H),
3.36-3.89 (m, 12H), 2.66 (m, 2H), 1.20 (d, J = 6.8 Hz, 6H), 1.19 (d, J = 6.8 Hz, 6H). 1H NMR (CDCl3,
500 MHz, minor rotamer): δ 7.22-7.48 (m, 5H), 4.82 (s, 2H), 3.36-3.89 (m, 12H), 2.66 (m, 2H),
1.20 (d, J = 6.8 Hz, 6H), 1.19 (d, J = 6.8 Hz, 6H). 13C NMR (CDCl3, 125 MHz, major rotamer):
δ 157.1 (q, J = 36.0 Hz), 136.3, 128.7, 127.7, 127.6, 118.6, 116.8 (q, J = 288.2 Hz), 71.1 (d, J = 7.6 Hz), 67.8,
62.6 (d, J = 16.8 Hz), 58.4 (d, J = 19.2 Hz), 50.3, 46.7 (q, J = 2.9 Hz), 42.9 (d, J = 12.6 Hz), 24.0 (d, J = 7.2 Hz),
20.0. 13C NMR (CDCl3, 125 MHz, minor rotamer): δ 156.7 (q, J = 35.4 Hz), 135.7, 129.0, 127.9, 127.2,
118.0, 116.8 (q, J = 288.7 Hz), 71.0 (d, J = 7.7 Hz), 69.1, 62.7 (d, J = 17.1 Hz), 58.4 (d, J = 19.2 Hz),
51.5 (q, J = 3.2 Hz), 45.9, 42.9 (d, J = 12.6 Hz), 24.0 (d, J = 7.2 Hz), 20.0 (d, J = 6.9 Hz). 31P NMR (CDCl3,
202 MHz, major rotamer): δ 148.1. 31P NMR (CDCl3, 202 MHz, minor rotamer): δ 148.0. HRMS (ESI+)
m/z calcd 514.2053 obsd 514.2034 [M + Na]+.
4.4. Bis{N-[2-(2-hydroxyethoxy)ethyl]benzylaminato-C2,N} bis(μ-chloro) dipalladium(II) (4)
2-[2-(benzylamino)ethoxy]ethanol (2, 240 mg, 1.28 mmol) was dissolved in a mixture of H2O
(3 mL) and MeCN (3 mL). Li2PdCl4 (336 mg, 1.28 mmol) was dissolved in a mixture of H2O (10 mL)
and MeCN (10 mL) and the resulting solution was added to the solution of 2. After stirring for 16 h
at 25 ◦C, the reaction mixture was evaporated to dryness. The residue was purified by silica gel
column chromatography eluting with a mixture of EtOAc and hexane (8:2, v/v), affording the desired
product 4 as a mixture of cisoid and transoid stereoisomers (189 mg, 44% yield). 1H NMR (CDCl3,
500 MHz, major stereoisomer): δ 7.34-7.47 (m, 4H), 4.46 (ddd, J1 = 10.6 Hz, J2 = 10.4 Hz, J3 = 2.5 Hz,
1H), 4.28 (dd, J1 = 13.1 Hz, J2 = 6.7 Hz, 1H), 4.03 (m, 1H), 3.44-3.80 (m, 6 H), 3.02 (m, 1H), 2.38 (m, 1H).
1H NMR (CDCl3, 500 MHz, minor stereoisomer): δ 7.34-7.47 (m, 4H), 4.33 (m, 1H), 4.24 (dd, J1 = 13.0 Hz,
J2 = 7.6 Hz, 1H), 4.03 (m, 1H), 3.44-3.80 (m, 6 H), 3.02 (m, 1H), 2.38 (m, 1H). 13C NMR (CDCl3, 125 MHz,
major stereoisomer): δ 147.5, 135.0, 129.9, 129.7, 128.9, 128.6, 72.8, 67.8, 61.6, 57.35, 50.8. 13C NMR
(CDCl3, 125 MHz, minor stereoisomer): δ 142.7, 135.2, 129.9, 129.7, 128.9, 128.6, 72.8, 67.6, 61.4, 57.26,
51.5. HRMS (ESI+) m/z calcd 300.0216 obsd 300.0152 [M/2 − Cl]+.
4.5. Oligonucleotide Synthesis
The modified oligonucleotides ON1b, ON2b, ON3b and ON4b were assembled on an Applied
Biosystems 3400 (Applied Biosystems, Waltham, MA, USA) automated DNA/RNA synthesizer
using conventional phosphoramidite strategy. For the benzylamine building block 1, an extended
coupling time (600 s) was used. Removal of the base and phosphate protections and release of the
oligonucleotides from the solid support was accomplished by treatment with 25% aq. NH3 for 16 h
at 55 ◦C. The cyclopalladated oligonucleotides ON1b-Pd, ON2b-Pd, ON3b-Pd and ON4b-Pd were
prepared by incubating ON1b, ON2b, ON3b and ON4b (192, 260, 290 and 173 nmol, respectively) and
Li2PdCl4 (384, 520, 580 and 346 nmol, respectively) in a mixture of H2O (530 μL) and MeCN (30 μL)
for 16 h at 25 ◦C. All modified oligonucleotides were purified by reversed-phase high performance
liquid chromatography (RP-HPLC) on a Hypersil ODS C18 column (250 × 4.6 mm, 5 μm, Thermo
Fisher Scientific, Waltham, MA, USA) eluting with a linear gradient (0 to 30% over 25 min) of MeCN
in 50 mM aqueous triethylammonium acetate. The flow rate was 1.0 mL·min−1 and the detection
wavelength 260 nm. The purified oligonucleotides were characterized by electrospray ionization
mass spectrometry (ESI-MS) and quantified UV spectrophotometrically using molar absorptivities
calculated by an implementation of the nearest-neighbors method. Molar absorptivity of both free and
cyclopalladated benzylamine was assumed to be negligible.
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4.6. Melting Temperature Measurements
Melting profiles were recorded on a PerkinElmer Lambda 35 UV-Vis spectrometer equipped
with a Peltier temperature control unit (PerkinElmer, Waltham, MA, USA). Samples were prepared
by mixing the appropriate oligonucleotides (3.0 μM) in 20 mM cacodylate buffer (pH 7.4), the ionic
strength of which was adjusted to 0.10 M with NaClO4. When applicable, 2-mercaptoethanol was
used in 100 μM concentration and added after mixing of the oligonucleotides. Before measurement,
the samples were annealed by heating to 90 ◦C and gradually cooling to room temperature. UV melting
curves were acquired by monitoring the absorbance at λ = 260 nm over a temperature range of 10–90 ◦C,
sampling at 10 ◦C intervals. The melting temperatures were determined as inflection points on the UV
melting curves.
4.7. CD Measurements
CD spectra were recorded on an Applied Photophysics Chirascan spectropolarimeter equipped
with a Peltier temperature control unit (Applied Photophysics, Leatherhead, UK). Samples used in
the CD measurements were identical to those used in the UV melting temperature measurements.
CD spectra were acquired between λ = 200 and 400 nm over a temperature range of 10–90 ◦C,
sampling at 10 ◦C intervals. At each temperature, samples were allowed to equilibrate for 600 s
before acquisition.
5. Conclusions
Cyclopalladated benzylamine, tethered at a terminal position of a short oligonucleotide by
a flexible linker, promotes hybridization despite a significant entropy penalty for “freezing” the linker
in an appropriate conformation. Sensitivity to the presence of competing ligands suggests direct
coordination of Pd(II) to a nucleobase of the complementary strand as the origin of stabilization by the
palladacyclic moiety. In light of these results, oligonucleotides furnished with palladacyclic “warheads”
could prove useful as a sequence-selective alternative to current platinum-based anticancer agents.
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Abstract: Herein, we have synthesized and characterized a new benzimidazole-derived “BnI”
ligand and its copper(II) complex, [Cu(BnI)2], 1, and zinc(II) complex, [Zn(BnI)2], 2, using
elemental analysis and various spectroscopic techniques. Interaction of complexes 1 and 2 with
the biomolecules viz. HSA (human serum albumin) and DNA were studied using absorption
titration, fluorescence techniques, and in silico molecular docking studies. The results exhibited the
significant binding propensity of both complexes 1 and 2, but complex 1 showed more avid binding
to HSA and DNA. Also, the nuclease activity of 1 and 2 was analyzed for pBR322 DNA, and the
results obtained confirmed the potential of the complexes to cleave DNA. Moreover, the mechanistic
pathway was studied in the presence of various radical scavengers, which revealed that ROS
(reactive oxygen species) are responsible for the nuclease activity in complex 1, whereas in complex 2,
the possibility of hydrolytic cleavage also exists. Furthermore, the cytotoxicity of the ligand and
complexes 1 and 2 were studied on a panel of five different human cancer cells, namely: HepG2,
SK-MEL-1, HT018, HeLa, and MDA-MB 231, and compared with the standard drug, cisplatin.
The results are quite promising against MDA-MB 231 (breast cancer cell line of 1), with an IC50 value
that is nearly the same as the standard drug. Apoptosis was induced by complex 1 on MDA-MB 231
cells predominantly as studied by flow cytometry (FACS). The adhesion and migration of cancer cells
were also examined upon treatment of complexes 1 and 2. Furthermore, the in vivo chronic toxicity
profile of complexes 1 and 2 was also studied on all of the major organs of the mice, and found them
to be less toxic. Thus, the results warrant further investigations of complex 1.
Keywords: metal complexes; interaction with biomolecules; nuclease activity; cytotoxicity; toxicity
1. Introduction
The serendipitous discovery of cisplatin [1] as an anticancer chemotherapeutic agent [2–4] swiftly
marked significant breakthroughs in the field of metallodrugs as potential anticancer agents [5],
and prompted several researchers and groups to explore the field of the metal-based chemotherapeutic [6].
Several potential metallodrugs were discovered since then and were used in clinics worldwide to treat
cancers, starting from cisplatin, oxaliplatin, carboplatin, etc. However, the severe side effects and resistance
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by the cancer cells confine their clinical application widely [7]. To curb increasing resistance and the
unbearable cost of treatment, it is a necessity to design potential alternatives.
Continual efforts have been made to design and develop non-classical
metal-based chemotherapeutics. Among them, NAMI-A “(imidazole)RuCl4(DMSO)(imidazole)”
and KP1019 “(indazole)RuCl4(DMSO)(indazole)” as ruthenium-centered potential anticancer drugs
entered into the clinical trials, but still lead to side effects, and cost remains a hurdle. So, many scientists
concentrated their attention on transition metals, particularly copper and zinc, to design novel metal-based
anticancer agents. Both the metal ions are bio-essential elements that play a prominent role in the active
site of many metalloproteins. Copper redox systems are involved in the catalytic process in the body [8,9].
Copper generates reactive oxygen species (ROS), endogenous DNA damage, and nucleobase affinity,
and thus favors proliferative activity [10–12]. For growth and development, zinc ion is needed; it regulates
the metabolism of the cells and is also a major regulatory ion in the metabolism of cells, which shrink the
cardiotoxicity and hepatotoxicity that is associated with several anticancer drugs [13,14].
Furthermore, copper and zinc also possess affinity towards protein and DNA, although
their propensity of binding mostly depends on the organic motifs. Thus, the role of the organic
moiety/coordinated ligand is also pivotal. In this context, benzimidazole moieties are unique and
interesting as they bear coordination potential for metal centers, planarity, and mimic the imidazole
functions in proteins [15,16]. The benzimidazole core is also present inside the body as a component of
Vitamin B12 [17]. The importance of this core can be understood by its presence in active drugs such as
mebendazole (“Vermox” anthelmintic agents) [18]. The presence of biologically active pharmacophore,
an imidazole ring, gives it versatility in possessing broad biological activities, from antihistaminic,
antitubercular, anti-HIV, NSAIDs, antihypertensive to anticancer, etc. [19–23]. Thus, benzimidazole-derived
moieties’ introduction to the drug design may enhance the biological activities.
Prompted by the impetus of the above findings, we have synthesized and characterized new copper(II)
and zinc(II) complexes of the benzimidazole-derived organic motif. Further, we have studied their
interaction with HSA (human serum albumin) and DNA using spectroscopic techniques and in silico
molecular docking studies. Moreover, both complexes and the ligand were tested against five human
cancer cell lines, and their chronic toxicity profile in vivo was studied.
2. Results and Discussion
2.1. Synthesis and Characterization
The tridentate biologically active pharmacophore, the benzimidazole-derived ligand, was synthesized
by stirring the mixture of 2-aminobenzimdazole and 1-methyl-1H-imidazole-2-carbaldehyde in toluene
as solvent and in the presence of glacial acetic acid as a catalyst at 80 ◦C for 12 h. The yellow precipitate
was isolated via rotavapor and recrystallized in methanol as a yellow-crystalline material suitable for
X-ray crystallography. This organic motif “BnI” was characterized by UV, Fourier transform infrared
(FT-IR), NMR, and elemental analysis.
The synthesis of complexes [Cu(BnI)2] 1 and [Zn(BnI)2] 2 was straightforward as the reaction was
carried out between the ligand BnI and Cu(acetate)2·nH2O (1)/Zn(acetate)2·nH2O (2) in methanol solution
in a molar ratio of 2:1, respectively (Figure 1).
Both the complexes 1 and 2 were isolated as green/yellow precipitate in reasonably good
yield (73–86%). Complexes 1 and 2 were characterized by elemental microanalysis and various
spectroscopic techniques. After several attempts, we failed to get crystals suitable for single
X-ray crystallography. The electrospray ionization mass spectra (ESI-MS) of the complexes 1 and 2
revealed the presence of a molecular ion in significantly good agreement of the calculated and experimental
m/z values.
The FT-IR spectrum of the ligand showed a characteristic strong peak at 1613 cm−1, which is associated
with the C=N vibration of the Schiff base (Figure S1). Upon complexation with metal acetates, the FT-IR
spectra of the complexes exhibited that both the signals of C=N vibrations got the significant shift to
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1642 cm−1 for 1 (Figure S2) and 1644 cm−1 for 2 (Figure S3), thus confirming the coordination of the metal
center with the ‘BnI’ ligand. The peak associated with M–N exhibited at 428 cm−1 and 438 cm−1 for
complexes 1 and 2, respectively (Figures S2 and S3).
Figure 1. Schematic representation of the synthesis of the benzimidazole-derived ligand and its
copper(II) complex [Cu(BnI)2], 1 and zinc(II) complex, [Zn(BnI)2], 2.
The 1H NMR spectrum of the ligand exhibited a broad signals singlet for N–H of the benzimidazole
ring at δ = 12.67 ppm (Figure S4). The characteristic signal for the aldimine proton HC=N was
observed at 9.21 ppm, and the aromatic proton peak appeared in the range of 7.57–7.16 ppm for all
six protons. Also, the singlet peak that was associated with the N–H3 protons appeared at 4.11 ppm.
Upon complexation with Zn(OAc)2 (2) (Figure S5), the 1H NMR spectrum shows the absence of NH proton.
Furthermore, the characteristic signal of aldimine protons gets shifted to 9.69 ppm and the aromatic protons
also get shifted to a range of 7.24–6.84 ppm, which is suggestive of the coordination of the metal center
with the nitrogens of the benzimidazole moiety and aldimine group. The protons of the imidazole ring
appeared with a very little shift at 7.574 ppm from 7.571 ppm (0.003 ppm), thus confirming that the free
movement of the imidazole ring may be because of the steric hindrance provided by the methyl group
(N–CH3) over it. The peak associated with N–CH3 appeared at 3.92 ppm.
The 13C NMR spectra of the ligand and complex 2 further ascertain our proposed structure. The peak
attributed to the ligand appeared in the range of 155.35 ppm for HC=N and 154.49–110.89 ppm for aromatic
carbons, and at 35.42 ppm for the N–CH3 (Figure S6). Upon complexation with Zn(OAc), the organic
moiety showed significant shifts in the signals. The characteristic signal associated with the aldimine
carbon appears at 155.74 ppm (Figure S7). Other aromatic carbon peaks also get shifted and exhibited
in the range of 143.29–120.44 ppm. The N–CH3 signal appeared at 64.90 ppm. Thus, the NMR of the
complex 2 (Zn(II) complex) further confirmed the above-proposed structure.
The stability of the complexes 1 and 2 using absorption spectroscopy was studied in a dimethyl
sulfoxide (DMSO) and phosphate buffer mixture that was incubated at room temperature and studied
for 24 h. Both the complexes were quite stable; however, complex 2 showed signs of hydrolysis after 24 h.
2.2. HSA–Metal Complex Interaction by Spectroscopy
2.2.1. Quenching Experiment
In this study, we followed quenching in human serum albumin (HSA) fluorescence emission in the
presence of complexes 1 and 2 at different temperatures (298, 303, and 308 K). The emission intensity
of HSA at 338 nm (λmax) was decreased significantly to 70% (Figure 2A and inset) and 63% (Figure 2D
and inset) respectively for complexes 1 and 2 when the molar ratio of HSA:complex was 1:10. Stern–Volmer
plots (Figure 2B,F) and the results presented in Table 1 shows that the KSV values of the two complexes
(1 and 2) were of the order of 104 M−1, thereby indicating a very strong quenching phenomenon. The linear
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dependency of emission quenching as a function of the concentrations of complexes 1 and 2 suggested
that only one type of quenching mechanism (either static or dynamic) was operational, and there was
only one type of equivalent binding site on HSA for complex 1 and 2. We also calculated the bimolecular
quenching constant (kq) after taking the τo of HSA as 5.71 × 10−9 s [24]. The kq values for 1 and 2 were
of the order of 1012 M−1 s−1, which were at least 100 times more than the maximum collision constant
of 1010 M−1 s−1 [25]. These results clearly indicate that the quenching of HSA emission intensity in the
presence of complexes 1 and 2 was due to the formation of a complex rather than merely a collision event.
Further, the type of quenching process that was involved was determined by evaluating the dependence
of emission intensity quenching at different temperatures. The decreased values of KSV and kq at elevated
temperatures showed that a static quenching mechanism was involved in HSA and the systems of
complexes 1 and 2 (Table 1). Furthermore, the slope of the modified Stern–Volmer plot indicated that both
complexes 1 and 2 had only one type of binding site present on HSA (Figure 2C,F). Also, an intercept of
the modified Stern–Volmer plot indicated that the binding constants of the two complexes 1 and 2 were
of the magnitude of 104 M−1, thus indicating a strong binding of complexes 1 and 2 with HSA (Table 1).
Earlier studies also indicated that several ligands bind strongly to HSA with a binding constant ranging
between 103 M−1 to 105 M−1 [26–29].
Figure 2. Molecular interaction between human serum albumin (HSA) and complexes 1 and 2.
(A,D) represent quenching in the fluorescence of HSA in the presence of complex 1 and 2, respectively;
(B,E) represent the Stern–Volmer plots of HSA-complex 1 and HSA-complex 2 respectively; (C,F) represent
modified Stern–Volmer plots of HSA-complex 1 and HSA-complex 2 respectively; (G) represents the van’t
Hoff plots for determining thermodynamic parameters; (H,I) represent FRET between HSA and complex 1
and 2, respectively.
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Table 1. Quenching constants and binding parameters for HSA–metal complex interactions.
Binding Parameters
Complex
Temp KSV kq n Kb
(K) ×104 (M−1) ×1012 (M−1 s−1) ×104 (M−1)
1
298 2.02 3.54 1.09 1.58
303 1.75 3.24 1.12 1.27
308 1.51 2.64 1.20 0.86
2
298 2.74 4.79 0.99 2.78
303 2.39 4.19 1.03 2.19






















×10−15 (M−1 cm−1) (nm) (nm)
1 3.26 2.04 2.35
2 4.63 2.16 2.36
The thermodynamic parameters associated with the interaction between complexes 1 and 2 and
HSA were estimated by assuming that the change in enthalpy (ΔH) was not significant over the studied
temperature range. Figure 3G shows the correlation between the binding constant (Ka) and 1/T, the slope
and intercept of which gives the values of −ΔH/R and ΔS/R, respectively. We found that the values
of ΔH and ΔS for the HSA-1 interaction were −11.12 kcal/mol and −18.17 cal/mol/K, respectively.
Similarly, for the HSA-2 interaction, the ΔH and ΔS values were −11.48 kcal/mol and −18.14 cal/mol/K,
respectively (Table 1). It is inferred from the above values that the enthalpy and entropy changes involved
in the binding of complexes 1 and 2 to HSA were of a similar nature and magnitude. The negative values of
ΔH and ΔS suggest that hydrogen bonding and van der Waal’s interactions were predominantly responsible
for the formation of a stable HSA-1 and HSA-2 complex. Moreover, the interaction of HSA with complexes
1 and 2 was spontaneous, as suggested by the negative ΔG values (Table 1). At 298 K, the changes in Gibb’s
free energy for HSA-1 and HSA-2 interactions were −5.71 kcal/mol and −6.08 kcal/mol, respectively.
2.2.2. Förster Resonance Energy Transfer (FRET) between HSA and Metal Complexes
FRET occurs when the emission spectrum of the donor overlaps with the absorption spectrum
of the acceptor [30]. Figure 2H,I depicts the overlap between the HSA fluorescence spectrum and
the absorption spectrum of complexes 1 and 2, respectively. We found that the efficiency of the
energy transfer between HSA and the metal complexes was in the range of 30–37%. The value
of r (distance between HSA and the metal complexes) for complexes 1 and 2 was 2.35 nm and
2.36 nm, respectively. Likewise, the values of Ro (distance at which the efficiency of energy transfer
becomes 50%) for complexes 1 and 2 with HSA interaction were 2.04 nm and 2.16 nm, respectively
(Table 1). The deduced r values satisfied the condition of FRET that it should be within the 2–8 nm range.
Moreover, the r values were within the range of 0.5Ro < r < 1.5Ro, thereby indicating that the quenching
of HSA emissions was due to a complex formation between HSA and metal complexes (i.e., static
quenching mechanism).
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2.3. Molecular Docking Studies with HSA by Autodock
Prediction of Binding Sites of Metal Complexes on HSA
HSA is the most abundant protein in the plasma, and is responsible for the transportation of
drugs. Three independent domains (I–III) are present in the structure of HSA. Domain I spans residues
1–195, domain II extends from residues 196–383, and domain III extends from residues 384–585; these
are the basic HSA folds. Each domain has been divided into two subdomains, namely A and B [28].
The two principal binding sites of HSA are located in the hydrophobic cavities of subdomain IIA
(Sudlow’s site I) and subdomain IIIA (Sudlow’s site II). A new binding site on HSA that is located
at subdomain IB has been recently identified [31]. The binding site of metal complexes on HSA was
predicted by an in silico approach using Autodock 4.2 software (The Scripps Research Institute, La
Jolla, CA, USA). We found that both complexes 1 and 2 were bound to HSA at domain IIA near
Sudlow’s site I mainly through hydrogen bonding and hydrophobic interactions (Table 2, Figure 3). In
the HSA-1 complex, a hydrogen bond (3.71 Å) between the H-atom of metal complex 1 and the O-atom
of Asp451 was observed along with six hydrophobic interactions with Lys195, Lys199, Trp214, Arg218,
and His242. Also, other key residues involved in stabilizing the HSA-1 metal complex through van
der Waal’s interactions were Gln196, Phe211, Arg218, Arg222, Arg257, Ala291, and Glu292. Similarly,
complex 2 has been observed to interact with HSA by forming two hydrogen bonds with Ala291 and
His242, and forming seven hydrophobic interactions with Lys195, Lys199, Trp214, Leu238, His242,
and Ala291. Also, other residues involved in stabilizing the HSA-1 complex through van der Waal’s
interactions were Gln196, Ala215, Arg218, Arg222, and Arg257 (Table 2, Figure 3). The binding energy
and Gibb’s free energy for complex 1 were 7.8 × 106 M−1 and −9.4 kcal/mol, while for metal complex
2, the binding affinity and Gibb’s free energy were 4.2 × 107 M−1 and −10.4 kcal/mol, respectively. It is
clear from the Table 2 and Figure 3 that complexes 1 and 2 were bound near Trp214, which explains the
quenching of HSA fluorescence in the presence of these metal complexes. However, it should be noted
that the values of ΔG obtained from in vitro binding experiments and computational prediction differ
significantly. The ΔG value obtained in the in vitro experiment accurately measured the interaction
between HSA and metal complexes in a solvent mimicking physiological conditions (i.e., it is global
phenomenon). Conversely, the ΔG value acquired from the in silico docking experiment measured the
interaction of metal complexes at the binding site of the protein only (i.e., it is a local phenomenon).
Table 2. List of residues of HSA interaction with different complexes.
Interaction Nature of Interaction Bond Length (Å) Binding Affinity, Kd (M−1) ΔG (kcal/mol)
Complex 1
Unk:C—Asp451:Oδ2 Hydrogen Bond 3.71
7.8 × 106 −9.4
Lys199:Cβ—Unk Hydrophobic (π-σ) 3.89
Trp214—Unk Hydrophobic (π-π) 4.79
His242—Unk Hydrophobic (π-π) 5.25
Unk—Trp214 Hydrophobic (π-π) 4.91
Unk—Arg218 Hydrophobic (π-alkyl) 5.23
Unk—Lys195 Hydrophobic (π-alkyl) 4.92
Complex 2
Unk:C—His242:Ne2 Hydrogen Bond 3.25
4.2 × 107 −10.4
Unk:C—Ala291:O Hydrogen Bond 3.62
Lys199:Cβ—Unk Hydrophobic (π-σ) 3.68
Ala291:Cβ—Unk Hydrophobic (π-σ) 3.59
His242—Unk Hydrophobic (π-π) 4.86
His242—Unk Hydrophobic (π-π) 4.69
Unk—Trp214 Hydrophobic (π-π) 5.05
Unk—Lys195 Hydrophobic (π-alkyl) 5.02
Unk—Leu238 Hydrophobic (π-alkyl) 5.15
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Figure 3. Molecular docking of complexes 1 and 2 with HSA. Panels (A,C) show the binding of
complexes 1 and 2 near Sudlow’s site I in subdomain IIA respectively, and panels (B,D) represent the
involvement of different amino acid residues of HSA in stabilizing complex with 1 and 2, respectively.
The amino acid residues are color coded according to element properties.
2.4. DNA Binding/Nuclease Activity
DNA is thought to be one of the primary targets of the metallodrugs after cisplatin, which is
an unanticipated finding for anticancer chemotherapeutics. Hence, we studied the binding affinity
of complexes 1 and 2 with CT-DNA using spectroscopic studies such as absorption titration and
an ethidium-bromide displacement assay. In the absorption studies, with the incremental addition
of CT-DNA, the spectra exhibited hyperchromism with significant 6–9 nm blue-shifts, which is
attributed to the binding of complexes 1 and 2 with CT-DNA via electrostatic mode (external groove)
or partial intercalation (Figure 4A,B). Furthermore, the binding strengths were evaluated in the form
of an intrinsic binding constant ‘Kb’ using Wolfe–Shimer equation [32]. The Kb values were found to be
2.67 × 104 M−1 and 1.07 × 104 M−1 for complexes 1 and 2, respectively.
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Figure 4. Absorption spectra of (A) complex 1; and (B) complex 2 with CT-DNA. Fluorescence quenching
spectra of (C) complex 1; and (D) complex 2 with EthBr-DNA adduct. Both experiments were carried
out in 5 mM Tris-HCl/50mM NaCl buffer, pH = 7.5, at room temperature. The spectra in different colors
represent the effect of increasing concentrations (symbolized by an arrow) of complexes 1 and 2 on the
studied spectroscopic properties.
A further mode of interaction of complexes 1 and 2 with CT-DNA was studied via ethidium-bromide
(EtBr) displacement assay, which involved competitive binding between a standard intercalator and
complexes 1 and 2 against CT-DNA (Figure 4C,D). In this experiment, the pre-treated CT-DNA with EtBr
was used in the standard ratio (EtBr is weakly emissive, whereas the DNA+EtBr adduct exhibits high
emission intensity). The DNA-EtBr adduct was treated with an increasing concentration of complexes
1 and 2; the results give rise to a significant reduction in the fluorescence intensity but don’t diminish
the emission intensity 100%. These results ascertain that complexes 1 and 2 are not typical intercalators,
but the possibilities of partial intercalation cannot be ruled out. The extent of quenching was evaluated by
using the Stern–Volmer equation, and the KSV values were calculated and were found to be 2.03 M−1 and
1.21 M−1 for complexes 1 and 2, respectively.
We have further evaluated the nuclease activity of complexes 1 and 2 against pBR322 DNA.
The concentration-dependent cleavage pattern was obtained with an increasing concentration of complexes
1 and 2 (0.5–2.5 μM) with pBR322 DNA (100 μM) (Figure 5).
Figure 5. Electrophoretic pattern of pBR322 DNA (100 ng) by (A) complex 1 and (B) complex 2
(0.5–2.5 μM) in 50 mM Tris-HCl/NaCl buffer pH, 7.4 after 45 min of incubation at various concentrations.
Lane 1: DNA alone (control); Lane 2: DNA + 0.5 μM 1; Lane 3: DNA + 1.0 μM 1; Lane 4: DNA + 1.5 μM 1;
Lane 5: DNA + 2.0 μM 1; Lane 6: DNA + 2.5 μM 1; Lane 7: DNA alone (control); Lane 8: DNA + 0.5 μM 2;
Lane 9: DNA + 1.0 μM 2; Lane 10: DNA + 1.5 μM 2; Lane 11: DNA + 2.0 μM 2; Lane 12: DNA + 2.5 μM 2.
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The electrophoretic pattern that was observed exhibited significantly good cleavage with
complex 1, and was exhibited by the appearance of form III (linear form from the supercoiled circular
‘native form’), which ascertained the double-stranded incision of the DNA. However, complex 2
displayed moderate cleavage activity, giving rise to form II (nicked circular form), which resulted due
to the single-stranded incision of the DNA. However, the appearance of the broad band swelling of
bands in the presence of complex 2 ascertains the hydrolysis of the DNA. Furthermore, the mechanistic
pathway of the DNA cleavage by complexes 1 and 2 was also examined, and the results are presented
in Figure 6. In this experiment, the DNA and complex reaction mixture were treated with radical
scavengers (hydroxyl radical scavengers viz., DMSO, EtOH), a singlet oxygen radical scavenger
(viz., NaN3) and a superoxide radical scavenger (viz., SOD). The electrophoretic pattern observed
confirms that the generation of hydroxyl radical, singlet oxygen radical, and superoxide radicals are
the responsible species for the cleavage of the DNA. Thus, both complexes 1 and 2 cleave the DNA by
the freely diffusible radical mechanism. At higher concentrations, that complex 2 exhibits hydrolytic
cleavage is quite possible. To get into the insight of the DNA groove-binding propensity of complexes 1
and 2, the DNA cleavage was also carried out in the presence of 4',6-diamidino-2-phenylindole (DAPI,
minor groove binder) and methyl green (MG, major groove binder) standards. The mixture of DNA
and known groove binders were treated with the complexes and the results exhibited that complexes 1
and 2 possess the minor groove-binding tendency (Figure 6).
Figure 6. Mechanistic electrophoretic pattern of pBR322 DNA (100 ng) by (A) complex 1 and
(B) complex 2 (0.5–2.5 μM) in 50 mM of Tris-HCl/NaCl buffer pH 7.4 after 45 min of incubation at
various concentrations. Lane 1: DNA alone (control); Lane 2: DNA + DAPI + 1; Lane 3: DNA + MG + 1;
Lane 4: DNA + DMSO + 1; Lane 5: DNA + EtOH + 1; Lane 6: DNA + NaN3 + 1; Lane 7: DNA + SOD+ 1;
Lane 8: DNA + DAPI + 2; Lane 9: DNA + MG + 2; Lane 10: DNA + DMSO + 2; Lane 11: DNA + EtOH + 2;
Lane 12: DNA + NaN3 + 2; Lane 13: DNA + SOD + 2.
2.5. Molecular Docking Studies with DNA by Hex
Prediction of Binding Sites of Metal Complexes on DNA
In the present study, we have used Hex 8.0 software (Dave Ritchie, Capsid research team at the
LORIA/Inria, Nancy, France) to probe the binding site of complexes 1 and 2 on the dodecameric DNA
molecule, and the molecular interactions involved in stabilizing the complex (Table 3, Figure 7).
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Figure 7. Molecular docking of complexes 1 and 2 with DNA. Panels (A,C) represent the binding of
complexes 1 and 2 at the major groove of DNA, respectively; and panels (B,D) depict the residues
of DNA making contacts with complexes 1 and 2, respectively. Different strands and nucleotides of
DNA are represented by separate color (Magenta and Blue in (A,B), and Green and Yellow in (C,D)).
Metal complexes 1 and 2 are represented according to element composition.
Table 3. Molecular interactions between DNA and complexes 1 and 2.
Interaction Bond Distance (Å) Nature of Interaction Etotal Value
Complex 1
Unk:H—B:d21:O2 2.57 Hydrogen Bond
−238.14
Unk:H—B:dG22:O4′ 2.25 Hydrogen Bond
Unk:H—A:dA5:N3 2.34 Hydrogen Bond
Unk:H—A:dA5:N3 2.98 Hydrogen Bond
Unk:H—B:d21:O2 2.79 Hydrogen Bond




Unk:H—A:dG10:O3′ 2.01 Hydrogen Bond
Unk:H—A:d11:O4′ 2.89 Hydrogen Bond
Unk:H—A:dG10:OP1 2.93 Hydrogen Bond
Unk:H—B:dA18:O3′ 2.62 Hydrogen Bond
Unk:H—B:dT19:OP1 2.81 Hydrogen Bond
B:dA18:OP1—Unk 2.88 Electrostatic (π-Anion)
B:dA18:OP2—Unk 4.88 Electrostatic (π-Anion)
B:dA17:O3′—Unk 2.87 π-Lone Pair
B:dA17:O3′—Unk 2.55 π-Lone Pair
Findings of the docking results further support our in vitro results that the most preferred binding
site of complexes 1 and 2 on DNA was located at the minor groove of DNA, with an overall binding
score of −238.14 and −248.34, respectively. It was bound in a GC-rich region in such a fashion that
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allowed the planar part of the molecule to form favorable interactions with the nitrogenous bases of
the DNA molecule (Table 3).
The DNA-complex 1 adduct was stabilized by five hydrogen bonds (dA5:N3 of chain A and
d21:O2 of chain B formed two hydrogen bonds each with complex 1, while dG22:O4′ formed
one hydrogen bond with complex 1). Moreover, the DNA-complex 1 adduct was stabilized by
one electrostatic interaction with d23:OP1 of chain B. Similarly, complex 2 formed three electrostatic
interactions and five hydrogen bonds along with two π-lone pair interactions with DNA molecules
(Table 3, Figure 7). The metal ligand Zn was electrostatically involved with dA18:OP1 of chain B.
Also, dA18:OP1 of chain B formed two electrostatic interactions, while dA17:O3′ of chain B formed
two π-lone pair interactions. Moreover, the overall DNA-complex 2 adduct was further stabilized by
five hydrogen bonds with d10:O3′, dG10:O4′, and d11:O4′ of chain A, and dA18:O3′ and dT19:OP1 of
chain B.
2.6. In Vitro Cytotoxicity Assays
2.6.1. Analysis of Growth Inhibition Using 5-Diphenyltetrazolium Bromide (MTT) Assay
In view of the above findings, the two novel complexes 1 and 2 were investigated for their
anticancer efficacy in vitro. The cytotoxic effect of the synthesized complexes was examined on
a panel of cancer cells. The cytotoxic efficacy was expressed in terms of IC50 values, as shown
in Table 4. The newly synthesized complex 1 inhibited the cell growth of all the five tested cell lines
in a dose-dependent manner. MDA-MB 231 was observed to be the most sensitive to complex 1, followed
by HeLa > HepG2 > HT108 > SK-MEL-1. On the other hand, the novel complex 2 inhibited the cell growth
of four out of five tested cell lines in a dose-dependent manner. Complex 2 was most effective on SK-MEL-1
followed by HepG2 > HeLa > HT108. However, complex 2 showed the least effect on MDA-MB 231
(Table 4). In comparison with complex 2, complex 1 showed potential in vitro anticancer activity against
all of the tested cancer cell lines. However, no activity against particular cancer cell lines was observed
with free ligands. Nevertheless, the anticancer potential of complex 1 was due to the presence of its
copper moiety, which efficiently inhibited the growth of cancer cells. Considering this, we continued our
anticancer study further with complex 1 only. Complex 1 showed significant activity when compared with
standard drugs and some of the previously reported copper(II) complexes. For example, the copper(II)
complex of 4′-methoxy-5,7-dihydroxy-isoflavone exhibited cytotoxic effects against cancer cell lines
viz., A549, HeLa, HepG2, SW620, and MDA-MB-435), with IC50 values in the 10−50 μM range [33].
Also, the copper complexes [Cu(L)Cl(H2O)]Cl·3H2O of 2-methyl-1H-benzimidazole-5-carbohydrazide (L)
displayed cytotoxicity against A549 cancer cells (IC50 = 20 μM) [34].
Table 4. IC50 values of complexes 1, 2, the ligand, and cisplatin against five human cancer cell lines.
Complex
HepG2 SK-MEL-1 HT018 HeLa MDA-MB 231
(Liver) (Skin) (Colon) (Cervical) (Breast)
(μM) (μM) (μM) (μM) (μM)
1 14 ± 2.2 17.8 ± 2.7 15 ± 2.1 13 ± 2.2 3.5 ± 2.4
2 19 ± 2.6 18 ± 2.3 25 ± 4.0 24.5 ± 2.2 26.7 ± 4.1
Ligand NA NA NA NA NA
Vehicle control (0.1%
DMSO) NA NA NA NA NA
Cisplatin (Positive control) 6 ± 0.4 5.6 ± 0.8 5.7 ± 0.2 6 ± 0.6 3.1 ± 0.2
NA stands for Not Active.
2.6.2. Effect on Cancer Cell Adhesion/Migration
Cancer metastasis is the spread of cancer cells to tissues and organs far from where a tumor originated.
Cancer cells must be able to stick together, move, and migrate in order to spread. The properties of cell
adhesion and cell migration are fundamental in regulating cell movement and cancer metastasis, and are
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necessary for the cells to move into the bloodstream. To further characterize the anticancer activity of
the potent complex 1, its inhibitory effect was investigated on the adhesion and migration of cancer cells
at an IC50 concentration for the respective cancer cell lines. Complex 1 was tested at concentrations of
14 μM, 17.8 μM, 15 μM, 13 μM, and 3.5 μM against HepG2, SK-MEL-1, HT 018, HeLa, and MDA-MB 231,
respectively. We found that complex 1 inhibited cell adhesion by about 16.4% (14 μM), 21.3% (17.8 μM),
16.5% (15 μM), 12.2% (13 μM), and 35.2% (3.5 μM) of HepG2, SK-MEL-1, HT 018, HeLa, and MDA-MB 231,
respectively (Figure 8A). As far as migration is concerned, complex 1 inhibited the migration phenomenon
of the tested cancer cells. However, the rate of inhibition varied with the respective cell lines, respectively
(Figure 8B). Therefore, we conclude that complex 1 was able to affect the metastatic potential of cancer cells
by inhibiting their adhesion as well as migration properties.
Figure 8. Effect of complex 1 on (A) cell adhesion and (B) cell migration against five cancer cell lines.
Assays for adhesion and migration were performed with a cytoselect 24-well plate, and the absorbance
of extracted samples was read at 560 nm.
2.6.3. Annexin V Apoptosis Detection Assay
Apoptosis and necrosis are two primary mechanisms of cell death. Cells that are damaged
by external injury undergo necrosis, while cells that are induced to commit programmed suicide
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because of internal or external stimuli undergo apoptosis. An increasing number of chemopreventive
agents have been shown to stimulate apoptosis in pre-malignant and malignant cells in vitro or
in vivo [35]. A gross majority of classical apoptotic attributes can be quantitatively examined by flow
cytometry (FACS). The apoptotic effect of complex 1 was evaluated using annexin-V staining. All of the
tested cancer cells were harvested after treatment by complex 1 for 48 h and incubated with annexin
V-FITC and PI. First, 10,000 cells were analyzed per determination. Dot plots show annexin V–FITC
binding on the X-axis and propidium iodide (PI) staining on the Y-axis (Figure 9).
Figure 9. The apoptotic effect of complex 1 using annexin-V staining of tested cancer cell lines.
Dots represent cells as follows: lower left quadrant, normal cells (FITC−/PI−); lower right quadrant,
early apoptotic cells (FITC+/PI−); upper left quadrant, necrotic cells (FITC−/PI+); upper right quadrant,
late apoptotic cells (FITC+/PI+).
Data of all of the cell lines after treatment with complex 1 showed a decrease in viable cancer cells.
Distinct 3.9% (HepG2), 1.9% (SK-MEL-1), 1.0% (HT018), 0.2% (HeLa), and 32.6% (MDA-MB 231)
increases in apoptotic cell population was recorded. After 48 h of exposure time, due to late apoptosis,
the cell population increased to 7.2%, 2.7%, 1.2%, 1.5%, and 26.1% for HepG2, SK-MEL-1, HT018, HeLa,
and MDA-MB 231, respectively. We found that complex 1 was the most effective on MDA-MB-231 cells.
The cytotoxic effect of the complex was not correlated to the increase of the necrotic cell population.
2.7. In Vivo Chronic Toxicity Studies of Complex 1 vs. 2
To evaluate the safety of complexes 1 and 2, we studied their chronic toxicity in male as well as
female mice. The hematology studies revealed that both complexes 1 and 2 increased the count of
red blood cells (RBC) and white blood cells (WBC) in male mice, as well as hemoglobin, platelets,
neutrophils, and lymphocytes, with neutrophils and lymphocytes being the most significantly affected
cells (Figure 10A). Complex 2 was more potent in increasing the count of these cells than complex 1.
This might be due to the stimulation of bone marrow or increased protection of it from the deleterious
effects, leading to the production of cells. In female mice, complex 1 showed weak activity against
the above-mentioned cells except for neutrophils and lymphocytes, where it possessed significantly
increased initial counts. Although both complexes significantly increased the clotting time in both
male and female mice, complex 2 seemed to be more potent. Interestingly, both complexes increased
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fertility in mice. Both had reduced dead fetus percentages at the end of term, with complex 2 having
a far lower dead fetus percentage.
In liver function tests (Figure 10B), both complexes did not alter liver functions in male
animals except SGOT (Serum Glutamic Oxaloacetic Transaminase), which was significantly elevated
by both complexes. Both complexes significantly lowered blood glucose levels, with complex 2
possessing stronger blood sugar lowering activity. However, both complexes significantly elevated
SGOT, SGPT (Serum Glutamic Pyruvic Transaminase), GGT (Gamma-Glutamyl Transferase),
ALP (Alkaline Phosphatase), and bilirubin in female animals. Moreover, both complexes significantly
decreased blood glucose levels.
In renal function tests (Figure 10C), both complexes significantly increased sodium and potassium
levels, but decreased calcium, urea, uric acid, and blood creatinine in male mice to significant
(and potent) levels. Both complexes possessed the same activity in female mice, but decreased
potassium blood levels.
Figure 10. Chronic toxicity profile of complexes 1 and 2. Effect of complexes 1 and 2 on
(A) blood components; (B) biochemical parameters of liver function; (C) biochemical parameters
of kidney function; and (D) biochemical parameters of lipids and heart function. M and F denote male
and female mice, respectively. Statistical analysis was performed by two-way ANOVA, as well as the
Dunnett test as the post-hoc test, compared with control (C), n = 4. (* p < 0.05; ¤p < 0.01; × p < 0.005;
# p < 0.001).
The lipid profile and protein tests (Figure 10D) confirmed that both the complexes decreased
significant levels of blood triglycerides, cholesterol, LDL (Low Density Lipoproteins), and VLDL
(Very Low Density Lipoproteins), but significantly increased the blood levels of HDL and total proteins
in both male and female mice. In cardiac function tests (Figure 10D), both complexes significantly
lowered the blood levels of LDH and creatine kinase in both male and female mice. Complex 2 showed
stronger activity on both enzymes.
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3. Experimental Section
3.1. Material
First, 2-aminobenzimidazole, 1-methyl-1H-imidazole-2-carbaldehyde, Cu(CH3COO)2·H2O,
Zn(CH3COO)2·2H2O, pBR322 DNA, sodium azide, superoxide dismutase, H2O2, DAPI, methyl green
(MG), the sodium salt of CT-DNA, and HSA essentially fatty acid-free (≥98%) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl)
was of analytical grade and also obtained from Sigma-Aldrich (St. Louis, MO, USA). Rosewell
Park Memorial Institute (RPMI)-1640 medium, Dulbecco’s minimum essential medium (DMEM),
fetal calf serum (FCS), dimethyl sulphoxide (DMSO), trypsin-EDTA solution, dithiothreitol (DTT);
3-4,5-dimethylthiazol-2-yl-2, 5-diphenyltetrazolium bromide (MTT), and cisplatin were procured from
Sigma-Aldrich (St. Louis, MO, USA). All of the other chemicals used were also of the highest purity.
Cell adhesion and cell migration kits were obtained from Cell Biolabs, Inc (San Diego, CA, USA).
A Vybrant Apoptosis Assay Kit was procured from Molecular Probe (Eugene, OR, USA). Solvents were
used as received.
3.2. Synthesis Procedure of Schiff Base
A mixture of 2-aminobenzimidazole (5.0 mmol) and 1-aminoimizole-2-carboxyaldehyde
(5.0 mmol) in 25 mL of toluene by adding a few drops of acetic acid was stirred at 80 ◦C for 12 h.
The yellow coloration of the mixture deepened, and after 12 h of stirring, the solvent was removed
by rotavapor. A yellow-colored compound was isolated. To recrystallize the compound, it was
dissolved in MeOH, and the resulting solution was kept for slow evaporation. Yellow single crystals
were isolated after two days. Yield: (68%). M.p. 265 ◦C. Anal. Calc. for 12H11N5: C, 63.99; H, 4.92;
N, 31.09. Found: C, 63.86; H, 4.89; N, 31.05%. FT-IR (KBr pellet, cm−1): 3384, 3050, 2979, 1612, 1565,
1463, 1427, 1380, 1279, 1159, 740. 1H NMR (CDCl3, δ, 293 K): 12.67 (s, 1H, 1NH), 9.21 (s, 1H, HC=N),
7.51–7.16 (ArH, 6H), 4.11 (s, 3H, N–CH3), ESI-MS: 226.1.
3.3. Copper Complex: [Cu(BnI)2], (1)
Yield: (86%). M.p.198 ◦C. Anal. Calc. for C24H20N10Cu: C, 56.30; H, 3.94; N, 27.36. Found: C, 56.46;
H, 4.03; N, 27.29%. ESI MS (+ve) DMSO, m/z: 515.0 for C24H20N10Cu + 3H+. FT IR (KBr pellet, cm−1): 3408,
3062, 1642, 1597, 1469, 1390, 1272, 742, 672, 662, 507, 438. ΛM (1 × 10−3 M, DMSO): 15.90 Ω−1 cm2 mol−1
(non-electrolyte in nature). UV-vis (1 × 10−3 M, DMSO, λnm): 656 nm. μeff (B.M.) = 1.89. EPR (solid state,
gav, 298 K) = 2.09.
3.4. Zinc Complex, [Zn(BnI)2], (2)
Yield: (73%). M.p. 174 ◦C. Anal. Calc. for C24H20N10Zn: C, 56.09; H, 3.92; N, 27.26. Found: C, 55.86;
H, 3.89; N, 27.21%. ESI-MS (+ve) DMSO, m/z: 516.2 for C24H20N10Zn + 2H+. FT IR (KBr pellet, cm−1):
3408, 3055, 1644, 1582, 1466, 1392, 1271, 741, 668, 647, 512, 428. 1H NMR (DMSO, δ, 293 K): 9.68 (s, 2H,
HC=N), 7.58-6.84 (ArH, 12H), 3.92 (s, 6H, N–CH3).
3.5. Fluorescence Quenching Measurements
Samples of HSA were prepared in 20 mM of sodium phosphate buffer (pH 7.4), while the
1-mM stock solution of complexes 1 and 2 in 10% DMSO was prepared and further diluted in
20 mM of sodium phosphate buffer to reach the desired concentration. In all of the samples,
the final concentration of DMSO was below 1%. The concentration of HSA was determined from
Beer–Lambert’s law using the molar extinction coefficient of 36,500 M−1 cm−1 at 280 nm [36].
Quenching in the fluorescence emission intensity of HSA was measured on a JASCO
spectrofluorometer (FP-8300) fitted with a thermostatically controlled cell holder attached to
a water bath. To the HSA sample, (2 μM, 3 mL) 2 μM of complexes 1 and 2 was successively
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added in such a manner that the total volume of metal complexes added was not more than 30 μL.
Fluorescence quenching was measured by exciting Trp214 of HSA at 295 nm, and the fluorescence
emission spectrum was collected between 300–450 nm [27]. Excitation and emission slits were kept
at 5 nm. All of the fluorescence emission intensities were corrected for the inner filter effect using the
following equation:
FCorr = FObs × e(Aex+Aem)/2 (1)
The quenching parameters were deduced using the following Stern–Volmer (Equation (2)) and
modified Stern–Volmer (Equation (3)) equations:
Fo
F
= 1 + KSV [Q] = 1 + kqτo[Q] (2)
where Fo and F are the fluorescence emission intensities of HSA before and after metal complex binding;
KSV is the Stern–Volmer constant; [Q] is the molar concentration of the quencher, i.e., metal complex;





= log Ka + n log[Q] (3)
where Fo and F are the fluorescence intensities of HSA before and after metal complex binding; Ka is the
binding constant; n is the number of binding sites, and [Q] is the molar concentration of the quencher.
The thermodynamic parameters for the interactions between HSA and complexes 1 and 2 were
determined by measuring emission quenching at three different temperatures (298, 303, and 308 K).
The following van’t Hoff and thermodynamic equations (equations (4) and (5)) were used to deduce







ΔG = ΔH − TΔS (5)
3.6. FRET Measurements
The FRET between HSA and complexes 1 and 2 were observed by measuring the absorption
spectra of complexes 1 and 2, and the emission spectra of HSA in the 300–450 nm range. All of the
intensities were normalized as described earlier [30]. The distance (r) between Trp214 of HSA and




= 1 − F
Fo
(6)
R6o = 8.79 × 10−25K2n−4φJ (7)
where E is the efficiency of the energy transfer; Ro is the distance at which the efficiency of energy
transfer becomes 50%; r is the distance between HSA (donor) and the metal complex (acceptor); F and Fo
are the emission intensities of HSA in the presence and absence of the metal complex (quencher); K2 is
the geometry of the dipoles (K2 = 2/3 for HSA); n is the refractive index of the medium (here, it is 1.33);
ϕ is the emission quantum yield of HSA in the absence of quencher (ϕ = 0.118), and J is the overlap
integral of the HSA emission spectrum and the absorption spectrum of the metal complex.
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where Fλ is the fluorescence intensity of HSA at the wavelength λ; and ελ is the molar extinction
coefficient of the metal complex at the wavelength λ.
3.7. DNA Binding and Nuclease Activity
The standard protocol [32] was adopted for both the experiments, with the slight modifications
that we reported earlier [36–40].
3.8. Molecular Docking Studies
3.8.1. Preparation of Ligands and Receptors
The three-dimensional structures of HSA (PDB Id:1AO6) and B-DNA dodecamer
d(CGCGAATTCGCG)2 (PDB Id:1BNA) that were used for docking were retrieved from the RCSB
PDB database bank [41]. Structures of the ligands (complexes 1 and 2) were drawn in CHEMSKETCH
(Available online: http://www.acdlabs.com) and converted to a PDB file using OPENBABEL
(Available online: http://www.vcclab.org/lab/babel). The energies of complexes 1 and 2 were
minimized using a MMFF94 forcefield. The water molecules and any heteroatoms were deleted from
the receptor files (i.e., HSA and DNA) before setting up the docking program.
3.8.2. Molecular Docking of Complexes 1 and 2 with DNA
HEX 8.0.0 software was used to study the binding of complexes 1 and 2 with a DNA molecule with
default settings. The binding site of the ligand on the receptor was searched on the basis of shape as
well as electrostatics, and the post-processing was done by optimized potentials for liquid simulations
(OPLS) minimization. The GRID dimension was set at 0.6, and 10,000 solutions were computed. The results
were analyzed in Discovery Studio 4.0 (Accelrys Software Inc., San Diago, USA, 2013) [42].
3.8.3. Molecular Docking of Complexes 1 and 2 with HSA
Autodock4.2 was used for the docking of complexes 1 and 2 with HSA as described previously [27].
Briefly, Gasteiger partial charges were added to the atoms of complexes 1 and 2. Non-polar hydrogen
atoms were merged, and rotatable bonds were defined. Essential hydrogen atoms, Kollman united-atom
charges, and solvation parameters were added to HSA with the aid of the AutoDockTool. Affinity grid
maps of 120 × 120 × 120 Å grid points and 0.7 Å spacing were generated using the AutoGrid program.
Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the Solis and Wets
local search methods. Initial positions, orientations, and torsions of the ligand molecules were set randomly.
All of the rotatable torsions were released during docking. Each run of the docking experiment was set to
terminate after a maximum of 2.5 × 106 energy evaluations. The population size was set to 150. During the
search, a translational step of 0.2 Å and quaternion and torsion steps of five were applied. The docking
figures for publication were prepared in Discovery Studio 4.0 (Accelrys Software Inc., 2013) [42].
3.9. Cytotoxicity
3.9.1. Cell Lines and Culture Conditions
Human cancer cell lines HepG2 (Liver), SK-MEL-1 (Skin), HT 018 (Colon), HeLa (Cervical),
and MDA-MB 231 (Breast) were procured from the American Type Culture Collection (Rockville, MD, USA).
MDA-MB-231 and HepG2 cell lines were maintained in DMEM; whereas SK-MEL-1, HeLa, and HT-018
were maintained in RPMI medium. The complete growth medium was supplemented with 10% (v/v)
heat-inactivated FCS, 2 mM L-glutamine, and antimycotic-antibiotic solution. All of the cells were
maintained in a standard culture condition of 37 ◦C temperature and 95% humidified atmosphere
containing 5% CO2. Cells were screened periodically for mycoplasma contamination.
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3.9.2. MTT Assay
The novel complexes 1 and 2 were examined for their cytotoxicity against five different types of cancer
cell lines viz., HepG2, SK-MEL-1, HT 018, HeLa, and MDA-MB 231 using a standard MTT reduction assay,
according to Khan et al. (2012) [35]. Briefly, cells at a concentration of 1 × 106 cells/200 mL/well were
plated in 96-well plates and further grown in their respective medium containing 10% FCS. After 24 h,
cells were incubated with 0–25 μM concentrations of test complexes or respective free ligands. Cells with
0.1% DMSO (vehicle control) and cisplatin (positive control) were also cultured under the same conditions.
Cells only were used as negative control. Ensuing 48 h of incubation, old medium from treated cells was
replaced with fresh medium. MTT reagent (5 mg/mL in PBS) was added to each well, and cells were
further incubated for 2–3 h at 37 ◦C. After treatment, the supernatants were carefully removed, and 100 μL
of DMSO was added to each well. Absorbance was measured at 620 nm in a multi-well plate reader,
and drug sensitivity was expressed in terms of the concentration of drug required for a 50% reduction of
cell viability (IC50).
3.9.3. Measurement of Cancer Cell Adhesion
Assay for adhesion was performed with cytoselect 24-well cell adhesion as per protocol [43].
For quantitative analysis, the IC50 concentration of respective complexes (in triplicate) was tested on HepG2,
SK-MEL-1, HT 018, HeLa, and MDA-MB 231 cancer cells. Cancer cell (0.1–1.0 × 106 cells/mL) suspension
in serum-free medium was added to the inside of each well of a pre-warmed adhesion plate. The plates
were incubated for 30–90 min in a CO2 incubator and treated as per the protocol [43]. After air-drying
the wells, stained adhered cells were extracted using an extraction solution. Then, the absorbance of the
extracted sample (adhered cells) was read at 560 nm in a microtiter plate reader.
3.9.4. Measurement of Cancer Cell Migration
The cell migration assay was performed with a cytoselect 24-well cell adhesion assay according to
the protocol (Khan et al., 2013) [43] on HepG2, SK-MEL-1, HT 018, HeLa, and MDA-MB 231 cancer
cell lines. For quantitative analysis, the IC50 concentration of the respective complexes (in triplicate)
was tested on HepG2 (Liver), SK-MEL-1 (Skin), HT 018 (Colon), Hela (Cervical), and MDA-MB 231
(Breast) cancer cells. The test complexes were supplemented with medium containing 10% FBS in the
lower well of the migration plate. To the inside of each insert, 100 μL of 0.5–1.0 × 106 cells/mL of cell
suspension was added. The plates were then incubated for 8 h at 37 ◦C in a humidified CO2 incubator.
Finally, the absorbance of 100 μL of each sample was then read at 560 nm.
3.9.5. Analysis of Annexin-V Binding by Flow Cytometry
Annexin-V staining was performed according to the protocol (Khan et al., 2017) [44].
For quantitative analysis, the IC50 concentration of respective complexes (in triplicate) was tested
on HepG2 (Liver), SK-MEL-1 (Skin), HT 018 (Colon), Hela (Cervical), and MDA-MB 231 (Breast)
cancer cells. Cancer cell (0.1–1.0 × 107 cells/mL) suspension in serum-free medium was incubated
with respective complexes in six-well plates in a CO2 incubator. After treating with complexes for
48 h, the cancer cells were harvested and incubated with annexin V-FITC and propidium iodide (PI).
The fluorescence emission of Annexin-V stained cells was measured at 530–575 nm in a flow cytometer
(MACSQuant, Bergisch Gladbach, Germany). Dots represent cells as follows: lower left quadrant,
normal cells (FITC−/PI−); lower right quadrant, early apoptotic cells (FITC+/PI−); upper left quadrant,
necrotic cells (FITC−/PI+); upper right quadrant, late apoptotic cells (FITC+/PI+).
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3.10. In Vivo Toxicity
3.10.1. Toxicity Study Design
Mice (males) were randomly divided into different groups (n = 6–10). Different doses of complexes
1 and 2 (0.5, 1, 2, 5, 8 and 10 g/kg) were administered intraperitoneally. The complexes were suspended
in 0.2% aqueous Tween 80 or 0.25% carboxymethylcellulose. The animals were observed for 72 h for
signs of toxicity and mortality, and LD50 was calculated according to a published method [45].
3.10.2. Chronic Toxicity Study
A total of 40 male and 40 female Swiss albino mice were randomly allocated to the control and
test groups. The complexes 1 and 2 in each case were mixed with drinking water for the feasibility of
administration due to long treatment duration. The dose selected was 1/10th of the LD50. The treatment
was continued for a period of 12 weeks [46] (WHO Scientific Group, Geneva, 1967). The animals
were then observed for all external general symptoms of toxicity, body weight changes, and mortality.
Ten male and 10 female rats were used in each group, having one control and two treated groups.
One group of treated female rats was mated with treated males, and pregnancy outcomes were studied.
Urine was collected 1–2 days before the end of the treatment. The treated animals were fasted for 12 h
and then anesthetized with ether. Blood samples were collected via heart puncture and centrifuged at
3000 rpm for 10 min. The plasma was then stored at −20 ◦C pending for analysis of the biochemical
parameters. Vital organs were removed, weighed, and investigated for apparent signs of toxicity,
and stored in 10% formalin for histological studies. The percentage of each organ relative to the body
weight of the animal was calculated.
3.10.3. Hematological Studies
Whole non-centrifuged blood was used for the determination of some hematological parameters.
The blood was analyzed for WBC and RBC count, hemoglobin, platelets, neutrophils, and lymphocytes
measurements using Contraves Digicell 3100H (Zurich, Switzerland) [47].
3.10.4. Serum Analysis of Biochemical Parameters
A colorimetric method was used for the determination of the biochemical parameters (SGPT,
SGOT, GGT, ALP, bilirubin, and lipid profile) in plasma. The enzyme activity was quantified
spectrophotometrically using commercial enzymatic kits (Crescent diagnostics test kits, Jeddah, KSA).
3.10.5. Statistical Analysis
The results were presented as a mean ± standard error of the mean (S.E.M). Statistical differences
were analyzed using ANOVA with the Dunnett test as a post-hoc test. A value of p < 0.05 was
considered statistically significant [48].
4. Conclusions
The new copper(II) (1) and zinc(II) (2) complexes have been designed and prepared with the
benzimidazole-derived ligand as a biologically active moiety. The focus of our work was on its
biological significance, in particular its anticancer property. Thus, complexes 1 and 2 were studied
to examine the propensity of binding with HSA and DNA, which confirmed the avid binding.
DNA cleavage experiments showed the evident nuclease activity of complex 1 with a double-stranded
cleavage mechanism, and further revealed that ROS were responsible for the cleavage activity.
Interestingly, the cytotoxicity of both the complexes and the ligand was examined on the five different
cancer cells line, and the results showed that the activity of complex 1 was considerably good on breast
cancer cells, with the IC50 values comparable to the standard drug cisplatin. Furthermore, we have
studied the cell adhesion and cell migration properties of different cancer cell line in the presence
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of complex 1. Our findings exhibited that complex 1 showed significant anti-metastatic potential by
inhibiting the adhesion and migration property of cancer cells. Moreover, the in vivo chronic toxicity of
both complexes 1 and 2 revealed that they were safe and could be developed as a potential anticancer
drug for human consumption. Overall, the results of this study ascertain that copper complex (1) can
be a promising chemotherapeutic intervention for future application in cancer therapy, but warrants
further investigations.
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Abstract: Recognition of unusual left-handed Z-DNA by specific binding of small molecules
is crucial for understanding biological functions in which this particular structure participates.
Recent investigations indicate that zinc cationic porphyrin (ZnTMPyP4) is promising as a probe
for recognizing Z-DNA due to its characteristic chiroptical properties upon binding with Z-DNA.
However, binding mechanisms of the ZnTMPyP4/Z-DNA complex remain unclear. By employing
time-resolved UV-visible absorption spectroscopy in conjunction with induced circular dichroism
(ICD), UV-vis, and fluorescence measurements, we examined the binding interactions of ZnTMPyP4
towards B-DNA and Z-DNA. For the ZnTMPyP4/Z-DNA complex, two coexisting binding modes
were identified as the electrostatic interaction between pyridyl groups and phosphate backbones,
and the major groove binding by zinc(II) coordinating with the exposed guanine N7. The respective
contribution of each mode is assessed, allowing a complete scenario of binding modes revealed for the
ZnTMPyP4/Z-DNA. These interaction modes are quite different from those (intercalation and partial
intercalation modes) for the ZnTMPyP4/B-DNA complex, thereby resulting in explicit differentiation
between B-DNA and Z-DNA. Additionally, the binding interactions of planar TMPyP4 to DNA were
also investigated as a comparison. It is shown that without available virtual orbitals to coordinate,
TMPyP4 binds with Z-DNA solely in the intercalation mode, as with B-DNA, and the intercalation
results in a structural transition from Z-DNA to B-ZNA. These results provide mechanistic insights
for understanding ZnTMPyP4 as a probe of recognizing Z-DNA and afford a possible strategy for
designing new porphyrin derivatives with available virtual orbitals for the discrimination of B-DNA
and Z-DNA.
Keywords: Z-DNA; ZnTMPyP4; transient absorption spectroscopy; binding mode
1. Introduction
DNA molecules are highly polymorphic and can form multiple conformations under different
physiological conditions [1,2]. The most common structure of DNA is known as B-DNA, a right-handed
double helix with the negatively charged deoxyribose-phosphate backbone outside and stacked
base pairs inside. In some conditions, e.g., high ionic strengths, in the presence of highly charged
cations or some small molecules, certain B-DNA sequences can transform to left-handed helical
conformations called Z-DNA with the zig-zag backbone and the stacked base pairs partially exposed
to the outside [2–4]. With the unique structure and higher energy, Z-DNA is less common than
B-DNA [5,6]. Nevertheless, a considerable number of studies have demonstrated that Z-DNA is
relevant to many biological processes; for example, it has been found that Z-DNA sequences
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participate in chromatin-dependent activation of the CSF1 (the human colony-stimulating factor
1 gene) promoter [7].
Differentiating B-DNA and Z-DNA is of fundamental importance for investigating the role played
by Z-DNA in many biological processes [1]. Generally, recognition of Z-DNA is achieved by utilizing
Z-DNA binding small molecules, which have particular binding modes to Z-DNA that are distinct
from those to B-DNA, thus allowing the specific DNA form to be determined [8,9]. Although a large
number of small molecules such as porphyrin molecules and its analogues, have been reported to bind
with B-DNA and Z-DNA, only a few of them can recognize Z-DNA via detection of particular binding
modes with Z-DNA [9–12]. This indicates that selecting an appropriate small molecule as a probe
for Z-DNA requires a deep mechanistic understanding for the binding modes of small molecules to
B-DNA and Z-DNA.
As a derivative of meso-tetrakis[4-(N-methylpyridiumyl)]-21H,23H-porphyrin (TMPyP4), zinc(II)
cationic porphyrin (ZnTMPyP4) has received much attention, because zinc(II) can additionally afford
an axial coordination in the center of porphyrin, which may enable ZnTMPyP4 to become a promising
probe for recognizing Z-DNA through different DNA binding behaviors. Balaz et al. investigated the
binding of ZnTMPyP4 to B-DNA and Z-DNA (i.e., B-poly(dG-dC)2 and Z-poly(dG-dC)2) by using
induced circular dichroism (ICD) spectroscopy [9,13], and obtained distinct ICD signals in the Soret
region of ZnTMPyP4 with a small negative peak for B-DNA and a very intense bisignate curve for
Z-DNA. They assumed that such a dramatic change in ICD spectra might be ascribed to different
interaction modes between the binding of ZnTMPyP4 with B-DNA and Z-DNA. The small negative
ICD peak suggests ZnTMPyP4 should be partially intercalated between GC pairs of B-DNA, whereas
the intense bisignate curve reflects the electronic interaction between two bound ZnTMPyP4, and each
ZnTMPyP4 may adopt its central metal zinc(II) to bind with guanine N7 of Z-DNA exposed externally
(Scheme 1) [14].
Scheme 1. Schematic diagram for the central metal zinc(II) of ZnTMPyP4 coordinating with guanine
N7 of Z-DNA.
Recently, Gong et al. studied the interactions of ZnTMPyP4 with Z-DNA (i.e., Z-poly(dG-dC)2)
and B-DNA (i.e., B-poly(dG-dC)2) by means of linear dichroism (LD) spectroscopy [15]. They observed
a strong positive LD peak in the Soret region for the ZnTMPyP4/Z-DNA complex, which is quite
different from the LD spectrum of the ZnTMPyP4/B-DNA complex, which shows a very weak negative
peak in the same region. By calculating angles of the Bx and By transitions of ZnTMPyP4 relative to
the DNA helix axis, they proposed two possible ways for ZnTMPyP4 to bind with the major groove of
Z-DNA: the molecular plane of porphyrin either parallel or perpendicular to the DNA helix axis.
To further understand the binding mechanisms underlying these spectroscopic changes, this work
attempts to examine the binding of ZnTMPyP4 towards B-DNA and Z-DNA (B-poly(dG-dC)2 and
Z-poly(dG-dC)2) respectively by employing time-resolved UV-visible absorption spectroscopy in
conjunction with multiple steady-state spectroscopic techniques of ICD, UV-vis and fluorescence.
The steady-state spectroscopic results first indicate a partial intercalation binding mode for the
ZnTMPyP4/B-DNA complex and an external groove binding mode for ZnTMPyP4/Z-DNA complex.
174
Int. J. Mol. Sci. 2018, 19, 1071
Further, time-resolved UV-visible absorption spectroscopy monitors the triplet-state decay kinetics of
the bound ZnTMPyP4 with B-DNA and Z-DNA, and reveals that there are two coexisting binding
modes for ZnTMPyP4 with each DNA. For ZnTMPyP4 interacting with B-DNA, the two lifetime
components of 30.4 ± 0.1 μs (58%) and 11.9 ± 0.2 μs (42%) are separately assigned to the intercalation
mode and partial intercalation mode, according to the degree of shielding of triplet states from oxygen
quenching. For the binding of ZnTMPyP4 with Z-DNA, the shorter-lived component (3.4 ± 0.3 μs)
arises from the electrostatic interaction between pyridyl groups of ZnTMPyP4 and phosphate
backbones of Z-DNA, allowing two sides of the ZnTMPyP4 macrocycle to be almost fully exposed to
oxygen quenching. The exposed guanine N7 atom in Z-DNA provides a site for axial coordination with
the central zinc(II) of ZnTMPyP4. The longer-lived component (14.8 ± 0.2 μs) thereby corresponds to a
major groove binding mode in which the central metal zinc(II) of ZnTMPyP4 coordinates with guanine
N7 of Z-DNA. This assignment validates the existence of the axially coordinated binding between
ZnTMPyP4 and Z-DNA. In addition, the binding interactions of planar TMPyP4 to DNA are also
investigated. The comparison of TMPyP4 with ZnTMPyP4 reveals the key roles of the coordination
ability of Zn(II) in altering the binding behavior of porphyrin. These results provide clear pictures of
binding modes for ZnTMPyP4/DNA interactions and shed light on the mechanistic understanding of
ZnTMPyP4 as a probe for recognizing the structural change form B-DNA and Z-DNA.
2. Results and Discussion
2.1. Characterizing the Formation of B-DNA and Z-DNA Conformations
The alternating purine–pyrimidine sequence poly(dG-dC)2 (poly(deoxyguanylicdeoxycytidylic)
acid; approximate average length in base pairs is 800) forms a typical B-DNA structure [9] and is
subject to favorable transition to the Z-form conformation in the presence of micromolar concentrations
of protonated spermine [13]. Figure 1 shows the Circular dichroism (CD) spectrum of B-poly(dG-dC)2
(denoted by B-DNA hereafter), which features a complex positive CD band centered at 274 nm
and a negative CD band at 253 nm. Under the experimental conditions of spermine (12 μM) and
Na-cacodylate buffer (1 mM, pH = 7.0), the CD spectrum presents a negative CD band at 293 nm and a
positive CD band at 263 nm (Figure 1), which is characteristic for Z-DNA, indicating that the B-DNA
has been successfully induced to the Z-poly(dG-dC)2 (denoted by Z-DNA hereafter).
Figure 1. The CD spectra of B-DNA (50 μM) and Z-DNA (50 μM) in the presence of spermine (12 μM)
in Na-cacodylate buffer (1 mM, pH = 7.0).
2.2. Interaction of TMPyP4 with B-DNA and Z-DNA
For comparison with ZnTMPyP4/DNA interactions, we first investigated the binding behaviors
of planar porphyrin TMPyP4 with B-DNA and Z-DNA. Figure 2a shows the absorption spectra of
TMPyP4 (2 μM) in the absence and presence of B-DNA (50 μM) in Na-cacodylate buffer. Compared to
free TMPyP4, large hypochromic effects (H = 38%) and red-shifts (22 nm, from 422.0 to 444.0 nm) of the
175
Int. J. Mol. Sci. 2018, 19, 1071
Soret band of TMPyP4 are observed in the presence of B-DNA, indicating the intercalative binding of
TMPyP4 with B-DNA [16,17]. The ICD spectrum of TMPyP4 further confirms this intercalation binding
mode, which displays an induced negative ICD band at 438 nm (−2.8 mdeg) in the presence of B-DNA,
as shown in Figure 3a [16,18,19]. In addition, Figure S1a shows the splitting of the emission into
two peaks and the decreased fluorescence intensity of the TMPyP4/B-DNA complex relative to free
TMPyP4. This quenching may originate from a good π-π stacking between TMPyP4 and GC pair of
B-DNA, implying the existence of the intercalation mode [20]. Interestingly, identical hypochromicity
and bathochromic shift, similar negative ICD bands at 436 nm and fluorescence quenching also appear
in the absorption, ICD and fluorescence spectra of TMPyP4 (Figure 2b, Figure 3b and Figure S1b) when
B-DNA is replaced by Z-DNA. These spectroscopic results suggest that TMPyP4 also intercalates into
Z-DNA, which is in good agreement with previous reports [10,11].
Figure 2. (a,b) Steady-state UV/Vis absorption spectra and (c,d) transient UV/Vis absorption spectra
recorded instantly (50 ns) after laser flash photolysis upon 355 nm excitation for free TMPyP4 (2 μM)
and its complexes with each of the two DNA (50 μM) in Na-cacodylate buffer (1 mM, pH = 7.0).
Normalized triplet decay signals after laser flash photolysis of TMPyP4 (2 μM) upon 355 nm excitation
in the absence (black) and presence of B-DNA (50 μM) (e) and Z-DNA (50 μM) (f). Fitted curves are
shown by solid lines. The fits are all obtained from complete decay traces.
Second, transient absorption spectroscopy was performed to examine the binding of TMPyP4 to
B-DNA and Z-DNA by monitoring the triplet state of TMPyP4. In the transient absorption spectrum
of free TMPyP4, a positive peak at 470 nm due to triplet excited-state formation and the negative
peak of ground-state depletion at 420 nm are observed, as shown in Figure 2c,d. Accompanying
the hypochromicity, the transient absorption of the triplet state is red-shifted to 480 nm when the
TMPyP4 is bound with either B-DNA or Z-DNA. Therefore, the triplet excited-state decay kinetics
were monitored for free TMPyP4 at 470 nm and DNA/TMPyP4 complexes at 480 nm.
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Figure 3. CD spectra of (a) B-DNA (50 μM) and (b) Z-DNA (50 μM) in the presence of different TMPyP4
concentrations from 2 to 6 μM in Na-cacodylate buffer (1 mM, pH = 7.0).
Figure 2e,f displays the triplet decay curves for TMPyP4 bound, respectively, with B-DNA
and Z-DNA, in comparison with free TMPyP4. As can be seen, the triplet decay of free TMPyP4
follows a monoexponential law with a lifetime of 1.7 ± 0.02 μs, which matches early reports [21–23].
When TMPyP4 is bound with B-DNA or Z-DNA, the triplet decays become pronouncedly slower and
exhibit first-order exponential laws separately with a lifetime of 27.8 ± 0.3 μs for B-DNA and a lifetime
of 28.6 ± 0.2 μs for Z-DNA. Similar lifetimes might correspond to similar binding sites, since the
triplet lifetime reflects the microenvironment of TMPyP4 bound with the duplex DNA, which could
screen the triplet state from being quenched by oxygen molecules in bulk solution. According to
the literature [24], the lifetime components of 27.8 ± 0.3 μs for B-DNA and 28.6 ± 0.2 μs for Z-DNA
can both be assigned to the population in intercalation mode, which is consistent with the above
steady-state experimental results.
From the steady-state and transient experimental results, it can be concluded that an identical
binding mode (intercalation mode) is observed for TMPyP4 interacting with B-DNA or Z-DNA.
Furthermore, intercalative TMPyP4 can cause the structural transition of Z-DNA to B-DNA,
as evidenced by the disappearance of the marked CD peaks of Z-DNA and the appearance of the
characteristic bands of B-DNA (Figure 3b) [10]. These results indicate that the planar TMPyP4 cannot
serve as a probe for recognizing Z-DNA.
2.3. Interaction of ZnTMPyP4 with B-DNA and Z-DNA
2.3.1. Interaction of ZnTMPyP4 with Right-Handed B-DNA
Parallel spectroscopic studies were carried out for the binding of ZnTMPyP4 to B-DNA. Similar
to TMPyP4, the ICD spectrum of ZnTMPyP4 displays an induced negative CD band at 448.0 nm
(−2.7 mdeg) (Figure 4a), and the fluorescence spectrum shows reduced intensity (Figure S2a). However,
the absorption spectrum of ZnTMPyP4 shows a similar hypochromic effect (H = 37%), but with a
relative small bathochromic shift (10 nm) (Figure 5a) compared to TMPyP4. From these observations,
an atypical intercalation mode—namely, partial intercalation—is suggested for the pentacoordinated
ZnTMPyP4 with B-DNA, and this may be caused by the steric hindrance of the axially coordinated
water molecule on zinc(II), which is in agreement with general knowledge of ZnTMPyP4 [13,23].
The interaction of ZnTMPyP4 with B-DNA was further examined using transient absorption
spectroscopy by monitoring the triplet excited-state decay kinetics of ZnTMPyP4. As shown in
Figure 5c, a positive peak (triplet excited-state formation) and negative peak (ground-state depletion)
are observed at 480 nm and 440 nm in the transient absorption spectrum of free ZnTMPyP4.
When ZnTMPyP4 binds to B-DNA, large hypochromicity and small redshifts (10 nm) are observed
for both triplet excited-state formation and ground-state depletion, which is in accordance with the
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steady-state absorption spectra. Therefore, the triplet decay kinetics of free ZnTMPyP4 and the
ZnTMPyP4/B-DNA complex were measured at 480 nm and at 490 nm, respectively.
Figure 4. CD spectra of (a) B-DNA (50 μM) and (b) Z-DNA (50 μM) in the presence of different
ZnTMPyP4 concentrations from 2 to 6 μM in Na-cacodylate buffer (1 mM, pH = 7.0).
Figure 5. (a,b) Steady-state UV/Vis absorption spectra and (c,d) transient UV/Vis absorption spectra
recorded instantly (50 ns) after laser flash photolysis upon 355 nm excitation for free ZnTMPyP4 (2 μM)
and its complexes with each of the two DNA (50 μM)) in Na-cacodylate buffer (1 mM, pH = 7.0).
Normalized triplet decay signals after laser flash photolysis of ZnTMPyP4 (2 μM) upon 355 nm
excitation in the absence (black) and presence of B-DNA (50 μM) (e) and Z-DNA (50 μM) (f). Fitted
curves are shown by solid lines. The fits are all obtained from complete decay traces.
As shown in Figure 5e, a monoexponential decay behavior with a triplet lifetime of 2.6 ± 0.01 μs
is exhibited for free ZnTMPyP4, and this inherent triplet lifetime is longer than that of TMPyP4.
In contrast, the triplet state decay kinetics of the ZnTMPyP4/B-DNA complex becomes much slower
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and can be well fitted by two exponential components with lifetimes of 11.9 ± 0.2 μs and 30.4 ± 0.1 μs
(Figure 5e, Table 1). As mentioned above, the triplet state lifetime reflects the degree of shielding of the
triplet ligand from oxygen quenching; thus, the biexponential decay for the bound ZnTMPyP4 strongly
implies the simultaneous existence of two binding modes. One of the two coexisting binding modes
should be the partial intercalation mode, which is also suggested by the steady-state experiments.
Since the intercalation of ZnTMPyP4 between GC base pairs of the duplex was characterized in
previous work [20], and the axial water was assumed to be released by gaining enough energy during
its intercalation process, the other binding mode may possibly be the intercalation mode. Obviously,
the intercalation mode much better protects the porphyrin macrocycle from molecular oxygen access,
which quenches the triplet state, than the partial intercalation mode. The currently observed longer
lifetime component of 30.4 ± 0.1 μs should thus correspond to the population bound in the intercalation
mode, whereas the shorter lifetime component of 11.9 ± 0.2 μs is assigned to the population bound
in the partial intercalation mode. The 30.4 ± 0.1 μs lifetime is comparable with the intercalative
mode of TMPyP4 (27.8 ± 0.3 μs or 28.6 ± 0.2 μs) in poly(dG-dC)2, indicating the reasonability of
this assignment.
Table 1. Triplet decay lifetimes of TMPyP4 and ZnTMPyP4 in air-saturated solution and in their
complexes with B-DNA and Z-DNA. Pre-exponential factors of the two lifetime components in the
biexponential fitting I = I0 + A1e−t/τ1 + A2e−t/τ2 yield the respective percentages of two binding
modes (values shown in brackets).
Sample τ1 (μs) τ2 (μs)
TMPyP4 1.7 ± 0.02
TMPyP4+B-DNA 27.8 ± 0.3
TMPyP4+Z-DNA 28.6 ± 0.2
ZnTMPyP4 2.6 ± 0.01
ZnTMPyP4+B-DNA 11.9 ± 0.2 (42%) 30.4 ± 0.1 (58%)
ZnTMPyP4+Z-DNA 3.4 ± 0.3 (53%) 14.8 ± 0.2 (47%)
In addition, the triplet reporter method also assesses the contribution of different binding modes.
With the biexponential fitting, the pre-exponential factors obtained for the two lifetime components
actually correspond to the respective percentages of the binding modes, and these values are also
listed in Table 1. From Table 1, it is shown that intercalation is the main binding mode for nearly 58%,
while the partial intercalation mode accounts for ~42%.
2.3.2. Interaction of ZnTMPyP4 with Left-Handed Z-DNA
The binding of ZnTMPyP4 with Z-DNA was further examined, and is different from that with
B-DNA, interestingly. As shown in Figure 5b, addition of ZnTMPyP4 to the spermine-induced Z-form
of poly(dG–dC)2 results in a bathochromic shift (Δλ = 4 nm, from 435 to 439 nm) and no hypochromicity
of the Soret band, which is quite different from the absorption spectrum of ZnTMPyP4/B-DNA,
which displays large hypochromic effects (H = 37%) and red-shifts (10 nm). Normally, for the interaction
of porphyrin with duplexes, the intercalation mode results in a strong bathochromic shift (≥15 nm)
and marked hypochromicity (H ≥ 35%) in the Soret band [16,17], whereas the external groove binding
mode exhibits a smaller bathochromic shift (≤8 nm) and weaker hypochromicity (H ≤ 10%) [16,19].
Therefore, in the current work, such a small red-shift and absence of hypochromicity suggest an
external groove binding mode for the ZnTMPyP4/Z-DNA complex (Scheme 2), instead of the partial
intercalation and intercalation modes that are detected for the ZnTMPyP4/B-DNA complex.
The different binding behavior can also be seen from the fluorescence spectrum of the
ZnTMPyP4/Z-DNA complex, which is shown in Figure S2b. Unlike TMPyP4, the fluorescence
of ZnTMPyP4 is not quenched upon binding to Z-DNA, and the emission at 635 nm is obviously
blue-shifted to 627 nm. This is clearly indicative of the absence of π-π interactions between GC base
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pair and ZnTMPyP4 core and the existence of an external groove binding mode in which guanine
N7 atom of Z-DNA is available for coordination with Zn(II), as concluded in previous fluorescence
studies [9].
Figure 4b shows the CD spectrum of ZnTMPyP4 in the presence of Z-DNA, which reveals a
bisignate signal in the Soret region with a negative CD band at 450 nm (−26 mdeg) and a positive CD
band at 436 nm (+14 mdeg). As discussed by previous reports, the induced bisignate CD signals may
originate from long-distance through-space, electric dipole–dipole, and exciton coupling of the two
ZnTMPyP4 chromophores [9,25], which might adopt a groove binding mode with substitution of the
axial water molecule in ZnTMPyP4 by guanine N7 of Z-DNA.
Scheme 2. Depiction of the possible binding modes of ZnTMPyP4 to the Z-DNA: (a) the major groove
coordination binding mode; (b) the electrostatic interaction binding mode. (Crystal structure of the
Z-DNA with about half a turn was extracted from RCSB, PDB entry: 5EBI [26]).
To further reveal the binding modes of ZnTMPyP4 with Z-DNA, transient absorption spectroscopy
measurements were performed. In the transient absorption spectrum of the bound ZnTMPyP4
with Z-DNA, no hypochromicity and slight redshifts are observed for triplet state formation and
ground-state depletion (Figure 5d). The triplet state decay kinetics of ZnTMPyP4/Z-DNA complex
was measured at 480 nm. Figure 5f shows its triplet decay behavior, which is obviously distinct
from that of the ZnTMPyP4/B-DNA complex. The ZnTMPyP4 triplet state follows a second-order
exponential decay with two lifetime components of 3.4 ± 0.3 μs and 14.8 ± 0.2 μs, which suggests the
existence of two coexisting binding modes with their respective percentages of 53% and 47%.
The long lifetime of 14.8 ± 0.2 μs is much shorter than the typical intercalative lifetime
(~30 μs) [24], which first excludes the possibility of the intercalation mode for ZnTMPyP4/Z-DNA
complex. The possibility of a partial intercalation mode for ZnTMPyP4/Z-DNA complex can be
also ruled out, according to the structural features of Z-DNA. Previous structural inspections of
Z-DNA have indicated that the alternate anti and syn conformation of nucleobases leads to exposure
of guanine atoms N7 and C8, which are both shielded in the B form [2]. In Z-DNA, the nitrogen atom
N7 is available for coordination with transition-metal ions, as shown previously by IR study [27,28],
and thus can provide a site for axial coordination with the central Zn(II) of ZnTMPyP4 (Scheme 2a).
It is well known that the nitrogen atom N is less electronegative and more easily renders electron pairs
than the oxygen atom O, resulting in its stronger coordination ability. Therefore, the central Zn(II)
of ZnTMPyP4 should more readily coordinate with the guanine atom N7 of Z-DNA than the water
molecule in the solution, which facilitates the coordination binding of ZnTMPyP4 with the guanine N7
of Z-DNA, and rules out the possibility of partial intercalation binding.
Additionally, it should also be noted that the minor groove of Z-DNA is narrow and deep,
and spermine is located here [29,30], preventing the binding of the ZnTMPyP4 in the minor groove.
In this case, the most plausible binding mode for the long lifetime of 14.8 ± 0.2 μs is coordination
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binding in the major groove with substitution of the axial water molecule in ZnTMPyP4 by guanine N7
of Z-DNA, as shown in Scheme 2a. In the geometry associated with this binding mode, one side of the
prophyrin macrocycle faces the major groove of Z-DNA, while the other side is exposed to the solution.
It follows that only one side of ZnTMPyP4 can receive efficient protection from oxygen access, leading
to a moderate triplet state lifetime. This assignment of the coordination binding in the major groove
is corroborated by the CD research results of the ZnTMPyP4/Z-DNA complex, in which induced
bisignate CD signals due to the electronic coupling of the two ZnTMPyP4 chromophores are observed.
As for the short lifetime of 3.4 ± 0.3 μs of Z-DNA/ZnTMPyP4 complex, it is close to the typical
triplet lifetime corresponding to electrostatic interaction binding mode, which was obtained for
ZnTMPyP4 in B-poly(dG-dC)2 (3.5 μs) at high ionic strength by Chirvony, V.S. et al. [20]. Consequently,
the 3.4 ± 0.3 μs lifetime component can be assigned to the population in the electrostatic interaction
binding mode. In this binding geometry (Scheme 2b), ZnTMPyP4 is bound electrostatically by the
positively charged pyridyl groups to negatively charged phosphate backbones on the outside with
minimal interaction between the ZnTMPyP4 macrocycle and Z-DNA, allowing the exposure of two
sides of ZnTMPyP4 to oxygen quenching and thus causing a short triplet state lifetime of ~3.4 μs.
This assignment is supported by LD study, which proposed that the ZnTMPyP4 molecule also binds
across the groove by electrostatic interaction, with the molecular plane of porphyrin perpendicular to
the DNA helix axis [15].
Notably, the short lifetime of 3.4 ± 0.3 μs of ZnTMPyP4/Z-DNA complex is only 31% longer
than that of free ZnTMPyP4 (2.6 ± 0.01 μs). Should this lifetime component also be ascribed
to the unbound ZnTMPyP4 in the solution? To scrutinize this possibility, additional CD spectra
of ZnTMPyP4 were measured at different [ZnTMPyP4]/[Z-DNA] molar ratios ranging from 0.04
to 0.16. As shown in Figure 4b, the intensity of the bisignate peak at the soret region increases
with increasing [ZnTMPyP4]/[Z-DNA] ratio. The saturation of the ICD signal is observed at the
[ZnTMPyP4]/[Z-DNA] of 0.12 with the ICD of −26 mdeg (Figure S3). In our triplet state experiment,
the concentration of the Z-poly(dG–dC)2 (per base pair) is 50 μM and the concentration of the
ZnTMPyP4 is 2 μM. Therefore, the [ZnTMPyP4]/[Z-DNA] ratio used in this work is 0.04, which
is much lower than the binding saturation ratio 0.12. This indicates that each ZnTMPyP4 molecule is
bound to the Z-DNA, thus ruling out the possibility that the short lifetime component of 3.4 ± 0.3 μs is
caused by free ZnTMPyP4.
In brief, the triplet state kinetics results, together with the steady-state experimental results, reveal
the simultaneous existence of major groove binding by forming N7-Zn coordination bond and an
electrostatic binding for the ZnTMPyP4/Z-DNA complex, which are quite different from the case of
the ZnTMPyP4/B-DNA complex. In addition, compared with planar TMPyP4, ZnTMPyP4 provides
a virtual orbital to coordinate with the exposed guanine N7 atom of Z-DNA, leading to the unusual
binding mode of ZnTMPyP4 distinguishing Z-DNA from B-DNA. These results not only provide
mechanistic insights for ZnTMPyP4 acting as a probe for recognizing Z-DNA, but also afford a possible
strategy for designing new porphyrin derivatives with available virtual orbitals for the discrimination
of B-DNA and Z-DNA.
3. Materials and Methods
3.1. Materials
The porphyrin derivative meso-tetrakis[4-(N-methylpyridiumyl)]-21H,23H-porphyrin (TMPyP4)
in the form of tetra-p-tosylate salt was purchased from Tokyo Chemical Industry (TCI, Tokyo, Japan)
and used as received. Zinc(II)-meso-tetrakis(4-(N-methylpyridiumyl))-porphyrin (ZnTMPyP4) was
purchased from Frontier Scientific (Logan, UT, USA) and used without any further purification.
Poly(deoxyguanylic–deoxycytidylic) acid sodium salt (poly(dG–dC)2), sodium cacodylate, sodium
chloride, spermine tetrahydrochloride (C10H26N4·4HCl) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Deionized water was obtained from a Milli-Q system with a resistivity of
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18.2 MΩ·cm. DNA samples were prepared in a sodium cacodylate buffer (1 mM, pH 7.0), annealed at
70 ◦C for 20 min, and then cooled to 10 ◦C at 1 ◦C/min, and kept at 4 ◦C for 12 h. The concentration of
the poly(dG–dC)2 (per base pair) was quantified by UV-vis spectroscopy using the extinction coefficient
ε = 8.8 × 103 M−1·cm−1 at 260 nm [13]. The porphyrin stock solutions were prepared in a sodium
cacodylate buffer (1 mM, pH 7.0), and the concentration was determined by UV-vis spectroscopy
using the following extinction coefficients ε = 2.26 × 105 M−1·cm−1 at 424 nm for TMPyP4 [22] and
ε = 2.04 × 105 M−1·cm−1 at 437 nm for ZnTMPyP4 [16].
3.2. Steady-State Spectroscopy
CD spectra were recorded at room temperature on a Jasco J-815 spectropolarimeter (JASCO,
Oklahoma City, OK, USA). Each sample was collected from 550 to 200 nm at a scan speed of
200 nm/min with a response time of 0.5 s in a 1 cm quartz cell. The reported spectroscopy was
the average of three scans. The spectrum from a blank sample containing only buffer was used as the
background that was subtracted from the averaged data. Steady-state absorption spectroscopy was
recorded with a UV-vis spectrometer (model U-3010, Hitachi, Tokyo, Japan). Quartz cuvettes of 1 cm
path length were used for all absorption measurement. Fluorescence spectroscopy was measured with
a fluorescence spectrometer (F4600, Hitachi). All samples were excited at 355 nm.
3.3. Laser Flash Photolysis
Transient UV-visible spectroscopy and triplet state kinetics were measured by a nanosecond
time-resolved laser flash photolysis (LFP) setup that has been described previously [22]. Briefly, the
instrument comprises an Edinburgh LP920 spectrometer (Edinburgh Instrument Ltd., Livingstone, UK)
combined with an Nd:YAG laser (Surelite II, Continuum Inc., Christiansburg, VI, USA). The excitation
wavelength is a 355 nm laser pulse from Q-switched Nd:YAG laser (1 Hz, fwhm ≈ 7 ns, 10 mJ/pulse).
The analyzing light is from a 450 W pulsed xenon lamp. A monochromator equipped with a
photomultiplier for collecting the spectroscopy range from 350 to 700 nm was used to analyze transient
absorption spectroscopy. The signals from the photomultiplier were displayed and recorded as a
function of time on a 100 MHz (1.25 Gs/s sampling rate) oscilloscope (Tektronix, Beaverton, OR, USA,
TDS 3012B), and the data were transferred to a personal computer. Data were analyzed by the online
software of the LP920 spectrophotometer. The fitting quality was judged by weighted residuals and
reduced χ2 value. Sample solutions were freshly prepared for each measurement.
3.4. Structural Transition from B-DNA to Z-DNA
Micromolar concentration of spermine (a fully protonated tetraamine at pH = 7.0) was used to
induce the B-DNA to Z-DNA transition in vitro. Z-DNA was formed by incubating at 60 ◦C with 12 μM
spermine for 10 min, then slowly cooled down to room temperature. The successful transition from
B-DNA to Z-DNA was ensured by CD spectroscopic results showing the characteristics of left-handed
Z-DNA: negative CD bands at 293 nm, and a positive CD band at 263 nm [13].
4. Conclusions
In this work, we comprehensively studied the binding interactions of ZnTMPyP4 with two
different duplex DNA, B-DNA and Z-DNA, by combining transient UV-vis absorption spectroscopy
with steady-state measurements (UV-vis, fluorescence, and ICD). For the ZnTMPyP4/B-DNA complex,
it is found that the partial intercalation and intercalation modes through π-π stacking of ZnTMPyP4
macrocycle with GC base pairs coexist. In contrast to this type of π-π stacking interaction mode,
ZnTMPyP4 binds with Z-DNA by means of another two interaction modes, i.e., the electrostatic
interaction between pyridyl groups and phosphate backbones, and major groove binding by Zn(II)
coordinating with the exposed guanine N7. The unusual binding behaviors of ZnTMPyP4 with Z-DNA
thus make it possible to utilize ZnTMPyP4 as a probe for discerning Z-DNA from B-DNA. In addition,
we also investigated the binding of planar TMPyP4 to B-DNA and Z-DNA as a comparison. It is
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shown that without available virtual orbitals to coordinate, TMPyP4 binds with Z-DNA solely in the
intercalation mode, which is identical to B-DNA. The intercalation of TMPyP4 results in structural
transition from Z-DNA to B-ZNA. These results elaborate the binding mechanisms of ZnTMPyP4 with
Z-DNA in comparison with B-DNA and reveal the key roles of the coordination ability of the Zn(II)
cation in altering the binding behavior of porphyrin, thus providing valuable guidance for the design
and selection of molecular probes in recognizing the important Z-DNA structure.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/4/
1071/s1.
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Abstract: Together with tremendous progress in biotechnology, nucleic acids, while retaining their
status as “molecules of life”, are becoming “molecular wires”, materials for the construction of
molecular structures at the junction between the biological and abiotic worlds. Herein, we present an
overview of the approaches for incorporating metal centers into nucleic acids based on metal–boron
cluster complexes (metallacarboranes) as the metal carriers. The methods are modular and versatile,
allowing practical access to innovative metal-containing DNA for various applications, such as
nucleic acid therapeutics, electrochemical biosensors, infrared-sensitive probes, and building blocks
for nanoconstruction.
Keywords: DNA; metallacarboranes; boron clusters; oligonucleotide probes; therapeutic nucleic acids
1. Introduction
Metal complexes, due to their versatility in redox and photophysical features, together with
well-defined, though diverse coordination geometries, represent a class of advantageous functional
components with broad applicability for nucleic acids modification. The incorporation of metal centers
into nucleic acids offers difficult to compete opportunities to create a new type of material that
merges the informational properties of nucleic with the electronic, magnetic, and optical properties
characteristic of metals and their complexes. As a result, materials possessing physical and chemical
features that differ significantly from those accessible in bio-organic or inorganic compounds only can
be fabricated [1,2].
One can distinguish between two different goals of nucleic acid modification. The first focuses
on modulation and improvement of the natural properties of nucleic acids such as specificity and
selectivity of binding towards complementary sequences or stability in a biological environment in
order to improve the designed, specific activities. This approach is mainly used if modified nucleic
acids are applied as therapeutic agents such as antisense oligonucleotides, ribozymes, or interfering
RNAs, and perform their natural or nearly natural functions in biological systems [3].
The second goal of nucleic acids modification focuses on incorporation of new, “unnatural”
properties into their structures such as fluorescence, luminescence, specific redox activity, radioactivity,
and specific affinity-bearing residues. The purpose of these modifications is to equip a nucleic acid with
constituents that provide detectable signals under designed conditions. In these technological rather
than biological applications, a modified nucleic acid is often used as a material for the construction
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Int. J. Mol. Sci. 2018, 19, 3501
of diagnostic tests and biosensors. Modified DNA-oligomers used as primers for polymerase chain
reaction (PCR) also find broad and diverse applications in molecular biology and molecular medical
diagnostics. New applications of nucleic acids as materials for nanoconstruction are still emerging [4,5].
There is a wide variety of entities designed for nucleic acids modification, including the following:
(1) fluorescent and affinity labels, (2) redox labels, and (3) modified nucleobases with different
properties and applications. There are also different types of metal complexes and organometallic
compounds used for that purpose. Some of them have been employed in molecular medicine,
diagnostics, and technology, providing a range of useful advantages and practical applications [6–8].
The metal-containing nucleic acids can be divided into the following types: (1) nucleic acids
with a metal incorporated in the form of a complex with chelate, (2) metallated-nucleic acids
containing metal ions that form a complex directly with double-stranded DNA, and (3) metal-labeled
nucleic acids containing metal complexes covalently bound to the DNA strand. The latter type is
a major focus of the present outline. Detailed discussion of the specific topics of chemistry and
applications of metal-containing nucleic acids is available in several general reviews and books
published recently [4,5,9,10]. The present overview is focused on the modification of nucleic acids with
metallacarboranes, a unique class of metal complexes consisting of metal ion(s) and boron clusters as
metal ligands.
2. Metallacarboranes
Polyhedral boron-rich compounds (boron clusters: closo-borates and carboranes) [11] have
a broad spectrum of practical applications, from catalysis, optoelectronics, and new materials to
medical chemistry and drug design [12,13]. One of the important features of a boron-rich system,
such as the dicarbaborate anion (nido-7,8-C2B9H122−), is the ability to serve as a ligand to form
stable complexes with metal ions, that is, metallacarboranes [14]. Metallacarboranes are a large
family of metallocene-type complexes containing at least one carborane polyhedron and one or more
metallocenters (M = Co, Fe, Ni, Cr, Re, Al, Au, Ir, Mn, Pt, etc.) (Figure 1).
Figure 1. Structure and atom numbering of 3-metal-bis(1,2-dicarbollide) ate [M(C2B9H11)2]−. M = Co,
Fe, Ni, Cr, Re, Al, Au, Ir, Mn, Pt, etc. Hydrogen atoms of C–H groups and B–H groups of the boron
clusters, symbolized by the polygen vertex, were omitted for the clarity.
Metallacarboranes can be viewed as metal sandwich complexes in which a metal ion is facially
coordinated to a carborane ligand analogous to metal–cyclopentadiene interactions in metallocenes.
In most cases, the metal–carborane binding is strong, and separation of the ligand from the metal
is rarely observed. The electron-delocalized bonding in these compounds has a strong stabilizing
influence. Thus, both high and low formal metal oxidation states are stabilized as the effects of
oxidation or reduction at the metal center are moderated via distribution over the cage skeleton [15].
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Two general approaches have been developed for the modification of nucleic acids with
carboranes and metallacarboranes: (1) de novo, step-by-step chemical synthesis of DNA oligomers
with the use of metallacarborane-modified nucleoside monomers [16] for incorporation of the
metallacarborane at specific locations; and (2) post-synthetic attachment of the metallacarborane
to the suitably functionalized DNA oligonucleotides [17,18]. Recently, an enzymatic method for DNA
modification with carboranes was also developed [19]. The expansion of the enzymatic approach for
the incorporation of metallacarboranes into the nucleic acid chain seems feasible.
DNA containing metallacarborane groups via de novo synthesis was obtained using the following
methods: (A) solid-phase synthesis employing H-phosphonate chemistry or (B) solid-phase synthesis
employing phosphoramidite chemistry. The post-synthetic modification approach (C) is based
on a one-step procedure employing copper(I)-catalyzed Huisgen–Meldal–Sharpless 1,3-dipolar
cycloaddition of azides and alkynes [20] (Scheme 1).
 
Scheme 1. Methods for the synthesis of oligonucleotides modified with metallacarborane: (A) de novo
solid-phase, step-by-step synthesis employing H-phosphonate chemistry; (B) de novo solid-phase,
step-by-step synthesis employing phosphoramidite chemistry; (C) post-synthetic one-step procedure
based on copper(I)-catalyzed Huisgen–Meldal–Sharpless 1,3-dipolar cycloaddition of azides and
alkynes. Hydrogen atoms of C–H groups and B–H groups of the boron clusters, symbolized by the
polygen vertex, were omitted for clarity.
3. Synthesis of DNA Modified with Metallacarborane Complexes via de novo, Step-by-Step
Chemical Synthesis
Originally, H-phosphonate chemistry was applied to synthesize oligonucleotides modified
with carborane and metallacarborane of a sequence complementary to the fragment of
the UL55 gene of human cytomegalovirus (HCMV) [21]. The solid-phase synthesis of
modified oligonucleotide containing the 3,3′-iron-1,2,1′,2′-dicarbollide (BEFeC) at the 5′ end of
5′-d(BEFeCACGAGTCTTCGGCTCCGGA)-3′ oligomer was performed using an automated DNA
synthesizer. The β-cyanoethyl phosphoramidite chemistry was used to synthesize the unmodified
part of the oligonucleotide, and H-phosphonate chemistry was used to add the modified monomer
bearing the metallacarborane moiety (Scheme 2). The expected nucleoside composition and the
presence of the metallacarborane modification in the obtained oligomer was confirmed by enzymatic
digestion [21]. Metallacarborane-containing dinucleotides bearing metallacarborane complexes
were also synthesized using H-phosphonate chemistry and the solution-phase synthesis mode [22].
The same oligonucleotide, 5′-d(BEFeCACGAGTCTTCGGCTCCGGA)-3′, has been used as a target for
biosensor devices [23]. The aqueous solution of the modified oligonucleotide was placed onto the
electrode to allow hybridization with the unmodified oligonucleotide. Electrochemical signals were
observed from the metallacarborane group, especially when a 3,3′-iron-1,2-1′,2′-dicarbollide complex
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was located far away from the electrode after hybridization. These studies confirmed the usefulness of
the metallacarborane-containing Fe (III) ion as an effective redox marker.
 
Scheme 2. Solid-phase synthesis of DNA modified with metallacarborane using H-phosphonate
chemistry. (A) Synthesis of the H-phosphonate monomer: (i) dimethoxytrityl chloride (DMTCl)l and
pyridine; (ii) PCl3, imidazole, Et3N, CH2CH2, and H2O, −40 ◦C. (B) Synthesis of DNA oligonucleotides:
(iii) detritylation: 3% dichloroacetic acid (DCA) in CH2Cl2; (iv) coupling: unmodified monomers,
phosphoramidite chemistry; (v) oxidation: 0.1 mol/L I2 in THF/pyridine/H2O (13:6:1); (vi) capping: 1
mol/L (CH3CO)2O in THF/pyridine (1:8) and 0.5 mol/L 4-dimethylaminopyridine (DMAP) in THF;
(vii) coupling: modified monomer, H-phosphonate chemistry; (viii) oxidation: 10% H2O in CCl4, Et3N,
N-methylimidazole (9.0:0.5:0.5, v/v/v); (ix) cleavage from the support: 30% NH3 aq., 1 h, RT; base
deprotection: 30% NH3 aq. 2 h, 50 ◦C. Hydrogen atoms of C–H groups and B–H groups of the boron
clusters, symbolized by the polygen vertex, were omitted for clarity.
DNA oligomers modified simultaneously with carborane (2′-O-(o-carboran-1-yl)methyluridine,
2′-CBM) and metallacarborane (2-N-{5-[3-cobalt bis(1,2-dicarbollide)-8-yl]-3-oxa-pentoxy}-2′-O-
deoxyguanosine, BEMC) nucleosides complementary to the insulin receptor substrate (IRS-1) gene
were also synthesized using a phosphoramidite approach for the introduction of carborane or
metallacarborane groups-containing nucleoside monomers to the oligonucleotide [24]. Unmodified
parts of the oligonucleotides were prepared by automated solid-phase synthesis (Scheme 3).
The manual step was used for the insertion of phosphoramidites of 2′-CBM and BEMC bearing
carborane or metallacarborane modification, respectively. It should be noted that because of the
treatment of the oligonucleotide product with a concentrated solution of ammonia in water during the
cleavage from the solid support and deprotection, the electroneutral closo-form of the carborane in
2′-CBM is transformed into a negatively charged nido-counterpart.
The physicochemical and biological properties of modified DNA were studied. The lipophilicity
and resistance to enzymatic degradation by snake venom phosphodiesterase (SVPDE) of the modified
oligonucleotides was higher than the unmodified counterparts, especially in the case of simultaneous
modification at the 3′ and 5′ ends with 2′-CBM and BEMC groups, respectively. An effective formation
of the doubled stranded structure with the complementary DNA-oligomers was shown [24].
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Scheme 3. Solid-phase synthesis of DNA modified with carborane and metallacarborane using
phosphoramidite chemistry: (i) detritylation, (ii) coupling, (iii) oxidation and capping, and (iv) cleavage
from the solid support and deprotection [25]. Hydrogen atoms of C–H groups and B–H groups of the
boron clusters, symbolized by the polygen vertex, were omitted for clarity.
5′-O-Monomethoxytrityl-4-O-diethyleneoxy-8-[3-cobalt bis(1,2-dicarbollide)-8-yl]-thymidine-
3′-O-(N,N-diisopropyl-β-cyanoethyl)phosphoramidite was used to synthesize DNA containing
metallacarborane, 5′-d(BEMCTGCTGGTTTGGCTG)-3′, using a β-cyanoethyl phosphoramidite cycle
and an automated DNA synthesizer. The metallacarborane-modified nucleoside was attached to
the 5′ end of the oligomer. In the oxidation step, t-BuOOH was applied instead of I2, which is
routinely used as the oxidizing agent. The synthesized oligonucleotide labeled with a metallacarborane
cage was used as one of two primers in polymerase chain reaction (PCR) amplification of a
fragment of HCMV DNA, strain AD 169. The other primer was unmodified oligonucleotide P12
(5′-AAACGGCGCAGCCACATAAGG-3′). The susceptibility of the primer with metallacarborane
modification at its 5′ end to an extension by Taq DNA polymerase was proved by PCR amplification
of the HCMV genome fragment on the junction of US14 and US13 gene. The 812-bp amplification
product was obtained as expected [26].
Expanding these works, we have developed a general method for the synthesis of four
canonical nucleosides T, dC, dA, and dG modified with 1,2-dicarba-closo-dodecaborane (C2B10H11)
cage, and their phosphoramidites, suitable for automated synthesis of DNA [27]. The modified
nucleoside monomers bearing boron cluster were prepared from suitable 5-ethynyl derivatives in
one-step reaction using cooper(I)-catalyzed Huisgen–Meldal–Sharpless 1,3-dipolar cycloaddition
of azides and alkynes to give triazoles. The 5′-O-(4,4′-dimethoxytrityl)-3′-O-(N,N-diisopropyl-
β-cyanoethyl)-N3-{[(O-carboran-1-yl)propyl)]-1N-1,2,3-triazol-4-yl}methylenethymidine phosphoramidite
was used to synthesize four modified DNA oligonucleotides of various lengths and sequences of
nucleobases. All the oligomers contained one carborane modification at the 5′-end, and two of them
were additionally equipped with an amino linker C6 (Scheme 4). The oligonucleotides were obtained
by solid-phase synthesis using a standard β-cyanoethyl cycle [25].
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Scheme 4. Synthesis of oligonucleotides containing carborane cluster at the 5′-end of the
oligonucleotide chain: (i) detritylation; (ii) coupling; (iii) oxidation and capping; (iv) cleavage from the
solid support and deprotection. Hydrogen atoms of C–H groups and B–H groups of the boron clusters,
symbolized by the polygen vertex, were omitted for clarity.
Mass spectrometry analysis proved that the carborane cage is, as expected, in nido-form
(7,8-dicarba-nido-undecaborate ion). The conversion of the boron cluster from closo- to nido-form takes
place during the cleavage of the synthesized oligomer from the support and nucleic bases’ deblocking
under treatment with concentrated ammonia solution in water [28]. The modified oligonucleotides
containing negatively charged, redox active 7,8-dicarba-nido-undecaborate have been used as a
probe for electrochemical detection of specific DNA sequences derived from the cytomegalovirus
(HCMV) [29]. Alternatively, they can be used as precursors for post-synthetic modification of the
oligonucleotides with metallacarborane unit based on the 3,3,3-tricarbonyl-3-metal complex formation
with 7,8-dicarba-closo-dodecaboran-1-yl ligand [30], according to the procedure shown in Scheme 5.
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Scheme 5. Synthesis of a uridine-bearing 3,3,3-(CO)3-closo-3,1,2-ReC2B9H10 complex: (i) TEAFaq.,
EtOH, [Net4]2[ReBr3(CO)3], 100 ◦C, 30 h; (ii) 25% NH3aq., MeOH, 35 ◦C, 30 min. Hydrogen atoms of
C–H groups and B–H groups of the boron clusters, symbolized by the polygen vertex, were omitted
for clarity.
Using this approach, synthesis of a new type of nucleoside–metallacarborane conjugate,
2′-O-(3,3,3-tricarbonyl-3-rhenium-7,8-dicarba-closo-dodecaboran-1-yl) methyluridine, was recently
achieved [31]. The method was based on the de novo formation of a metallacarborane complex via the
reaction of [Net4]2[ReBr3(CO)3] with the uridine-bearing carborane as a metal ligand (Scheme 5).
4. Post-Synthetic Labeling of DNA with Metallacarboranes via a “Click Chemistry” Approach
The CuI-catalyzed 1,3-dipolar Huisgen–Meldal–Sharpless cycloaddition (HMSC) of azide and
alkyne leads to the formation of a triazole moiety. This process, often called “click chemistry” or
“chemical ligation”, became an important tool for chemical modification of biomolecules [20,32].
The azide and alkyne components have several advantages. They can be conveniently introduced in
an independent manner, are relatively stable and do not react with common organic reagents nor with
a majority of functional groups present in biomolecules (are orthogonal). The formation of triazoles
is irreversible and usually proceeds in high yield. In addition, this reaction is remarkably versatile
because of the extremely mild and chemoselective copper(I) catalyst system, which is surprisingly
insensitive to many solvents and operate well in a wide pH range. The advantages of the “click
chemistry” approach, based not only on HMSC but also on other types of bioorthogonal chemistries
such as Diels–Alder “click” reactions, allow for its application in areas such as synthesis on solid
supports, combinatorial chemistry, or “organic chemistry in vivo” [33]. The click chemistry approach
was used to label a DNA oligomer with the 3,3′-iron-1,2,1′,2′-dicarbollide group [34,35] using an alkyne
derivative of DNA (with an acetylene moiety located close to the 5′ end) and an azide component
bearing the metallacarborane group at the end of a diethylenoxy linker (Scheme 6).
 
Scheme 6. Synthesis of DNA containing a metallacarborane moiety using Huisgen–Meldal–Sharpless
cycloaddition (HMSC): (i) tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), sodium ascorbate,
CuSO4 × 5 H2O, [8-N3-(CH2CH2O)2-3-iron bis(dicarbollide)], H2O. Hydrogen atoms of C–H groups
and B–H groups of the boron clusters, symbolized by the polygen vertex were omitted for clarity.
The obtained oligonucleotide deposited on a gold electrode acted as a main part of a
novel electrochemical genosensor capable of electrochemical determination of the DNA sequences
derived from avian influenza virus (AIV), type H5N1. The oligonucleotide probes containing
an NH2 group close to the 5′-end nucleotide were covalently attached to the electrode via
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coupling of N-hydroxysuccinimide/N-(3-dimethyl-aminopropyl)-N-ethylcarbodiimide hydrochloride
(NHS/EDC) and 3-mercaptopropionic acid. The latter was previously deposited on the surface of gold
electrode as a self-assembled monolayer (SAM). For the measurement, an Osteryoung square-wave
voltammetry method was applied. The changes in the redox activity of the Fe(III) center of the
metallacarborane complex before and after the hybridization process were found to be diagnostic
and displayed good selectivity and sensitivity towards several complementary targets derived from
AIV, H5N1. The calculated detection limits recorded for an ssDNA 20-mer and PCR products having
complementary sequences at the 3′ end and in the middle of the oligonucleotide based on experimental
data ranged from 0.03 to 0.08 fM, respectively; thus the genosensor was superior to many others
previously reported. Its additional advantage was the ability to distinguish PCR products containing
complementary sequences in different positions [34].
Another type of HMSC driven labeling of nucleic acids with metallacarboranes (shown in
Schemes 7 and 8) consisted of two steps [35]. First, oligonucleotides containing, at a given position,
a thymidine unit modified with 4-pentyn-1-yl substituent at the position 3-N were obtained by the use
of corresponding phosphoramidite monomer. Also, oligomers bearing a uridine unit modified with a
2′-O-propargyl group were synthesized using commercially available monomer. In the second step,
the alkyne-modified oligomers were post-synthetically conjugated to alkyl azide derivatives of boron
clusters via HMSC [20,36].
For the proof of concept, a 22-mer antisense oligodeoxyribonucleotide (ASO) of the sequence
5′-d(TTT CTT TTC CTC CAG AGC CCGA)-3′ was chosen, which recognizes the epidermal growth
factor receptor (EGFR) mRNA, known for being overexpressed in cancerous cells. The synthesized
ASO oligonucleotides contained one or two thymidine or uridine metallacarboranes conjugates
(of thymidine (TB)-type or uridine (UB)-type, respectively; Scheme 7) in positions 7 or/and 11 of
the oligomer chain [35]. The metallacarborane moieties were anchored at position 3-N of thymidine
(TB) or alternatively at 2′-oxygen atom of uridine (UB) unit. In addition, two UB-type ASOs (heavily
loaded with metallacarborane, Scheme 8) [37] were also obtained according to the above procedure
(see Table 1 for the sequences and modification type and position). The obtained models were used for
evaluation of physicochemical and biological properties of DNA–metallacarborane conjugates.
 
Scheme 7. Example synthesis of boron cluster-modified anti-epidermal growth factor receptor (EGFR)
antisense oligonucleotides via post-synthetic modification using HMSC. DNA oligonucleotides bearing
3-N-metallacarborane-modified thymidine unit(s) (as in the upper reaction scheme) are assigned
thymidine (TB)-type, while those bearing 2′-O-metallacarborane modified uridine units (a lower
panel) are assigned uridine (UB)-type. Adapted in part from the literature [35]. Hydrogen atoms of
C–H groups and B–H groups of the boron clusters, symbolized by the polygen vertex, were omitted
for clarity.
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Scheme 8. Antisense UB-type DNA oligonucleotide targeted EGFR obtained via Cu(I)-assisted “click”
conjugation, bearing five Fe (III)-metallacarborane units. Hydrogen atoms of C–H groups and B–H
groups of the boron clusters, symbolized by the polygen vertex, were omitted for clarity.
Table 1. Binding affinity of the anti-epidermal growth factor receptor (EGFR) metallacarborane
antisense oligonucleotides to the complementary RNA strand assessed by thermal dissociation
assay (Tm), lipophilicity (LogP), RP-HPLC mobility (retention time RT), and antisense activity
(antisense oligodeoxyribonucleotide (ASO) activity) assessed by a dual fluorescence assay (DFA)
against EGFR mRNA.
Name Oligonucleotide Sequence a Tm b [◦C] ASO Activity
c
[%]
LogP (RT d [min]) Ref.
NM 5′-d(TTTCTTTTCCTCCAGAGCCCGA)-3′ 69.5 65 ± 1 −1.17 ± 0.36 (11.6) [35]
TB7 5′-d(TTTCTTTB7TCCTCCAGAGCCCGA)-3′ 62.5 46 ± 4 −0.60 ± 0.15 [35]
TB11 5′-d(TTTCTTTTCCTB11CCAGAGCCCGA)-3′ 57.5 82 ± 2 nd [35]
TB7,11 5′-d(TTTCTTTB7TCCTB11CCAGAGCCCGA)-3′ 45.0 24 ± 2 nd [35]
UB7 5′-d(TTTCTTUB7TCCTCCAGAGCCCGA)-3′ 65.5 34 ± 2 −0.71 ± 0.42 (17.5) [35,37]
UB11 5′-d(TTTCTTTTCCUB11CCAGAGCCCGA)-3′ 67.5 89 ± 2 nd [35]
UB7,11 5′-d(TTTCTTUB7TCCUB11CCAGAGCCCGA)-3′ 63.5 68 ± 1 nd (20.1) [35,37]
UB2,5,8,11 5′-d(TUB2TCUB5TTUB8CCUB11CCAGAGCCCGA)-3′ 60.9 54 ± 2 (22.2) [37]
UB1,3,5,8,11 5′-d(UB1TUB3CUB5TTUB8CCUB11CCAGAGCCCGA)-3′ 60.4 62 ± 3 (23.9) [37]
a The thymidine (TB) or uridine (UB) metallacarborane conjugates are inserted in the indicated positions of the
oligonucleotide chains. b Melting temperatures (Tm) of ASO/RNA duplexes are given with ±0.5 ◦C accuracy.
c Antisense activity of anti-EGFR ASO in HeLa cells at 200 nM concentration in DFA. d RT [min]—RP HPLC
retention time on a C18 reverse phase HPLC column, a gradient of acetonitrile in aqueous ammonium acetate
solution (0.1 M CH3COONH4) from 0% to 70% of acetonitrile as an eluting solvent system was used.
5. Physicochemical and Biological Properties of Metallacarborane Modified Oligonucleotides of
TB- and UB-Types
Binding affinity to complementary sequences. The affinity of the metallacarborane modified oligomers
of TB- or UB-type (Table 1) to their complementary target RNA strand 3′-AAA GAA AAG
GAG GUC UCG GGCU-5′ was assessed by the thermal dissociation assay. The measurement of
melting temperatures (Tm) has shown that metallacarborane modified ASO/RNA duplexes are
thermodynamically less stable than the reference duplex containing the non-modified ASO strand
(NM-ASO) complexed with complementary RNA (NM-ASO/RNA). However, the presence of the
UB-type modifications decreased the duplex stability less than those of the TB-type. This is because the
nucleotide of UB-type with the metallacarborane moiety present at the 2′-position adopts preferentially
the C3′-endo conformation typical for the RNA units, and thus it well accommodates in the DNA/RNA
helices, known for adopting the overall conformation of the A-type.
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In contrast, in the TB unit, the metallacarborane group occupies the 3-N position of nucleobase,
therefore, there is a disruption of the Watson–Crick base pairing with the complementary adenine
nucleotide. Thus, one may conclude that ASOs modified with the UB-type units are advantageous
for recognition of the target mRNA sequences and activation of the RNase H, a prerequisite for gene
expression regulation by the antisense approach [38].
Lipophilicity of UB- and TB-type ASOs. The metallacarborane units lead to substantially increased
lipophilicity of their oligonucleotide conjugates (listed in Table 1) compared with the non-modified
reference precursor MN-ASO, as shown by the values of the partition coefficients in the water/1-octanol
bi-phase system (LogP) [35] and by the changes of chromatographic mobility on a C18 reverse phase
HPLC column (RT are given in parentheses in Table 1) [35,37]. The increasing number of the UB units
loaded leads to the linear increase of the lipophilicity of the UB-type ASOs [35,37].
Circular dichroism (CD) measurements of UB-type ASOs. CD is a powerful tool for monitoring
structural changes of DNA and RNA duplexes resulting from the presence of modified units in their
strands. As shown previously, the CD spectra of the UB-type ASO bound to the complementary RNA
strand exhibit only minute deviations from the CD profile of the reference, non-modified DNA/RNA
duplex [35,37]. This observation indicates that the UB-type units inserted in the oligonucleotide chain
slightly alter the structure of the ASO/RNA duplexes. This feature is important for recognition of
mRNA and for induction of the RNase H activity. In this respect, the UB-type ASO metallacarborane
conjugates may be useful in the antisense or boron neutron capture therapy (BNCT) applications.
Infrared (IR) activity of metallacarborane labeled DNA. To date, detection of nucleic acids using
infrared light sensitive labels and IR spectroscopy has not been used very often, mostly because of the
lack of labels absorbing electromagnetic radiation within a 1900–2600 cm−1 window, where nucleic
acids (and typical organic molecules) are transparent. Boron clusters attached to DNA or RNA
oligonucleotides make a difference because IR spectra of carborane (C2B10H12) or metallacarborane
[3-Co-(1,2-C2B9H11)2]− moieties contain a unique band attributed to the B–H vibration at ca. 2600
cm−1 [39,40]. The HMSC method allowed for further improvement of this labeling approach.
Incrusting of an oligonucleotide probe with multiple metallacarborane labels, each containing 18 B–H
bonds, resulted in significant enhancement of the diagnostic B–H signal and increased sensitivity of the
detection [37]. For ASOs of the UB-type, containing four or five metallacarborane units at positions 2, 5,
8, 11 or 1, 3, 5, 8, 11 of the oligonucleotide chain, the B–H related bands occurred in the 2500–2650 cm−1
region, similar to the signals in free Fe(III)-metallacarborane [3-Fe-(1,2-C2B9H11)2]−, as well as the
signals of the B–H bonds found in uridine nucleoside bearing Fe(III)-metallacarborane modification at
2′-position [37]. Thus, the metallacarborane moieties inserted into the oligonucleotide chain show the
bands characteristic for the B–H vibration and can be used as an infrared light sensitive marker.
Biological evaluation of the UB-type ASOs. The silencing activity (inhibition of protein biosynthesis)
of boron cluster-modified ASOs was tested against the mRNA of EGFR protein in a dual florescence
assay (DFA), in which the fusion plasmid coding green fluorescent protein (GFP) and the target
fragment of EGFR (pEGFP-EGFR) was exogenously expressed in HeLa cells, and was assessed by
comparison of the level of fluorescence of EGFP and of the control red fluorescent protein (RFP)
simultaneously expressed from pDsRed-N1 plasmid. Considerable silencing activity, depending upon
the location of the modification within the oligonucleotide chain, was observed for the selected ASOs.
In the antisense approach, the ASO oligonucleotides operate by sequence-specific hybridization
to the complementary RNA followed by recruitment of RNase H, which hydrolyses the target RNA.
Although the requirements that the ASOs have to meet to inhibit a protein expression are not known
precisely, modifications in a sugar moiety, for example, change of the sugar type or its orientation,
are reported to affect the RNase H activation [41]. From the other side, borane clusters are known for
binding to the cellular proteins [42] and modulation of their cellular function. Therefore, the observed
differences in the silencing activity of the ASO-metallacarborane conjugates may be of different origin.
In the reported case, single modified ASOs of the TB- and UB-type in position 11 of the ASO chain (as
in TB11 and UB11) used in 200 nM concentration exhibit enhanced silencing potential compared with
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the reference ASO (by ca. 20%, Table 1). In contrast, location of the metallacarborane units at position 7
of ASOs (as in TB7 and UB7) decreased their silencing activity. For highly modified UB-type ASOs, the
silencing effect is balanced by positive and negative features of the metallacarborane units, leading to
ASOs of similar antisense activity as the reference ASO.
Redox properties of Fe (III)-metallacarborane ASO conjugates. The tested ASOs, when used at low
concentrations (up to 50 μM), exhibited pro-oxidative activity by inducing reactive oxygen species
(ROS) production and an increase in the mitochondrial activity of HeLa cells. In contrast, when used
at higher concentrations, the ASOs exhibited antioxidative properties, lowering the level of ROS [37].
Inside cells, the highly metallacarborane-loaded ASOs containing redox-active Fe(III) ions
generate ROS as a result of oxidative stress. At low concentrations, these compounds enhance the
metabolic activity. Along with the increase of concentration, the amount of Fe(III) ions (free radicals
scavenger) also increases, so the antioxidative properties of the ASOs are observed. When concentration
of ASOs reaches ≈200 nM, the ROS levels are the same as in the control cells, suggesting that the
rates of ROS formation and elimination are equal. It is suggested that the silencing of EGFR by the
use of high concentrations of oligonucleotide–metallocarborane conjugates occurs without noticeable
increase of ROS concentration. It should be emphasized that the delivery of unmodified antisense and
nonsense oligonucleotides did not result in a significant increase of the ROS levels. Therefore, it is
hypothesized that the high metallacarborane-loaded DNA oligomers may be used as potential BNCT
and antisense oligonucleotide (dual-action) anticancer agents.
6. Summary and Conclusions
DNA modified with boron cluster-metal complexes, metallacarboranes [M(C2B9H11)2], represent a
new class of metal containing nucleic acids. Metallacarboranes provide probably the most versatile
platform for modification of nucleic acids with metals, though this immense potential is awaiting
full exploration. Not all metallacarboranes are stable in a biological (water) environment, but a
plethora of metallacarboranes suitable for use as metal carriers for biomolecules’ modification can be
selected. The methods described in this overview are modular and versatile, allowing practical access
to innovative metal-containing DNA. These and new methods developed in future may open the way
for more widespread use of metal-labeled nucleic acids for a variety of applications.
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Abstract: Platinum (Pt)-based antitumor agents have been effective in treating many human
malignancies. Drug importing, intracellular shuffling, and exporting—carried out by the high-affinity
copper (Cu) transporter (hCtr1), Cu chaperone (Ato x1), and Cu exporters (ATP7A and ATP7B),
respectively—cumulatively contribute to the chemosensitivity of Pt drugs including cisplatin and
carboplatin, but not oxaliplatin. This entire system can also handle Pt drugs via interactions between
Pt and the thiol-containing amino acid residues in these proteins; the interactions are strongly
influenced by cellular redox regulators such as glutathione. hCtr1 expression is induced by acute Cu
deprivation, and the induction is regulated by the transcription factor specific protein 1 (Sp1) which
by itself is also regulated by Cu concentration variations. Copper displaces zinc (Zn) coordination
at the zinc finger (ZF) domains of Sp1 and inactivates its DNA binding, whereas Cu deprivation
enhances Sp1-DNA interactions and increases Sp1 expression, which in turn upregulates hCtr1.
Because of the shared transport system, chemosensitivity of Pt drugs can be modulated by targeting
Cu transporters. A Cu-lowering agent (trientine) in combination with a Pt drug (carboplatin) has
been used in clinical studies for overcoming Pt-resistance. Future research should aim at further
developing effective Pt drug retention strategies for improving the treatment efficacy.
Keywords: high-affinity copper transporter; hCtr1; Sp1; cisplatin; ovarian cancers; drug-resistance
1. Introduction
Platinum (Pt)-based drugs represent an extraordinary accomplishment in antitumor inorganic metal
drug development [1]. They have been the mainstay of cancer chemotherapy in many different types
of human malignancies for the last four decades since FDA approved cis-diamminedichloroplatinum(II)
(cisplatin, cDDP) in 1978 [1,2]. These drugs are effective in treating advanced testicular cancers and
ovarian cancers with cure rates of about 90% and 70%, respectively [3]. Together with carboplatin
(Cbp) and oxaliplatin (Oxl), these Pt-based agents have shown a wide spectrum of antitumor activities
including cancers of lung, bladder, breast, colon, and head and neck. It has been recognized that
Pt drugs can attack many cellular targets including the plasma membrane, cellular organelles
(mitochondria and endo-lysosomes), endoplasmic reticulum and cytoskeleton (see review in ref. [4]
and references therein), but DNA damages are the principle cause of Pt drug-induced cell lethality.
Another important factor that affects the treatment efficacy is the transport system which includes
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drug accumulation, intracellular drug shuffling and drug efflux (Figure 1A). This system cumulatively
regulates the steady-state of intracellular drug contents which are directly correlated with the extent
of DNA damage and cellular lethality [5,6]. Reduced cellular Pt content is an important hallmark of
cDDP resistance in a wide variety of drug-resistant cell lines and tumors derived from Pt-refractory
patients [7–9].
Figure 1. The similarity of transport systems between Cu(I) and cDDP. (A) routings of Cu(I) and cDDP
from influx, intracellular trafficking (shuffling), to efflux; (B) schematic diagram depicting structure of
hCtr1; (C) structure of ATP7A and ATP7B.
Previous works suggested that cDDP enters cells via a simple passive diffusion mechanism,
because drug import is unsaturable and cannot be competed by cDDP analogues [6,10,11].
These findings suggest that cDDP influx may not require a transporter or carrier. However, because
cDDP is a highly polar compound and its ability to across cellular membrane is limited, it is
believed that the primary mechanism of Pt drug transport requires transporters. Indeed, studies have
demonstrated that several copper (Cu) transporters are actively involved in the import, intracellular
distribution, and export of Pt drugs [3]. These observations demonstrated that Cu ions and cDDP
share similar transport mechanisms and mutually interfere with their cellular accumulations. In this
review, we will first discuss the underlying mechanisms of how the Cu transporter system impedes
Pt drugs from entering, following intracellular trafficking, and then exiting the cells. We will then
focus on the transcriptional regulation of Cu transporter that bears clinical relevance to the treatment
efficacy of Pt-based cancer chemotherapy.
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2. Roles of the Copper Transporters in Pt Drug Transport Mechanism
2.1. Cisplatin Importers
It has been established that the high-affinity copper transporter 1 (Ctr1, also known as SLC31A1)
is the primary transporter for cDDP [3,12]. Ctr1 also transports Cbp with reduced efficacy, but does not
transport Oxl. cDDP-resistant cell lines show reduced accumulation of cDDP but not Oxl or satraplatin
(JM216), and no cross-resistance to these analogues [13]. The major influx transporters of Oxl are
organic cation/carnitine transporter (OCT1 and OCT2) [14,15]. Ctr1 is an evolutionarily conserved
Cu(I) ion transporter shared from yeast to humans. The important roles of Ctr1 in cDDP uptake
were initially demonstrated by genetic ablations in yeast cells and in mouse embryonic fibroblasts,
which exhibited decreased cDDP uptake and increased cDDP resistance [16]. This was also confirmed
by the finding that overexpression of human Ctr1 (hCtr1) in small cell lung cancer cells increases
cDDP uptake [17]. However, these observations may depend on cell sources, because overexpressing
ectopic hCtr1 was seen in cDDP-resistant cells but not in its drug sensitive cells [18,19]. While the
precise mechanism of this discrepancy is not known, it may be relevant to the cellular capacity of Cu
homeostasis and regulation mechanisms, which will be discussed below.
The hCtr1 is a 190-amino acid membrane protein that contains three transmembrane domains
with the N-terminus extracellularly located and the C-terminus inside the cytoplasm. Site-directed
mutagenic analyses have identified multiple conserved amino acids in hCtr1 that are critical for
transport of Cu(I) and cDDP transports. These include 40MMMMxM in the N-terminal extracellular
domain (where M denotes methionine and x denotes variable amino acids), 150MxxxxM in the
second transmembrane domains [20], 189HCH in the cytoplasmic C-terminal domain, and others [21]
(Figure 1B). However, mutations at the GG-4 motif (167GxxxG) reduces Cu(I) but not cDDP
transport [20], suggesting the subtle differences in hCtr1-mediated transport between these substrates.
It is suggested that cDDP (chemical formula: cis[Pt(Cl2(NH3)2)] interacts with the extracellularly
exposed methionine (M)-motifs by forming the [Pt(Met)Cl(NH3)2] intermediate, resulting in induced
hCtr1 conformational changes and stabilization of the trimeric formation as revealed by protein
cross-linking agents [20]. cDDP and Cu(I) are thought to transverse through the axis of the trimeric
hCtr1 channel and move inward by an intermolecular sulfur-sulfur exchange mechanism [3].
Electron cryostallography of 2D protein crystals in a native phospholipid bilayer provides an estimate
of ~9 angstroms for the pore size of the hCtr1 homotrimer configuration [22]. cDDP has two each of
chloride (Cl) and aminonia (NH3) ligands coordinated to the central Pt in a square-planar structure.
While the precise molecular dimension of cDDP is unclear, it is estimated to be at least three to four
orders of magnitude (~1 nm) larger than the pore size [23], suggesting that conformational changes are
involved in hCtr1-mediated cDDP passing.
Humans also have a low-affinity Cu transporter hCtr2 (SLC31A2) arisen by gene duplication
from hCtr1 [24]. hCtr2 shares substantial structural homology with hCtr1, but has only 143 amino acid
residues because the majority of the N-terminal Met-rich sequence is missing. mCtr2-knockout mice
show elevated Cu accumulation in several tissues with increased mCtr1 expression [25]. Expression of
hCtr2 is mainly localized in intracellular vesicles. Recent studies demonstrated that mCtr2 interacts
with mCtr1 and causes truncation of mCtr1 through cleavage of its ectodomain by a cathepsin
protease, resulting in substantially reduced Cu(I) and cDDP transport capacities, and thus affecting
the effectiveness of cDDP killing [26]. However, another recent study using CRISPR-Cas9 genomic
editing strategy to knockout hCtr2 in two human tumor cell lines demonstrated only modest changes
in cDDP sensitivity compared to the parental cell lines [27]. The discrepancies of these results are yet
to be determined. In 40 ovarian cancers, it was reported that while high hCtr1 expression is associated
with chemosensitivity of Pt-based drugs, patients with low hCtr1 and high hCtr2 in their tumors have
poor treatment outcomes and shorter overall survival (OS) time [28]. In another study, it also reported
that ovarian cancer patients with high hCtr2/hCtr1 ratios in the tumor lesions are resistant to Pt-based
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chemotherapy [29]. These results demonstrated that hCtr2, in conjunction with hCtr1, may also involve
in chemosensitivity of Pt drugs.
2.2. Cisplatin Chaperone
Once inside the cells, cDDP, like Cu(I), is carried away by different Cu chaperones for intracellular
delivery to various compartments [30]. Antioxidant protein 1 (Atox1), one of the Cu chaperones,
receives Cu(I) directly from the C-terminal end of hCtr1 at the cytoplasmic membrane. The Cu-Atxo1
complex delivers Cu(I) to the Cu-efflux pumps, ATP7A and ATP7B, which are two P-type ATPases
and located at trans-Golgi network (TGN) [31–33] (Figure 1A). The driving force for this directional
trafficking is thought to be due to affinity gradients between protein partners along the route [34].
The human Atox1 contains 68 amino acids and has a β1α1β2β3α2β4 ferredox-like structure.
The Cu binding motif 12CXXC of Atox1 is located between the β1 ανδ α1 loops [35]. It has been
demonstrated that cDDP also binds this motif when delivering cDDP to ATP7A/ATP7B efflux
pumps [36]. Deletion of Atox1 results in resistance to cDDP, indicating its important role in Pt
drug sensitivity [37,38].
Atox1 also contains a nuclear targeting signal (38KKTGK) between the α2 ανδ β4 loop for
Cu-dependent nuclear translocation of Atox1 [39]. Nuclear Atox1 functions as a transcriptional
regulator for the mammalian cell proliferation gene cyclin D1 by interacting with the 5′-GAAAGA
sequence about 500 bp upstream of the transcription start site. Other Atox1-regulated genes include
extracellular superoxide dismutase (SOD3) which encodes a secretory Cu-containing antioxidant
enzyme [40], and OCT4 which codes for a pluripotency factor in embryonic development [41].
The nuclear targeting property of Atox1 may deliver cDDP to elicit its lethal effect of DNA damage.
2.3. Role of ATP7A and ATP7B in cDDP Efflux
ATP7A and ATP7B, contain 1500 and 1465 amino acids, respectively, each have 8 transmembrane
domains (TMDs). They share 67% amino acid sequence identity. Both ATPases contain several
functionally conserved domains, i.e., six metal-binding domains (N-MBD) at the N-terminus, each with
a CXXC motif; the nucleotide-binding domain (N-domain) for ATPase catalytic activity; the P-domain
for phosphorylation at the 1207Asp residue; and the A-domain for actuator/dephosphorylation
(Figure 1C). There are also multiple Cu-binding sites located at transmembrane domain (TM) 4,
TM5, and TM6 [42,43]. ATP7A is mainly expressed in the intestinal epithelium for Cu absorption from
food. Mutations in ATP7A result in systemic Cu deficiency that causes the Menkes’ disease. ATP7B
is mainly located in the liver and brain. Mutations of ATP7B result in massive Cu buildup in these
organs, resulting in Wilson’s disease [44,45].
Detailed mechanisms of how Cu/Pt-Atox1 transfers the metal ions into ATP7A and ATP7B and
how these metals are subsequently eliminated remain largely unknown. Current understanding
suggests that similar protein folding of the CXXC metal binding motifs between Atox1 and the N-MBD
of ATPases may facilitate rapid intermolecular metal transfer through electrostatics, hydrogen bonding,
and hydrophobic interactions [46]. Another critical amino acid residue in Atox1 is 60lysine which is
essential for protein heterodimerization with ATPases for processing Cu(I) transfer [47,48].
While Cu-Atox1 can potentially interact with all the six N-MBDs of ATP7A and ATP7B,
it preferentially interacts with the N-MBDs 1 to 4 [42]. Interactions of Cu-Atox1 with these N-MBDs
induce conformational changes and activate ATPase catalytic activity by mobilizing N-MBD to
cross-talk with the N-domain of ATP7B [49]. These interactions induce autophosphorylation of
Asp1027 in the P domain by ATP, and phosphorylation of several serine residues in the TMDs by
protein kinase D (PKD). However, it was found that deletion of the first five N-MBDs did not suppress
the autophosphorylation of Asp1027, whereas PKD-induced phosphorylation of the serine residues
was downregulated [42,50]. Furthermore, recent results showed that native ATP7B forms dimeric
configuration in the TGN, however, deleting the four MBDs from the N-terminus reshuffles the protein
to the secretary vesicles, suggesting that the N-MBDs may also serve as a Golgi-retention signal [43].
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These observations demonstrated the structural complexity involved in intramolecular transfer of
metals by the mammalian ATPases.
Work on the bacterial system suggests that Cu chaperones can deliver Cu ions to TM-MBDs.
Upon enzyme phosphorylation, Cu(I) is processed within the transmembrane region. Following the
opening of the TM-MBD, Cu(I) is then released into the vesicles [51], which then traffic to the cellular
membrane where Cu(I) is exported [52]. It was demonstrated that hydrolysis of one ATP molecule is
sufficient to confer one molecule of Cu(I) translocation by the microbial ortholog CopA [51]. However,
it is currently unclear whether this holds true for the mammalian Cu-ATPases.
Evidence has accumulated indicating that Pt(II) shares substantial similarity in coordination
chemistry with Cu(I). The Cu-binding CXXC-motifs in Atox1 and ATP7A/ATP7B are also involved in
cDDP binding [53]. Binding of cDDP to these sites may [54] or may not [55] displace Cu(I) binding.
Mechanistic details of cDDP translocation in ATP7A/ATP7B is largely unknown because cellular levels
of these ATPases are very low. Using microsomal fraction enriched in recombinant ATP7B (or ATP7A)
absorbed onto a solid supported membrane, it was demonstrated that Pt drugs activate Cu-ATPases
following a mechanism analogous to that of Cu(I) [54]. This in vitro study supports the roles of ATP7A
and ATP7B in Pt drug transport. It has been reported that deletion of Atox1 resulted in an inability
of cDDP delivery to ATP7A/ATP7B [37,38] and overexpression of ATP7A and ATP7B, resulting in
impaired cDDP elimination, consequently resulting in cellular resistance to cDDP [56–59], Cbp [60],
and Oxl [61].
3. Modulating cDDP Sensitivity through Redox Regulation of Cu Homeostasis
One of the important hallmarks in Pt-based chemotherapy is the induction of reactive oxygen
species (ROS)-related oxidative stress that leads to cell killing [62]. It has been abundantly
demonstrated that cDDP treatment induces expression of redox-regulating enzymes that are involved
in the biosynthesis of glutathione (GSH), such as γ-glutamylcysteine synthetase (γGCS) and
glutathione synthetase (GS) (see review in [62] and references therein). GSH is an abundant
cellular redox regulator (in mM quantity) (see reviewers in [63,64]) (Figure 2). cDDP-resistant cell
lines established by long-term exposure to cDDP display elevated expression of these enzymes,
and depleting GSH using buthionine sulfoximine (BSO) reverses cDDP resistance [62,63,65]. Glutamate
(Glu) and cysteine (Cys) are the upstream substrates of GSH biosynthesis, and their cellular transports
are carried out by the xCT cysteine-glutamate antiporter (Figure 2). Pharmacological inhibition of
xCT increases cDDP sensitivity [66]. cDDP-resistant cells also show increased glutamine (Gln) uptake,
which is the precursor of Glu biosynthesis [67]. Moreover, Gln-fed rats reduced cDDP-induced
nephrotoxicity in the proximal tubules [68]. These results, collectively, support the important roles of
the GSH biosynthetic system in cDDP resistance.
However, we demonstrated that increased GSH by transfection with recombinant DNA encoding
γGCS confers sensitization, but not resistance, to cDDP’s cell killing [64,65]. γGCS is the rate-limiting
enzyme for the biosynthesis of GSH. These findings demonstrate that elevated GSH does not per
se confer cDDP resistance. We reason that the elevated expression of GSH and its biosynthetic
enzymes observed in the cDDP-resistant cells under long-term cDDP exposure are likely due to
CDDP-associated oxidative stress because these enzymes are redox-regulated. Instead, sensitization
of the γGCS-transfected cells to cDDP is due to alternation of hCtr1 expression. In another study,
Franzini et al. [69] reported that overexpression of γ-glutamyltransferase (GGT) exhibited reduced
GSH levels in the transfected cells which displayed increased resistance to cDDP. No description of the
expression of hCtr1 was mentioned in this work, because hCtr1 as a cDDP transporter was reported
in the subsequent year [70]. We will discuss this further in light of GSH regulation of Cu(I)/cDDP
transport below.
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Figure 2. Regulation of Cu(I) and cDDP transports by the redox mechanism. The biosynthesis
of GSH which plays important roles in redox regulation of Cu(I) and cDDP transport is shown
here. The substrates of γGCS are glutamine and cysteine which are transported by xCT. GSH is
oxidized to GSSG by Gpx and GSSG is reduced back to GSH by Gred. GSH can facilitate Cu(I)
and Pt(II) delivery to Atox1 and ATP7A/ATP7B. GSH can upregulate hCtr1 expression because of
its chelation with Cu(I). GSSG and Pt-GS conjugate can be transported by the MRP2 efflux pump.
Abbreviations: xCT, cysteine-glutamine anti-polar transporter; Gpx, glutathione peroxidase; GS,
glutathione synthetase; γGCS, γ-glutamylcysteine synthetase; Gred, glutathione reductase; MRP2,
multidrug resistance protein 2.
The redox system plays multiple roles in regulating Cu(I)/cDDP transport activities. First,
extracellular Cu is normally present in an oxidized Cu(II) form. It is reduced to Cu(I) by cell
membrane-associated reductases for the hCtr1, Atox1, and ATP7A/ATP7B transport cascade. Although
Cu(I) can be converted into Cu(II) under oxidative stress conditions by the Fenton reaction, Cu(II)
cannot be transported by these proteins. Second, Cu(I) and cDDP can bind to the major redox regulator,
GSH and metallothionine (MT), resulting in reduction of bioavailability of Cu(I) that leads to increased
hCtr1 expression (see below). This can explain why GCS-transfection confers cDDP sensitivity [64,65].
Chelation of GSH by Cu(I) or Pt(II) induce GSH depletion, resulting in increased reactive oxygen
species (ROS) production, which are generated from complex III in the mitochondria. The resultant
ROS can modulate the expression of a whole spectrum of redox-regulating enzymes, including GSH
peroxidase (Gpx) which converts GSH into GSSG, an oxidized form of GSH [63]. GSSG can be
eliminated by the multidrug resistant protein transporter MRP2 (Figure 2). Third, the cytochrome c
oxidase Cu chaperone (Cox17), which delivers Cu(I) to mitochondrial cytochrome c oxidase (CCO),
can also deliver cDDP to mitochondria, the powerhouse of ROS production [71]. Platination of Cox17
affects the function of CCO, an important enzyme in the mitochondrial respiratory chain. Fourth,
GSH can assist the conjugation of Cu(I) and Pt(II) with their chaperones and facilitate intracellular
translocations of these metal ions. While apoAtox1 does not bind Cu-ATPases and is normally in
monomeric configuration, Cu-Atox1 often exists as a dimer and its formation is strictly influenced
by cellular redox conditions [72,73]. Under physiologic redox conditions, conjugation of Cu(I) and
GSH exits as a polymer, which assists Cu(I) transferring to Atox1. GSH can also assist cDDP complex
formation with Atox1. Moreover, Cu(I)-loaded Atox1 promotes the binding of cDDP and form the
Atox1-Cu-Pt tertiary complex via sulfur-bridge linkages [74,75]. Likewise, GSH can facilitate the
formation of Pt-Cox17 [71]. These findings demonstrate the important roles of GSH in Cu(I) and cDDP
transport systems. Finally, Pt-(GSH)2 conjugate is also a known substrate of MRP2 efflux pump [76,77]
(Figure 2), and elevated expression of MRP2 is associated with cDDP resistance [78].
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4. Modulating cDDP Sensitivity through Transcriptional Regulation of hCtr1 Expression
4.1. Regulation of Ctr1 Internalization by Cu Bioavailability
The findings that cDDP highjacks the Cu-transport system for its own transport underscore the
importance of Cu transporters in regulating cDDP sensitivity in cancer chemotherapy. Homeostatic
regulation of Ctr1 expression is an evolutionarily conserved mechanism from yeast [79] to
humans [3,80,81]. Levels of Ctr1 are induced under Cu starvation conditions but are downregulated
by Cu overload. A previous study in the yeast Saccharomyces cerevisiae demonstrated that Cu-induced
yCtr1 internalization is one mechanism of Cu(I) acquisition, and that the internalized yCtr1 is rapidly
degraded [82]. Cu-induced hCtr1 internalization has also been reported in human cells [83,84].
However, detailed mechanisms on how mobilization of Ctr1 movements in response to Cu availability
remain to be investigated.
4.2. Transcriptional Regulation of Ctr1 Expression by Cu Bioavailability
Transcriptional regulation of Ctr1 involves a variety of transcription factors. These transcription
regulators generally contain Cu-sensing domains which bear DNA binding activities and
transactivation domains for transcriptional activation. Budding yeast Mac1 is the transcriptional
regulator controlling the expression of yCtr1 and yCtr3 and reductase Fre1, together encoding the
Cu transport system. The N-terminal 40 amino acids of Mac1 contains zinc finger (ZF)-like motifs
which have DNA-binding activities. Two cysteine (C)-rich transactivation domains are located at its
C-terminus. Under low Cu conditions, Mac1 activates the expression of Cu transport genes by binding
to the promoters of these genes. At high Cu concentrations, four Cu(I) ions each bind the C-rich
transactivation domains, inducing conformational changes of Mac1, resulting in its fall-off from the
target genes and shutting down of transcription [85]. In the meantime, another transcriptional factor,
Ace1, is activated through the formation of a tetracopper-thiolate cluster within the Cu regulatory
domain [86,87], and binds the promoter of CUP1 and CRS5 encoding Cu-chelating metallothionein
(MT) [88]. Thus, yeasts use Mac1 and Ace1 in coordinating their activation and inactivation in response
to Cu depletion and repletion conditions, respectively, to regulate Cu homeostasis.
Zinc finger-like transcriptional factors are also involved in regulating Ctr1 gene expression
in other organisms. These include metal responsive transcription factor 1 (MTF-1) for the dCtr1B
in Drosophila [89], CRR1 for the Chlamydomonas Cu transporters Cyc6, CPX1, and CRD1 [90],
and SQUAMOS promoter-binding protein like-7 (SPL-7) factor for three Arabidopsis Cu transporters,
COPT1, COPT2 and COPT6 [91,92]. The schematic structure of transcription factors for Ctr1 genes in
different species is shown in Figure 3 [93].
In humans, we previously identified that specific protein (Sp1) is the transcription factor that
regulates hCtr1 expression [94,95]. Sp1 by itself is regulated by Cu homeostasis via transcriptional
interactions with at least 10 Sp1-binding sites located at the Sp1 promoter. High Cu conditions
downregulate Sp1 expression (Figure 4A), whereas reduced Cu conditions by Cu chelation upregulate
Sp1 (Figure 4B). Sp1 in turn regulates the expression of hCtr1 in response to Cu concentration variations
accordingly (Figure 4A,B) by interacting with two Sp1-binding sites located 25 bp downstream from
the hCtr1 transcriptional start site. Systemic mutations of these Sp1-binding sites abolish the Cu
responsiveness of Sp1 and hCtr1 expression [95].
Another transcriptional unit with opposite direction, named FKBP133 (also known KIAA0674)
encodes an FK506-binding protein-like transcript, and is located −201 bp upstream of the hCtr1
locus. FKBP133 is also regulated by Cu stressed conditions using the same Sp1 binding sites for the
hCtr1 regulation (our unpublished result). How this Sp1-mediated bidirectional transcription and the
fine-turning of its targeted gene expression under Cu stressed conditions remains to be investigated.
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Figure 3. Schematic diagrams showing the structures of transcription factors for copper transporters
from different species. Black boxes refer to ZF-like domains; yellow boxes, transactivation domains
(see the text for details).
Figure 4. Mechanisms of transcriptional regulation of Sp1 and hCtr1 in response to various challenges:
(A) downregulation by Cu overload; (B) upregulation by Cu chelator; (C) upregulation by Cu(I) and
cDDP combination.
4.3. The Sensing Mechanisms of Cu Bioavailability by Sp1
Sp1 is a ubiquitous transcription factor consisting of a DNA-binding domain at the C-terminus
that contains three ZF and a transactivation domain that contains two serine/threonine-rich and two
glutamine-rich (Q-rich 1 and Q-rich 2) subdomains (Figure 3). The ZF of Sp1 is constitutively bound by
Zn(II) because apoSp1 is very unstable [96]. Each ZF consists of Cys2-His2 residues that is coordinated
by one Zn(II) molecule. Elevated Cu ions displace Zn(II) binding of Sp1 [97]. Although this causes
only minor structural alternations, the “Cu-finger” cannot interact with the hCtr1 promoter [98]. Thus,
Cu is a negative regulator of Sp1 by poisoning its ZF DNA binding domains.
Sp1 is a member of the Sp/KLF (Krüppel-like factor) transcription factor family sharing the
general three copies of C2H2-type ZFs [99]. However, ZF domains in this family have a variety of
structures and at least eight different topologies have been categorized; many of these ZF-binding
proteins do not respond to Cu challenges [100]. Even Sp3, which is the closest member of Sp1, does not
regulate hCtr1 expression [94].
Interaction between cDDP and Sp1 is very weak at best, although it can interact with other
ZF-containing proteins, i.e., the retroviral protein NCp7 [101] and DNA polymerase 1 [102]. However,
it has been reported that the reactivity of Pt(II) with ZFs can be modulated by reducing agents such as
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tris(2-carboxyethyl)phosphine) (TCEP) [103] which is commonly used to maintain cysteine residues at
the reduced state [102]. In contrast, the trans-platinum thiazole Pt complex [PtCl2(NH3)(thiazole)] is
highly reactive towards Sp1-ZF2, but the resulting Pt-thiazole complex prevents nuclear trafficking
of Sp1 [103]. Moreover, the reactivity of Sp1-ZF3 with the cDDP complex is increased when the NH3
ligands of cDDP are replaced by the chelating ethylenediamine (en) in [PtCl2(en)] [104]. These reactions
cause conformational distortion of ZFs, rendering it unable to bind DNA. These results illustrate the
capacity for interaction of Pt compounds with ZF-proteins. However, the pharmacological relevance
of the interaction of Pt compounds with ZF proteins remains to be further studied.
We previously demonstrated that cDDP can transcriptionally induce Sp1 and hCtr1 expression in
time- and concentration-dependent manners [105]. Since cDDP does not directly act upon Sp1, these
results can be interpreted by virtue that cDDP acts as a competitor for hCtr1-mediated Cu(I) transport,
resulting in reduced cellular Cu levels that leads to upregulation of Sp1/hCtr1 (Figure 4C). In this
context, cDDP may be considered as a Cu-lowering agent, further supporting the integral role of cDDP
in Cu homeostasis regulation.
4.4. The Capacity of hCtr1 Regulation and Cellular Cu Bioavailability
Copper is an essential micronutrient for growth but is toxic when in excess. This is evidenced
by the findings that ablation of both murine mCtr1 alleles results in embryonic lethality and the
associated toxic effects in Menkes’ and Wilson’s diseases due to Cu anomalies in the intestine and liver,
respectively, as mentioned above. It has been reported that almost all cellular Cu(I) are chelated by
cellular constituents and only a small fraction of Cu(I) is bioavailable [106]. Thus, the bioavailable Cu
pools have to be tightly regulated. While a yeast (S. cerevisiae) cell contains as high as 0.01–0.1 M of total
Cu ions, but the bioavailable Cu(I) concentration is estimated to be only in the range of 8.9 × 10−17 to
5.1 × 10−23 M. This was estimated using the highly Cu(I)-selective and -sensitive transcription factors
Mac1 and Ace1 for the lower and upper limits, respectively [107]. Estimation of bioavailable Cu(I)
pools in human cells cannot be similarly carried out using Sp1 as a probe because of its abundant
target genes.
It is conceivable that bioavailable Cu(I) pools are different from cell type to cell type and play
a critical role in determining the capacity of Cu homeostasis regulation under Cu stressed conditions.
Intestinal epithelium is the primary cell type acquiring Cu from food. Intestinal epithelial cell-specific
knockout mice show drastic reduction of Cu in different organs, i.e., about 95% in the liver but
only about 30% in the kidneys as compared respectively with those in normal mice [108], refracting
differential capacities of Cu homeostatic regulation in different tissues.
A great variety of human malignancies have shown elevated Cu levels in the serum and tumors,
and elevated Cu levels are often positively correlated with cancer progression (see review in [109]
and references therein). Elevated Cu levels in tumors are correlated with high levels of hCtr1 in lung
cancers [110]. Likewise, Sp1 expression levels are elevated in many human tumors, including tumors
of stomach, pancreas, breast, brain, and thyroid (see [111] and references therein). These findings
suggest that capacity of Cu bioavailability regulation may differ between human cancers and their
normal counterparts.
5. Modulation of hCtr1 Transcriptional Regulation for Overcoming cDDP Resistance in
Cancer Chemotherapy
By analyzing a publicly available database containing 91 ovarian cancers, Ishida et al. [70]
reported that patients with high hCtr1 levels were associated with longer disease-free survival time
after adjuvant chemotherapy with a Pt drug and taxane. We analyzed a database of 243 patients with
endometrioid tumors of the ovary treated with first line Pt/taxane chemotherapy and found that
patients with high hCtr1 levels, but not ATP7A and ATP7B, have significantly longer progression-free
survival (PFS) and OS than those with low hCtr1 [20]. Recently, a more comprehensive study based
on eight datasets containing 2149 patients from nine countries, Sun et al. [8] reported that high hCtr1
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expression is associated with favorable treatment outcomes in ovarian and lung cancer patients who
underwent Pt-based chemotherapy. These results suggest that cancers with high hCtr1 expression have
a better response to Pt-based drugs, suggesting that transcriptional upregulation of hCtr1 expression
by Cu-lowering agents can be an attractive strategy for improving chemosensitivity to Pt drugs
with the following considerations. Firstly, we demonstrated in a cultured cell study that hCtr1
mRNA and protein levels can be induced by Cu chelators within one hour, but it takes several
days for the upregulated hCtr1 mRNA and protein to return to basal levels upon removal of the
chelators. These results suggest that induced hCtr1 by Cu chelation is considerably stable. Neither
ATP7A nor ATP7B mRNA is altered under Cu chelation [112]. Secondly, as stated, while multiple
mechanisms are involved cDDP resistance, reduced hCtr1 expression is a common mechanism.
Moreover, we found that cDDP-resistant cancer cells exhibit a greater magnitude of hCtr1 upregulation
by Cu-lowering agents as compared with their drug-sensitive counterparts. These results were
demonstrated in three independent cDDP-resistant cell lines treated with three different Cu-lowering
agents, i.e., trientine, D-pencillamide (D-pen), and tetrathiomolybdate (TM). The reduced levels
of hCtr1 in these cDDP-resistant cells were recovered to those comparable with the corresponding
drug-sensitive counterparts. The effectiveness of these Cu-lowering agents have little cell line- and
agent-specificities [112]. These findings demonstrate that Cu-lowering agents can overcome cDDP
resistance [112]. Third, Cu-lowering agents by themselves have been in many clinical trials for treating
various human malignancies because Cu is involved in tumor growth pathways, such as metastatic
tumor angiogenesis [113] and the oncogenic transformation pathway [114,115].
Based on these pre-clinical observations, a phase I clinical trial using Cbp plus trientine
in 55 patients with advanced malignancies, 45 of which had prior failure in Pt drug treatment,
was conducted at MD Anderson Cancer. About 19% of patients (n = 9) who maintained low serum
Cu levels after the treatments had significantly longer median PFS (p = 0.001) and OS (p = 0.03) as
compared with those patients (n = 38) who did not [116,117]. However, while the response rate remains
low—given the heterogeneity of patient population and multiple mechanisms of drug resistance that
may be involved, and the intrinsic variation in the capacity of hCtr1 induction by Cu-lowering agent
as mentioned above—there are options for improvement using this strategy (see below).
6. Conclusions and Perspectives
Pt drugs have been effective in treating many human malignancies, however, treatment efficacy
has been hampered by drug resistance. Mechanisms of cDDP resistance are complex, and defective
drug transport is commonly associated with cDDP resistance [63,118,119]. Recent studies have
established that the Pt drug transport system is an integral mechanism of Cu homeostasis regulation.
Preclinical studies have established that interventions of expression of hCtr1 transporter, Atox1
chaperone, and ATP7A/ATP7B efflux pumps can affect chemosensitivity of Pt drugs. However,
targeting this transport system for overcoming cDDP resistance has not been translated into
a therapeutic benefit. Our laboratories have discovered that hCtr1, but not ATP7A/ATP7B, expression
can be transcriptionally modulated by Cu concentration variations via the transcriptional factor Sp1.
The ZF domains of Sp1 are sensors of both Cu repletion and depletion conditions and transcriptionally
down- and up-regulates Sp1 accordingly. Sp1 in turn regulates hCtr1 expression, which is the
major regulator of cellular Cu content. This constitutes the Cu-Sp1-hCtr1 homeostatic self-regulatory
loop [3,120].
Not only does hCtr1 function as an important importer for cellular cDDP accumulation,
its expression is also upregulated by cDDP, because cDDP functions as a potent competitor for
hCtr1-mediated Cu transport, resulting in reduced intracellular Cu content. These observations have
led to an exploratory clinical investigation using the Cu-lowering agent trientine to enhance hCtr1
expression for overcoming Pt resistance in multiple cancer types [116]. Although the outcome of
this first-in-human trial remains low, the established mechanistic basis has important potentials
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for further clinical studies in improving the treatment efficacy of Pt-based chemotherapy, with the
following considerations.
Firstly, the ZF transcription regulators have been firmly assessed in Cu sensing to transcriptionally
regulate Pt drug transporters in eukaryotic cells. There are 23,299 genes encoding ZF-containing
proteins in the human genome [121]. This provides a vast wealth of opportunities for exploring
other ZF regulators that may control the cellular concentration of Pt drugs. These ZF proteins may
directly regulate the expression of Pt transporters, or indirectly function as intracellular metal chelators
that regulate global Cu ion bioavailability which regulates the expression of the Pt transport system.
Secondly, given the observations that Ctr1 expression is tissue-specific, and its responses to Cu
depletion differs in different organs [108], it is important to elucidate tissue-specific mechanisms of
hCtr1 expression using the Cu-chelation strategy. This research may identify specific tumor types that
are favorable for Cu chelation therapy. As an example, we found that expression of hCtr1 mRNA
and proteins are higher in 20 out of 20 ovarian tumor biopsies as compared with their adjacent naïve
tissues in patients prior to chemotherapy (HHWC, unpublished data). These results, together with
those published previously [8,70,112], may explain why ovarian cancers are preferentially sensitive to
Pt-based chemotherapy [122,123], and why cDDP-refractory ovarian cancers may seem to have better
response rates to the trientine plus Cbp combination therapy than other tumors in our exploratory
clinical investigation [117]. Thirdly, previous clinical studies demonstrated that better treatment
outcomes are associated in patients with reduced serum Cu levels after the trientine/Cbp combination
therapy [116,117]. These results suggest that effective therapy may lie in the Cu-lowering ability of the
treatment. Thus, identification of predictive biomarkers for Cu chelation in patients may be critical.
Fourthly, the current clinical study used trientine; the effectiveness of other potent Cu-lowering agents
such as desferal [124] and TM [125] still need to be explored. Fifthly, cytotoxic effects associated
with combination therapy using a Pt drug and copper-lowering agent need to be critically evaluated.
Finally, while we have learned much about hCtr1 regulation, other transport components such as
Atox1 and ATP7B/ATP7B remains a largely uncharted area of research. Exploitation of drug retention
by targeting these transporters may be fruitful.
In summary, we have highlighted the importance of targeting drug transporters in this review.
The described transcriptional regulation of hCtr1 presented here may serve as the translational
basis for future investigations for improving the treatment efficacy of cancer chemotherapy using
Pt-based drugs.
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Abstract: The cancer chemotherapeutic drug, bleomycin, is clinically used to treat several neoplasms
including testicular and ovarian cancers. Bleomycin is a metallo-glycopeptide antibiotic that requires
a transition metal ion, usually Fe(II), for activity. In this review, the properties of bleomycin are
examined, especially the interaction of bleomycin with DNA. A Fe(II)-bleomycin complex is capable
of DNA cleavage and this process is thought to be the major determinant for the cytotoxicity
of bleomycin. The DNA sequence specificity of bleomycin cleavage is found to at 5′-GT* and
5′-GC* dinucleotides (where * indicates the cleaved nucleotide). Using next-generation DNA
sequencing, over 200 million double-strand breaks were analysed, and an expanded bleomycin
sequence specificity was found to be 5′-RTGT*AY (where R is G or A and Y is T or C) in cellular DNA
and 5′-TGT*AT in purified DNA. The different environment of cellular DNA compared to purified
DNA was proposed to be responsible for the difference. A number of bleomycin analogues have
been examined and their interaction with DNA is also discussed. In particular, the production of
bleomycin analogues via genetic manipulation of the modular non-ribosomal peptide synthetases
and polyketide synthases in the bleomycin gene cluster is reviewed. The prospects for the synthesis of
bleomycin analogues with increased effectiveness as cancer chemotherapeutic agents is also explored.
Keywords: bleomycin analogues; DNA interaction; double-strand breaks; genome-wide; next-generation
sequencing; sequence specificity
1. Introduction
The bleomycins (Figure 1) are a group of structurally related metallo-glycopeptide antibiotics
discovered by Umezama and colleagues [1] and are clinically used as cancer chemotherapeutic agents.
The bleomycins are isolated from Streptomyces verticillis and the bacterium uses modular non-ribosomal
peptide synthetases and polyketide synthases to synthesise bleomycin [2–6]. Bleomycin can be
separated by chromatography into bleomycin A and B [1] and both A and B can be further
separated into different components. The clinical product, Blenoxane, consists of 60% bleomycin
A2, 30% bleomycin B2 and other minor components. The initial studies showed that bleomycin
inhibited DNA synthesis in E. coli and HeLa cells and also suppressed the growth of cancer cells
including Ehrlich carcinoma and mouse sarcoma [7]. In chemotherapy, bleomycin is currently used
in combination with other drugs to treat malignant germ-cell tumours, Hodgkin’s lymphoma and
carcinomas of skin, head, and neck [8–12]. In particular, a treatment regimen of bleomycin, etoposide,
and cisplatin is able to cure 90% of patients with testicular cancer [11]. Additionally, a combination of
bleomycin, vinblastine, and cisplatin have been successfully used to treat metastatic ovarian cancer [13].
Bleomycin’s cytotoxicity is attributed to its ability to cause double- and single-strand DNA breaks,
which then lead to extended cell cycle arrest, apoptosis, and mitotic cell death [14,15]. Double-strand
breaks are thought to be the most important for anti-tumour activity [16–19].
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Figure 1. The structure of bleomycin with the four functional domains indicated. The precursor
amino acids are shown as well as the propionate moiety derived from polyketide synthases (PKS).
The positively charged tails (R′) are shown for the various bleomycin congeners. The green arrow
indicates the site of bleomycin hydrolase cleavage. The figure is adapted from [15] and reprinted by
permission from Springer Nature.
2. Bleomycin Is Composed of Four Functional Domains
Bleomycin is a relatively large molecule and is composed of four structural domains (Figure 1):
a metal-binding region; a linker region; a disaccharide; and a bithiazole tail [20]. Congeners of the
bleomycin family are differentiated by the positively charged region on the bithiazole tail.
The metal binding region contains nitrogen atoms that are involved in coordination with transition
metals [21–24]. Bleomycin is able to coordinate with a number of metals including: Fe, Co, Cu, Mn, V,
and Zn. Fe ions are thought to be the biologically important divalent cations that are responsible for
the cytotoxic activity of bleomycin. The metal-binding region is also thought to play an important role
in the DNA sequence specificity of bleomycin. Structural studies of Co(III)-bleomycin bound to DNA
show the interaction of the N3 and C4-NH2 of the bleomycin pyrimidine moiety with the C2-NH2 and
N3 of guanine [20].
In conjunction with the metal-binding and linker region, the C-terminal bithiazole tail is important
for DNA recognition and binding of bleomycin with DNA. The bithiazole tail and its C- terminal region
is thought to contribute to DNA binding by intercalation or minor groove interaction [15,25,26]. With a
positive charge on the R′-group, this tail facilitates the electrostatic interaction between bleomycin and
DNA. Drugs with a planar fused ring system can interact with DNA via intercalation and hence it is
expected that the coplanar bithiazole tail of bleomycin can intercalate between bases of the DNA to
increase DNA affinity [23,27]. However, other studies pointed out that bleomycin might interact with
DNA via minor grove binding [25,26,28]. More recent research using X-ray crystallography indicates
that intercalative binding is the main form of DNA binding (see below) [15,20].
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The function of the disaccharide region of bleomycin is not thoroughly understood because
of the lack of analogues with varying sugar groups [29]. The disaccharide moiety consists of
an L-gulose and 3-O-carbamoyl-D-mannose. A modified bleomycin complex, deglycobleomycin,
where the disaccharide moiety is replaced with hydrogen, demonstrated a reduced efficiency of
DNA cleavage [30]. Studies by the Hecht group have highlighted the role of the disaccharide
moiety in the selectivity and uptake of bleomycin by tumour cells [31]. They demonstrated that
the bleomycin disaccharide alone was sufficient for selective uptake by tumour cells [32–34].
The 3-O-carbamoyl-D-mannose moiety appears to be crucial for this function [35,36]. This is consistent
with related work that provided evidence that this sugar region is involved in tumour cell uptake
via glucose transport. Glycolysis is accelerated in tumour cells due to their high energy demands.
Bleomycin may be effective in targeting cancer cells because the drug can be mistaken as glucose due
to its disaccharide moiety and hence, freely enter into tumour cells via protein channels [33,34].
The linker region plays a role as a bridge that joins the metal binding and DNA binding
domains [37]. The linker connects the metal binding region and bithiazole tail; and consists of a
valerate and L-threonine subunit. Systematic modifications to the substituents of these subunits
revealed their importance for the efficiency of bleomycin-mediated DNA cleavage [29,38–40]. Notably,
these analogues exhibit significant reduction in DNA cleavage (compared to deglycobleomycin)
but maintained a similar sequence specificity. On the other hand, analogues methylated at the
valerate-threonine amide were reported to have diminished sequence specificity [41]. These studies
suggest the importance of the linker in inducing an optimal conformation of bleomycin with respect
to DNA binding. The X-ray crystal structure revealed that the valerate was hydrogen bonded to the
minor groove of DNA [20].
3. Bleomycin DNA Cleavage Mechanism
When bleomycin, in its metal-free form, is administrated intravenously, it rapidly binds to Cu(II)
in the blood serum to create a stable complex, bleomycin-Cu(II) [23]. When this complex is transferred
inside a cell, bleomycin is reduced to bleomycin-Cu(I). The new complex can enter the nucleus and
exchange with Fe(II) to form bleomycin-Fe(II).
The degradation of DNA by bleomycin is preceded by the formation of an activated form of
bleomycin [15]. Activated bleomycin has been shown to form in the presence of O2, when bleomycin-Fe(II)
binds to O2, forming bleomycin-Fe(II)-OO•, which then accepts an electron and H+ to generate
the “activated bleomycin” complex, bleomycin-Fe(III)-OOH. Regardless of the presence of DNA,
the activated bleomycin complex decays rapidly, with a half-life of approximately 2 min at 4 ◦C and
ultimately forms bleomycin-Fe(III) [42].
Activated bleomycin participates in the abstraction of the C4′ hydrogen atom from the deoxyribose
moiety of a pyrimidine nucleotide 3′- to a guanine (Figure 2) [23,28,43]. This results in the formation of
a C4′ radical intermediate that can proceed via two separate pathways, depending on the presence of
O2. In the absence of O2, 98% of the C4′ radical is converted to 4′-oxidised abasic sites [44]. On the
other hand, in the presence of 1 atmosphere of O2, approximately 70% undergoes strand scission
and forms 3′-phosphoglycolate and 5′-phosphate ends, while the remainder forms 4′-oxidised abasic
sites [45,46].
218
Int. J. Mol. Sci. 2018, 19, 1372‘
 
Figure 2. Mechanism of bleomycin-mediated DNA cleavage. The Bleomycin-Fe(III)-OOH activated
form is generated in the presence of a one-electron reductant, Fe2+ and oxygen. The activated bleomycin
then abstracts the hydrogen atom (red square) from C4′ of the deoxyribose moiety of DNA to form
the intermediate 4′ radical. This intermediate can partition into two pathways. In the abundance
of oxygen, the 4′ radical initiates a series of chemical transformations, leading to a direct strand
break and producing 3′-phosphoglycolate and 5′-phosphate ends, and release of a base propenal.
However, in the absence of oxygen, the intermediate reacts with an oxidant in the presence of water,
generating 4′-oxidized abasic sites. The figure is adapted from [15] and reprinted by permission from
Springer Nature.
In the oxygen-dependent pathway, the C4′ radical reacts with O2 to form a peroxyl radical,
which is then reduced to a 4′-hydroperoxide (Figure 2). The latter undergoes further chemical
transformations that ultimately leads to DNA strand scission, releasing a base propenal. The resulting
gap comprises 3′-phosphoglycolate and 5′-phosphate terminal ends. Alternatively, the C4′ radical
can also initiate an oxygen-independent pathway where the C4′ radical undergoes oxidation to form
a 4′-carbocation that is subsequently hydroxylated and finally generates a C4′-oxidised abasic site.
The 4′-oxidised abasic site is unstable, with a half-life of 8–26 h at pH 7; it is also alkali labile and
capable of undergoing β-elimination that results in DNA strand scission, forming a phosphate and
4′-ketodeoxyribose at the 5′- and 3′-ends, respectively [46,47].
Activated bleomycin has also been reported to catalyse the degradation of other cellular
components including RNA [48], lipids [49], and proteins [50]. Cleavage of RNA by bleomycin
was shown to be selective, depending on the secondary and tertiary structure of the substrate [51,52].
The significance of these bleomycin cellular targets is not fully understood since the cytotoxic nature of
bleomycin is thought to mainly stem from its ability to mediate double-strand DNA cleavage [16–19].
4. Bleomycin Cleavage Specificity with Purified DNA
With the addition of Fe2+, the cleavage of purified DNA by bleomycin can be observed. Using defined
sequences of purified DNA, the DNA sequence specificity of bleomycin cleavage can be determined.
Bleomycin preferentially cleaves DNA at particular dinucleotide sequences. DNA sequence specificity
studies with purified plasmid sequences have indicated that the dinucleotides 5′-GT* and 5′-GC*
are preferentially cleaved by bleomycin [53–68]. For ease of discussion in this review, the bleomycin
cleavage site nucleotides are numbered with respect to the cleavage site at nucleotide position 0,
and the positions discussed are from −3 to +2 (see Table 1). The * indicates the nucleotide at position 0
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that is cleaved and destroyed during the reaction. Bleomycin has also been observed to cleave, to a
lesser extent, at the dinucleotides GG*, GA*, AT*, AC*, and AA* [58,59].
Table 1. The preferred nucleotides at the bleomycin cleavage site.







Position −3 −2 −1 0* +1 +2
Early 32P-end-label
experiments
SSB T G T 5′-TGT*
Random DNA sequence SSB T G T A 5′-TGT*A 5′-TGT*A
Systematically altered









DSB G T G T A ns 5′-GTGT*A 5′-RTGT*AY
The preferred nucleotides at the bleomycin cleavage site are shown from the −3 to the +2 positions. Only the most
highly preferred nucleotides are shown. The preferred nucleotides from the genome-wide data for cellular and
purified human DNA are depicted for the top 50,000 cleavage sites. Note that the individual nucleotide analysis at
the bleomycin cleavage site (second method), is shown in this Table except for the column on the right where the
complete sequence (first method) data is shown. SSB—single-strand break; DSB—double-strand break; ns—not
significant. The * indicates the nucleotide at position 0 that is cleaved and destroyed during the reaction.
Early studies noted that the relative intensity of cleavage between different sites with the same
dinucleotide (e.g., 5′-GT*) can vary, suggesting that the DNA sequence determinant of the specificity
of bleomycin cleavage is not confined to just two nucleotides [57,58]. Murray et al. found that the
nucleotide immediately 5′ to the bleomycin dinucleotide cleavage site (position −2) affected the
cleavage intensity; an adjacent thymine enhanced, whereas guanine and adenine reduced the cleavage
intensity [58,59]. It was also observed that alternating purine-pyrimidine sequences were preferred
cleavage sites for bleomycin [59].
Hecht’s group utilised hairpin DNA containing a motif with a randomised sequence to identify
variations that are strongly bound by bleomycin [69]. These hairpins consisted of single-stranded
DNA of 64 nucleotides in length and when self-annealed, the hairpin DNA contained an 8 bp
double-stranded motif with a randomised sequence at the centre. A mixture of these randomised
hairpin DNAs was then incubated with resin-bound bleomycin and variations that strongly bound to
bleomycin were isolated and sequenced. From this, they identified hairpin variations that were shown
to strongly inhibit bleomycin cleavage of a 5′-GC-3′-containing hairpin in a competition assay [63,70].
It is interesting to note that among these hairpin variations, some did not contain any 5′-GT* or
5′-GC* cleavage sites and yet they exhibited strong competition against the assay hairpin. They also
examined the sequence specificity of bleomycin cleavage with these hairpins. While the strongest
cleavage was observed at the canonical 5′-GT* and 5′-GC* sites, they also reported efficient cleavage at
non-conventional sites containing AT-rich dinucleotides [63,71]. Later studies reported that hairpins
with a 5′-GCGT sequence bound strongly to bleomycin and produced high intensity double-strand
breaks [66]. It is not clear whether the hairpin structures that were used in these experiments had
unusual DNA microstructure that influenced the results.
5. Bleomycin Cleavage Specificity with Purified DNA Using Updated Technology
More recently, updated technology using capillary electrophoresis with laser-induced fluorescence
(CE-LIF) and automated DNA sequencers, has permitted a more accurate and precise determination of
the DNA sequence specificity of bleomycin DNA damage in longer purified DNA sequences [72–79].
In addition, the use of separate 5′- and 3′-end-labelling in a DNA sequence specificity study contributes
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to the precision of the process by greatly reducing end-label bias [78,79]. It should be noted that
experiments with end-labelled DNA mainly detect single-strand breaks (see below).
Using these techniques, a more detailed bleomycin sequence specificity was elucidated using two
random DNA sequence of 247 and 425 bp in length [78]. For a random DNA sequence to contain all
the possible sequences, it must be sufficiently long. For a four bp recognition sequence, it must be at
least 256 bp and for a five bp recognition sequence, it must be at least 1024 bp in length. Hence, for the
247 and 425 bp sequences, a 4 bp recognition sequence could be extracted. It was found that bleomycin
preferentially cleaved at 5′-TGT*A DNA sequences [78].
Our genome-wide studies (see below) indicated that in human cells, the DNA sequence
5′-RTGT*AY (where R is G or A, and Y is T or C) was preferentially cleaved by bleomycin [80].
This 5′-RTGT*AY sequence was systematically altered by varying these nucleotides in a cloned
DNA sequence. The bleomycin cleavage efficiency was then investigated in these variant nucleotide
sequences. This study permitted the importance of flanking nucleotides around the 5′-GT, 5′-GT*A and
5′-TGT*A core sequences to be evaluated. It was observed that the preferred nucleotide sequence for
high intensity bleomycin cleavage was 5′-YYGT*AW (where W is A or T) (Table 1). The DNA sequence
that had the highest intensity of bleomycin cleavage was 5′-TCGT*AT and the seven highest intensity
bleomycin cleavage sites conformed to the 5′-YYGT*AW consensus sequence [79]. This study permitted
a precise evaluation of crucial neighbouring nucleotides that produced high intensity bleomycin DNA
cleavage sites. This approach of systematically altering the nucleotides around bleomycin cleavage
sites is a powerful method of analysis because every possible nucleotide is included in the analysis
and no variant is omitted [79]. This is in contrast to an analysis of random DNA sequences where
some nucleotide variants may not be present in the analysis. This study confirmed that 5′-GT, 5′-GT*A,
and 5′-YGT*A were core sequences for high intensity bleomycin cleavage sites.
Human telomeres are composed of tandem repeats of the DNA sequence 5′-GGGTTA. Seventeen
tandem repeats of this sequence were cloned into a plasmid DNA and the bleomycin sequence
specificity was investigated [72,75]. It was found that bleomycin preferentially cleaved at 5′-GT
dinucleotides in the telomeric sequence. Hence, telomeric DNA sequences are an important genomic
site for bleomycin cleavage (Figure 3).
Figure 3. Sites of possible genomic cellular DNA damage by Bleomycin. Red arrows indicate bleomycin
cleavage sites, while blue arrows are transcription start sites. The green rectangle is a promoter and the
orange ovals are nucleosome cores.
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6. Sequence Specificity at Bleomycin-Induced Abasic Sites
As well as cleaving DNA, bleomycin also produces abasic sites in DNA. The enzyme endonuclease
IV is able to cleave DNA at abasic sites. Hence endonuclease IV can be used to examine the sequence
specificity of bleomycin abasic site damage. It was found that bleomycin abasic DNA damage
preferentially occurs at 5′-GC and 5′-GT sites compared with the 5′-GT preference observed for
bleomycin-induced phosphodiester strand breaks [77].
Abasic DNA damage is enhanced in the absence of molecular oxygen and tumours are thought
to be hypoxic [81,82]. Hence, the sequence specificity of bleomycin-induced abasic DNA damage is
important for the effectiveness of anti-tumour agents and should be taken into account during the
design of bleomycin analogues [2,29].
7. X-ray Crystal Structure of Bleomycin with DNA
An X-ray crystal structure of bleomycin bound to DNA has been determined [20]. In this structure,
a Co(III)-bleomycin B2 was bound to a DNA sequence containing a 5′-GT. It was shown that the
bithiazole moiety intercalated into DNA. The metal binding and disaccharide domains were bound
in the minor groove of DNA utilising hydrogen bonding. The Co(III) metal coordination involved
the primary amine of β-aminoalanine as an axial ligand; and the secondary amine of β-aminoalanine,
imidazole, histidine amide, and pyrimidine N1 as equatorial ligands. A modelled hydroperoxide
ligand coordinated to Co(III) was perfectly positioned for abstraction of a hydrogen atom from C4′-H.
A caveat about this X-ray crystal structure was that Co(III) was used instead of the physiologically
important Fe(II).
An important feature of the X-ray crystal structure was that the bithiazole moiety was shown
to be intercalated into DNA; whereas previously, minor groove binding of the bithiazole group was
suggested [25,26,28]. The linker methylvalerate OH was found to be involved in hydrogen bonding to
DNA. The NH2 of 3-O-carbamoyl-D-mannose was also shown to hydrogen bond with DNA in the
minor groove; whereas no function could be discerned for the L-gulose since it was not involved in
DNA binding.
Concerning the sequence specific interaction of the Co(III)-bleomycin B2 complex with DNA,
a number of hydrogen bonds were made between the bleomycin complex and the minor groove of
DNA. With reference to the 5′-TAGT*TAAC sequence used in the experiments, there were three
hydrogen bonds with the crucial G nucleotide at position −1, one at position −2, and one at
position −3. This explains the importance of the G nucleotide at position −1, but also shows that an
extended bleomycin sequence specificity could be due to hydrogen bonding at positions upstream and
downstream from the dinucleotide cleavage site. In addition, the hydroperoxide ligand was positioned
close to the C4′-H of the T nucleotide at position 0 that would result in the cleavage of DNA at this
T nucleotide.
The bleomycin complex was bound to a 5 bp section of DNA. The bithiazole group was
intercalated between the 5′-T*T dinucleotide (positions 0 and +1); and the intercalation unwound the
double helix 3′ to the 5′-GT* dinucleotide (positions −1 and 0). These features have implications for
the DNA sequence specificity of bleomycin (see below).
8. Mechanism of Bleomycin-Induced Double-Strand Break Formation
Double-strand breaks are primarily derived from single-strand breaks and the ratio of
double-strand to single-strand breaks has been reported to be in the range 1:3 to 1:20 [16,27,83–86].
Both single-strand and double-strand break pathways share the common intermediate of a 4′-radical;
however, the double-strand break process strictly occurs in the presence of oxygen [86–88].
A bleomycin double-strand cleavage event generates new DNA fragments with either blunt or
5′-staggered ends depending on the recognition sequences. A double-strand cleavage model proposed
by Steighner and Povirk suggested that a single molecule of bleomycin carried out the cleavage events
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on both strands of DNA [84,86,87,89]. After cleaving at one site designated as the primary site, the
molecule must be reactivated and swiftly relocate itself to the secondary site on the other strand to
make another cut [84]. As a result, the ratio of double-strand to single-strand breaks is dependent on
the likelihood of bleomycin reactivation after the primary cleavage, on the rate of molecular relocation
and reorganisation, as well as the DNA sequences present. During the relocation, the DNA-binding
domain (the bithiazole tail) plays a role in maintaining strong binding with the DNA so that the
molecule is able to relocate itself to the secondary cleavage site without dissociating from the DNA.
Therefore, a good primary cleavage site is more likely to give rise to the secondary cleavage site
because in this case the bleomycin molecule has a strong interaction with DNA from its primary
contact and its dissociation is low [89]. Through structural studies of bleomycin-Co(II)-OOH with
2D NMR, the mechanism of this rearrangement was proposed to involve the rotation of the partially
intercalated bleomycin molecule after the primary cleavage event [23,88,90]. Acting together with the
tail, the linker region acts as a tether to bring over the cleaving metal-binding domain to the secondary
cleavage site. This might explain why modifying the linker region not only affects the efficiency of
DNA cleavage but also reduces the double-strand to single-strand break ratio [91,92].
Studies with short sequences (500 bp) with a small number of sites (100 cleavage sites) have
been used to detect and quantify double-strand breaks. It was proposed that a double-strand break
primarily comes from a strong primary site which is 5′-GY* (5′-GT* or 5′-GC*) and the secondary
cleavage site is determined by the nucleotide that is 3′- to the Y nucleotide. If this 3′-adjacent nucleotide
is a pyrimidine, then the second cleavage will generate blunt-end fragments. In contrast, if it is a
purine, then 5′-staggered-end fragments are produced [27,83,84,86,87,89]. Their studies also found
that the palindromic site 5′-GT*AC was a hotspot for double-strand cleavage.
It was also observed that, subsequent to the cleavage of the primary site, the secondary site
can partition into the formation of either a strand scission, containing the 3′-phosphoglycolate and
5′-phosphate ends; or a 4′-oxidised abasic site. In contrast, the primary cleavage site was always
observed to form 3′-phosphoglycolates at the double-strand breaks [84]. Additionally, Absalon et al.
reported that bleomycin-induced double-strand breaks do not form under oxygen-depleted conditions
and this further supports the observation that the primary cleavage site must be a bleomycin-induced
strand scission [87].
The single-strand to double-strand cleavage ratio of bleomycin was found to be conserved over
a large range of bleomycin concentrations [83,86]. This observation is not consistent with the theory
that the formation of double-strand breaks arises via the accumulation of random and independent
single-strand cleavages, where one would expect the single-strand to double-strand break ratio to
decrease when the concentration of bleomycin is increased. These findings have led to the proposal of
a model which involves the reactivation of a single bleomycin to produce a double-strand break via
cleavage on both strands.
9. The Sequence Specificity in Intact Human Cells
Bleomycin DNA damage has also been examined in intact human cells [93]. The bleomycin
DNA sequence specificity was determined in human cells with repetitive centromeric alphoid DNA
sequences [93], telomeric DNA sequences [74], globin [94–96], and retinoblastoma genes [97], with the
DNA sequence specificity again found to be concentrated at the dinucleotides 5′-GT* and 5′-GC* in
human cells. For the globin and retinoblastoma DNA sequences, bleomycin was able to footprint
transcription factors and positioned nucleosomes in human cells. Bleomycin is known to cleave in the
linker region of nucleosomes [93,98,99] and hence bleomycin is also a useful agent to probe chromatin
structure in human cells (Figure 3).
Human telomeric sequences are composed of the tandemly repeated DNA sequence (GGGTTA)n.
Since the 5′-GT* dinucleotide is a main site for bleomycin cleavage, telomeric sequences are expected
to be a major site for bleomycin cleavage (Figure 3). This was found to be the case where bleomycin
preferentially cleaved at telomeric 5′-GT* dinucleotides in human cells [74]. Since telomeres are
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important in chromosome replication, it has been hypothesised that telomeres could be a crucial
genomic site for the cytotoxicity of bleomycin [74,75].
10. Sequence Specificity of Bleomycin Double-Strand Breaks in the Entire Human Genome
In our laboratory, the sequence specificity of bleomycin-induced double-strand breaks in the entire
human genome has been studied by use of massively parallel next-generation sequencing technology.
Contrary to the approximately 100 sites investigated with the previous techniques, the next-generation
sequencing technology has enabled more than 200 million bleomycin double-strand break sites in
both cellular and purified DNA to be assessed in order to determine the genome-wide sequence
specificity [80,99–101]. It should be noted that the genome-wide studies mainly detect double-strand
breaks, whereas the experiments with purified end-labelled DNA sequences (discussed above) mainly
detect single-strand breaks.
The genome-wide study calculated the frequency of occurrence of dinucleotide, trinucleotide,
tetranucleotide, pentanucleotide, and hexanucleotide DNA sequences at bleomycin cleavage sites
as well as the nucleotide frequency at each position for the ten nucleotides 5′ to the cleavage site
and eleven nucleotides 3′ to the cleavage site. These analyses were performed for the 50,000 highest
intensity cleavage sites to reveal the genome-wide DNA sequence specificity of bleomycin in human
cells. This genome-wide method gave a longer preferred bleomycin cleavage site DNA sequence
specificity than previous methods. For the 50,000 highest intensity cleavage sites, the preferred
bleomycin cleavage sites were at 5′-GT* dinucleotide sequences, 5′-GT*A and 5′-TGT* trinucleotide
sequences, 5′-TGTA tetranucleotide sequences and 5′-ATGT*A pentanucleotide sequences. For cellular
DNA, the hexanucleotide DNA sequence 5′-RTGT*AY was the most highly cleaved DNA sequence.
This finding strongly agreed with the observation that alternating purine-pyrimidine sequences are
preferentially cleaved by bleomycin [78,80]. The core bleomycin cleavage site is probably the 5′-TGT*A
tetranucleotide sequence since it was more frequently cleaved by about three-fold compared to the
next-ranked tetranucleotide sequence.
There were differences between the genome-wide DNA sequence specificity of bleomycin cleavage
in purified DNA compared with cellular DNA. These differences mainly occurred at sequences flanking
the core 5′-TGT*A tetranucleotide cleavage sequence. With cellular DNA, the most highly cleaved
sequence was the hexanucleotide 5′-RTGT*AY; whereas it was the pentanucleotide 5′-TGT*AT for
purified DNA (Table 1).
There are two methods for analysing the genome-wide DNA sequence specificity of bleomycin
cleavage. In the first method, the entire sequence present at the bleomycin cleavage site is examined;
this is the method of analysis discussed in the previous paragraph and involves dinucleotides,
trinucleotides, tetranucleotides, pentanucleotides, and hexanucleotides. In the second method,
the individual nucleotides present at the bleomycin cleavage site are examined by frequency
calculations. Using the second method, the statistically preferred nucleotides for cellular DNA were
GTGT*A; whereas it was TGT*AW for purified human DNA. Again, the core sequence was the same,
5′-TGT*A, but there were variations in the flanking sequences at positions −3 and +2 (Table 1).
However, the first method of analysis (the complete sequence) gives probably the most accurate
representation of the sequence specificity of bleomycin DNA cleavage since the second method suffers
from the drawback that the nucleotides at the bleomycin cleavage site may not exist together at the
actual cleavage sequence [80].
11. Comparison of the Bleomycin Genome-Wide DNA Sequence Specificity with Purified
Plasmid DNA Sequences
The genome-wide bleomycin DNA sequence specificity was compared to results obtained from
end-labelled purified plasmid DNA sequences. By examining the bleomycin sequence specificity in a
cloned section of human DNA, a comparison could be made between a DNA sequence in purified
DNA and the identical sequence in the genome-wide data. Human mitochondrial DNA sequences
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were utilised for this task after cloning into plasmids. Two sections of human mitochondrial DNA
were investigated, and it was found that at individual bleomycin cleavage sites, there was a very low
level of correlation in the intensity of bleomycin cleavage in the two environments [78]. However,
at an overall level the bleomycin sequence specificity, 5′-TGT*A, was similar in the two environments.
As described above, the sequence in the human genome that was preferentially cleaved by
bleomycin was found to be 5′-RTGT*AY [80]. This sequence along with systematically altered
nucleotide variations, was placed into a plasmid construct called the RTGT*AY plasmid. The consensus
DNA sequence derived from the most highly cleaved bleomycin cleavage sites with this plasmid was
5′-YYGT*AW [79]; while from the genome-wide data, it was 5′-TGT*AW for purified genomic DNA
from the individual nucleotide data; and 5′-TGT*AT for purified genomic DNA from the complete
sequence data (Table 1). There was a consistent core of 5′-GT*A in these consensus sequences. At the
−3 position, it was C > T for the plasmid, and no statistically significant nucleotide preference for the
purified genome-wide (Table 1). At the −2 position, it was C = T for the plasmid, and T for the purified
genome-wide. At the +2 position, it was T = A for the plasmid, and T > A for the purified genome-wide.
The differences between the plasmid and the purified genome-wide can probably be attributed to
the techniques used to obtain the data; the end-labelled plasmid data detected single-strand breaks,
while purified genome-wide detected double-strand breaks. A similar process is thought to occur in
the production of these breaks, but a double-strand break is thought to be a more extreme event [15,84].
During the genome-wide procedure, double-strand breaks are ligated to linkers before being
added to the Illumina flowcell. This ligation procedure may not be sequence independent and may
introduce sequence bias into the results; whereas the CE-LIF end-labelling procedure is simpler and
has fewer steps.
The main drawback of the end-labelling procedure is that only a small number of DNA sequence
sites can be examined; whereas hundreds of millions of double-strand breaks can be examined in the
genome-wide procedure. In addition, the sequences in the genome-wide experiments are essentially
random; whereas the sequence composition is constrained in plasmid constructs.
12. Comparison of the Bleomycin Genome-Wide Sequence Specificity in Cellular DNA
Compared with Purified Genomic DNA Sequences
There were differences between the genome-wide DNA sequence specificity of bleomycin in
purified DNA compared with cellular DNA. Both sets of data were derived from the Illumina system
and therefore double-strand breaks were detected for both types of DNA environments.
The consensus DNA sequence derived from the most highly cleaved bleomycin cleavage sites was
5′-TGT*AW for purified genomic DNA and 5′-GTGT*A for cellular DNA from the individual nucleotide
data; and 5′-TGT*AT for purified genomic DNA and 5′-RTGT*AY for cellular DNA from the complete
sequence data (Table 1). The main differences were at the −3 and +2 positions since the core 5′-TGT*A
was the same for the two environments. At the −3 position, no statistically significant nucleotide
preference was found for the purified genome-wide, and G or R for the cellular genome-wide (Table 1).
At the +2 position, it was T > A for the purified genome-wide and no nucleotide preference or Y for
the cellular genome-wide.
The environment of cellular DNA is different to purified DNA in a number of ways. Cellular DNA
is complexed with proteins and DNA-bound cellular proteins have a large influence on the interaction
of bleomycin with cellular DNA. Bleomycin is a relatively large molecule (1500 daltons) and has
difficulty accessing DNA bound to proteins. Cellular DNA is mainly found complexed with
histones in the form of nucleosomes. Nucleosome cores are known to protect DNA from bleomycin
cleavage [98,102]. DNA binding proteins, for example transcription factors, have also been observed
to protect DNA from bleomycin cleavage [94–97,102]. Proteins bound to DNA can distort the structure
of DNA and this can lead to an alteration in the DNA sequence specificity of bleomycin cleavage in
cellular DNA compared to purified genomic DNA. In addition, cellular DNA is supercoiled and hence
has a distorted DNA structure that could also lead to changes in bleomycin sequence specificity.
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DNA is also a dynamic molecule in cells where DNA replication and transcription produce
transient single-stranded regions that will result in an altered bleomycin interaction. The cellular
environment contains many different chemical constituents and the cation bound to bleomycin can vary
inside cells where not all of the Cu(I)- or Cu(II)-bleomycin may be exchanged with Fe(II); whereas in
the purified experiment, the metal cation bound to bleomycin can be completely controlled.
13. Conformation of DNA and the DNA Sequence Specificity of Bleomycin
The DNA microstructure is likely to be very important for the intensity of bleomycin cleavage at
each lesion site. The conformation of DNA is derived from the DNA sequence where the order of bases
has a major influence on the DNA microstructure [103–106]. Hence, the consensus DNA sequence that
is found from the DNA sequence specificity experiments will give rise to a particular DNA structure
that is highly conducive to bleomycin cleavage; while other DNA sequences will have a different
DNA structure that is less productive for bleomycin cleavage. The features of DNA structure that
are likely to be important for bleomycin binding and cleavage are: the intercalation of the bithiazole
group into the DNA helix; the productive binding in the minor groove by the metal binding, linker,
and disaccharide domains; and the positioning of the complex to abstract a hydrogen atom from C4′-H.
If these major features are optimally present, then a high intensity bleomycin cleavage site is likely
to occur.
The other important parameter is the interactions of the bleomycin molecule with specific
nucleotides in DNA. These interactions were revealed by the X-ray crystal structure of bleomycin
with DNA and indicated that hydrogen bonding between the bleomycin complex and particular
nucleotides, especially the G nucleotide at position −1, in the minor groove of DNA were important.
Hence, a combination of specific DNA sequence interactions and the microstructure of DNA are
likely to be the main determinant of the DNA sequence specificity of bleomycin. Of course, the DNA
sequence informs the microstructure of DNA and the two are interrelated.
The X-ray crystal structure found that the bleomycin complex was bound to a 5 bp section of
DNA [20]. This is consistent with the pentanucleotide and hexanucleotide consensus sequences
presented above for the DNA sequence specificity of bleomycin. The bithiazole group was intercalated
between the dinucleotide at positions 0 and +1.
The binding of proteins to DNA and other cellular parameters will also alter the DNA
conformation and lead to differences in bleomycin DNA cleavage in cells compared to purified DNA.
14. Chromatin Structure Affects the Interaction of Bleomycin with Cellular DNA
As mentioned above, chromatin structure affects the interaction of bleomycin with cellular DNA
where nucleosome cores and other DNA binding proteins prevent bleomycin from cleaving DNA [102].
It has been demonstrated that bleomycin targets the linker region of nucleosomes rather than the core
DNA and it can be used to footprint chromatin structure in human cells [98,107,108].
Our genome-wide Illumina next-generation sequencing studies revealed an enhanced cleavage
pattern for bleomycin at transcription start sites (Figure 4). The peaks of the enhanced bleomycin
cleavage were approximately 200 bp apart. This implies that positioned nucleosomes are present at
transcription start sites and that bleomycin preferentially cleaves in the linker region of the nucleosome
and the nucleosome core protects DNA from bleomycin cleavage [109–111]. Hence, bleomycin can be
used to detect chromatin structure at actively transcribed genes [99].
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Figure 4. Bleomycin damage at Transcription Start Sites (TSSs) for actively transcribed genes (blue)
and non-transcribed genes (red) in human HeLa cells. The cellular/purified DNA ratio is on the y-axis
and this ratio removed any bias due to the DNA sequence preference of bleomycin cleavage. These data
were compiled from the 24,402 most highly-expressed genes in HeLa cells and 82,596 non-transcribed
genes in HeLa cells [99]. Note that the spacing between peaks is approximately 200 bps and probably
corresponds to phased nucleosomes in these transcribed regions. The x-axis is the position of DNA
cleavage at each nucleotide (bp) relative to the TSS. Reprinted by permission from Springer Nature [99].
Bleomycin preferentially damaged actively transcribed genes (Figure 4) and the degree of
bleomycin cleavage correlated with the level of transcription [99]. This enhanced bleomycin damage
occurred within 1000 bp of transcription start sites (TSSs). The 143,600 identified human TSSs were
split into non-transcribed genes (82,596) and transcribed genes (61,004) for HeLa cells. The bleomycin
cleavage pattern at highly transcribed gene TSSs was greatly enhanced compared with non-transcribed
gene TSSs. Genes that are actively being transcribed have a more open chromatin structure compared
with non-transcribed genes; hence bleomycin will be able to cleave at these active genes compared
with the more closed chromatin structure of non-transcribed genes. There were also differences that
depended on whether the sense or antisense strand were analysed.
For individual genes, the degree of bleomycin cleavage at TSSs was also determined and a ratio
of cellular/purified DNA cleavage was calculated. As expected, it was found that highly transcribed
genes had a higher cellular/purified ratio than non-expressed genes. In particular the following genes
had a high cellular/purified ratio: SERF2, TM4SF1, and TUBA1B (tubulin). Targeting of actively
transcribed genes in conjunction with bleomycin could enhance the cancer chemotherapeutic efficacy
of bleomycin [112,113]. In combination with nucleic acid-based techniques that target these crucial
genes, bleomycin cytotoxicity could be increased by focusing on these important genes.
15. Cancer Signal Transduction Pathways Affected by Bleomycin
It has been estimated for bleomycin that 500 double-strand breaks or 150,000 single-strand
breaks were required to induce apoptosis in Chinese hamster fibroblasts [19]. Bleomycin appeared to
mediate two types of cell death, depending on the intracellular accumulation of the drug. By using
electropermeabilisation, Tounekti et al. could control the amount of bleomycin that is introduced into
DC-3F Chinese hamster fibroblasts and the human head and neck carcinoma cell line A-253 [114].
At low cellular concentrations, cells were observed to enter cell cycle arrest at the G2-M phase that
eventually led to mitotic death. On the other hand, at high concentrations, bleomycin was proposed to
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act as a micronuclease since it was observed to rapidly cause significant fragmentation to the DNA
and induced an apoptosis-like pathway.
Treatment of cells with DNA-damaging agents, such as bleomycin, is associated with the
activation of p53 [115,116]. Subsequently, the activated p53 can mediate apoptosis via the regulation
of the Bcl-2 protein family and the release of cytochrome c from the mitochondria. For example,
bleomycin treatment of HEp-2 cells resulted in apoptosis via the activation of p53 and a conformational
change of Bax, coupled with the release of cytochrome c and the apoptosis-inducing factor [116].
Bleomycin has been observed to induce p53- and Bcl-2-independent apoptosis in squamous
carcinoma cells [117]. Furthermore, p53-deficient HL-60 cells were able to induce mitochondria-mediated
apoptosis [118]. Alternatively, the apoptosis-inducing factor promotes apoptosis via a caspase-
independent cell death. The release of the apoptosis-inducing factor and the DNase endonuclease
G from the mitochondria, and subsequent translocation into the nucleus, causes large-scale DNA
fragmentation [119,120].
Bleomycin has a major effect on a number of signal transduction pathways. With regard to the
signal transduction pathways involved in cancer, we utilised several tools to visualise the effect of
bleomycin on these pathways. Using the Comparative Toxicogenomics Database and the Database for
Annotation, Visualization, and Integrated Discovery tools, the bleomycin-affected genes were mapped
onto the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathways in Cancer (Figure 5) [121].
The red stars in Figure 5 indicate the proteins/genes that were affected by bleomycin and it reveals that
bleomycin impacts a number of signal transduction pathways involved in cancer. These include
the PI3K-Akt, MAPK, p53, PPAR, and other pathways. This results in changes to caspases in
apoptotic pathways; changes in proliferation, repair, DNA damage response, cell cycle, angiogenesis,
evading apoptosis, differentiation, and insensitivity to anti-growth signals.
Note that the signal transduction pathways in cancer are highly complex and not fully understood;
but the important point revealed in Figure 5 is that bleomycin acts at a number of these pathways and
this could provide an explanation for the effectiveness of bleomycin as a cancer chemotherapeutic
agent. Instead of affecting a single section of one pathway or a single crucial modification site,
bleomycin impacts on a number of signal transduction pathways. Hence, it is more difficult for a
tumour cell to develop resistance to these multiple blocks in signal transduction pathways compared
with a single blockage that could be overcome by a single mutation/modification. In order to develop
resistance to the multiple blocks caused by bleomycin, a number of resistance mechanisms must be
generated simultaneously which is much harder than for a single block [121–124].
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16. Repair of Bleomycin-Induced DNA Damage
16.1. Processing the 3′-Phosphoglycolate Termini
The direct scission of phosphodiester linkages in DNA by bleomycin results in the formation of
3′-phosphoglycolate termini at the site of cleavage. The repair of these lesions requires the removal
of the 3′-phosphoglycolate ends and an array of enzymes has been discovered that possess this
3′-phosphodiesterase activity. These include apurinic/apyrimidinic endonuclease I (APE1) and APE2;
tyrosyl-DNA phosphodiesterase 1 (TDP1); human nuclease Artemis; and Aprataxin [125,126]. It is
generally thought that these enzymes work together to remove specific subsets of the bleomycin-
induced 3′-phosphoglycolates, although the precise details are not fully understood.
Izumi et al. showed that the APE1 was a limiting factor in the repair of bleomycin-induced DNA
damage [127]. The repair of bleomycin-damaged DNA by a human cellular extract was shown to
be enhanced when supplemented with exogenous APE1. However, while APE1 is highly efficient
at processing 3′-phosphoglycolates at gapped DNA, the enzyme was observed to be less efficient at
removing phosphoglycolates from a 3′-terminus that is located at a recessed or blunt end; and highly
inefficient at 3′-overhangs [128].
APE2 was shown to be able to remove phosphoglycolates from 3′-recessed ends [129,130],
although it is not known how it compares with APE1.
The endonuclease activity of Artemis can trim long overhangs that contain 3′-phosphoglycolate
ends, however, it appears to be less efficient at processing short overhangs [131–133]. Fibroblasts from
patients who are deficient in Artemis are more sensitive to bleomycin [133]. Transfection of wild-type
Artemis cDNA into the deficient fibroblasts restored its resistance to bleomycin [134].
TDP1 was reported to preferentially remove 3′-phosphoglycolates on single-strand DNA or
at double-strand breaks [135,136]. Additionally, processing of phosphoglycolates at 3′-overhangs
was observed to be three times more efficient, compared to blunt ends; and 10 times more efficient,
compared to recessed ends [137]. This enzyme converts the phosphoglycolate terminus into phosphates,
which is then likely to be a substrate for the polynucleotide kinase/phosphatase. Cellular extracts
from patients deficient in TDP1 were unable to process phosphoglycolates at single-stranded DNA or
3′-overhangs [138]. Tdp1−/− mice and Tdp1−/− chicken DT10 cells were reported to be hypersensitive
to bleomycin [139,140].
In summary, it is likely that TDP1 is the main enzyme responsible for removing 3′-phosphoglycolate
termini from bleomycin cleaved DNA although other enzymes may also play a role.
16.2. Genome-Wide Bleomycin Repair
In our genome-wide experiments with bleomycin in HeLa cells, we examined the repair of
3′-phosphoglycolate termini at gene transcription start sites (TSSs) [100]. We found that repair of
bleomycin DNA damage preferentially occurred at actively transcribed genes. The most actively
transcribed genes had the highest level of repair, while the least actively transcribed genes had the
lowest level of repair that was close to non-transcribed genes. There were also differences in repair
that depended on whether the transcribed or non-transcribed strand was analysed.
16.3. Single-Strand Break Damage Repair
Bleomycin-generated single-strand breaks and 4′-oxidised abasic sites can be repaired by the
base excision repair pathway [15,141]. As described above, repair of single-strand breaks is preceded
by the removal of the blocking 3′-phosphoglycolate terminus, probably by TDP1 in human cells.
Bleomycin-induced 4′-oxidised abasic sites are efficiently processed by the apurinic/apyrimidinic
endonuclease activity of APE1, which incises the deoxyribose backbone 5′ to the abasic site.
This generates a nick in the DNA and produces a terminal 5′-phosphate at the 4′-oxidised abasic site.
APE1 also recruits DNA polymerase β, which possesses a lyase activity that subsequently removes
the 5′-phosphate 4′-oxidised abasic site, generating a single nucleotide gap in the DNA [142,143].
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The single nucleotide gap is then filled and ligated by DNA polymerase β and the XRCC1/DNA ligase
3 complex, respectively [144]. Alternatively, the gap-filling process in base excision repair can also be
undertaken via the long patch repair pathway.
16.4. Repair of Double-Strand Breaks
Double-strand breaks can be repaired via homologous recombination or the non-homologous end
joining pathway. Both pathways involve an array of protein factors and are still actively being studied
(reviewed in [145,146]). Similar to the single-strand damage repair, repair of the bleomycin-induced
double-strand breaks requires the removal of the 3′-phosphoglycolate ends.
16.5. Repair and Bleomycin Resistance
It is expected that the DNA repair machineries can contribute to the resistance of DNA damaging
agents such as bleomycin [102]. Suppression of DNA repair proteins can confer sensitivity of cells to
bleomycin and other DNA damaging agents. Conversely, increased expression of proteins known
to be involved in DNA repair have also been shown to increase the resistance of cells. For example,
overexpression of APE1 in germ cell tumours was shown to increase resistance of these cells to
bleomycin [147].
17. Cellular Transport of Bleomycin
Bleomycin is administered intravenously as a mixture (Blenoxane), containing predominantly
the A2 and B2 congeners in metal-free form [47]. Once administered, bleomycin has a terminal
half-life in the plasma of approximately 90 min, and 65% of it is excreted in the urine within 24
h [12,148,149]. Cu(II) from blood plasma binds to the intravenous bleomycin, forming bleomycin-Cu(II),
which is believed to be the complex that is transported into the cells [15,150]. Once inside the cell,
it is proposed that the bleomycin-Cu(II) complex is reduced to bleomycin-Cu(I) by cysteine and
glutathione [46,151,152]. The Cu(I) ligand can be displaced by Fe(II) and this results in the active
bleomycin-Fe(II) complex [153,154].
Bleomycin is a large molecule and hydrophilic, which makes it difficult to cross the cell membrane.
However, studies with cobalt-bound bleomycin have shown that the drug binds to a receptor protein
on the plasma membrane and then enters the cell via vesicles or receptor-mediated endocytosis. A 250
kDa protein was identified in Chinese hamster fibroblasts as well as in a human head and neck
carcinoma cell line [155,156]. However, this protein has not yet been characterised. The subsequent
release of bleomycin from endocytotic vesicles is also not fully understood.
A different transport mechanism was reported from studies using S. cerevisiae and fluorescently
labelled bleomycin. It was found that the L-carnitine transporter Agp2 was able to carry out the
uptake of bleomycin. Also, these studies indicated that bleomycin might share a common transport
pathway with spermidine or polyamine [157,158]. The pathway requires two kinases Ptk2 and Sky1 to
upregulate the transport. Yeast mutants that lack the carnitine transporter Agp2 as well as kinases
Ptk2 and Sky1 were shown to have their bleomycin uptake level significantly decreased. The fate
of bleomycin entering cells via the energy-dependent transport pathway hinges on whether it is
sequestered into cytoplasmic vacuoles for cellular detoxification. The cytotoxicity of bleomycin is
only present when it is not degraded by the vacuoles and can diffuse into the cytosol and ultimately
the nucleus for DNA cleavage. The human analogue of the L-carnitine transporter, hCT2, was also
identified and demonstrated to be involved in bleomycin uptake. The hCT2 protein is highly expressed
in human testicular cells, which might explain the effectiveness of bleomycin in the treatment of
testicular cancer. In contrast, resistance to the drug seen in human colon and breast cancer might be
attributed to the fact that hCT2 is poorly expressed in those tissues [159].
The ability of cells to accumulate intracellular bleomycin is a factor that may contribute to
bleomycin resistance or sensitivity. Certain cell membrane proteins, notably the human high affinity
L-carnitine transporter, can modulate the accumulation of and subsequently the sensitivity of tumour
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cells to bleomycin. It was found that overexpression of the yeast polyamine transporter TPO1 increased
resistance to bleomycin [160]. The yeast TPO1 transporter was previously found to be involved in the
efflux of polyamines from the cell [161,162].
18. Bleomycin Hydrolase
Pulmonary toxicity is the major dose-limiting side effect of cancer treatment with bleomycin.
Up to 46% of patients encounter pneumonitis or lung inflammation. Long-term usage can lead to lung
fibrosis and up to 3% of patients face fatal consequences from pulmonary toxicity [12,15,163].
Bleomycin-induced lung inflammation is thought to result from the low level of bleomycin
hydrolase in lung tissue since it is 5–15 fold lower than other tissues [164]. Bleomycin hydrolase,
an aminopeptidase, is an enzyme that biochemically deactivates bleomycin. This enzyme catalyses
the hydrolysis of the carboxamide group of the β-aminoalanine moiety and forms deamido
bleomycin [165]. Deamido bleomycin exhibited DNA cleavage activity, with similar sequence
specificity as bleomycin, but was significantly reduced in its ability to mediate double-strand
breaks [85,166]. Additionally, studies have shown that the level of bleomycin hydrolase in the lungs
correlated with the susceptibility to pulmonary toxicity [164,167]. It is also known that human skin
and lungs have low levels of expression of this enzyme, which correlates with the major side effects
of the bleomycin treatment [12]. Expression of the yeast bleomycin hydrolase homologue (known to
metabolise bleomycin) in mouse NIH3T3 cells increased its resistance to bleomycin—an effect that was
reversed when the cells were treated with the cysteine proteinase inhibitor E-64 [168]. In another study,
bleomycin hydrolase was knocked-down by RNAi and HeLa cells became 3.4-fold more sensitive
to bleomycin [169]. In addition, the bleomycin hydrolase gene has been identified as a methylated
tumour suppressor gene in a hepatocellular carcinoma [170].
However, the significance of bleomycin hydrolase in mediating resistance against bleomycin is
controversial since other studies have reported that bleomycin hydrolase did not appear to confer
resistance in yeast cells [171].
19. Bleomycin Analogues
There are a number of naturally occurring bleomycin analogues. Studies have reported differences
in the cleavage profiles of bleomycin and its naturally occurring analogues, such as talisomycin and
phleomycin [56,57]. Notably, the cleavage profile of talisomycin included enhancement for 5′-GA*-3′
sites, which were rarely cleaved by bleomycin [57].
Bleomycin is a complex molecule that makes it difficult to conduct structure-activity studies
and there have been relatively few bleomycin analogues produced and tested compared with other
clinically-used anti-cancer agents.
Several bleomycin analogues have been produced by altering the His, Ala, Thr, and Cys
(bithiazole) amino acids (Figure 1) [14,172]. Alterations to the His and Thr residues resulted in
bleomycin analogues with decreased DNA cleavage. However, a phenyl or isopropyl replacement of
the methyl group in Ala and a chlorinated bithiazole, produced bleomycin analogues with enhanced
DNA cleavage.
The same research group was also able to alter the carbohydrate region of bleomycin A5 and
produced three analogues with differences in the carbohydrate region [173]. They found that changes
in the carbohydrate region led to major changes in the DNA cleaving ability of the bleomycin analogue.
Shen et al. have also found that alterations in the carbohydrate region gave rise to large changes in the
DNA cleaving ability of a bleomycin analogue [29].
The successful replacement of a methyl group with a bulky phenyl or isopropyl group at the
Ala residue would indicate that other hydrophobic bulky substituents may produce more effective
bleomycin analogues. There are also grounds to suspect that bulky group additions to the linker Thr
may also lead to more effective analogues [172]. Chlorination of the bithiazole produced interesting
bleomycin analogues and hence manipulations of this part of the molecule may also prove productive.
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In addition, alterations to the disaccharide region resulted in analogues with altered properties and
hence this region of the molecule would be a fruitful area to investigate. In particular the replacement
of a hydroxyl group with a hydrogen atom resulted in a large change in the DNA cleaving ability of
the bleomycin analogue [29].
Bleomycin is natively produced in S. verticillis from a large 120 kb gene cluster. However,
S. verticillus is refractory to transformation, and DNA manipulation and recombinant DNA techniques
have proved to be extremely difficult in this bacterium [5]. To avoid this problem, Shen and co-workers
have utilised the closely-related bacterium Streptomyces flavoviridis to manipulate and express the
bleomycin gene cluster [29]. Bleomycin is synthesised using non-ribosomal peptide synthetases and
polyketide synthetases from a large 120 kb gene cluster [2–6]. On expressing this 120 kb bleomycin gene
cluster in S. flavoviridis, three bleomycin analogues, zorbamycin (ZBM), BLM Z, and 6′-deoxy-BLM Z
were produced and purified [29].
The structures of bleomycin and the three bleomycin analogues are shown in Figure 6 and they
differ at a small number of positions shown in red. On expressing the bleomycin gene cluster in
S. flavoviridis, the C-terminal tail is derived from the S. flavoviridis biosynthetic apparatus. Thus,
the BLM Z, and 6′-deoxy-BLM Z C-terminal tails are similar to ZBM [29]. The structure of bleomycin
and BLM Z are exactly the same apart from the C terminal tail (Figure 6).
 
Figure 6. The chemical structures of bleomycin, 6′-deoxy-BLM Z, BLM Z, and ZBM. Differences in
chemical structures are shown in red.
These three bleomycin analogues that were produced in S. flavoviridis were tested for their ability
to cleave purified plasmid DNA and it was found that 6′-deoxy-BLM Z was the most efficient at DNA
cleavage, followed by ZBM, BLM Z, and bleomycin [29].
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The DNA sequence specificity of these three bleomycin analogues was also investigated and it
was observed that bleomycin, BLM Z, and 6′-deoxy-BLM Z were very similar, but in comparison,
ZBM had a different sequence specificity profile [174]. Bleomycin, BLM Z, and 6′-deoxy-BLM Z were
found to mainly cleave at 5′-TGT*A sequences; while the cleavage preference of ZBM was 5′-TGT*G
and 5′-TGT*A [174].
Using human HeLa cells, the cytotoxicity was examined and the IC50 was 2.9 μM for 6′-deoxy-BLM
Z, 3.2 μM for BLM Z, 4.4 μM for bleomycin, and 7.9 μM for ZBM [101].
The genome-wide DNA sequence specificity of 6′-deoxy-BLM Z and ZBM was determined in
human HeLa cells and compared with bleomycin [175]. More than 200 million double-strand breaks
were analysed for each analogue. For 6′-deoxy-BLM Z, the individual nucleotide consensus sequence
was 5′-GTGY*MC (where M is A or C); it was 5′-GTGY*MCA for ZBM; and 5′-GTGT*AC for bleomycin.
The most highly ranked tetranucleotides were 5′-TGC*C and 5′-TGT*A for 6′-deoxy-BLM Z; 5′-TGC*C,
5′-TGT*A, and 5′-TGC*A for ZBM; and 5′-TGT*A for bleomycin. Hence, 6′-deoxy-BLM Z and ZBM
had a preference for 5′-GC* and 5′-GT* dinucleotides, while it was 5′-GT* for bleomycin in human
cellular DNA.
In experiments with purified human genomic DNA, the individual nucleotide consensus sequence
was 5′-TGT*A for 6′-deoxy-BLM, 5′-RTGY*AYR for ZBM, and 5′-TGT*A for bleomycin. Thus, the purified
genome-wide DNA sequence specificity was similar for bleomycin and 6′-deoxy-BLM, but was different
for ZBM. In addition, the cellular DNA sequence specificities for the analogues, were different in
cellular DNA compared with purified DNA. As mentioned above, there are many differences in the
cellular environment compared with purified DNA, for example, chromatin structure. The differences
in sequence specificity between the two environments are greater for the two analogues compared with
bleomycin. Hence, the analogues must be more sensitive to these differences than bleomycin. It also
shows that caution should be applied when extrapolating results with purified DNA to cellular DNA.
We also examined the effect of chromatin structure on the cellular DNA cleavage of the two
analogues in comparison with bleomycin [101]. As for bleomycin, it was found that 6′-deoxy-BLM Z
and ZBM preferentially cleaved at the transcription start sites (TSSs) of actively transcribed genes in
human cells. The extent of preferential cleavage at the TSSs was quantified and it was observed to
correlate with the cytotoxicity of the bleomycin analogues. This preferential cleavage at the TSSs is
consistent with the concept that DNA double-strand breaks are the crucial lesion for the cytotoxicity
of bleomycin.
As found for bleomycin, 6′-deoxy-BLM Z and ZBM cleaved in the linker region of the
nucleosome [99–101]. These analogues were also able to detect positioned nucleosomes at the TSSs in
human cells [99,101].
20. Production of Novel Bleomycin Analogues That Are Resistant to Cleavage by Bleomycin
Hydrolase
The modular structure of non-ribosomal peptide synthetases and polyketide synthetases on the
120 kb gene cluster enables facile modification and manipulation of this cluster to produce novel
bleomycin analogues [2–6]. Hence, the selective engineering of specific modules in the bleomycin
synthetic pathway via combinatorial biosynthesis [29] opens the door for efficient production of novel
bleomycin analogues that could have beneficial cancer chemotherapeutic properties.
As mentioned above, a major concern in the administration of bleomycin lies in its dose-limiting
side effect, pulmonary toxicity, and up to 46% of patients encounter this side effect [12]. This toxicity is
the major limitation for therapy and hence, it has been of interest to develop more effective analogues
that can overcome this limitation. As mentioned above, bleomycin is inactivated by the endogenous
enzyme bleomycin hydrolase and this enzyme is found at low levels in lung tissue. The production of
bleomycin analogues that are not cleavable by human bleomycin hydrolase would result in lung tissue
being as equally susceptible to bleomycin activity as other tissues. Hence this bleomycin analogue
would be more effective as an anti-cancer agent because the selective lung toxicity has been eliminated.
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Resistance to bleomycin in other tumour cell types via the over-expression of bleomycin hydrolase
would also be bypassed.
The bleomycin hydrolase cleaves the amide bond in the β-aminoalanine moiety (green arrow in
Figure 1). Manipulation of this part of the molecule could achieve the desired bleomycin analogue;
namely an analogue with DNA cleaving ability but refractory to cleavage by bleomycin hydrolase.
Other strategies, for example, the attachment of a large lipophilic group [176], may also prove viable.
There have been a number of studies where bleomycin analogues have been chemically
synthesised [172]. However, none of these studies examined whether bleomycin hydrolase could
cleave the bleomycin analogues.
21. Summary and Future Prospects
Bleomycin is a complex molecule and unlike other smaller anti-cancer agents, has not been
extensively modified to conduct structure-activity studies.
There are several possible approaches to establish a more effective bleomycin analogue.
1. One approach is to produce bleomycin analogues that are resistant to cleavage by bleomycin
hydrolase. The anti-tumour activity of bleomycin is limited by lung toxicity. The production
of bleomycin analogues that are not cleaved by human bleomycin hydrolase will result in
bleomycin analogues that are more effective as an anti-cancer agent because the lung toxicity
would be eliminated.
2. The engineering of an analogue that has improved uptake into cells, or even better, preferential uptake
into tumour cells would produce a more effective cancer chemotherapeutic agent. Alterations to the
disaccharide region could be prime areas for modification to achieve this aim.
3. The production of analogues with faster/greater binding to DNA would target the analogue to
the biological target DNA and eliminate side reaction with other molecules—the DNA targeting
hypothesis [177,178]. The bithiazole tail could be modified to produce greater DNA binding.
4. The creation of an analogue that is more efficient in producing the “activated” intermediate could
have beneficial properties.
5. More complicated and problematic would be the engineering of an analogue that is more effective
at producing double-strand breaks compared with single-strand breaks, since double-strand
breaks are thought to be the crucial lesion for the cytotoxicity of bleomycin.
6. Further investigations with genome-wide studies will determine the crucial genes that are
preferentially cleaved by bleomycin. In combination with nucleic acid-based techniques that
target these crucial genes, bleomycin cytotoxicity could be enhanced by focusing on these
important genes.
7. Synergies could also be found with other nucleic acid and antibody-based novel therapies to
enhance the action of these recently introduced therapeutics.
The clinical importance of bleomycin as a cancer chemotherapeutic agent suggests that improved
analogues based on bleomycin can be developed. Experiments that provide a deeper molecular
understanding of the crucial constituents of the bleomycin molecule could lead to directed synthesis
of highly effective bleomycin analogues. Tools exist that provide a quantitative and precise platform
whereby bleomycin analogues can be tested and compared. This information, along with knowledge
of their structure and their efficacy, could provide an informed basis for the development of new more
efficient anti-cancer analogues based on bleomycin.
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Abbreviations
APE1 and APE2 Apurinic/apyrimidinic endonuclease 1 and 2
CE-LIF Capillary electrophoresis with laser-induced fluorescence detection
TSS Transcription start site
TDP1 Tyrosyl-DNA phosphodiesterase 1
ZBM zorbamycin
M A or C nucleotides
R G or A nucleotides
W A or T nucleotides
Y T or C nucleotides
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